query,KEGG_id,KEGG_name,KEGG_formula,KEGG_pathway,KEGG_module,KEGG_brite,KEGG_enzyme,KEGG_reaction
1-Eicosanol NIST,NA,NA,NA,NA,NA,NA,NA,NA
1-Monopalmitin NIST,NA,NA,NA,NA,NA,NA,NA,NA
1-Tetracosanol NIST,NA,NA,NA,NA,NA,NA,NA,NA
4-2-hydroxyethylphenol  tyrosol,NA,NA,NA,NA,NA,NA,NA,NA
4-hydroxycyclohexanecarboxylic acid cis,NA,NA,NA,NA,NA,NA,NA,NA
4-hydroxyphenylacetic acid,cpd:C00642,4-Hydroxyphenylacetate;4-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C00642,1.2.1.5;1.2.1.29;1.2.1.39;1.2.1.53;1.2.3.13;1.14.13.18;1.14.14.9;4.1.1.83;6.2.1.-,R00042 R02514 R02516 R02695 R02697 R02698 R02699 R06790;R07312 R13086
beta-Sitosterol NIST,NA,NA,NA,NA,NA,NA,NA,NA
carbonate ion NIST,NA,NA,NA,NA,NA,NA,NA,NA
catechol,cpd:C00090,"Catechol;1,2-Benzenediol;o-Benzenediol;1,2-Dihydroxybenzene;Brenzcatechin;Pyrocatechol",C6H6O2,Chlorocyclohexane and chlorobenzene degradation;Benzoate degradation;Fluorobenzoate degradation;Dioxin degradation;Polycyclic aromatic hydrocarbon degradation;Naphthalene degradation;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Benzene/toluene degradation, benzene => catechol / toluene => 3-methylcatechol;Benzene degradation, benzene => catechol;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol;Catechol ortho-cleavage, catechol => 3-oxoadipate;Catechol meta-cleavage, catechol => acetyl-CoA / 4-methylcatechol => propanoyl-CoA;Anthranilate degradation, anthranilate => catechol",NA,1.1.3.14;1.3.1.19;1.3.1.20;1.3.1.25;1.3.1.-;1.10.3.1;1.13.11.1;1.13.11.2;1.14.12.1;1.14.12.13;1.14.12.23;1.14.13.1;1.14.13.7;1.14.13.31;1.14.13.244;1.14.14.20;1.14.14.-;1.14.18.1;1.14.-.-;2.1.1.6;3.7.1.-;4.1.1.46;4.1.1.63,R00058 R00080 R00812 R00813 R00814 R00815 R00816 R00817;R00818 R00821 R00822 R00823 R00825 R00827 R00828 R01033;R05361 R07700 R07706 R07803 R08106 R08122 R10043 R11653;R12301
catechol,cpd:C01014,3-Isopropylcatechol,C9H12O2,NA,NA,NA,NA,NA
catechol,cpd:C01502,o-Methoxyphenol;Guaiacol;Catechol mono methyl ether;2-Methoxyphenol,C7H8O2,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Therapeutic category of drugs in Japan [BR:br08301(D00117)]; 2  Agents affecting individual organs;  27  Dental preparations;   273  Analgesics and sedatives;    2730  Analgesics and sedatives;     D00117  Guaiacol (JAN);Risk category of Japanese OTC drugs [BR:br08312(D00117)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Guaiacol;    D00117  Guaiacol (JAN),1.11.1.14;1.11.1.16;1.14.14.-;2.1.1.6,R00827 R11501 R11503 R12301
catechol,cpd:C02012,Catecholamine,C8H9NO2R2,NA,NA,NA,NA,NA
catechol,cpd:C02235,4-Nitrocatechol,C6H5NO4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.14.13.29;1.14.-.-,R03023 R05265
catechol,cpd:C02375,4-Chlorocatechol,C6H5ClO2,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.13.11.1;1.13.11.2;1.14.13.20;1.14.-.-,R04258 R05406 R05441 R07793
catechol,cpd:C02526,"Biphenyl-2,3-diol;2,3-Dihydroxybiphenyl;3-Phenylcatechol",C12H10O2,Dioxin degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Biphenyl degradation, biphenyl => 2-oxopent-4-enoate + benzoate",NA,1.3.1.56;1.13.11.39;1.14.13.44,R03462 R03964 R05239
catechol,cpd:C02923,"2,3-Dihydroxytoluene;3-Methylcatechol",C7H8O2,Xylene degradation;Toluene degradation;Naphthalene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Benzene/toluene degradation, benzene => catechol / toluene => 3-methylcatechol;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.3.1.19;1.3.1.68;1.3.1.-;1.13.11.2;1.13.11.-;1.14.13.1;1.14.13.7;1.14.13.243,R03566 R03608 R04088 R04089 R05309 R05314 R06915
catechol,cpd:C02933,"3,5-Dichlorocatechol",C6H4Cl2O2,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.13.11.-;1.14.13.20,R03997 R05407
catechol,cpd:C03591,5-Chloro-3-methylcatechol,C7H7ClO2,NA,NA,NA,NA,NA
catechol,cpd:C03929,3-tert-Butyl-5-methylcatechol,C11H16O2,NA,NA,NA,NA,NA
catechol,cpd:C04798,"5-Amino-4-chloro-2-(2,3-dihydroxyphenyl)-3(2H)-pyridazinone;Chloridazon catechol;5-Amino-4-chloro-2-(2',3'-dihydroxyphenyl)-3(2H)-pyridazinone",C10H8ClN3O3,NA,NA,NA,1.13.11.36,R04602
catechol,cpd:C05618,3-Chlorocatechol,C6H5ClO2,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.119;1.13.11.39;1.13.11.-,R06839 R06857 R07827
catechol,cpd:C05801,2-Hexaprenyl-6-hydroxyphenol;3-Hexaprenylcatechol,C36H54O2,NA,NA,NA,1.14.13.-;2.1.1.-,R04980 R04981
catechol,cpd:C05811,2-Octaprenyl-6-hydroxyphenol;3-Octaprenylcatechol,C46H70O2,NA,NA,NA,1.14.13.240;2.1.1.222,R04987 R04988
catechol,cpd:C06336,"3-Sulfocatechol;2,3-Dihydroxybenzenesulfonate",C6H6O5S,Benzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.13.11.2;1.14.12.14,R05156 R07795
catechol,cpd:C06674,4-Sulfocatechol,C6H6O5S,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.13.11.-;1.14.12.-,R05278 R05279
catechol,cpd:C06727,"cis-1,2-Dihydro-3-ethylcatechol;cis-2,3-Dihydroxy-2,3-dihydroethylbenzene;cis-3-Ethyl-cyclohexa-3,5-diene-1,2-diol",C8H12O2,Ethylbenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.66;1.14.12.-,R05313 R05440
catechol,cpd:C06728,"3-Ethylcatechol;2,3-Dihydroxyethylbenzene;3-Ethyl-benzene-1,2-diol",C8H10O2,Ethylbenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.66;1.13.11.-,R05313 R05416
catechol,cpd:C06730,"4-Methylcatechol;3,4-Dihydroxytoluene;1,2-Dihydroxy-4-methylbenzene;4-Methyl-1,2-benzenediol",C7H8O2,Xylene degradation;Toluene degradation;Naphthalene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol;Catechol meta-cleavage, catechol => acetyl-CoA / 4-methylcatechol => propanoyl-CoA",NA,1.3.1.67;1.13.11.1;1.13.11.2;1.14.12.14;1.14.13.1;1.14.13.7,R03568 R05292 R05293 R05294 R05295 R05299 R06939
catechol,cpd:C07085,3-Vinylcatechol,C8H8O2,Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.19;1.13.11.2,R05354 R05404
catechol,cpd:C07094,"3,6-Dichlorocatechol",C6H4Cl2O2,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.119;1.13.11.-,R05397 R05409
catechol,cpd:C12127,(+)-Gallocatechin;Gallocatechol,C15H14O7,Flavonoid biosynthesis;Biosynthesis of secondary metabolites,NA,"Lipids [BR:br08002]; PK  Polyketides;  PK12 Flavonoids;   PK1202 Flavans, Flavanols and Leucoanthocyanidins;    C12127  (+)-Gallocatechin;Phytochemical compounds [BR:br08003]; Flavonoids;  Flavonoids;   Flavan 3-ols;    C12127  (+)-Gallocatechin",1.17.1.3,R06533
catechol,cpd:C12136,(-)-Epigallocatechin;Epigallocatechol,C15H14O7,Flavonoid biosynthesis;Biosynthesis of secondary metabolites,NA,"Lipids [BR:br08002]; PK  Polyketides;  PK12 Flavonoids;   PK1202 Flavans, Flavanols and Leucoanthocyanidins;    C12136  (-)-Epigallocatechin;Phytochemical compounds [BR:br08003]; Flavonoids;  Flavonoids;   Flavan 3-ols;    C12136  (-)-Epigallocatechin;Dietary phytochemicals [br08012.html]; Flavonoids;  C12136",1.3.1.77,R06543
catechol,cpd:C12831,"3,4,6-Trichlorocatechol",C6H3Cl3O2,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.119;1.13.11.-,R06832 R06833
catechol,cpd:C13626,5-Hydroxybisphenol A;5-Hydroxybisphenol;BPAcatechol,C15H16O3,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,NA,R06881 R06882
catechol,cpd:C14110,"4-Hydroxymethylcatechol;3,4-Dihydroxybenzyl alcohol",C7H8O3,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,1.14.13.1,R06936
catechol,cpd:C14243,"3,3'-Dihydroxyhexestrol;4,4'-(1,2-Diethylethylene)dipyrocatechol",C18H22O4,NA,NA,NA,NA,NA
catechol,cpd:C14843,4-Bromocatechol,C6H5BrO2,Metabolism of xenobiotics by cytochrome P450,NA,NA,NA,R07076 R07077 R07078
catechol,cpd:C15571,Catechol,C6H6O2,NA,NA,NA,2.1.1.6,R07330
catechol,cpd:C16472,3-Fluorocatechol,C6H5FO2,Fluorobenzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.25;1.3.1.-;1.13.11.1,R08111 R08114 R08123
catechol,cpd:C16473,4-Fluorocatechol,C6H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.25;1.3.1.-;1.13.11.1,R08105 R08112 R08113 R08115
catechol,cpd:C17551,"2-Polyprenyl-6-hydroxyphenol;3-Polyprenylcatechol;3-(all-trans-Polyprenyl)benzene-1,2-diol",C11H14O2(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol",NA,1.14.13.240;2.1.1.222,R08768 R08769
catechol,cpd:C18240,"Tetrachlorocatechol;Tetrachloro-1,2-benzenediol",C6H2Cl4O2,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.-;1.13.11.1,R09132 R09133 R09134
catechol,cpd:C18302,"4,6-Dichloro-3-methylcatechol",C7H6Cl2O2,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.-;1.13.11.-,R09213 R09214
catechol,cpd:C18315,4-Methyl-5-nitrocatechol,C7H7NO4,Nitrotoluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.24;1.14.13.210,R09233 R09234 R11150
catechol,cpd:C18351,"4-Aminocatechol;4-Amino-1,2-benzenediol;3,4-Dihydroxyaniline",C6H7NO2,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,5.4.4.3,R09284 R09285
catechol,cpd:C21801,(+)-Demethylpiperitol;Sesamin monocatechol,C19H18O6,NA,NA,NA,2.1.5.1,R11955 R11956
catechol,cpd:C21802,(+)-Didemethylpinoresinol;Sesamin dicatechol,C18H18O6,NA,NA,NA,2.1.5.1,R11956
catechol,cpd:C22355,"Benzo[a]pyrene-7,8-diol;Benzo[a]pyrene-7,8-catechol;B[a]P-7,8-catechol",C20H12O2,Chemical carcinogenesis - reactive oxygen species,NA,NA,NA,NA
cycloleucine,cpd:C03969,1-Aminocyclopentanecarboxylate;1-Aminocyclopentanecarboxylic acid;Cycloleucine,C6H11NO2,NA,NA,NA,NA,NA
D-galactaric acid,cpd:C00879,D-Galactarate;D-Mucic acid;D-Galactaric acid;Galactaric acid;Galactarate;Mucic acid,C6H10O8,Ascorbate and aldarate metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C00879  Galactaric acid,2.3.1.130;4.2.1.42;4.2.1.158,R01981 R03727 R05608 R11077
D-glucuronic acidM,NA,NA,NA,NA,NA,NA,NA,NA
D-lyxosylamine NIST,NA,NA,NA,NA,NA,NA,NA,NA
Docosanol NIST,NA,NA,NA,NA,NA,NA,NA,NA
fructose,cpd:C00085,D-Fructose 6-phosphate;D-Fructose 6-phosphoric acid;Neuberg ester,C6H13O9P,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Fructose and mannose metabolism;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Methane metabolism;Carbon fixation in photosynthetic organisms;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars;AMPK signaling pathway;Glucagon signaling pathway;Insulin resistance;Central carbon metabolism in cancer;Diabetic cardiomyopathy","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Gluconeogenesis, oxaloacetate => fructose-6P;Pentose phosphate pathway (Pentose phosphate cycle);Pentose phosphate pathway, non-oxidative phase, fructose 6P => ribose 5P;Ascorbate biosynthesis, plants, fructose-6P => ascorbate;Reductive pentose phosphate cycle (Calvin cycle);Formaldehyde assimilation, xylulose monophosphate pathway;Formaldehyde assimilation, ribulose monophosphate pathway;Pentose phosphate pathway, archaea, fructose 6P => ribose 5P;UDP-N-acetyl-D-glucosamine biosynthesis, eukaryotes, glucose => UDP-GlcNAc;UDP-N-acetyl-D-glucosamine biosynthesis, prokaryotes, glucose => UDP-GlcNAc",NA,1.1.1.17;1.1.1.140;2.2.1.1;2.2.1.2;2.4.1.14;2.4.1.246;2.6.1.16;2.7.1.1;2.7.1.4;2.7.1.11;2.7.1.61;2.7.1.90;2.7.1.105;2.7.1.146;3.1.3.11;3.1.3.46;3.5.99.6;4.1.2.22;5.1.3.40;5.1.3.-;5.3.1.8;5.3.1.9;5.3.1.27,R00756 R00758 R00760 R00761 R00762 R00763 R00764 R00765;R00766 R00767 R00768 R00769 R00770 R00771 R00772 R00876;R01067 R01140 R05339 R05805 R06073 R07133 R08406 R08575;R08947 R09031 R11623 R13199 R13202
fructose,cpd:C00095,D-Fructose;Levulose;Fruit sugar;D-arabino-Hexulose,C6H12O6,Fructose and mannose metabolism;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of nucleotide sugars;ABC transporters;Phosphotransferase system (PTS);Taste transduction;Insulin resistance;Carbohydrate digestion and absorption;Diabetic cardiomyopathy,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C00095  D-Fructose; Fruit sugar;Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  964  Saccharide preparations and blood substitutes;   9642  Fructose and preparations;    C00095  D-Fructose,1.1.1.11;1.1.1.14;1.1.1.15;1.1.1.67;1.1.1.124;1.1.1.138;1.1.2.2;1.1.5.14;1.1.99.28;2.4.1.4;2.4.1.5;2.4.1.7;2.4.1.13;2.4.1.125;2.4.1.362;2.4.1.372;2.4.1.373;2.7.1.1;2.7.1.3;2.7.1.4;2.7.1.61;2.7.1.202;3.1.3.68;3.1.3.-;3.2.1.10;3.2.1.20;3.2.1.26;3.2.1.48;3.2.1.80;3.2.1.219;5.1.3.30;5.1.3.31;5.3.1.5;5.3.1.7,R00760 R00801 R00803 R00806 R00865 R00866 R00867 R00868;R00870 R00872 R00873 R00874 R00875 R00876 R00877 R00878;R00879 R01140 R01823 R02120 R02410 R03232 R03635 R03921;R06034 R06036 R06052 R06066 R06087 R06100 R06101 R06208;R08406 R08407 R08548 R08651 R08676 R10817 R12349 R12527;R12528 R13126
fructose,cpd:C00273,5-Dehydro-D-fructose,C6H10O6,NA,NA,NA,1.1.1.123;1.1.1.124;1.1.3.11;1.1.5.14;1.1.99.12,R00871 R00873 R01694 R01695 R01696 R08651
fructose,cpd:C00354,"D-Fructose 1,6-bisphosphate",C6H14O12P2,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Fructose and mannose metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Methane metabolism;Carbon fixation in photosynthetic organisms;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Phosphotransferase system (PTS);AMPK signaling pathway;Glucagon signaling pathway;Central carbon metabolism in cancer","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Gluconeogenesis, oxaloacetate => fructose-6P;Reductive pentose phosphate cycle (Calvin cycle);Formaldehyde assimilation, xylulose monophosphate pathway;Formaldehyde assimilation, ribulose monophosphate pathway",NA,2.2.1.11;2.7.1.11;2.7.1.56;2.7.1.90;2.7.1.146;3.1.3.11;4.1.2.13,R00756 R00762 R00764 R00767 R00769 R00770 R01068 R05805;R09100 R10049 R13203
fructose,cpd:C00665,"beta-D-Fructose 2,6-bisphosphate;D-Fructose 2,6-bisphosphate",C6H14O12P2,Fructose and mannose metabolism;Metabolic pathways;AMPK signaling pathway;Glucagon signaling pathway;Central carbon metabolism in cancer,NA,NA,2.7.1.105;3.1.3.46;3.1.3.54,R00763 R02730 R02731 R02732 R13202
fructose,cpd:C00861,L-Rhamnulose;6-Deoxy-L-fructose,C6H12O5,Fructose and mannose metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,2.7.1.5;5.3.1.14,R02437 R03014
fructose,cpd:C01094,D-Fructose 1-phosphate,C6H13O9P,"Fructose and mannose metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments;Phosphotransferase system (PTS)",NA,NA,2.2.1.11;2.7.1.3;2.7.1.56;2.7.1.61;2.7.1.202;3.1.3.68;4.1.2.13,R00866 R02071 R02568 R03232 R08407 R08548 R10050 R13203
fructose,cpd:C01496,Fructose;arabino-Hexulose,NA,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; V VARIOUS;  V06 GENERAL NUTRIENTS;   V06D OTHER NUTRIENTS;    V06DC Carbohydrates;     V06DC02 Fructose;      C01496  Fructose,NA,NA
fructose,cpd:C01711,Inulobiose;1-O-beta-D-Fructo-furanosyl-D-fructose,C12H22O11,NA,NA,NA,4.2.1.178;4.2.1.179,R03685 R12927
fructose,cpd:C01719,L-Fructose;L-arabino-Hexulose,C6H12O6,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C01719  L-Fructose,1.1.1.15,R08536
fructose,cpd:C02336,beta-D-Fructose;beta-Fruit sugar;beta-D-arabino-Hexulose;beta-Levulose;Fructose,C6H12O6,NA,NA,NA,2.7.1.1;2.7.1.4;3.2.1.20;3.2.1.26;3.2.1.48;3.2.1.218,R00802 R03920 R06088 R06102 R13128
fructose,cpd:C03267,beta-D-Fructose 2-phosphate;beta-D-Fructofuranose 2-phosphate,C6H13O9P,Fructose and mannose metabolism;Metabolic pathways,NA,NA,3.1.3.54;3.1.3.-,R00872 R02730
fructose,cpd:C04333,"Bis-D-fructose 2',1:2,1'-dianhydride;Difructose anhydride I",C12H20O10,NA,NA,NA,4.2.1.179,R03685 R06161
fructose,cpd:C04420,"alpha-D-Fructofuranose-beta-D-fructofuranose 2',1:2,3'-dianhydride;Di-D-fructofuranose 1,2':2,3'-dianhydride;Difructose anhydride III",C12H20O10,NA,NA,NA,4.2.1.178,R12927
fructose,cpd:C05001,Fructose 1-phosphate(pyranose),C6H13O9P,NA,NA,NA,NA,NA
fructose,cpd:C05003,D-Fructose;D-arabino-Hex-2-ulopyranose,C6H12O6,NA,NA,NA,NA,NA
fructose,cpd:C05345,beta-D-Fructose 6-phosphate;beta-D-Fructofuranose 6-phosphate,C6H13O9P,NA,NA,NA,1.1.1.17;1.1.1.140;2.2.1.1;2.2.1.2;2.2.1.14;2.4.1.329;2.7.1.1;2.7.1.4;2.7.1.11;2.7.1.90;2.7.1.105;2.7.1.146;3.1.3.11;3.1.3.46;5.3.1.8;5.3.1.9;5.3.1.27,R00867 R01819 R01827 R01830 R02073 R02703 R02731 R02732;R02740 R03321 R03920 R04779 R04780 R05607 R09084 R09780;R10987 R12731
fructose,cpd:C05378,"beta-D-Fructose 1,6-bisphosphate",C6H14O12P2,NA,NA,NA,2.7.1.11;2.7.1.56;2.7.1.90;2.7.1.146;3.1.3.11;4.1.2.13,R01070 R02071 R02073 R04779 R04780 R09084
fructose,cpd:C06468,D-Psicose;D-ribo-Hex-2-ulose;D-ribo-2-Hexulose;D-ribo-2-Ketohexulose;D-erythro-Hexulose;D-Pseudofructose;D-Allulose;D-Altrulose,C6H12O6,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C06468  D-Psicose,5.1.3.30;5.1.3.31,R10817
fructose,cpd:C06485,"1,5-Anhydro-D-fructose",C6H10O5,NA,NA,NA,1.1.1.263;1.1.1.292;4.2.1.110;4.2.1.111,R05682 R08194 R09694 R09696
fructose,cpd:C08238,alpha-Galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-glucosyl-(1-2)-beta-fructose;Ajugose,C36H62O31,NA,NA,NA,NA,NA
fructose,cpd:C10906,D-Fructose,C6H12O6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00114)]; V VARIOUS;  V06 GENERAL NUTRIENTS;   V06D OTHER NUTRIENTS;    V06DC Carbohydrates;     V06DC02 Fructose;      D00114  Fructose (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00114)]; 3  Agents affecting metabolism;  32  Nutrients, tonics;   323  Saccharide preparations;    3232  Fructoses;     D00114  Fructose (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00114)]; Chemicals;  D00114  Fructose;  D00114  Fructose injection",1.1.1.124;2.4.1.13,R00871 R07256
fructose,cpd:C12214,Aminofructose 6-phosphate;Amino-D-fructose 6-phosphate,C6H14NO8P,Biosynthesis of ansamycins;Biosynthesis of secondary metabolites,NA,NA,2.2.1.1;5.3.1.-,R06589 R06590
fructose,cpd:C16488,Fructoselysine;N6-(D-Fructosyl)-L-lysine,C12H24N2O7,Phosphotransferase system (PTS),NA,NA,2.7.1.218;5.1.3.41,R08124 R11720
fructose,cpd:C16489,Fructoselysine 6-phosphate,C12H25N2O10P,Phosphotransferase system (PTS),NA,NA,2.7.1.218;3.5.-.-,R08124 R08125
fructose,cpd:C16848,"6-Deoxy-5-ketofructose 1-phosphate;1-Deoxy-D-threo-hexo-2,5-diulose 6-phosphate",C6H11O8P,"Phenylalanine, tyrosine and tryptophan biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites",NA,NA,2.2.1.10;2.2.1.11,R08568 R10049 R10050
fructose,cpd:C18050,beta-D-Fructofuranosyl-alpha-D-mannopyranoside 6F-phosphate;Mannosylfructose 6-phosphate,C12H23O14P,NA,NA,NA,2.4.1.246;3.1.3.79,R08947 R08982
fructose,cpd:C18068,beta-D-Fructofuranosyl-alpha-D-mannopyranoside;Mannosylfructose,C12H22O11,NA,NA,NA,3.1.3.79,R08982
fructose,cpd:C19633,Maltulose;4-O-alpha-D-Glucopyranosyl-D-fructose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19633  Maltulose,NA,NA
fructose,cpd:C19634,Melibiulose;6-O-alpha-D-Galactopyranosyl-D-fructose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19634  Melibiulose,NA,NA
fructose,cpd:C19636,Turanose;3-O-alpha-D-Glucopyranosyl-D-fructose;D-Turanose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19636  Turanose,NA,NA
fructose,cpd:C20830,6-Deoxy-6-sulfo-D-fructose,C6H12O8S,NA,NA,NA,2.2.1.14;2.2.1.15;2.7.1.184;5.3.1.31,R10765 R10970 R12731 R13000
fructose,cpd:C20831,6-Deoxy-6-sulfo-D-fructose 1-phosphate,C6H13O11PS,NA,NA,NA,2.7.1.184;4.1.2.57,R10760 R10970
fructose,cpd:C21364,[Fructose-bisphosphate aldolase]-L-lysine,C7H13N3O2R2,NA,NA,NA,NA,NA
fructose,cpd:C21365,"[Fructose-bisphosphate aldolase]-N6,N6,N6-trimethyl-L-lysine",C10H20N3O2R2,NA,NA,NA,NA,NA
fructose,cpd:C22310,Fructose 3-phosphate,C6H13O9P,Diabetic cardiomyopathy,NA,NA,NA,NA
fructose,cpd:C22502,alpha-D-Fructofuranose;alpha-D-Fructose,C6H12O6,NA,NA,NA,5.3.1.5,R00307
glycerol 3-phosphate,cpd:C00093,sn-Glycerol 3-phosphate;Glycerophosphoric acid;D-Glycerol 1-phosphate,C3H9O6P,Glycerolipid metabolism;Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;ABC transporters;Choline metabolism in cancer,Triacylglycerol biosynthesis,Risk category of Japanese OTC drugs [BR:br08312]; Third-class OTC drugs;  Inorganic and organic chemicals;   Calcium glycerophosphate;    C00093  sn-Glycerol 3-phosphate,1.1.1.8;1.1.1.94;1.1.1.177;1.1.3.21;1.1.5.3;2.3.1.15;2.3.1.198;2.3.1.275;2.4.1.96;2.4.1.137;2.4.1.213;2.7.1.30;2.7.1.142;2.7.7.39;2.7.8.5;3.1.3.21;3.1.4.2;3.1.4.3;3.1.4.44;3.1.4.46;3.1.4.-;3.6.1.16,R00841 R00842 R00844 R00845 R00846 R00847 R00848 R00849;R00850 R00851 R00853 R00854 R00855 R00856 R00857 R01030;R01193 R01470 R01801 R02027 R02617 R05328 R06872 R08657;R09380 R12241
glycerol 3-phosphate,cpd:C00416,"Phosphatidate;Phosphatidic acid;1,2-Diacyl-sn-glycerol 3-phosphate;3-sn-Phosphatidate",C5H7O8PR2,Glycerolipid metabolism;Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;cAMP signaling pathway;Phosphatidylinositol signaling system;Phospholipase D signaling pathway;Fc gamma R-mediated phagocytosis;GnRH signaling pathway;Fat digestion and absorption;Pathways in cancer;Pancreatic cancer;Choline metabolism in cancer,"Triacylglycerol biosynthesis;Phosphatidylethanolamine (PE) biosynthesis, PA => PS => PE","Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C00416  Phosphatidic acid;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1001 Diacylglycerophosphates;    C00416  1,2-Diacyl-sn-glycerol 3-phosphate",2.3.1.51;2.3.1.52;2.7.1.107;2.7.1.174;2.7.7.41;3.1.1.118;3.1.3.4;3.1.4.4;3.1.4.50;3.6.1.26;3.6.1.75,R01310 R01797 R01799 R02051 R02239 R02240 R02241 R02242;R02760 R04149 R06623 R07398 R09381 R09644 R09944 R12796
glycerol 3-phosphate,cpd:C00681,1-Acyl-sn-glycerol 3-phosphate;2-Lysophosphatidate;Lysophosphatidate;Lysophosphatidic acid,C4H8O7PR,Glycerolipid metabolism;Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Phospholipase D signaling pathway;Neuroactive ligand-receptor interaction;Gap junction;Regulation of actin cytoskeleton;Fat digestion and absorption;Vitamin digestion and absorption;Pathogenic Escherichia coli infection;Pathways in cancer,Triacylglycerol biosynthesis,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1005 Monoacylglycerophosphates;    C00681  1-Acyl-sn-glycerol 3-phosphate,1.1.1.101;2.3.1.15;2.3.1.51;2.3.1.275;2.7.1.94;3.1.3.2;3.1.3.106,R00851 R02241 R02617 R02756 R02757 R02760 R09380 R09381;R11527 R12241
glycerol 3-phosphate,cpd:C01264,2-Acetyl-1-alkyl-sn-glycero-3-phosphate;1-Alkyl-2-acetyl-sn-glycero-3-phosphate;1-Alkyl-2-acetyl-sn-glycerol 3-phosphate,C5H10O7PR,Ether lipid metabolism;Metabolic pathways,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1002 1-alkyl,2-acylglycerophosphates;    C01264  1-Alkyl-2-acetyl-sn-glycerol 3-phosphate",2.3.1.105;3.1.3.59,R03454 R03455
glycerol 3-phosphate,cpd:C03189,DL-Glycerol 1-phosphate;Glycerol 1-phosphate;Glycerol-3-phosphate;rac-Glycerol 1-phosphate;DL-Glyceryl 1-phosphate;DL-Glycerol 3-phosphate,C3H9O6P,NA,NA,NA,3.1.3.21;3.1.4.42,R02648 R08658
glycerol 3-phosphate,cpd:C03506,"Indoleglycerol phosphate;1-C-(Indol-3-yl)glycerol 3-phosphate;(3-Indolyl)-glycerol phosphate;C1-(3-Indolyl)-glycerol 3-phosphate;(1S,2R)-1-C-(Indol-3-yl)glycerol 3-phosphate;Indole-3-glycerol phosphate",C11H14NO6P,"Phenylalanine, tyrosine and tryptophan biosynthesis;Benzoxazinoid biosynthesis;Indole diterpene alkaloid biosynthesis;Biosynthesis of various plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of amino acids","Tryptophan biosynthesis, chorismate => tryptophan;Paspaline biosynthesis, geranylgeranyl-PP + indoleglycerol phosphate => paspaline;Benzoxazinoid biosynthesis, indoleglycerol phosphate => DIMBOA-glucoside",NA,4.1.1.48;4.1.2.8;4.2.1.20,R02340 R02722 R03508 R10349
glycerol 3-phosphate,cpd:C03849,Acyl-sn-glycerol 3-phosphate,NA,NA,NA,NA,2.7.1.94,R03754
glycerol 3-phosphate,cpd:C03892,"Phosphatidylglycerophosphate;1-(3-sn-Phosphatidyl)-sn-glycerol 3-phosphate;3-(3-Phosphatidyl)-D-glycerol 1-phosphate;1,2-Diacyl-sn-glycero-3-phospho-sn-glycerol 3'-phosphate",C8H14O13P2R2,Glycerophospholipid metabolism;Metabolic pathways,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP05 Glycerophosphoglycerophosphates;   GP0501 Diacylglycerophosphoglycerophosphates;    C03892  1,2-Diacyl-sn-glycero-3-phospho-sn-glycerol 3'-phosphate",2.7.8.5;3.1.3.27,R01801 R02029
glycerol 3-phosphate,cpd:C03968,1-Alkyl-sn-glycero-3-phosphate;1-Alkyl-sn-glycerol 3-phosphate;1-O-Alkyl-sn-glycerol 3-phosphate,C3H8O6PR,Ether lipid metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1006 Monoalkylglycerophosphates;    C03968  1-Alkyl-sn-glycerol 3-phosphate,1.1.1.101;2.3.1.105;2.3.1.-;2.7.1.93;3.1.4.39,R03455 R04126 R04360 R04361 R04362
glycerol 3-phosphate,cpd:C03974,2-Acyl-sn-glycerol 3-phosphate,C4H8O7PR,Glycerophospholipid metabolism;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1005 Monoacylglycerophosphates;    C03974  2-Acyl-sn-glycerol 3-phosphate,2.3.1.52;2.3.1.198;2.7.1.94;3.1.1.118,R02242 R02758 R06872 R12796
glycerol 3-phosphate,cpd:C04036,1-Palmitoylglycerol 3-phosphate;1-Hexadecanoyl-sn-glycero-3-phosphate,C19H39O7P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1005 Monoacylglycerophosphates;    C04036  1-Hexadecanoyl-sn-glycero-3-phosphate,1.1.1.101,R03357
glycerol 3-phosphate,cpd:C04641,2-(alpha-D-Galactosyl)-sn-glycerol 3-phosphate,C9H19O11P,NA,NA,NA,2.4.1.137,R00853
glycerol 3-phosphate,cpd:C04666,D-erythro-1-(Imidazol-4-yl)glycerol 3-phosphate;D-erythro-Imidazole-glycerol 3-phosphate;D-erythro-Imidazole-glycerol phosphate,C6H11N2O6P,Histidine metabolism;Biosynthesis of alkaloids derived from histidine and purine;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of amino acids,"Histidine biosynthesis, PRPP => histidine",NA,4.2.1.19;4.3.2.10,R03457 R04558 R12152
glycerol 3-phosphate,cpd:C04703,"alpha-D-Galactosyl-(1,1')-sn-glycerol 3-phosphate;1-O-alpha-D-Galactosyl-sn-glycerol 3-phosphate",C9H19O11P,NA,NA,NA,2.4.1.96,R00854
glycerol 3-phosphate,cpd:C05977,2-Acyl-1-alkyl-sn-glycero-3-phosphate;1-Alkyl-2-acyl-sn-glycerol 3-phosphate,C4H7O7PR2,Ether lipid metabolism;Metabolic pathways,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1002 1-alkyl,2-acylglycerophosphates;    C05977  1-Alkyl-2-acyl-sn-glycerol 3-phosphate",2.3.1.-;3.1.3.4,R04162 R04361
glycerol 3-phosphate,cpd:C10517,2-(alpha-D-Glucosyl)-sn-glycerol 3-phosphate,C9H19O11P,NA,NA,NA,2.4.1.213;3.1.3.69,R05328 R05791
glycerol 3-phosphate,cpd:C13889,1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate;1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol 3-phosphate,C37H71O8P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP10 Glycerophosphates;   GP1001 Diacylglycerophosphates;    C13889  1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate,NA,NA
Glyceryl-glycoside NIST,NA,NA,NA,NA,NA,NA,NA,NA
Heptanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
hydrocinnamic acid,cpd:C00166,Phenylpyruvate;Phenylpyruvic acid;alpha-Ketohydrocinnamic acid;keto-Phenylpyruvate;3-Phenyl-2-oxopropanoate;2-Oxo-3-phenylpropanoate,C9H8O3,"Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;D-Amino acid metabolism;Tropane, piperidine and pyridine alkaloid biosynthesis;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Phenylalanine biosynthesis, chorismate => phenylpyruvate => phenylalanine",NA,1.1.1.110;1.1.1.237;1.4.1.20;1.4.3.2;1.4.5.1;1.13.11.27;2.1.1.281;2.3.3.-;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.21;2.6.1.28;2.6.1.57;2.6.1.58;2.6.1.64;2.6.1.70;2.6.1.-;4.1.1.43;4.1.1.-;4.2.1.51;4.2.1.91;5.3.2.1,R00688 R00689 R00692 R00694 R00695 R01370 R01371 R01372;R01373 R01374 R01375 R01376 R01377 R01378 R01582 R10431;R10499 R10500 R11068
hydrocinnamic acid,cpd:C02763,2-Hydroxy-3-phenylpropenoate;enol-Phenylpyruvate;enol-Phenylpyruvic acid;enol-alpha-Ketohydrocinnamic acid,C9H8O3,Phenylalanine metabolism;Metabolic pathways,NA,NA,5.3.2.1,R01378
lactic acid,cpd:C00186,(S)-Lactate;L-Lactate;L-Lactic acid,C3H6O3,Glycolysis / Gluconeogenesis;Fructose and mannose metabolism;Pyruvate metabolism;Propanoate metabolism;Styrene degradation;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;cAMP signaling pathway;HIF-1 signaling pathway;Efferocytosis;Glucagon signaling pathway;Central carbon metabolism in cancer,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Hydroxycarboxylic acids;    C00186  L-Lactate; (S)-2-Hydroxypropanoate,1.1.1.27;1.1.1.436;1.1.2.3;1.1.3.2;1.1.99.7;1.2.1.22;1.13.12.4;2.8.3.1;3.7.1.26;4.1.1.101;4.1.2.36;5.1.2.1,R00196 R00319 R00703 R00753 R01446 R01447 R01449 R01450;R05508 R10691 R11074 R11996 R13050
lactic acid,cpd:C00256,(R)-Lactate;D-Lactate;D-Lactic acid;D-2-Hydroxypropanoic acid;D-2-Hydroxypropionic acid,C3H6O3,Pyruvate metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Vancomycin resistance,NA,NA,1.1.1.28;1.1.1.436;1.1.2.4;1.1.2.5;1.1.5.12;1.1.99.6;1.1.99.40;1.2.1.23;3.1.2.6;3.1.6.17;4.2.1.126;4.2.1.130;5.1.2.1;6.1.2.1,R00197 R00198 R00297 R00704 R01448 R01450 R01735 R01736;R08555 R09588 R09796 R11591 R11593 R13049
lactic acid,cpd:C00491,L-Cystine;L-Dicysteine;L-alpha-Diamino-beta-dithiolactic acid,C6H12N2O4S2,Cysteine and methionine metabolism;Metabolic pathways;ABC transporters;Ferroptosis;Protein digestion and absorption,NA,Risk category of Japanese OTC drugs [BR:br08312(D03636)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Cystine;    D03636  Cystine (USAN/INN);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D03636)]; Chemicals;  D03636  L-Cystine,1.8.1.6;1.8.4.3;1.8.4.4;4.4.1.1;4.4.1.13;4.4.1.35,R00892 R01113 R02408 R02409
lactic acid,cpd:C01207,"3-(3,4-Dihydroxyphenyl)lactate;3,4-Dihydroxyphenyllactic acid",C9H10O5,NA,NA,NA,NA,NA
lactic acid,cpd:C01420,Cystine;Dicysteine;alpha-Diamino-beta-dithiolactic acid,C6H12N2O4S2,NA,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C01420  Cystine,1.8.4.4,R01109
lactic acid,cpd:C01432,Lactate;Lactic acid;2-Hydroxypropanoic acid;2-Hydroxypropionic acid,C3H6O3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00111)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;   G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;    G01AD Organic acids;     G01AD01 Lactic acid;      D00111  Lactic acid (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00111)]; 7  Agents not mainly for therapeutic purpose;  71  Dispensing medicines;   714  Flavorings, deodorants, coloring agents;    7149  Others;     D00111  Lactic acid (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00111)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Lactic acid;    D00111  Lactic acid (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00111)]; Chemicals;  D00111  Lactic acid",1.1.1.436;3.5.1.124,R11562 R11563 R11564 R11676
lactic acid,cpd:C05568,Imidazole lactate;Imidazole lactic acid;2-Hydroxy-3-(1H-imidazol-5-yl)-propanoic acid,C6H8N2O3,Histidine metabolism;Metabolic pathways,NA,NA,NA,R04876
Lignoceric acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
L-lysine,cpd:C00047,"L-Lysine;Lysine acid;2,6-Diaminohexanoic acid",C6H14N2O2,"Lysine biosynthesis;Lysine degradation;D-Amino acid metabolism;Biotin metabolism;Tropane, piperidine and pyridine alkaloid biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;ABC transporters;Protein digestion and absorption","Lysine biosynthesis, succinyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, AAA pathway, 2-oxoglutarate => 2-aminoadipate => lysine;Lysine biosynthesis, mediated by LysW, 2-aminoadipate => lysine;Lysine degradation, lysine => saccharopine => acetoacetyl-CoA;Lysine biosynthesis, acetyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, DAP dehydrogenase pathway, aspartate => lysine;Lysine biosynthesis, DAP aminotransferase pathway, aspartate => lysine;Ethynylserine biosynthesis, lysine => ethynylserine;Aerobactin biosynthesis, lysine => aerobactin;Lysine degradation, bacteria, L-lysine => succinate;Lysine degradation, bacteria, L-lysine => glutarate => succinate/acetyl-CoA;Lysine degradation, bacteria, L-lysine => D-lysine => succinate",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00047  Lysine (Lys);Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02304)]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05X I.V. SOLUTION ADDITIVES;    B05XB Amino acids;     B05XB03 Lysine;      D02304  Lysine (USAN/INN);Risk category of Japanese OTC drugs [BR:br08312(D02304)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Lysine;    D02304  Lysine (USAN/INN),1.4.1.15;1.4.1.18;1.4.3.14;1.4.3.20;1.5.1.7;1.5.1.8;1.5.1.16;1.5.3.4;1.13.12.2;1.14.13.59;1.14.20.-;2.1.3.8;2.1.4.3;2.3.1.32;2.3.1.306;2.6.1.36;2.6.1.71;2.6.1.105;3.4.13.4;3.4.14.13;3.5.1.12;3.5.1.17;3.5.1.130;3.5.2.11;3.5.-.-;4.1.1.18;4.1.1.20;4.3.1.28;4.3.2.8;5.1.1.5;5.1.1.10;5.4.3.2;5.4.99.58;6.1.1.6;6.3.2.7;6.3.2.11;6.3.2.20;6.3.2.59;6.3.4.19,R00445 R00446 R00447 R00448 R00449 R00451 R00452 R00453;R00454 R00457 R00458 R00459 R00460 R00461 R00462 R00463;R00545 R00612 R00715 R00716 R00910 R00911 R01077 R01396;R01620 R02786 R03095 R03658 R07598 R07646 R08125 R09597;R09779 R10010 R10011 R10054 R10277 R10699 R11190 R11862;R12407 R12506
L-lysine,cpd:C00449,"N6-(L-1,3-Dicarboxypropyl)-L-lysine;Saccharopine;L-Saccharopine;N-[(S)-5-Amino-5-carboxypentyl]-L-glutamic acid",C11H20N2O6,Lysine biosynthesis;Lysine degradation;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of amino acids,"Lysine biosynthesis, AAA pathway, 2-oxoglutarate => 2-aminoadipate => lysine;Lysine degradation, lysine => saccharopine => acetoacetyl-CoA",NA,1.5.1.7;1.5.1.8;1.5.1.9;1.5.1.10;1.5.3.18,R00715 R00716 R02313 R02315 R09495
L-lysine,cpd:C01028,N6-Hydroxy-L-lysine,C6H14N2O3,Biosynthesis of various other secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,"Aerobactin biosynthesis, lysine => aerobactin",NA,1.14.13.59;2.3.1.102,R00448 R03168
L-lysine,cpd:C01211,"Procollagen 5-hydroxy-L-lysine;Procollagen L-erythro-5-hydroxylysine;[Procollagen]-(2S,5R)-5-hydroxy-L-lysine",C7H13N3O3R2,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.4;2.4.1.50,R03376 R03380
L-lysine,cpd:C01242,[Protein]-S8-aminomethyldihydrolipoyllysine;[H-protein]-S-aminomethyldihydrolipoyllysine;S-Aminomethyldihydrolipoylprotein;[Glycine-cleavage complex H protein]-S-aminomethyl-N6-dihydrolipoyl-L-lysine;[GCSH]-S-aminomethyl-N6-dihydrolipoyl-L-lysine;[GcvH]-S-aminomethyl-N6-dihydrolipoyl-L-lysine,C9H19N2OS2R,"Glycine, serine and threonine metabolism;Lipoic acid metabolism;Metabolic pathways",Glycine cleavage system,NA,1.4.4.2;2.1.2.10,R03425 R04125
L-lysine,cpd:C01259,"(3S)-3-Hydroxy-N6,N6,N6-trimethyl-L-lysine",C9H21N2O3,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.8;4.1.2.-,R03284 R03451
L-lysine,cpd:C01997,Histone N6-acetyl-L-lysine;Acetylhistone,C9H15N3O3R2,NA,NA,NA,2.3.1.48;2.3.1.286,R03552 R10633
L-lysine,cpd:C02051,Lipoylprotein;[H-protein]-lipoyllysine;[GCSH]-N6-lipoyl-L-lysine;[GcvH]-N6-lipoyl-L-lysine;[Glycine cleavage system H]-N6-lipoyl-L-lysine;[Glycine-cleavage complex H protein]-N6-lipoyl-L-lysine,C8H14NOS2R,"Glycine, serine and threonine metabolism;Lipoic acid metabolism;Metabolic pathways",Glycine cleavage system,NA,1.4.4.2;1.8.1.4;2.3.1.200;6.3.1.20,R03425 R03815 R12426 R12433
L-lysine,cpd:C02188,Protein lysine;Peptidyl-L-lysine;[Protein]-L-lysine,C7H13N3O2R2,Lysine degradation;Metabolic pathways,NA,NA,1.4.3.13;1.14.11.4;1.14.11.27;1.14.11.63;1.14.11.65;1.14.11.67;1.14.99.66;2.1.1.59;2.1.1.60;2.1.1.354;2.1.1.355;2.1.1.356;2.1.1.357;2.1.1.359;2.1.1.360;2.1.1.361;2.1.1.364;2.1.1.367;2.1.1.368;2.1.1.369;2.1.1.370;2.1.1.371;2.1.1.372;2.3.1.286;2.6.1.121;3.5.1.119;3.5.1.124;6.3.1.19,R03376 R03875 R03876 R04239 R09511 R10056 R10634 R11207;R11208 R11563 R12315 R12461 R12462 R12464 R12935 R12948;R12949 R12952
L-lysine,cpd:C02415,Histone-L-lysine,C7H13N3O2R2,NA,NA,NA,2.3.1.48;2.3.1.286,R03552 R03938 R10633
L-lysine,cpd:C02444,N6-Acyl-L-lysine,C7H13N2O3R,NA,NA,NA,3.5.1.17,R00545
L-lysine,cpd:C02727,N6-Acetyl-L-lysine,C8H16N2O3,Lysine degradation;Metabolic pathways,NA,NA,2.3.1.32;2.3.1.306;2.6.1.65;3.5.1.17,R00454 R00458 R01620 R04029
L-lysine,cpd:C02728,N6-Methyl-L-lysine,C7H16N2O2,NA,NA,NA,1.5.3.4,R00612
L-lysine,cpd:C02816,Calmodulin L-lysine,C7H13N3O2R2,NA,NA,NA,2.1.1.60,R04062
L-lysine,cpd:C02837,"L-Lysine 1,6-lactam;L-2-Aminohexano-6-lactam;L-alpha-Aminocaprolactam;(S)-2-Aminohexano-6-lactam",C6H12N2O,NA,NA,NA,3.5.2.11;5.1.1.15,R00463 R04736
L-lysine,cpd:C02972,Dihydrolipoylprotein;[H-protein]-dihydrolipoyllysine;[GCSH]-N6-[(R)-dihydrolipoyl]-L-lysine;[GcvH]-N6-[(R)-dihydrolipoyl]-L-lysine;[Glycine cleavage system H]-N6-[(R)-dihydrolipoyl]-L-lysine,C8H16NOS2R,"Glycine, serine and threonine metabolism;Lipoic acid metabolism;Metabolic pathways;Biosynthesis of cofactors","Glycine cleavage system;Lipoic acid biosynthesis, plants and bacteria, octanoyl-ACP => dihydrolipoyl-E2/H;Lipoic acid biosynthesis, eukaryotes, octanoyl-ACP => dihydrolipoyl-H;Lipoic acid biosynthesis, animals and bacteria, octanoyl-ACP => dihydrolipoyl-H => dihydrolipoyl-E2",NA,1.8.1.4;2.1.2.10;2.8.1.8,R03815 R04125 R12424 R12432 R12691
L-lysine,cpd:C03105,Cytochrome c L-lysine,C7H13N3O2R2,NA,NA,NA,2.1.1.59,R04145
L-lysine,cpd:C03318,[alpha-Tubulin]-L-lysine,C7H13N3O2R2,NA,NA,NA,2.3.1.108,R04192
L-lysine,cpd:C03366,5-Phosphooxy-L-lysine;(5R)-5-Phosphooxy-L-lysine;5-Phosphonooxy-L-lysine;O-Phosphohydroxy-L-lysine;(5R)-5-Phosphonooxy-L-lysine,C6H15N2O6P,Lysine degradation;Metabolic pathways,NA,NA,2.7.1.81;4.2.3.134,R03378 R10270
L-lysine,cpd:C03702,Histone N6-methyl-L-lysine,C8H15N3O2R2,NA,NA,NA,NA,R03938
L-lysine,cpd:C03793,"N6,N6,N6-Trimethyl-L-lysine",C9H20N2O2,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.8;3.4.-.-,R03451 R04313
L-lysine,cpd:C03941,Calmodulin N6-methyl-L-lysine,C8H15N3O2R2,NA,NA,NA,2.1.1.60,R04062
L-lysine,cpd:C03955,N6-Acetyl-N6-hydroxy-L-lysine;N6-Acetyl-N6-hydroxylysine,C8H16N2O4,Biosynthesis of various other secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,"Aerobactin biosynthesis, lysine => aerobactin",NA,2.3.1.102;6.3.2.38;6.3.2.39,R03168 R10090 R10091
L-lysine,cpd:C04020,D-Lysopine;N2-(D-1-Carboxyethyl)-L-lysine;Lysopine,C9H18N2O4,Lysine degradation,NA,NA,1.5.1.16,R00452
L-lysine,cpd:C04061,Cytochrome c N6-methyl-L-lysine,C8H15N3O2R2,NA,NA,NA,2.1.1.59,R04145
L-lysine,cpd:C04149,[alpha-Tubulin]-N6-acetyl-L-lysine,C9H15N3O3R2,NA,NA,NA,2.3.1.108,R04192
L-lysine,cpd:C04211,N(6)-[(Indol-3-yl)acetyl]-L-lysine;N6-[(Indol-3-yl)acetyl]-L-lysine,C16H21N3O3,NA,NA,NA,6.3.2.20,R03095
L-lysine,cpd:C04419,Carboxybiotin-carboxyl-carrier protein;[Biotin carboxyl-carrier protein]-carboxybiotin-N6-L-lysine;[Biotin carboxyl-carrier protein]-N6-carboxybiotinyl-L-lysine,C18H26N5O6SR2,NA,NA,NA,2.1.3.15;6.3.4.14,R04385 R04386
L-lysine,cpd:C04487,5-(D-Galactosyloxy)-L-lysine-procollagen;Procollagen 5-(D-galactosyl)-L-lysine;Procollagen 5-(D-galactosyloxy)-L-lysine;Procollagen beta-D-galactosyl-L-hydroxylysine,C13H23N3O8R2,Lysine degradation;Metabolic pathways,NA,NA,2.4.1.50;2.4.1.66,R03380 R04491
L-lysine,cpd:C04679,Protein N6-[(R)-4-amino-2-hydroxybutyl]-L-lysine;[eIF5A-precursor]-hypusine,C11H22N4O3R2,NA,NA,NA,1.14.99.29,R04437
L-lysine,cpd:C04700,UDP-N-acetylmuramoyl-L-alanyl-alpha-D-glutamyl-L-lysine,C34H55N7O24P2,NA,NA,NA,NA,NA
L-lysine,cpd:C04759,"1,2-D-Glucosyl-5-D-(galactosyloxy)-L-lysine-procollagen;Procollagen alpha-D-glucosyl-1,2-beta-D-galactosyl-L-hydroxylysine",C19H33N3O13R2,NA,NA,NA,2.4.1.66,R04491
L-lysine,cpd:C04876,N-Acetyl-D-glucosaminyl-N-acetylmuramoyl-L-Ala-D-glutamyl-6-carboxy-L-lysine,C33H54N6O20,NA,NA,NA,NA,NA
L-lysine,cpd:C05341,beta-Alanyl-L-lysine,C9H19N3O3,beta-Alanine metabolism;Metabolic pathways,NA,NA,3.4.13.4;6.3.2.11,R00910 R00911
L-lysine,cpd:C05544,Protein N6-methyl-L-lysine,C8H15N3O2R2,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.27;1.14.11.65;1.14.11.66;1.14.11.67;1.14.11.68;1.14.11.69;1.14.99.66;2.1.1.59;2.1.1.60;2.1.1.354;2.1.1.355;2.1.1.356;2.1.1.357;2.1.1.359;2.1.1.360;2.1.1.361;2.1.1.362;2.1.1.364;2.1.1.367;2.1.1.368;2.1.1.369;2.1.1.370;2.1.1.371;2.1.1.372,R03875 R04866 R09510 R09511 R12459 R12463 R12464
L-lysine,cpd:C05545,"Protein N6,N6-dimethyl-L-lysine",C9H17N3O2R2,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.27;1.14.11.65;1.14.11.66;1.14.11.67;1.14.11.68;1.14.11.69;1.14.99.66;2.1.1.59;2.1.1.60;2.1.1.354;2.1.1.355;2.1.1.356;2.1.1.357;2.1.1.359;2.1.1.360;2.1.1.362;2.1.1.366;2.1.1.368;2.1.1.370;2.1.1.371;2.1.1.372,R04866 R04867 R09510 R10056 R12460 R12462 R12463
L-lysine,cpd:C05546,"Protein N6,N6,N6-trimethyl-L-lysine",C10H20N3O2R2,Lysine degradation;Metabolic pathways,NA,NA,1.14.11.66;1.14.11.67;1.14.11.68;1.14.11.69;2.1.1.59;2.1.1.60;2.1.1.354;2.1.1.355;2.1.1.356;2.1.1.359;2.1.1.360;2.1.1.366;2.1.1.372;3.4.-.-,R04313 R04867 R12459 R12460 R12461
L-lysine,cpd:C05552,Biocytin;N6-D-Biotinyl-L-lysine;epsilon-N-Biotinyl-L-lysine,C16H28N4O4S,Biotin metabolism;Metabolic pathways;Vitamin digestion and absorption,NA,NA,3.4.-.-;3.5.1.12,R01077 R04869
L-lysine,cpd:C05892,UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysine;UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysine;UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-gamma-D-glutamyl-L-lysine,C34H55N7O24P2,Peptidoglycan biosynthesis;Metabolic pathways;Vancomycin resistance,NA,NA,6.3.2.7;6.3.2.10,R02786 R04573
L-lysine,cpd:C06249,Apo-[carboxylase];[Biotin carboxyl-carrier protein]-L-lysine,C7H13N3O2R2,NA,NA,NA,6.3.4.9;6.3.4.10;6.3.4.11;6.3.4.15,R05145
L-lysine,cpd:C06250,Holo-[carboxylase];Biotin-carboxyl-carrier protein;[Biotin carboxyl-carrier protein]-biotin-N6-L-lysine;[Biotin carboxyl-carrier protein]-N6-biotinyl-L-lysine,C17H27N5O4SR2,Biotin metabolism;Metabolic pathways,NA,NA,2.1.3.15;3.4.-.-;6.3.4.9;6.3.4.10;6.3.4.11;6.3.4.14;6.3.4.15,R04385 R04386 R04869 R05145
L-lysine,cpd:C06403,"[Ribulose-1,5-bisphosphate carboxylase]-L-lysine;[Ribulose-bisphosphate carboxylase large chain]-L-lysine;[RbcL]-L-lysine",C7H13N3O2R2,NA,NA,NA,2.1.1.127,R05179
L-lysine,cpd:C06404,"[Ribulose-1,5-bisphosphate carboxylase]-N6,N6,N6-trimethyl-L-lysine;[Ribulose-bisphosphate carboxylase large chain]-N6,N6,N6-trimethyl-L-lysine;[RbcL]-trimethyl-L-lysine",C10H20N3O2R2,NA,NA,NA,2.1.1.127,R05179
L-lysine,cpd:C06446,"2-N,6-N-Bis(2,3-dihydroxybenzoyl)-L-lysine",C20H22N2O8,NA,NA,NA,NA,NA
L-lysine,cpd:C06447,"2-N,6-N-Bis(2,3-dihydroxybenzoyl)-L-lysine amide",C20H23N3O7,NA,NA,NA,NA,NA
L-lysine,cpd:C07105,Lys-vasopressin;Lypressin;8-L-Lysine vasopressin;LVP,C46H65N13O12S2,NA,NA,"Bioactive peptides [BR:br08005]; Pituitary hormones;  Posterior pituitary hormone;   C07105  Lys-vasopressin;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00366)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES;   H01B POSTERIOR PITUITARY LOBE HORMONES;    H01BA Vasopressin and analogues;     H01BA03 Lypressin;      D00366  Lypressin (USAN/INN);Drug groups [BR:br08330(D00366)]; Cardiovascular agent;  DG01952  Vasopressin analog;   D00366  Lypressin;Target-based classification of drugs [BR:br08310(D00366)]; G Protein-coupled receptors;  Rhodopsin family;   Vasopressin;    AVPR1;     D00366  Lypressin (USAN/INN);    AVPR2;     D00366  Lypressin (USAN/INN)",NA,NA
L-lysine,cpd:C07282,[eIF5A-precursor]-deoxyhypusine;Protein N6-(4-Aminobutyl)-L-lysine,C11H22N4O2R2,NA,NA,NA,1.14.99.29;2.5.1.46,R04437 R05329 R07478
L-lysine,cpd:C08440,Phaseolotoxin;N5-[Amino(sulfoamino)phosphinyl]-L-ornithyl-L-alanyl-N6-(aminoiminomethyl)-L-lysine,C15H34N9O8PS,NA,NA,NA,NA,NA
L-lysine,cpd:C12989,N2-Acetyl-L-lysine;N(alpha)-Acetyllysine,C8H16N2O3,NA,NA,NA,NA,NA
L-lysine,cpd:C15972,Enzyme N6-(lipoyl)lysine;Lipoamide-E;[E2 protein]-N6-lipoyl-L-lysine;[Lipoyl-carrier protein E2]-N6-lipoyl-L-lysine,C8H14NOS2R,"Glycolysis / Gluconeogenesis;Citrate cycle (TCA cycle);Valine, leucine and isoleucine degradation;Lysine degradation;Pyruvate metabolism;Propanoate metabolism;Lipoic acid metabolism;Metabolic pathways;Biosynthesis of cofactors","Citrate cycle (TCA cycle, Krebs cycle);Citrate cycle, second carbon oxidation, 2-oxoglutarate => oxaloacetate;Lysine degradation, lysine => saccharopine => acetoacetyl-CoA;Leucine degradation, leucine => acetoacetate + acetyl-CoA;Pyruvate oxidation, pyruvate => acetyl-CoA",NA,1.2.4.1;1.2.4.2;1.2.4.4;1.2.4.-;1.8.1.4;1.11.1.28;2.3.1.200;2.3.1.313;6.3.1.20,R01699 R01700 R01701 R01702 R01940 R03270 R03316 R04225;R07600 R07602 R07604 R07618 R10997 R12426 R12435 R12449;R12450 R12603 R13167 R13186
L-lysine,cpd:C15973,Enzyme N6-(dihydrolipoyl)lysine;Dihydrolipoamide-E;[E2 protein]-N6-[(R)-dihydrolipoyl]-L-lysine;[Lipoyl-carrier protein E2]-N6-[(R)-dihydrolipoyl]-L-lysine,C8H16NOS2R,"Glycolysis / Gluconeogenesis;Citrate cycle (TCA cycle);Valine, leucine and isoleucine degradation;Lysine degradation;Pyruvate metabolism;Propanoate metabolism;Lipoic acid metabolism;Metabolic pathways;Biosynthesis of cofactors","Citrate cycle (TCA cycle, Krebs cycle);Citrate cycle, second carbon oxidation, 2-oxoglutarate => oxaloacetate;Lysine degradation, lysine => saccharopine => acetoacetyl-CoA;Leucine degradation, leucine => acetoacetate + acetyl-CoA;Pyruvate oxidation, pyruvate => acetyl-CoA;Lipoic acid biosynthesis, plants and bacteria, octanoyl-ACP => dihydrolipoyl-E2/H;Lipoic acid biosynthesis, animals and bacteria, octanoyl-ACP => dihydrolipoyl-H => dihydrolipoyl-E2;Lipoic acid biosynthesis, octanoyl-CoA => dihydrolipoyl-E2",NA,1.8.1.4;1.11.1.28;2.3.1.12;2.3.1.61;2.3.1.168;2.8.1.8,R02569 R02570 R02571 R02662 R03174 R04097 R07618 R10998;R12423 R12432 R12603
L-lysine,cpd:C16236,[Protein]-N6-(octanoyl)-L-lysine;Protein N6-(octanoyl)lysine,C8H16NOR,NA,NA,NA,2.3.1.181;2.8.1.8,R07766 R07767
L-lysine,cpd:C16240,[Lipoyl-carrier protein]-L-lysine;Apoprotein,NH2R,NA,NA,NA,2.3.1.181;2.3.1.313;6.3.1.20,R07766 R07769 R07771 R11143 R13186
L-lysine,cpd:C16488,Fructoselysine;N6-(D-Fructosyl)-L-lysine,C12H24N2O7,Phosphotransferase system (PTS),NA,NA,2.7.1.218;5.1.3.41,R08124 R11720
L-lysine,cpd:C16740,Procollagen L-lysine,C7H13N3O2R2,NA,NA,NA,NA,NA
L-lysine,cpd:C16741,L-Hydroxylysine;5-Hydroxy-L-lysine;L-erythro-5-Hydroxylysine;(5R)-5-Hydroxy-L-lysine,C6H14N2O3,Lysine degradation;Metabolic pathways,NA,NA,2.7.1.81,R03378
L-lysine,cpd:C16742,allo-Hydroxy-L-lysine;Allohydroxy-L-lysine,C6H14N2O3,NA,NA,NA,NA,NA
L-lysine,cpd:C16743,Phosphoallohydroxy-L-lysine,C6H15N2O6P,NA,NA,NA,NA,NA
L-lysine,cpd:C16832,[Protein]-N6-[(R)-dihydrolipoyl]-L-lysine;[Lipoyl-carrier protein]-N6-[(R)-dihydrolipoyl]-L-lysine;Protein N6-(dihydrolipoyl)lysine,C8H16NOS2R,NA,NA,NA,1.8.1.4;1.11.1.28;2.8.1.8,R07767 R08550 R12602
L-lysine,cpd:C19889,LysW-gamma-L-lysine,C11H20N3O5R,Lysine biosynthesis;Metabolic pathways;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids,"Lysine biosynthesis, mediated by LysW, 2-aminoadipate => lysine",NA,2.6.1.118;3.5.1.130,R09778 R09779
L-lysine,cpd:C20278,"(2R,3R)-3-Methylornithinyl-N6-lysine;N6-[(3R)-3-Methyl-D-ornithinyl]-L-lysine",C12H26N4O3,Lysine biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.4.1.-;6.3.2.59,R10011 R10012
L-lysine,cpd:C20333,N2-Citryl-N6-acetyl-N6-hydroxy-L-lysine;N2-Citryl-N6-acetyl-N6-hydroxylysine,C14H22N2O10,Biosynthesis of various other secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,"Aerobactin biosynthesis, lysine => aerobactin",NA,6.3.2.38;6.3.2.39,R10090 R10091
L-lysine,cpd:C20743,Protein N6-acetyl-L-lysine;Acetylprotein;[Protein]-N6-acetyl-L-lysine,C9H15N3O3R2,NA,NA,NA,2.3.1.286,R10634
L-lysine,cpd:C21160,L-Alanyl-gamma-D-glutamyl-L-lysine;L-Ala-gamma-D-Glu-L-Lys,C14H26N4O6,NA,NA,NA,3.4.14.13,R11190
L-lysine,cpd:C21178,Pupylated protein;N6-([Prokaryotic ubiquitin-like protein]-gamma-L-glutamyl)-[protein]-L-lysine,C12H19N4O5R3,NA,NA,NA,3.5.1.119;6.3.1.19,R11207 R11208
L-lysine,cpd:C21364,[Fructose-bisphosphate aldolase]-L-lysine,C7H13N3O2R2,NA,NA,NA,NA,NA
L-lysine,cpd:C21365,"[Fructose-bisphosphate aldolase]-N6,N6,N6-trimethyl-L-lysine",C10H20N3O2R2,NA,NA,NA,NA,NA
L-lysine,cpd:C21467,Protein N6-(1-hydroxy-2-oxopropyl)-L-lysine;[Protein]-N6-(1-hydroxy-2-oxopropyl)-L-lysine,C10H17N3O4R2,NA,NA,NA,3.5.1.124,R11563
L-lysine,cpd:C21616,Psicoselysine;N6-(D-Psicosyl)-L-lysine,C12H24N2O7,NA,NA,NA,5.1.3.41,R11720
L-lysine,cpd:C21730,epsilon-(gamma-L-Glutamyl)-L-lysine,C11H21N3O5,NA,NA,NA,4.3.2.8,R11862
L-lysine,cpd:C22076,[Protein]-(3S)-3-hydroxy-L-lysine,C7H13N3O3R2,NA,NA,NA,1.14.11.63,R12315
L-lysine,cpd:C22137,4-Chloro-L-lysine,C6H13ClN2O2,Biosynthesis of various other secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites,"Ethynylserine biosynthesis, lysine => ethynylserine",NA,1.14.20.-;1.14.99.-,R12407 R12408
L-lysine,cpd:C22157,Glycine cleavage system H;[Glycine cleavage system H]-L-lysine;[GcvH]-L-lysine;[GCSH]-L-lysine,NH2R,NA,NA,NA,2.3.1.181;2.3.1.200;2.3.1.204;6.3.1.20,R12425 R12426 R12428 R12432 R12433
L-lysine,cpd:C22158,Lipoyl-carrier protein E2;[Lipoyl-carrier protein E2]-L-lysine;[E2 protein]-L-lysine,NH2R,NA,NA,NA,2.3.1.181;2.3.1.200;2.3.1.204;2.3.1.-;6.3.1.20,R12425 R12426 R12427 R12429 R12431 R12432 R12435 R12449;R12450
L-lysine,cpd:C22159,[Glycine cleavage system H]-N6-octanoyl-L-lysine;[GcvH]-N6-octanoyl-L-lysine;[GCSH]-N6-octanoyl-L-lysine,C8H16NOR,Lipoic acid metabolism;Metabolic pathways;Biosynthesis of cofactors,"Lipoic acid biosynthesis, plants and bacteria, octanoyl-ACP => dihydrolipoyl-E2/H;Lipoic acid biosynthesis, eukaryotes, octanoyl-ACP => dihydrolipoyl-H;Lipoic acid biosynthesis, animals and bacteria, octanoyl-ACP => dihydrolipoyl-H => dihydrolipoyl-E2",NA,2.3.1.181;2.3.1.204;2.8.1.8,R12424 R12425 R12428 R12691
L-lysine,cpd:C22160,[Lipoyl-carrier protein E2]-N6-octanoyl-L-lysine;[E2 protein]-N6-octanoyl-L-lysine,C8H16NOR,Lipoic acid metabolism;Metabolic pathways;Biosynthesis of cofactors,"Lipoic acid biosynthesis, plants and bacteria, octanoyl-ACP => dihydrolipoyl-E2/H;Lipoic acid biosynthesis, octanoyl-CoA => dihydrolipoyl-E2",NA,2.3.1.181;2.3.1.204;2.3.1.-;2.8.1.8;6.3.1.20,R12423 R12425 R12427 R12429 R12431
L-lysine,cpd:C22465,"[Protein]-N6-[(2S,3R)-2-amino-8-carboxyoctan-3-yl]-L-lysine",C16H30N4O4R2,NA,NA,NA,2.6.1.121,R12949 R12950 R12952 R12953
L-ornithine,cpd:C00077,"L-Ornithine;(S)-2,5-Diaminovaleric acid;(S)-2,5-Diaminopentanoic acid;(S)-2,5-Diaminopentanoate",C5H12N2O2,"Arginine biosynthesis;Arginine and proline metabolism;D-Amino acid metabolism;Glutathione metabolism;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;ABC transporters;Efferocytosis","Proline biosynthesis, glutamate => proline;Ornithine biosynthesis, glutamate => ornithine;Urea cycle;Polyamine biosynthesis, arginine => ornithine => putrescine;Ornithine biosynthesis, mediated by LysW, glutamate => ornithine;Cycloserine biosynthesis, arginine/serine => cycloserine;Arginine biosynthesis, ornithine => arginine;Staphyloferrin A biosynthesis, L-ornithine => staphyloferrin A;Proline metabolism",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00077  L-Ornithine,1.5.1.24;1.14.13.195;1.14.13.196;2.1.3.3;2.1.4.1;2.1.4.2;2.1.4.3;2.3.1.35;2.3.1.127;2.3.2.30;2.6.1.13;3.5.1.14;3.5.1.16;3.5.1.20;3.5.1.132;3.5.3.1;3.5.3.25;4.1.1.17;4.3.1.12;5.1.1.9;5.1.1.10;5.1.1.12,R00551 R00565 R00664 R00665 R00666 R00667 R00668 R00669;R00670 R00671 R00672 R01343 R01398 R01686 R01989 R02282;R03477 R05547 R10466 R10789 R10790 R10933 R11801 R12506
L-ornithine,cpd:C00437,N-Acetylornithine;N2-Acetyl-L-ornithine,C7H14N2O3,Arginine biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids,"Ornithine biosynthesis, glutamate => ornithine;Arginine biosynthesis, glutamate => acetylcitrulline => arginine",NA,2.1.3.9;2.3.1.35;2.6.1.11;3.5.1.14;3.5.1.16,R00669 R02282 R02283 R07245
L-ornithine,cpd:C02858,N5-Acyl-L-ornithine,C6H11N2O3R,NA,NA,NA,3.1.1.48,R04070
L-ornithine,cpd:C03415,N2-Succinyl-L-ornithine;(2S)-5-Amino-2-(3-carboxypropanoylamino)pentanoic acid,C9H16N2O5,Arginine and proline metabolism;Metabolic pathways,"Arginine succinyltransferase pathway, arginine => glutamate",NA,2.1.3.11;2.6.1.81;3.5.3.23,R04189 R04217 R08937
L-ornithine,cpd:C03625,N5-Acyl-L-ornithine ester,C6H10N2O3R2,NA,NA,NA,3.1.1.48,R04070
L-ornithine,cpd:C03712,"N2,N5-Dibenzoyl-L-ornithine;L-Ornithuric acid",C19H20N2O4,NA,NA,NA,2.3.1.127,R00664
L-ornithine,cpd:C04210,N5-(L-1-Carboxyethyl)-L-ornithine,C8H16N2O4,NA,NA,NA,1.5.1.24,R00666
L-ornithine,cpd:C04541,N5-Dinitrophenyl-L-ornithine methyl ester,C18H20N4O6,NA,NA,NA,NA,NA
L-ornithine,cpd:C05945,L-Arginine phosphate;N5-[Imino(phosphonoamino)methyl]L-ornithine;omega-N-Phosphoarginine;Arginine phosphate;L-Arginine-NG-phosphoric acid;Phosphoarginine A;N-Phospho-L-arginine;N(omega)-Phospho-L-arginine;Phosphoarginine,C6H15N4O5P,Arginine and proline metabolism,NA,NA,2.7.3.3,R00554
L-ornithine,cpd:C07997,"Eflornithine;DL-Ornithine, 2-(difluoromethyl)-",C6H12F2N2O2,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07883)]; D DERMATOLOGICALS;  D11 OTHER DERMATOLOGICAL PREPARATIONS;   D11A OTHER DERMATOLOGICAL PREPARATIONS;    D11AX Other dermatologicals;     D11AX16 Eflornithine;      D07883  Eflornithine (INN); L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L01 ANTINEOPLASTIC AGENTS;   L01X OTHER ANTINEOPLASTIC AGENTS;    L01XX Other antineoplastic agents;     L01XX79 Eflornithine;      D07883  Eflornithine (INN); P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS;  P01 ANTIPROTOZOALS;   P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS;    P01CX Other agents against leishmaniasis and trypanosomiasis;     P01CX03 Eflornithine;      D07883  Eflornithine (INN);Target-based classification of drugs [BR:br08310(D07883)]; Enzymes;  Lyases (EC4);   Carboxy-lyases;    ODC1;     D07883  Eflornithine (INN);Antimicrobials [BR:br08307(D07883)]; Antiparasitics;  Agents against Leishmaniasis and Trypanosomiasis;   Others;    D07883  Eflornithine (INN)",NA,NA
L-ornithine,cpd:C20850,N5-Hydroxy-L-ornithine;delta-N-Hydroxyornithine,C5H12N2O3,NA,NA,NA,1.14.13.195;1.14.13.196;4.8.1.1,R10789 R10790 R12913
L-ornithine,cpd:C20951,LysW-L-ornithine,C10H18N3O5R,Arginine biosynthesis;Metabolic pathways;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids,"Ornithine biosynthesis, mediated by LysW, glutamate => ornithine",NA,2.6.1.-;3.5.1.132,R10932 R10933
L-tyrosine,cpd:C00082,L-Tyrosine;(S)-3-(p-Hydroxyphenyl)alanine;(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid;Tyrosine,C9H11NO3,"Ubiquinone and other terpenoid-quinone biosynthesis;Monobactam biosynthesis;Tyrosine metabolism;Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Novobiocin biosynthesis;Cyanoamino acid metabolism;Methane metabolism;Thiamine metabolism;Phenylpropanoid biosynthesis;Isoquinoline alkaloid biosynthesis;Betalain biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of vancomycin group antibiotics;Biosynthesis of enediyne antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Dopaminergic synapse;Melanogenesis;Prolactin signaling pathway;Protein digestion and absorption;Parkinson disease;Cocaine addiction;Amphetamine addiction;Alcoholism;Central carbon metabolism in cancer","Tyrosine biosynthesis, chorismate => HPP => tyrosine;Monolignol biosynthesis, phenylalanine/tyrosine => monolignol;Tyrosine biosynthesis, chorismate => arogenate => tyrosine;Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline;Thyroid hormone biosynthesis, tyrosine => triiodothyronine/thyroxine;Tyrosine degradation, tyrosine => homogentisate;Thiamine biosynthesis, prokaryotes, AIR (+ DXP/tyrosine) => TMP/TPP;Cyanogenic glycoside biosynthesis, tyrosine => dhurrin;C-1027 beta-amino acid moiety biosynthesis, tyrosine => 3-chloro-4,5-dihydroxy-beta-phenylalanyl-PCP;Maduropeptin beta-hydroxy acid moiety biosynthesis, tyrosine => 3-(4-hydroxyphenyl)-3-oxopropanoyl-PCP;Puromycin biosynthesis, ATP => puromycin;Methanofuran biosynthesis;Betacyanin biosynthesis, L-tyrosine => amaranthin",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00082  Tyrosine (Tyr);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00022)]; Chemicals;  D00022  L-Tyrosine,1.2.1.101;1.3.1.43;1.3.1.78;1.3.1.79;1.4.1.20;1.4.3.2;1.10.3.1;1.11.1.8;1.11.2.6;1.14.14.36;1.14.16.1;1.14.16.2;1.14.18.1;1.14.-.-;1.21.1.1;2.1.1.304;2.5.1.122;2.5.1.147;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.57;2.6.1.58;2.6.1.103;4.1.1.25;4.1.1.28;4.1.1.108;4.1.99.2;4.1.99.19;4.1.99.24;4.3.1.23;4.3.1.25;5.4.3.6;6.1.1.1;6.3.2.24;6.3.2.25,R00031 R00728 R00729 R00730 R00731 R00732 R00733 R00734;R00735 R00736 R00737 R00739 R01795 R01815 R02078 R02918;R03539 R04730 R05671 R06626 R06751 R07211 R07212 R08825;R09254 R09521 R09830 R10059 R10246 R10671 R10964 R10968;R11366 R11917 R12150 R12161 R12235 R12540 R12541 R12611;R12759 R13031
L-tyrosine,cpd:C00355,"3,4-Dihydroxy-L-phenylalanine;L-Dopa;3-Hydroxy-L-tyrosine;L-beta-(3,4-Dihydroxyphenyl)alanine;Levodopa;Dihydroxy-L-phenylalanine",C9H11NO4,Tyrosine metabolism;Isoquinoline alkaloid biosynthesis;Betalain biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Dopaminergic synapse;Prolactin signaling pathway;Parkinson disease;Cocaine addiction;Amphetamine addiction;Alcoholism,"Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline;Betacyanin biosynthesis, L-tyrosine => amaranthin","Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00355  3,4-Dihydroxy-L-phenylalanine; Hormones and transmitters;  Neurotransmitters;   Amino acids;    C00355  Dopa;Prodrugs [br08324.html]; C00355;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00059)]; N NERVOUS SYSTEM;  N04 ANTI-PARKINSON DRUGS;   N04B DOPAMINERGIC AGENTS;    N04BA Dopa and dopa derivatives;     N04BA01 Levodopa;      D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00059)]; Antiparkinson Agents;  Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors;   Levodopa;    D00059  Levodopa (JP18/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D00059)]; 1  Agents affecting nervous system and sensory organs;  11  Agents affecting central nervous system;   116  Antiparkinsonian agents;    1164  Levodopas;     D00059  Levodopa (JP18/USP/INN);Drug groups [BR:br08330(D00059)]; Neuropsychiatric agent;  DG01472  Dopamine agonist;   D00059  Levodopa;  DG01967  Antiparkinson agent;   D00059  Levodopa;Drug classes [BR:br08332(D00059)]; Neuropsychiatric agent;  DG01967  Antiparkinson agent;   D00059  Levodopa;Target-based classification of drugs [BR:br08310(D00059)]; G Protein-coupled receptors;  Rhodopsin family;   Dopamine;    DRD;     D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00059)]; Chemicals;  D00059  Levodopa;New drug approvals in Europe [br08329.html(D00059)]; European public assessment reports (EPAR) authorised medicine;  D00059;Prodrugs [br08324.html(D00059)]; D00059",1.10.3.1;1.11.2.6;1.13.11.29;1.13.11.30;1.13.11.-;1.13.12.15;1.14.16.2;1.14.18.1;1.14.-.-;2.6.1.49;4.1.1.25;4.1.1.28;4.1.1.107;4.3.1.22,R00031 R00045 R00731 R01815 R02075 R02076 R02077 R02078;R02080 R03672 R07212 R08443 R08827 R08836 R08846 R08920;R11916 R12541 R12611 R13031 R13032
L-tyrosine,cpd:C00585,Protein tyrosine;[Protein]-L-tyrosine,C10H10N2O3R2,NA,NA,NA,2.7.10.1;2.7.10.2;2.7.10.3;2.7.12.1;2.7.12.2;2.8.2.20;3.1.3.48,R02584 R02585 R02586
L-tyrosine,cpd:C01060,"3,5-Diiodo-L-tyrosine;3,5-Diiodotyrosine;L-Diiodotyrosine",C9H9I2NO3,Tyrosine metabolism;Metabolic pathways;Thyroid hormone synthesis,"Thyroid hormone biosynthesis, tyrosine => triiodothyronine/thyroxine","Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C01060  3,5-Diiodo-L-tyrosine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H03 THYROID THERAPY;   H03B ANTITHYROID PREPARATIONS;    H03BX Other antithyroid preparations;     H03BX01 Diiodotyrosine;      C01060  3,5-Diiodo-L-tyrosine",1.11.1.8;1.21.1.1;2.6.1.24,R03207 R03208 R03953 R03973 R09522 R10059
L-tyrosine,cpd:C01167,Protein tyrosine phosphate;[Protein]-L-tyrosine phosphate,C10H11N2O6PR2,NA,NA,NA,2.7.10.1;2.7.10.2;2.7.10.3;2.7.12.1;2.7.12.2;3.1.3.48,R02584 R02585
L-tyrosine,cpd:C01281,[L-Glutamate:ammonia ligase (ADP-forming)];[L-Glutamate:ammonia ligase (ADP-forming)]-L-tyrosine;[Glutamine synthetase]-L-tyrosine,C10H10N2O3R2,NA,NA,NA,2.7.7.42;2.7.7.89,R03473 R03474
L-tyrosine,cpd:C01299,Adenylyl-[L-glutamate:ammonia ligase (ADP-forming)];[L-Glutamate:ammonia ligase (ADP-forming)] inactive form;[L-Glutamate:ammonia ligase (ADP-forming)]-O4-(5'-adenylyl)-L-tyrosine;[Glutamine synthetase]-O4-(5'-adenylyl)-L-tyrosine,C20H22N7O9PR2,NA,NA,NA,2.7.7.42;2.7.7.89,R03473 R03474
L-tyrosine,cpd:C01657,Ac-Tyr-OEt;N-Acetyl-L-tyrosine ethyl ester;Ethyl N-alpha-acetyl-tyrosinate,C13H17NO4,NA,NA,NA,NA,NA
L-tyrosine,cpd:C01829,"Thyroxine;Levothyroxin;L-Thyroxine;O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine;3,5,3'5'-Tetraiodo-L-thyronine;T4",C15H11I4NO4,Tyrosine metabolism;Metabolic pathways;Neuroactive ligand-receptor interaction;Thyroid hormone synthesis;Thyroid hormone signaling pathway;Bile secretion;Autoimmune thyroid disease,"Thyroid hormone biosynthesis, tyrosine => triiodothyronine/thyroxine",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C01829  L-Thyroxine; Hormones and transmitters;  Other hormones;   Thyroid hormones;    C01829  Thyroxine;  Neurotransmitters;   Amino acids;    C01829  Thyroxine;Drug groups [BR:br08330(D08125)]; Hormonal agent;  DG01953  Thyroid preparation;   DG01608  Thyroid hormone replenisher;    DG00510  Levothyroxine;     D08125  Levothyroxine;Target-based classification of drugs [BR:br08310(D08125)]; Nuclear receptors;  Thyroid hormone like receptors;   Thyroid hormone receptor (THR);    NR1A (THR);     D08125  Levothyroxine (BAN),1.11.1.8;1.21.99.3;1.21.99.4,R03208 R03734 R07230 R08525
L-tyrosine,cpd:C02515,3-Iodo-L-tyrosine,C9H10INO3,Tyrosine metabolism;Metabolic pathways;Thyroid hormone synthesis,"Thyroid hormone biosynthesis, tyrosine => triiodothyronine/thyroxine",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C02515  3-Iodo-L-tyrosine,1.11.1.8;1.21.1.1,R03539 R03953 R03973 R09521 R09522
L-tyrosine,cpd:C03004,N-Hydroxy-L-tyrosine,C9H11NO4,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,"Cyanogenic glycoside biosynthesis, tyrosine => dhurrin",NA,1.14.14.36,R00730 R04460
L-tyrosine,cpd:C03224,"3,5-Dibromo-L-tyrosine",C9H9Br2NO3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08659)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H03 THYROID THERAPY;   H03B ANTITHYROID PREPARATIONS;    H03BX Other antithyroid preparations;     H03BX02 Dibromotyrosine;      D08659  3,5-Dibromo-L-tyrosine;Drug groups [BR:br08330(D08659)]; Hormonal agent;  DG01934  Antithyroid agent;   D08659  3,5-Dibromo-L-tyrosine",NA,NA
L-tyrosine,cpd:C03225,"3,5-Dinitro-L-tyrosine",C9H9N3O7,NA,NA,NA,NA,NA
L-tyrosine,cpd:C03347,"3,5-Dichloro-L-tyrosine",C9H9Cl2NO3,NA,NA,NA,NA,NA
L-tyrosine,cpd:C03404,L-Tyrosine methyl ester,C10H13NO3,NA,NA,NA,2.8.2.9,R04213
L-tyrosine,cpd:C04201,L-Tyrosine methyl ester 4-sulfate,C10H13NO6S,NA,NA,NA,2.8.2.9,R04213
L-tyrosine,cpd:C15503,"N,N-Dihydroxy-L-tyrosine",C9H11NO5,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,"Cyanogenic glycoside biosynthesis, tyrosine => dhurrin",NA,1.14.14.36,R04460 R07190
L-tyrosine,cpd:C16731,"[Thyroglobulin]-3,5-diiodo-L-tyrosine",C10H8I2N2O3R2,NA,NA,NA,1.11.1.8,R08521 R08522 R08523
L-tyrosine,cpd:C16732,[Thyroglobulin]-3-iodo-L-tyrosine,C10H9IN2O3R2,NA,NA,NA,1.11.1.8,R08520 R08521 R08522
L-tyrosine,cpd:C16733,[Thyroglobulin]-L-tyrosine,C10H10N2O3R2,NA,NA,NA,1.11.1.8,R08519 R08520
L-tyrosine,cpd:C20800,3-Methyl-L-tyrosine,C10H13NO3,NA,NA,NA,1.11.2.5;2.1.1.304,R10721 R10964
L-tyrosine,cpd:C20801,3-Hydroxy-5-methyl-L-tyrosine,C10H13NO4,NA,NA,NA,1.11.2.5,R10721
L-tyrosine,cpd:C20983,4-O-Dimethylallyl-L-tyrosine;4-O-Prenyl-L-tyrosine,C14H19NO3,NA,NA,NA,2.5.1.122,R10968
L-tyrosine,cpd:C21325,Azatyrosine;2-Aza-L-tyrosine,C8H10N2O3,Biosynthesis of enediyne antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Kedarcidin 2-aza-3-chloro-beta-tyrosine moiety biosynthesis, azatyrosine => 2-aza-3-chloro-beta-tyrosyl-PCP",NA,5.4.3.-,R11391
L-tyrosine,cpd:C21889,(2S)-3-(4-Hydroxyphenyl)-2-isocyanopropanoate;L-Tyrosine isonitrile,C10H9NO3,Biosynthesis of various other secondary metabolites,NA,NA,1.14.20.9;1.14.20.10;4.1.99.24,R12076 R12081 R12150
L-tyrosine,cpd:C22344,C-Terminal [mycofactocin precursor peptide]-glycyl-L-valyl-L-tyrosine,C16H22N3O5R,NA,NA,NA,1.3.98.7,R12724
L-valine,cpd:C00183,L-Valine;2-Amino-3-methylbutyric acid,C5H11NO2,"Valine, leucine and isoleucine degradation;Valine, leucine and isoleucine biosynthesis;Penicillin and cephalosporin biosynthesis;Cyanoamino acid metabolism;Pantothenate and CoA biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;ABC transporters;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;Pantothenate biosynthesis, valine/L-aspartate => pantothenate;Penicillin biosynthesis, aminoadipate + cycteine + valine => penicillin;Cephamycin C biosynthesis, aminoadipate + cycteine + valine => cephamycin C",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00183  Valine (Val);Risk category of Japanese OTC drugs [BR:br08312(D00039)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Valine;    D00039  Valine (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00039)]; Chemicals;  D00039  L-Valine,1.4.1.8;1.4.1.9;1.4.1.23;1.14.14.38;1.14.14.39;2.6.1.6;2.6.1.32;2.6.1.42;2.6.1.66;4.1.1.14;6.1.1.9;6.3.2.26;6.3.2.47,R01212 R01214 R01215 R01434 R01437 R02200 R03665 R04870;R08663 R10031 R10941 R10942
L-valine,cpd:C20313,N-Hydroxy-L-valine,C5H11NO3,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.38;1.14.14.39,R10031 R10032
L-valine,cpd:C20314,"N,N-Dihydroxy-L-valine",C5H11NO4,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.38;1.14.14.39,R10032 R10033
L-valine,cpd:C20962,Dapdiamide A;3-{[(2E)-4-Amino-4-oxobut-2-enoyl]amino}-L-alanyl-L-valine,C12H20N4O5,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Dapdiamides biosynthesis, L-2,3-diaminopropanoate => dapdiamide A/B/C",Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C20962,6.3.2.47,R10942
L-valine,cpd:C20965,"N(beta)-Epoxysuccinamoyl-DAP-Val;N(beta)-Epoxysuccinamoyl-diaminopropionyl-valine;3-({[(2R,3R)-3-Carbamoyloxiran-2-yl]carbonyl}amino)-L-alanyl-L-valine",C12H20N4O6,NA,NA,NA,6.3.2.47,R10941
Myo-Inositol phosphate NIST,NA,NA,NA,NA,NA,NA,NA,NA
orcinol,cpd:C00727,"Orcinol;5-Methyl-1,3-benzenediol;5-Methylresorcinol;3,5-Toluenediol;3,5-Dihydroxytoluene",C7H8O2,NA,NA,NA,1.14.13.6;4.1.1.58,R02830 R02831
orcinol,cpd:C01066,"Cyclohexane-1,3-dione;1,3-Cyclohexanedione;Dihydroresorcinol",C6H8O2,NA,NA,NA,1.1.99.26;3.7.1.10,R03211 R03212
orcinol,cpd:C01751,"Resorcinol;Resorcin;1,3-Benzenediol;1,3-Dihydroxybenzene;m-Hydroquinone",C6H6O2,Benzoate degradation;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00133)]; D DERMATOLOGICALS;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AX Other anti-acne preparations for topical use;     D10AX02 Resorcinol;      D00133  Resorcinol (USP) &lt;JP&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01A ANTIINFECTIVES;    S01AX Other antiinfectives;     S01AX06 Resorcinol;      D00133  Resorcinol (USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00133)]; 2  Agents affecting individual organs;  26  Epidermides;   261  Antimicrobial agents;    2619  Others;     D00133  Resorcinol (USP); Resorcin (JAN);Risk category of Japanese OTC drugs [BR:br08312(D00133)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Resorcin;    D00133  Resorcinol (USP),1.14.13.219;1.14.13.220;1.14.14.27;4.1.1.103,R05249 R05250 R11347 R11348 R11353
orcinol,cpd:C10802,5-(Heptadec-12-enyl)resorcinol,C23H38O2,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1503 Alkyl resorcinols and derivatives;    C10802  5-(Heptadec-12-enyl)resorcinol,NA,NA
orcinol,cpd:C10809,5-Pentadecylresorcinol;Cardol,C21H36O2,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1503 Alkyl resorcinols and derivatives;    C10809  5-Pentadecylresorcinol,NA,NA
orcinol,cpd:C12064,Resorcinol monoacetate,C8H8O3,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02393)]; D DERMATOLOGICALS;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AX Other anti-acne preparations for topical use;     D10AX02 Resorcinol;      D02393  Resorcinol monoacetate (USP); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01A ANTIINFECTIVES;    S01AX Other antiinfectives;     S01AX06 Resorcinol;      D02393  Resorcinol monoacetate (USP),NA,NA
orcinol,cpd:C18343,4-Butylresorcinol;4-n-Butylresorcinol;Rucinol (TN),C10H14O2,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1503 Alkyl resorcinols and derivatives;    C18343  4-Butylresorcinol,NA,NA
orcinol,cpd:C19228,Diglycidyl resorcinol ether,C12H14O4,NA,NA,NA,NA,NA
orcinol,cpd:C19750,"3,5-Dihydroxybiphenyl;3,5-Biphenyldiol;5-Phenylresorcinol",C12H10O2,NA,NA,NA,2.3.1.177,R09621
Serratene NIST,NA,NA,NA,NA,NA,NA,NA,NA
Stigmasterol NIST,NA,NA,NA,NA,NA,NA,NA,NA
3-Hydroxyphenylacetate,cpd:C05593,3-Hydroxyphenylacetate;3-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.13.63;1.14.14.9,R02515 R02517 R03299 R06791
4-Hydroxyphenylacetate,cpd:C00642,4-Hydroxyphenylacetate;4-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C00642,1.2.1.5;1.2.1.29;1.2.1.39;1.2.1.53;1.2.3.13;1.14.13.18;1.14.14.9;4.1.1.83;6.2.1.-,R00042 R02514 R02516 R02695 R02697 R02698 R02699 R06790;R07312 R13086
4-Hydroxyphenylacetate,cpd:C05582,Homovanillate;Homovanillic acid;3-Methoxy-4-hydroxyphenylacetate,C9H10O4,Tyrosine metabolism;Metabolic pathways;Dopaminergic synapse,NA,NA,1.2.1.5;2.1.1.6,R03304 R04888 R04889
Benzoate,cpd:C00108,Anthranilate;Anthranilic acid;o-Aminobenzoic acid;Vitamin L1;2-Aminobenzoate,C7H7NO2,"Tryptophan metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Phenazine biosynthesis;Dioxin degradation;Aminobenzoate degradation;Biosynthesis of various alkaloids;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Biosynthesis of amino acids;Benzoic acid family","Tryptophan biosynthesis, chorismate => tryptophan;Carbazole degradation, carbazole => 2-oxopent-4-enoate + anthranilate;Anthranilate degradation, anthranilate => catechol;Aurachin biosynthesis, anthranilate => aurachin A;Fumiquinazoline biosynthesis, tryptophan + alanine + anthranilate => fumiquinazoline",NA,1.4.-.-;1.7.1.17;1.13.11.23;1.14.12.1;1.14.13.35;1.14.14.8;2.1.1.111;2.1.1.277;2.3.1.113;2.3.1.144;2.4.2.18;3.5.1.9;3.7.1.3;3.7.1.13;4.1.1.24;4.1.3.27;6.2.1.32;6.3.2.40;6.3.2.-,R00823 R00825 R00980 R00982 R00983 R00984 R00985 R00986;R00987 R00988 R00989 R00990 R00991 R01073 R02453 R05365;R07734 R08473 R08477 R09517 R10451 R10495 R12035 R12417
Benzoate,cpd:C00156,4-Hydroxybenzoate;Hydroxybenzoic acid;4-Hydroxybenzoic acid;Hydroxybenzenecarboxylic acid,C7H6O3,Ubiquinone and other terpenoid-quinone biosynthesis;Benzoate degradation;Bisphenol degradation;Toluene degradation;Aminobenzoate degradation;Folate biosynthesis;Biosynthesis of phenylpropanoids;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Biosynthesis of cofactors;Benzoic acid family,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol;Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",Dietary phytochemicals [br08012.html]; Flavonoids;  C00156,1.2.1.7;1.2.1.28;1.2.1.64;1.2.1.96;1.13.11.41;1.13.-.-;1.14.13.2;1.14.13.33;1.14.13.64;1.14.14.92;1.14.19.55;1.14.99.15;1.14.99.-;2.4.1.194;2.4.2.54;2.5.1.39;2.5.1.93;3.1.1.-;3.1.2.23;3.2.1.-;3.8.1.6;4.1.1.61;4.1.1.123;4.1.3.40;6.2.1.27;6.2.1.50,R01238 R01293 R01294 R01295 R01296 R01297 R01298 R01299;R01300 R01301 R01302 R01303 R01304 R01305 R01306 R01307;R01308 R05000 R05603 R05615 R05616 R06889 R07273 R09039;R09040 R09105 R11102 R11608 R11872 R12013 R12015
Benzoate,cpd:C00180,Benzoate;Benzoic acid;Benzenecarboxylic acid;Phenylformic acid;Dracylic acid,C7H6O2,Benzoate degradation;Dioxin degradation;Toluene degradation;Aminobenzoate degradation;Biosynthesis of various alkaloids;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Toluene degradation, toluene => benzoate;Biphenyl degradation, biphenyl => 2-oxopent-4-enoate + benzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",Therapeutic category of drugs in Japan [BR:br08301(D00038)]; 7  Agents not mainly for therapeutic purpose;  73  Public health agents;   731  Antiseptics;    7319  Others;     D00038  Benzoic acid (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00038)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP); Third-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP);Animal drugs in Japan [BR:br08331]; 99  Agents for not mainly purpose of therapeutic;  992  Amphoteric soap and preparations;   9929  Other agents for disinfections;    C00180  Benzoate;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00038)]; Chemicals;  D00038  Benzoic acid,1.2.1.7;1.2.1.28;1.14.12.10;1.14.13.-;1.14.14.92;2.1.1.273;3.1.1.1;3.1.1.84;3.5.1.4;3.5.1.32;3.5.1.40;3.5.5.1;3.6.1.7;3.6.1.20;3.7.1.8;6.2.1.25,R01295 R01419 R01420 R01421 R01422 R01423 R01424 R01425;R01426 R01427 R02606 R05590 R05591 R05621 R05622 R06727;R06728 R07188 R07835 R08838 R09088 R10447
Benzoate,cpd:C00196,"2,3-Dihydroxybenzoate;2,3-Dihydroxybenzoic acid",C7H6O4,Benzoate degradation;Aminobenzoate degradation;Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,NA,NA,1.3.1.28;1.13.11.14;1.13.11.28;1.14.13.35;1.14.99.23;4.1.1.46;6.2.1.71;6.3.2.14,R00821 R00980 R01504 R01505 R01506 R01507 R01508 R07644;R12777
Benzoate,cpd:C00230,"3,4-Dihydroxybenzoate;3,4-Dihydroxybenzoic acid;Protocatechuate;Protocatechuic acid",C7H6O4,"Benzoate degradation;Phenylalanine, tyrosine and tryptophan biosynthesis;Toluene degradation;Polycyclic aromatic hydrocarbon degradation;Aminobenzoate degradation;Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds","Phthalate degradation, phthalate => protocatechuate;Terephthalate degradation, terephthalate => 3,4-dihydroxybenzoate;Phthalate degradation, phthalate => protocatechuate",Dietary phytochemicals [br08012.html]; Flavonoids;  C00230,1.3.1.53;1.13.11.3;1.13.11.8;1.14.12.8;1.14.12.-;1.14.13.2;1.14.13.23;1.14.13.33;1.14.13.64;1.14.13.82;1.14.13.-;1.14.19.55;2.1.1.341;2.1.1.382;4.1.1.55;4.1.1.63;4.1.1.69;4.2.1.118;6.2.1.62,R00822 R01296 R01298 R01627 R01628 R01629 R01630 R01631;R01632 R01633 R01634 R01635 R01636 R01637 R05274 R05280;R07668 R10136 R11197 R11198 R12018 R12019 R12575 R12576
Benzoate,cpd:C00568,4-Aminobenzoate;ABEE;4-Aminobenzoic acid;p-Aminobenzoate,C7H7NO2,Aminobenzoate degradation;Folate biosynthesis;Biosynthesis of phenylpropanoids;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02456)]; D DERMATOLOGICALS;  D02 EMOLLIENTS AND PROTECTIVES;   D02B PROTECTIVES AGAINST UV-RADIATION;    D02BA Protectives against UV-radiation for topical use;     D02BA01 Aminobenzoic acid;      D02456  Aminobenzoic acid (USP);Drug groups [BR:br08330(D02456)]; Neuropsychiatric agent;  DG02030  Anesthetics;   DG01675  Local anesthetic;    DG01674  Esterified local anesthetic;     DG00379  Aminobenzoic acid;      D02456  Aminobenzoic acid;Target-based classification of drugs [BR:br08310(D02456)]; Ion channels;  Voltage-gated ion channels;   Sodium channels;    SCN1A;     D02456  Aminobenzoic acid (USP);    SCN2A;     D02456  Aminobenzoic acid (USP);    SCN3A;     D02456  Aminobenzoic acid (USP);    SCN4A;     D02456  Aminobenzoic acid (USP);    SCN5A;     D02456  Aminobenzoic acid (USP);    SCN8A;     D02456  Aminobenzoic acid (USP);    SCN9A;     D02456  Aminobenzoic acid (USP);    SCN10A;     D02456  Aminobenzoic acid (USP);    SCN11A;     D02456  Aminobenzoic acid (USP),1.7.1.-;1.14.12.-;1.14.13.27;1.14.99.68;2.4.2.54;2.5.1.15;4.1.1.24;4.1.3.38,R01860 R02561 R02562 R03066 R03067 R05277 R05280 R05553;R10337 R12675
Benzoate,cpd:C00587,3-Hydroxybenzoate;3-Hydroxybenzoic acid;m-Hydroxybenzoic acid,C7H6O3,"Benzoate degradation;Phenylalanine, tyrosine and tryptophan biosynthesis;Toluene degradation;Polycyclic aromatic hydrocarbon degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds",NA,NA,1.2.1.7;1.2.1.28;1.2.1.64;1.14.13.23;1.14.13.24;1.14.99.23;4.1.1.55;4.1.3.45;6.2.1.37,R01427 R01508 R01628 R02589 R05375 R07666 R07667 R09589;R10597
Benzoate,cpd:C00628,"2,5-Dihydroxybenzoate;2,5-Dihydroxybenzoic acid;Gentisic acid;Hydroquinonecarboxylic acid;Gentisate",C7H6O4,Tyrosine metabolism;Benzoate degradation;Naphthalene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Salicylate degradation, salicylate => gentisate",NA,1.2.1.29;1.2.3.1;1.13.11.4;1.14.13.24;1.14.13.172;4.1.1.62,R02489 R02589 R02655 R02656 R02657 R07686 R07709 R07710
Benzoate,cpd:C00985,p-Mercuribenzoate;p-Mercuribanzoic acid,C7H5HgO2R,NA,NA,NA,NA,NA
Benzoate,cpd:C01424,"Gallate;Gallic acid;3,4,5-Trihydroxybenzoic acid;3,4,5-Trihydroxybenzoate;Pyrogallol-5-carboxylic acid",C7H6O5,Aminobenzoate degradation;Biosynthesis of various plant secondary metabolites;Biosynthesis of phenylpropanoids;Microbial metabolism in diverse environments,NA,Phytochemical compounds [BR:br08003]; Others;  Tannins and galloyl derivatives;   Galloyl derivatives;    C01424  Gallate;Dietary phytochemicals [br08012.html]; Flavonoids;  C01424,1.13.11.3;1.13.11.8;1.13.11.57;2.1.1.341;2.4.1.136;3.1.1.20;4.1.1.59,R00053 R01637 R03247 R03297 R03549 R03550 R03551 R09271;R09565 R12886
Benzoate,cpd:C01839,"Orsellinate;o-Orsellinic acid;2,4-Dihydroxy-6-methylbenzoic acid;2,4-Dihydroxy-6-methylbenzoate;4,6-Dihydroxy-o-toluic acid",C8H8O4,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1301 Monocyclic aromatic polyketides;    C01839  Orsellinic acid,3.1.1.40;4.1.1.58,R00054 R02831
Benzoate,cpd:C02236,4-Sulfobenzoate;4-Sulfobenzoic acid,C7H6O5S,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.2.1.62;1.14.12.8,R01636 R05272
Benzoate,cpd:C02357,2-Chlorobenzoate;2-Chlorobenzoic acid;o-Chlorobenzoic acid,C7H5ClO2,Fluorobenzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.13,R01033
Benzoate,cpd:C02359,2-Fluorobenzoate;2-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10,R08100 R08101
Benzoate,cpd:C02363,3-Ethoxybenzoate;3-Ethoxybenzoic acid,C9H10O3,NA,NA,NA,NA,NA
Benzoate,cpd:C02364,3-Fluorobenzoate;3-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10,R08108 R08109
Benzoate,cpd:C02370,4-Chlorobenzoate;4-Chlorobenzoic acid,C7H5ClO2,Fluorobenzoate degradation;Dioxin degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Biphenyl degradation, biphenyl => 2-oxopent-4-enoate + benzoate",NA,1.2.-.-;3.7.1.8;3.8.1.6;6.2.1.33,R01307 R03932 R05252 R05359 R05472
Benzoate,cpd:C02371,4-Fluorobenzoate;4-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10;6.2.1.33,R08110 R08117
Benzoate,cpd:C02519,4-Methoxybenzoate;4-Methoxybenzoic acid;4-Anisic acid,C8H8O3,Benzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.99.15,R01306
Benzoate,cpd:C02730,2-Succinylbenzoate;o-Succinylbenzoate;Succinylbenzoate,C11H10O5,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Menaquinone biosynthesis, chorismate (+ polyprenyl-PP) => menaquinol;Phylloquinone biosynthesis, chorismate (+ phytyl-PP) => phylloquinol",NA,4.2.1.113;6.2.1.26,R04030 R04031 R05454
Benzoate,cpd:C03057,2-Carboxybenzaldehyde;Phthalaldehydic acid;o-Formylbenzoic acid;2-Formylbenzoic acid;2-Formylbenzoate,C8H6O3,Polycyclic aromatic hydrocarbon degradation;Microbial metabolism in diverse environments,NA,NA,1.2.1.78;4.1.2.34,R03465 R05643 R07713
Benzoate,cpd:C03444,p-Chloromercuribenzoate;p-Chloromercuribenzoic acid;PCMB,C7H5ClHgO2,NA,NA,NA,NA,NA
Benzoate,cpd:C03522,N-Methyl-4-aminobenzoate,C8H9NO2,NA,NA,NA,NA,NA
Benzoate,cpd:C03885,3-Nonaprenyl-4-hydroxybenzoate;Nonaprenyl-4-hydroxybenzoate,C52H78O3,Biosynthesis of secondary metabolites,NA,NA,2.5.1.39,R07273
Benzoate,cpd:C03925,"3,5-Dibromo-4-hydroxybenzoate",C7H4Br2O3,Fluorobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,3.5.1.-;3.5.5.6,R04349 R07782 R07783
Benzoate,cpd:C03993,4-(beta-D-Glucosyloxy)benzoate;4-Hydroxybenzoate-O-glucoside,C13H16O8,Ubiquinone and other terpenoid-quinone biosynthesis,NA,NA,2.4.1.194;3.2.1.-,R01304 R09039
Benzoate,cpd:C04171,"(2S,3S)-2,3-Dihydro-2,3-dihydroxybenzoate;(2S,3S)-2,3-Dihydroxy-2,3-dihydroxybenzoate",C7H8O4,Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of secondary metabolites,NA,NA,1.3.1.28;3.3.2.1,R01505 R03037
Benzoate,cpd:C04524,"2-Protocatechoylphloroglucinolcarboxylate;2-(3,4-Dihydroxybenzoyloxy)-4,6-dihydroxybenzoate",C14H10O8,NA,NA,NA,1.13.11.24,R02156
Benzoate,cpd:C05200,"3-Hexaprenyl-4,5-dihydroxybenzoate",C37H54O4,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR02 Quinones and hydroquinones;   PR0201 Ubiquinones;    C05200  3-Hexaprenyl-4,5-dihydroxybenzoate",1.14.13.-;2.1.1.114,R04711 R06865
Benzoate,cpd:C05313,3-Hexaprenyl-4-hydroxy-5-methoxybenzoate,C38H56O4,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR02 Quinones and hydroquinones;   PR0201 Ubiquinones;    C05313  3-Hexaprenyl-4-hydroxy-5-methoxybenzoate,2.1.1.114,R04711 R06866
Benzoate,cpd:C05616,"3-O-Methylgallate;3-O-Methylgallic acid;5-Hydroxyvanillic acid;3,4-Dihydroxy-5-methoxybenzoate",C8H8O5,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C05616,1.13.11.8;1.13.11.-;2.1.1.341;2.1.1.-,R03551 R04280 R09270 R09271 R09272
Benzoate,cpd:C05809,3-Octaprenyl-4-hydroxybenzoate;4-Hydroxy-3-octaprenylbenzoate,C47H70O3,NA,NA,NA,2.5.1.39;4.1.1.98,R04986 R05615
Benzoate,cpd:C05848,4-Hydroxy-3-polyprenylbenzoate;4-Hydroxy-3-all-trans-polyprenylbenzoate;3-Polyprenyl-4-hydroxybenzoate,C12H14O3(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol;Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",Lipids [BR:br08002]; PR  Prenol lipids;  PR00 Other Prenol lipids;   C05848  4-Hydroxy-3-polyprenylbenzoate,1.14.13.-;2.5.1.39;4.1.1.98,R04985 R05000 R08770
Benzoate,cpd:C06670,"2,4-Dichlorobenzoate;2,4-Dichlorobenzoic acid",C7H4Cl2O2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,6.2.1.-,R05451
Benzoate,cpd:C06672,Vanillate;Vanillic acid;4-Hydroxy-3-methoxybenzoate;4-Hydroxy-3-methoxybenzoic acid,C8H8O4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C06672,1.2.1.67;1.2.3.9;1.14.13.82;2.1.1.341;2.1.1.382;2.4.1.300,R05273 R05274 R05699 R07668 R09278 R10136 R10259 R10296;R10297
Benzoate,cpd:C07138,5-Aminosalicylate;5-Amino-2-hydroxybenzoate,C7H7NO3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00377)]; A ALIMENTARY TRACT AND METABOLISM;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EC Aminosalicylic acid and similar agents;     A07EC02 Mesalazine;      D00377  Mesalamine (USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00377)]; Inflammatory Bowel Disease Agents;  Aminosalicylates and/or Prodrugs;   Mesalamine;    D00377  Mesalamine (USP);Therapeutic category of drugs in Japan [BR:br08301(D00377)]; 2  Agents affecting individual organs;  23  Digestive organ agents;   239  Miscellaneous;    2399  Others;     D00377  Mesalamine (USP); Mesalazine (JP18/INN);Drug groups [BR:br08330(D00377)]; Anti-inflammatory;  DG01504  Nonsteroidal anti-inflammatory drug (NSAID);   DG01909  Anti-inflammatory drug, salicylic acid derivatives;    D00377  Mesalamine;Drug classes [BR:br08332(D00377)]; Anti-inflammatory;  DG01504  Nonsteroidal anti-inflammatory drug (NSAID);   D00377  Mesalamine",1.13.11.86,R12147
Benzoate,cpd:C07211,m-Methylbenzoate;m-Toluic Acid;beta-Bethylbenzoic acid;m-Toluylic acid,C8H8O2,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Xylene degradation, xylene => methylbenzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.2.1.7;1.2.1.28;1.14.12.-,R05664 R05665
Benzoate,cpd:C07215,o-Toluate;o-Methylbenzoate;o-Toluic Acid;2-Methylbenzoic acid,C8H8O2,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Xylene degradation, xylene => methylbenzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.2.1.7;1.2.1.28;1.14.12.-,R05428 R05663
Benzoate,cpd:C07527,Benzocaine;Ethyl aminobenzoate,C9H11NO2,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00552)]; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AD Local anesthetics;     C05AD03 Benzocaine;      D00552  Benzocaine (USP/INN) &lt;JP&gt;; D DERMATOLOGICALS;  D02 EMOLLIENTS AND PROTECTIVES;   D02B PROTECTIVES AGAINST UV-RADIATION;    D02BA Protectives against UV-radiation for topical use;     D02BA01 Aminobenzoic acid;      D00552  Benzocaine (USP/INN) &lt;JP&gt;;  D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.;   D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.;    D04AB Anesthetics for topical use;     D04AB04 Benzocaine;      D00552  Benzocaine (USP/INN) &lt;JP&gt;; N NERVOUS SYSTEM;  N01 ANESTHETICS;   N01B ANESTHETICS, LOCAL;    N01BA Esters of aminobenzoic acid;     N01BA05 Benzocaine;      D00552  Benzocaine (USP/INN) &lt;JP&gt;; R RESPIRATORY SYSTEM;  R02 THROAT PREPARATIONS;   R02A THROAT PREPARATIONS;    R02AD Anesthetics, local;     R02AD01 Benzocaine;      D00552  Benzocaine (USP/INN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00552)]; 2  Agents affecting individual organs;  27  Dental preparations;   271  Local anesthetics;    2710  Local anesthetics;     D00552  Benzocaine (USP/INN); Ethyl aminobenzoate (JP18);Classification of Japanese OTC drugs [BR:br08313(D00552)]; Agents for digestive organs;  15 Stomach pain and cramp relievers;   D00552  Benzocaine (USP/INN); Agents for  urogenital organs and anus;  30 Hemorrhoid drugs for external use;   D00552  Benzocaine (USP/INN); Agents for integumentary system;  57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches);   D00552  Benzocaine (USP/INN); Agents for otolaryngologic use;  72 Other agents for otolaryngologic use;   D00552  Benzocaine (USP/INN);Risk category of Japanese OTC drugs [BR:br08312(D00552)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Ethyl aminobenzoate;    D00552  Benzocaine (USP/INN); Second-class OTC drugs;  Inorganic and organic chemicals;   Ethyl aminobenzoate;    D00552  Benzocaine (USP/INN); Third-class OTC drugs;  Inorganic and organic chemicals;   Ethyl aminobenzoate;    D00552  Benzocaine (USP/INN);Drug groups [BR:br08330(D00552)]; Neuropsychiatric agent;  DG02030  Anesthetics;   DG01675  Local anesthetic;    DG01674  Esterified local anesthetic;     DG00379  Aminobenzoic acid;      D00552  Benzocaine;Target-based classification of drugs [BR:br08310(D00552)]; Ion channels;  Voltage-gated ion channels;   Sodium channels;    SCN1A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN2A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN3A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN4A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN5A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN8A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN9A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN10A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;    SCN11A;     D00552  Benzocaine (USP/INN) &lt;JP&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00552)]; Chemicals;  D00552  Ethyl aminobenzoate",NA,NA
Benzoate,cpd:C08472,Avenanthramide A;5-Hydroxy-2-[(2E)-3-(4-hydroxyphenyl)prop-2-enamido]benzoate,C16H13NO5,NA,NA,NA,2.3.1.302,R12736
Benzoate,cpd:C08655,"Aconifine;Aconitane-3,8,10,13,14,15-hexol, 20-ethyl-4-(methoxymethyl)-1,6,16-trimethoxy-, 8-acetate 14-benzoate, (1-alpha,3-alpha,6-alpha,14-alpha,15-alpha,16-beta)-",C34H47NO12,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08655  Aconifine,NA,NA
Benzoate,cpd:C08681,"Elatine;Aconitane-4-methanol, 20-ethyl-7,8-(methylenebis(oxy))-, 1,6,14,16-tetramethoxy-2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoate(ester), (1-alpha,6-beta,14-alpha,16-beta)-",C38H50N2O10,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08681  Elatine,NA,NA
Benzoate,cpd:C09113,"Ingenol 3,20-dibenzoate",C34H36O7,NA,NA,"Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Others;    C09113  Ingenol 3,20-dibenzoate",NA,NA
Benzoate,cpd:C10833,"Syringic acid;Syringate;4-Hydroxy-3,5-dimethoxybenzoate;Gallic acid 3,5-dimethyl ether",C9H10O5,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C10833,2.1.1.-,R09270
Benzoate,cpd:C12107,3-Amino-5-hydroxybenzoate;AHBA;3-Amino-5-hydroxybenzoic acid;3-Ahba,C7H7NO3,Biosynthesis of ansamycins;Biosynthesis of secondary metabolites,NA,NA,4.2.1.144;6.2.1.74,R06595 R12789
Benzoate,cpd:C12115,"3-Amino-4-hydroxybenzoate;3-Amino-4-hydroxybenzoic acid;3,4-AHBA",C7H7NO3,Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Grixazone biosynthesis, aspartate 4-semialdehyde => grixazone B;Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,1.10.3.15;1.14.13.249;4.1.99.20,R08650 R10469 R10720 R12912
Benzoate,cpd:C12305,Methyl salicylate;Methyl 2-hydroxybenzoate,C8H8O3,Biosynthesis of phenylpropanoids,NA,"Therapeutic category of drugs in Japan [BR:br08301(D01087)]; 2  Agents affecting individual organs;  26  Epidermides;   264  Analgesics, anti-itchings, astringents, anti-inflammatory agents;    2641  Methyl salicylic acids;     D01087  Methyl salicylate (JP18/NF);Classification of Japanese OTC drugs [BR:br08313(D01087)]; Agents for respiratory organs;  27 Gargles;   D01087  Methyl salicylate (JP18/NF); Agents for integumentary system;  57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches);   D01087  Methyl salicylate (JP18/NF);Risk category of Japanese OTC drugs [BR:br08312(D01087)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Methyl salicylate;    D01087  Methyl salicylate (JP18/NF);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  953  Analgesics, anti-itchings, astringents and antiinflammatory agents;   9531  Methyl salicylate and preparations;    C12305  Methyl salicylate;Drug groups [BR:br08330(D01087)]; Anti-inflammatory;  DG01504  Nonsteroidal anti-inflammatory drug (NSAID);   DG01909  Anti-inflammatory drug, salicylic acid derivatives;    D01087  Methyl salicylate;Drug classes [BR:br08332(D01087)]; Anti-inflammatory;  DG01504  Nonsteroidal anti-inflammatory drug (NSAID);   D01087  Methyl salicylate;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01087)]; Chemicals;  D01087  Methyl salicylate",2.1.1.274,R10448
Benzoate,cpd:C12458,3-Dimethylallyl-4-hydroxybenzoate;4-Hydroxy-3-prenylbenzoate,C12H14O3,Novobiocin biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.13.12.23;6.3.1.15,R06759 R06763 R06776 R10453
Benzoate,cpd:C12537,Benzyl benzoate,C14H12O2,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01138)]; P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS;  P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS;   P03A ECTOPARASITICIDES, INCL. SCABICIDES;    P03AX Other ectoparasiticides, incl. scabicides;     P03AX01 Benzyl benzoate;      D01138  Benzyl benzoate (JP18/USP);Classification of Japanese OTC drugs [BR:br08313(D01138)]; Agents for sanitation;  82 Pesticides;   D01138  Benzyl benzoate (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01138)]; Chemicals;  D01138  Benzyl benzoate",2.3.1.196,R09528
Benzoate,cpd:C12961,Dexamethazone metasulfobenzoate sodium;Dexamethasone metasulfobenzoate sodium,C29H32FO9S. Na,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01510)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC02 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA09 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AB Corticosteroids, moderately potent (group II);     D07AB19 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XB Corticosteroids, moderately potent, other combinations;     D07XB05 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AA Corticosteroids, combinations for treatment of acne;     D10AA03 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB02 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AD Corticosteroids;     R01AD03 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA01 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB01 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA06 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;  S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;   S03B CORTICOSTEROIDS;    S03BA Corticosteroids;     S03BA01 Dexamethasone;      D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;USP drug classification [BR:br08302(D01510)]; Ophthalmic Agents;  Ophthalmic Anti-inflammatories;   Glucocorticoids, Ophthalmic;    Dexamethasone;     D01510  Dexamethasone metasulfobenzoate sodium (JAN);Therapeutic category of drugs in Japan [BR:br08301(D01510)]; 1  Agents affecting nervous system and sensory organs;  13  Agents affecting sensory organs;   131  Ophthalmic agents;    1315  Ophthalmic cortisones;     D01510  Dexamethasone metasulfobenzoate sodium (JAN);   132  Otic and nasal agents;    1329  Others;     D01510  Dexamethasone metasulfobenzoate sodium (JAN);Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  961  Hormone preparations (except agents for breeding and external use);   9612  Adrenal hormone preparations;    C12961  Dexamethasone metasulfobenzoate sodium;Drug groups [BR:br08330(D01510)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00011  Dexamethasone;     D01510  Dexamethasone metasulfobenzoate sodium; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00011  Dexamethasone;     D01510  Dexamethasone metasulfobenzoate sodium; Metabolizing enzyme inducer;  DG02853  CYP3A/CYP3A4 inducer;   DG01635  CYP3A4 inducer;    DG00011  Dexamethasone;     D01510  Dexamethasone metasulfobenzoate sodium;Drug classes [BR:br08332(D01510)]; Anti-inflammatory;  DG01955  Corticosteroid;   D01510  Dexamethasone metasulfobenzoate sodium;Target-based classification of drugs [BR:br08310(D01510)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D01510  Dexamethasone metasulfobenzoate sodium (JAN) &lt;JP&gt;;Drug metabolizing enzymes and transporters [br08309.html(D01510)]; Drug metabolizing enzymes;  D01510",NA,NA
Benzoate,cpd:C13403,Sodium caffeine benzoate,C8H10N4O2. C7H5O2. Na,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02409)]; V VARIOUS;  V04 DIAGNOSTIC AGENTS;   V04C OTHER DIAGNOSTIC AGENTS;    V04CG Tests for gastric secretion;     V04CG30 Caffeine and sodium benzoate;      D02409  Caffeine and sodium benzoate (JP18) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D02409)]; 2  Agents affecting individual organs;  21  Cardiovascular agents;   211  Cardiotonics;    2115  Caffeines;     D02409  Caffeine and sodium benzoate (JP18);Risk category of Japanese OTC drugs [BR:br08312(D02409)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Caffeine and sodium benzoate;    D02409  Caffeine and sodium benzoate (JP18);Animal drugs in Japan [BR:br08331]; 92  Agents affecting circulatory organs, respiratory organs and urinary organs;  921  Cardiotonics;   9212  Caffeine, prine, derivatives and preparations;    C13403  Sodium caffeine benzoate;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D02409)]; Chemicals;  D02409  Caffeine and sodium benzoate",NA,NA
Benzoate,cpd:C13425,3-Hexaprenyl-4-hydroxybenzoate;3-Hexaprenyl-4-hydroxybenzoic acid,C37H54O3,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR02 Quinones and hydroquinones;   PR0201 Ubiquinones;    C13425  3-Hexaprenyl-4-hydroxybenzoate,1.14.13.-;2.5.1.39,R05616 R06865
Benzoate,cpd:C13444,Estradiol benzoate;17-beta-Estradiol 3-benzoate,C25H28O3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01953)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03C ESTROGENS;    G03CA Natural and semisynthetic estrogens, plain;     G03CA03 Estradiol;      D01953  Estradiol benzoate (JP18/USP);Classification of Japanese OTC drugs [BR:br08313(D01953)]; Agents for integumentary system;  60 Hair remedies (incl. hair growth, hair tonic, anti-dandruff, and antipruritic);   D01953  Estradiol benzoate (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D01953)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Estradiol benzoate;    D01953  Estradiol benzoate (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Estradiol benzoate;    D01953  Estradiol benzoate (JP18/USP);Animal drugs in Japan [BR:br08331]; 94  Agents for breeding;  941  Hormone preparations (except posterior-pituitary hormone and preparations);   9414  Follicle stimulating hormone and preparations;    C13444  Estradiol benzoate;Drug groups [BR:br08330(D01953)]; Hormonal agent;  DG01986  Estrogen;   DG00462  Estradiol;    D01953  Estradiol benzoate;  DG01584  Estrogen receptor agonist;   DG00462  Estradiol;    D01953  Estradiol benzoate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00462  Estradiol;     D01953  Estradiol benzoate;Target-based classification of drugs [BR:br08310(D01953)]; Nuclear receptors;  Estrogen like receptors;   Estrogen receptor;    NR3A (ESR);     D01953  Estradiol benzoate (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01953)]; Chemicals;  D01953  Estradiol benzoate;  D01953  Estradiol benzoate injection (aqueous suspension);Drug metabolizing enzymes and transporters [br08309.html(D01953)]; Drug metabolizing enzymes;  D01953",NA,NA
Benzoate,cpd:C14168,3-(Dimethylamino)propyl benzoate,C12H17NO2,Local analgesics,NA,NA,NA,NA
Benzoate,cpd:C14259,Stanolone benzoate;Dihydrotestosterone benzoate;DHT benzoate,C26H34O3,NA,NA,NA,NA,NA
Benzoate,cpd:C14393,Benzylparaben;Benzyl parahydroxybenzoate;Benzyl 4-hydroxybenzoate,C14H12O3,NA,NA,NA,NA,NA
Benzoate,cpd:C14673,"Cholesta-5,7-dien-3beta-ol benzoate;7-Dehydrocholesterol benzoate",C34H48O2,NA,NA,NA,NA,NA
Benzoate,cpd:C14709,"1,1-Dimethylethyl benzoate;tert-Butyl benzoate",C11H14O2,NA,NA,NA,NA,NA
Benzoate,cpd:C14716,2-Ethylhexyl-4-hydroxybenzoate,C15H22O3,NA,NA,NA,NA,NA
Benzoate,cpd:C14718,Heptyl p-hydroxybenzoate;Heptylparaben,C14H20O3,NA,NA,NA,NA,NA
Benzoate,cpd:C14959,"Estra-1,3,5(10),16-tetraen-3-ol benzoate",C25H26O2,NA,NA,NA,NA,NA
Benzoate,cpd:C15171,17beta-Hydroxyestr-4-en-3-one benzoate;Nandrolone benzoate,C25H30O3,NA,NA,NA,NA,NA
Benzoate,cpd:C16234,o-Nitrobenzoate;2-Nitrobenzoic acid,C7H5NO4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.7.1.-,R07727
Benzoate,cpd:C16235,o-Hydroxylaminobenzoate;2-Hydroxylaminobenzoic acid,C7H7NO3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.4.-.-;1.7.1.-;5.4.99.-,R07727 R07730 R07734
Benzoate,cpd:C16571,2-Amino-3-methylbenzoate,C8H9NO2,Drug metabolism - cytochrome P450,NA,NA,NA,R08302
Benzoate,cpd:C17554,"3,4-Dihydroxy-5-polyprenylbenzoate;3-Polyprenyl-4,5-dihydroxybenzoate;3,4-Dihydroxy-5-all-trans-polyprenylbenzoate",C12H14O4(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",NA,1.14.13.-;2.1.1.114,R08770 R08771
Benzoate,cpd:C17559,3-Methoxy-4-hydroxy-5-polyprenylbenzoate;3-Polyprenyl-4-hydroxy-5-methoxybenzoate;3-Methoxy-4-hydroxy-5-all-trans-polyprenylbenzoate,C13H16O4(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",NA,2.1.1.114;4.1.1.-,R08771 R08772
Benzoate,cpd:C18090,Tricaine;3-Aminobenzoic acid;m-Aminobenzoate,C9H11NO2,NA,NA,NA,NA,NA
Benzoate,cpd:C18131,Geranyl-hydroxybenzoate,C17H22O3,Ubiquinone and other terpenoid-quinone biosynthesis;Biosynthesis of secondary metabolites,NA,NA,2.5.1.93,R09040 R09041
Benzoate,cpd:C18216,4-Hydroxyphenyl-4-hydroxybenzoate,C13H10O4,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.14.-.-;3.1.1.-,R09104 R09105
Benzoate,cpd:C18625,4-Nitrobenzoate;4-Nitrobenzoic acid;p-Nitrobenzoic acid,C7H5NO4,NA,NA,NA,1.14.99.68,R12675
Benzoate,cpd:C19459,Methyl red;o-Methyl red;2-(4-Dimethylaminophenyl)diazenylbenzoate,C15H15N3O2,NA,NA,NA,1.7.1.17,R12035
Benzoate,cpd:C19686,3-(1-Carboxyvinyloxy)anthranilate;2-Amino-3-[(1-carboxyethenyl)oxy]benzoate;3-Enolpyruvoylanthranilate,C10H9NO5,Biosynthesis of enediyne antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"C-1027 benzoxazolinate moiety biosynthesis, chorismate => benzoxazolinyl-CoA",NA,1.3.8.16,R09559 R11362
Benzoate,cpd:C19788,5-Nitroanthranilate;2-Amino-5-nitrobenzoate,C7H6N2O4,NA,NA,NA,3.5.99.8,R09661
Benzoate,cpd:C19789,5-Nitrosalicylate;2-Hydroxy-5-nitrobenzoate,C7H5NO5,NA,NA,NA,1.13.11.64;3.5.99.8,R09661 R10109 R10110
Benzoate,cpd:C20342,Isobutylparaben;Isobutyl parahydroxybenzoate,C11H14O3,NA,NA,NA,NA,NA
Benzoate,cpd:C20343,Isopropylparaben;Isopropyl 4-hydroxybenzoate,C10H12O3,NA,NA,NA,NA,NA
Benzoate,cpd:C20417,"2,4-Dihydroxy-6-pentylbenzoate;Olivetolic acid",C12H16O4,Biosynthesis of various plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites,"Cannabidiol biosynthesis, malonyl-CoA => cannabidiol/dronabinol",Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1504 Anacardic acids and derivatives;    C20417  Olivetolic acid,2.5.1.102;4.4.1.26,R10176 R10278
Benzoate,cpd:C20645,Methyl benzoate,C8H8O2,NA,NA,NA,2.1.1.273,R10447
Benzoate,cpd:C20772,3-[(1-Carboxyvinyl)oxy]benzoate;3-[(1-Carboxyethenyl)oxy]benzoic acid,C10H8O5,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Menaquinone biosynthesis, futalosine pathway;Menaquinone biosynthesis, modified futalosine pathway",NA,2.5.1.120;4.2.1.151,R10666 R10667
Benzoate,cpd:C21167,4-Hydroxy-3-methylbenzoate;4-Hydroxy-m-toluate,C8H8O3,Toluene degradation;Microbial metabolism in diverse environments,NA,NA,1.2.1.96,R11195 R11196
Benzoate,cpd:C21298,"2,6-Dihydroxybenzoate;gamma-Resorcylate",C7H6O4,Benzoate degradation;Microbial metabolism in diverse environments,NA,NA,4.1.1.103,R11353
Benzoate,cpd:C21347,"5-Iodo-2,3-dimethoxyorsellinate-[acp];4-Hydroxy-5-iodo-2,3-dimethoxy-6-methylbenzoate-[acp]",C10H10IO4SR,Biosynthesis of enediyne antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Calicheamicin biosynthesis, calicheamicinone => calicheamicin;Calicheamicin orsellinate moiety biosynthesis, malonyl-CoA => orsellinate-ACP => 5-iodo-2,3-dimethoxyorsellinate-ACP",NA,2.1.1.-,R11416 R11419
Benzoate,cpd:C21450,4-(2-Hydroxyethoxycarbonyl)benzoate;4-[(2-Hydroxyethoxy)carbonyl]benzoate;Mono(2-hydroxyethyl) terephthalate;Mono(ethylene terephthalate),C10H10O5,Polycyclic aromatic hydrocarbon degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,3.1.1.101;3.1.1.102,R11540 R11541
Benzoate,cpd:C21850,3-Bromo-4-hydroxybenzoate,C7H5BrO3,NA,NA,NA,1.14.19.55,R12015 R12016
Benzoate,cpd:C21853,"3-Bromo-4,5-dihydroxybenzoate",C7H5BrO4,NA,NA,NA,1.14.19.55,R12019 R12020
Benzoate,cpd:C22372,"Avenanthramide C;2-[(2E)-3-(3,4-Dihydroxyphenyl)prop-2-enamido]-5-hydroxybenzoate",C16H13NO6,NA,NA,NA,2.3.1.302,R12737
Benzoate,cpd:C22425,3-Amino-2-hydroxy-4-methoxybenzoate;3-Amino-2-hydroxy-4-methoxybenzoic acid,C8H9NO4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,2.1.1.380;6.7.1.1,R12928 R12943
Benzoate,cpd:C22455,"3-Amino-2,4-dihydroxybenzoate;3-Amino-2,4-dihydroxybenzoic acid",C7H7NO4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,1.14.13.249;2.1.1.380,R12912 R12928
Betaine,cpd:C00318,"L-Carnitine;L-gamma-Trimethyl-beta-hydroxybutyrobetaine;Vitamin BT;3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt;Levocarnitine;(R)-Carnitine",C7H15NO3,Thermogenesis;Bile secretion;Diabetic cardiomyopathy,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02176)]; A ALIMENTARY TRACT AND METABOLISM;  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;    A16AA Amino acids and derivatives;     A16AA01 Levocarnitine;      D02176  Levocarnitine (JAN/USP/INN) &lt;JP/US&gt;;Therapeutic category of drugs in Japan [BR:br08301(D02176)]; 3  Agents affecting metabolism;  39  Other agents affecting metabolism;   399  Miscellaneous;    3999  Others;     D02176  Levocarnitine (JAN/USP/INN);Risk category of Japanese OTC drugs [BR:br08312(D02176)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Carnitine;    D02176  Levocarnitine (JAN/USP/INN);New drug approvals in Japan [br08318.html(D02176)]; Drugs with new active ingredients;  D02176,1.14.13.239;2.1.1.383;2.3.1.21;2.3.1.137;2.8.3.21;3.1.1.28;3.5.1.73;6.2.1.48,R01922 R01923 R01924 R03779 R10643 R10644 R11632 R11875;R11911 R12930
Betaine,cpd:C00487,Carnitine;gamma-Trimethyl-hydroxybutyrobetaine;3-Hydroxy-4-trimethylammoniobutanoate,C7H16NO3,Lysine degradation;Metabolic pathways;ABC transporters,NA,Risk category of Japanese OTC drugs [BR:br08312]; Third-class OTC drugs;  Inorganic and organic chemicals;   Carnitine;    C00487  Carnitine,1.1.1.108;1.14.11.1;2.3.1.7;4.1.1.42,R02395 R02396 R02397 R02398
Betaine,cpd:C00576,Betaine aldehyde,C5H12NO,"Glycine, serine and threonine metabolism;Metabolic pathways","Betaine biosynthesis, choline => betaine",NA,1.1.1.1;1.1.3.17;1.1.99.1;1.2.1.8;1.14.15.7,R01022 R01025 R02565 R02566 R07409 R08211 R08557 R08558
Betaine,cpd:C00719,"Betaine;Trimethylaminoacetate;Glycine betaine;N,N,N-Trimethylglycine;Trimethylammonioacetate",C5H11NO2,"Glycine, serine and threonine metabolism;Metabolic pathways;ABC transporters","Betaine biosynthesis, choline => betaine;Betaine metabolism, animals, betaine => glycine;Betaine degradation, bacteria, betaine => pyruvate","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07523)]; A ALIMENTARY TRACT AND METABOLISM;  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;    A16AA Amino acids and derivatives;     A16AA06 Betaine;      D07523  Betaine (JAN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D07523)]; Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment;  Betaine;   D07523  Betaine (JAN);Therapeutic category of drugs in Japan [BR:br08301(D07523)]; 3  Agents affecting metabolism;  39  Other agents affecting metabolism;   399  Miscellaneous;    3999  Others;     D07523  Betaine (JAN);Risk category of Japanese OTC drugs [BR:br08312(D07523)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Betaine;    D07523  Betaine (JAN);New drug approvals in Europe [br08329.html(D07523)]; European public assessment reports (EPAR) authorised medicine;  D07523;New drug approvals in Japan [br08318.html(D07523)]; Drugs with new active ingredients;  D07523;New drug approvals in the USA, Europe and Japan [br08328.html(D07523)]; Approval dates by FDA, EMA and PMDA;  D07523",1.1.3.17;1.2.1.8;1.13.11.90;1.14.13.251;1.21.4.4;2.1.1.5;2.1.1.157;2.1.1.161;2.1.1.162;2.1.1.376,R02565 R02566 R02821 R07228 R07244 R08211 R08212 R10061;R10062 R12614 R12787 R13016
Betaine,cpd:C01004,N-Methylnicotinate;Trigonelline;Trigenelline;1-Methylpyridinio-3-carboxylate;Betaine nicotinate;Caffearin;Gynesine,C7H7NO2,"Tropane, piperidine and pyridine alkaloid biosynthesis",NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from nicotinic acid;   Pyridine alkaloids;    C01004  N-Methylnicotinate;Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C01004,2.1.1.7,R01721
Betaine,cpd:C01181,4-Trimethylammoniobutanoate;Butyro-betaine;gamma-Butyrobetaine,C7H16NO2,Lysine degradation;Metabolic pathways;ABC transporters,NA,NA,1.2.1.3;1.2.1.47;1.14.11.1;2.8.3.21,R02397 R03283 R10644
Betaine,cpd:C04114,(E)-4-(Trimethylammonio)but-2-enoate;Crotono-betaine;Crotonobetaine,C7H13NO2,ABC transporters,NA,NA,2.8.3.21,R10643
Betaine,cpd:C07345,Betaine aldehyde hydrate,C5H14NO2,NA,NA,NA,1.14.15.7,R05739
Betaine,cpd:C08263,beta-Alaninebetaine;beta-Alanine betaine;Propiobetaine;Trimethylalanine,C6H13NO2,NA,NA,NA,NA,NA
Betaine,cpd:C08269,(-)-Betonicine;Betonicine;trans-4-Hydroxy-L-proline betaine,C7H13NO3,NA,NA,NA,5.1.1.22,R11630
Betaine,cpd:C10172,Stachydrine;Proline betaine;L-Proline betaine,C7H13NO2,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from ornithine;   Pyrrolidine alkaloids;    C10172  Stachydrine,1.14.13.247;2.1.1.388;5.1.1.22,R11631 R12511 R12512 R13185
Betaine,cpd:C19331,Arsenobetaine,C5H11AsO2,NA,NA,NA,NA,NA
Betaine,cpd:C21513,Turicine;(+)-Turicine;cis-4-Hydroxy-D-proline betaine,C7H13NO3,NA,NA,NA,5.1.1.22,R11630
Betaine,cpd:C21514,D-Proline betaine,C7H13NO2,NA,NA,NA,5.1.1.22,R11631
Fructose,cpd:C00085,D-Fructose 6-phosphate;D-Fructose 6-phosphoric acid;Neuberg ester,C6H13O9P,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Fructose and mannose metabolism;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Methane metabolism;Carbon fixation in photosynthetic organisms;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars;AMPK signaling pathway;Glucagon signaling pathway;Insulin resistance;Central carbon metabolism in cancer;Diabetic cardiomyopathy","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Gluconeogenesis, oxaloacetate => fructose-6P;Pentose phosphate pathway (Pentose phosphate cycle);Pentose phosphate pathway, non-oxidative phase, fructose 6P => ribose 5P;Ascorbate biosynthesis, plants, fructose-6P => ascorbate;Reductive pentose phosphate cycle (Calvin cycle);Formaldehyde assimilation, xylulose monophosphate pathway;Formaldehyde assimilation, ribulose monophosphate pathway;Pentose phosphate pathway, archaea, fructose 6P => ribose 5P;UDP-N-acetyl-D-glucosamine biosynthesis, eukaryotes, glucose => UDP-GlcNAc;UDP-N-acetyl-D-glucosamine biosynthesis, prokaryotes, glucose => UDP-GlcNAc",NA,1.1.1.17;1.1.1.140;2.2.1.1;2.2.1.2;2.4.1.14;2.4.1.246;2.6.1.16;2.7.1.1;2.7.1.4;2.7.1.11;2.7.1.61;2.7.1.90;2.7.1.105;2.7.1.146;3.1.3.11;3.1.3.46;3.5.99.6;4.1.2.22;5.1.3.40;5.1.3.-;5.3.1.8;5.3.1.9;5.3.1.27,R00756 R00758 R00760 R00761 R00762 R00763 R00764 R00765;R00766 R00767 R00768 R00769 R00770 R00771 R00772 R00876;R01067 R01140 R05339 R05805 R06073 R07133 R08406 R08575;R08947 R09031 R11623 R13199 R13202
Fructose,cpd:C00095,D-Fructose;Levulose;Fruit sugar;D-arabino-Hexulose,C6H12O6,Fructose and mannose metabolism;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of nucleotide sugars;ABC transporters;Phosphotransferase system (PTS);Taste transduction;Insulin resistance;Carbohydrate digestion and absorption;Diabetic cardiomyopathy,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C00095  D-Fructose; Fruit sugar;Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  964  Saccharide preparations and blood substitutes;   9642  Fructose and preparations;    C00095  D-Fructose,1.1.1.11;1.1.1.14;1.1.1.15;1.1.1.67;1.1.1.124;1.1.1.138;1.1.2.2;1.1.5.14;1.1.99.28;2.4.1.4;2.4.1.5;2.4.1.7;2.4.1.13;2.4.1.125;2.4.1.362;2.4.1.372;2.4.1.373;2.7.1.1;2.7.1.3;2.7.1.4;2.7.1.61;2.7.1.202;3.1.3.68;3.1.3.-;3.2.1.10;3.2.1.20;3.2.1.26;3.2.1.48;3.2.1.80;3.2.1.219;5.1.3.30;5.1.3.31;5.3.1.5;5.3.1.7,R00760 R00801 R00803 R00806 R00865 R00866 R00867 R00868;R00870 R00872 R00873 R00874 R00875 R00876 R00877 R00878;R00879 R01140 R01823 R02120 R02410 R03232 R03635 R03921;R06034 R06036 R06052 R06066 R06087 R06100 R06101 R06208;R08406 R08407 R08548 R08651 R08676 R10817 R12349 R12527;R12528 R13126
Fructose,cpd:C00273,5-Dehydro-D-fructose,C6H10O6,NA,NA,NA,1.1.1.123;1.1.1.124;1.1.3.11;1.1.5.14;1.1.99.12,R00871 R00873 R01694 R01695 R01696 R08651
Fructose,cpd:C00354,"D-Fructose 1,6-bisphosphate",C6H14O12P2,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Fructose and mannose metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Methane metabolism;Carbon fixation in photosynthetic organisms;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Phosphotransferase system (PTS);AMPK signaling pathway;Glucagon signaling pathway;Central carbon metabolism in cancer","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Gluconeogenesis, oxaloacetate => fructose-6P;Reductive pentose phosphate cycle (Calvin cycle);Formaldehyde assimilation, xylulose monophosphate pathway;Formaldehyde assimilation, ribulose monophosphate pathway",NA,2.2.1.11;2.7.1.11;2.7.1.56;2.7.1.90;2.7.1.146;3.1.3.11;4.1.2.13,R00756 R00762 R00764 R00767 R00769 R00770 R01068 R05805;R09100 R10049 R13203
Fructose,cpd:C00665,"beta-D-Fructose 2,6-bisphosphate;D-Fructose 2,6-bisphosphate",C6H14O12P2,Fructose and mannose metabolism;Metabolic pathways;AMPK signaling pathway;Glucagon signaling pathway;Central carbon metabolism in cancer,NA,NA,2.7.1.105;3.1.3.46;3.1.3.54,R00763 R02730 R02731 R02732 R13202
Fructose,cpd:C00861,L-Rhamnulose;6-Deoxy-L-fructose,C6H12O5,Fructose and mannose metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,2.7.1.5;5.3.1.14,R02437 R03014
Fructose,cpd:C01094,D-Fructose 1-phosphate,C6H13O9P,"Fructose and mannose metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments;Phosphotransferase system (PTS)",NA,NA,2.2.1.11;2.7.1.3;2.7.1.56;2.7.1.61;2.7.1.202;3.1.3.68;4.1.2.13,R00866 R02071 R02568 R03232 R08407 R08548 R10050 R13203
Fructose,cpd:C01496,Fructose;arabino-Hexulose,NA,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; V VARIOUS;  V06 GENERAL NUTRIENTS;   V06D OTHER NUTRIENTS;    V06DC Carbohydrates;     V06DC02 Fructose;      C01496  Fructose,NA,NA
Fructose,cpd:C01711,Inulobiose;1-O-beta-D-Fructo-furanosyl-D-fructose,C12H22O11,NA,NA,NA,4.2.1.178;4.2.1.179,R03685 R12927
Fructose,cpd:C01719,L-Fructose;L-arabino-Hexulose,C6H12O6,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C01719  L-Fructose,1.1.1.15,R08536
Fructose,cpd:C02336,beta-D-Fructose;beta-Fruit sugar;beta-D-arabino-Hexulose;beta-Levulose;Fructose,C6H12O6,NA,NA,NA,2.7.1.1;2.7.1.4;3.2.1.20;3.2.1.26;3.2.1.48;3.2.1.218,R00802 R03920 R06088 R06102 R13128
Fructose,cpd:C03267,beta-D-Fructose 2-phosphate;beta-D-Fructofuranose 2-phosphate,C6H13O9P,Fructose and mannose metabolism;Metabolic pathways,NA,NA,3.1.3.54;3.1.3.-,R00872 R02730
Fructose,cpd:C04333,"Bis-D-fructose 2',1:2,1'-dianhydride;Difructose anhydride I",C12H20O10,NA,NA,NA,4.2.1.179,R03685 R06161
Fructose,cpd:C04420,"alpha-D-Fructofuranose-beta-D-fructofuranose 2',1:2,3'-dianhydride;Di-D-fructofuranose 1,2':2,3'-dianhydride;Difructose anhydride III",C12H20O10,NA,NA,NA,4.2.1.178,R12927
Fructose,cpd:C05001,Fructose 1-phosphate(pyranose),C6H13O9P,NA,NA,NA,NA,NA
Fructose,cpd:C05003,D-Fructose;D-arabino-Hex-2-ulopyranose,C6H12O6,NA,NA,NA,NA,NA
Fructose,cpd:C05345,beta-D-Fructose 6-phosphate;beta-D-Fructofuranose 6-phosphate,C6H13O9P,NA,NA,NA,1.1.1.17;1.1.1.140;2.2.1.1;2.2.1.2;2.2.1.14;2.4.1.329;2.7.1.1;2.7.1.4;2.7.1.11;2.7.1.90;2.7.1.105;2.7.1.146;3.1.3.11;3.1.3.46;5.3.1.8;5.3.1.9;5.3.1.27,R00867 R01819 R01827 R01830 R02073 R02703 R02731 R02732;R02740 R03321 R03920 R04779 R04780 R05607 R09084 R09780;R10987 R12731
Fructose,cpd:C05378,"beta-D-Fructose 1,6-bisphosphate",C6H14O12P2,NA,NA,NA,2.7.1.11;2.7.1.56;2.7.1.90;2.7.1.146;3.1.3.11;4.1.2.13,R01070 R02071 R02073 R04779 R04780 R09084
Fructose,cpd:C06468,D-Psicose;D-ribo-Hex-2-ulose;D-ribo-2-Hexulose;D-ribo-2-Ketohexulose;D-erythro-Hexulose;D-Pseudofructose;D-Allulose;D-Altrulose,C6H12O6,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C06468  D-Psicose,5.1.3.30;5.1.3.31,R10817
Fructose,cpd:C06485,"1,5-Anhydro-D-fructose",C6H10O5,NA,NA,NA,1.1.1.263;1.1.1.292;4.2.1.110;4.2.1.111,R05682 R08194 R09694 R09696
Fructose,cpd:C08238,alpha-Galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-galactosyl-(1-6)-alpha-glucosyl-(1-2)-beta-fructose;Ajugose,C36H62O31,NA,NA,NA,NA,NA
Fructose,cpd:C10906,D-Fructose,C6H12O6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00114)]; V VARIOUS;  V06 GENERAL NUTRIENTS;   V06D OTHER NUTRIENTS;    V06DC Carbohydrates;     V06DC02 Fructose;      D00114  Fructose (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00114)]; 3  Agents affecting metabolism;  32  Nutrients, tonics;   323  Saccharide preparations;    3232  Fructoses;     D00114  Fructose (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00114)]; Chemicals;  D00114  Fructose;  D00114  Fructose injection",1.1.1.124;2.4.1.13,R00871 R07256
Fructose,cpd:C12214,Aminofructose 6-phosphate;Amino-D-fructose 6-phosphate,C6H14NO8P,Biosynthesis of ansamycins;Biosynthesis of secondary metabolites,NA,NA,2.2.1.1;5.3.1.-,R06589 R06590
Fructose,cpd:C16488,Fructoselysine;N6-(D-Fructosyl)-L-lysine,C12H24N2O7,Phosphotransferase system (PTS),NA,NA,2.7.1.218;5.1.3.41,R08124 R11720
Fructose,cpd:C16489,Fructoselysine 6-phosphate,C12H25N2O10P,Phosphotransferase system (PTS),NA,NA,2.7.1.218;3.5.-.-,R08124 R08125
Fructose,cpd:C16848,"6-Deoxy-5-ketofructose 1-phosphate;1-Deoxy-D-threo-hexo-2,5-diulose 6-phosphate",C6H11O8P,"Phenylalanine, tyrosine and tryptophan biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites",NA,NA,2.2.1.10;2.2.1.11,R08568 R10049 R10050
Fructose,cpd:C18050,beta-D-Fructofuranosyl-alpha-D-mannopyranoside 6F-phosphate;Mannosylfructose 6-phosphate,C12H23O14P,NA,NA,NA,2.4.1.246;3.1.3.79,R08947 R08982
Fructose,cpd:C18068,beta-D-Fructofuranosyl-alpha-D-mannopyranoside;Mannosylfructose,C12H22O11,NA,NA,NA,3.1.3.79,R08982
Fructose,cpd:C19633,Maltulose;4-O-alpha-D-Glucopyranosyl-D-fructose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19633  Maltulose,NA,NA
Fructose,cpd:C19634,Melibiulose;6-O-alpha-D-Galactopyranosyl-D-fructose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19634  Melibiulose,NA,NA
Fructose,cpd:C19636,Turanose;3-O-alpha-D-Glucopyranosyl-D-fructose;D-Turanose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19636  Turanose,NA,NA
Fructose,cpd:C20830,6-Deoxy-6-sulfo-D-fructose,C6H12O8S,NA,NA,NA,2.2.1.14;2.2.1.15;2.7.1.184;5.3.1.31,R10765 R10970 R12731 R13000
Fructose,cpd:C20831,6-Deoxy-6-sulfo-D-fructose 1-phosphate,C6H13O11PS,NA,NA,NA,2.7.1.184;4.1.2.57,R10760 R10970
Fructose,cpd:C21364,[Fructose-bisphosphate aldolase]-L-lysine,C7H13N3O2R2,NA,NA,NA,NA,NA
Fructose,cpd:C21365,"[Fructose-bisphosphate aldolase]-N6,N6,N6-trimethyl-L-lysine",C10H20N3O2R2,NA,NA,NA,NA,NA
Fructose,cpd:C22310,Fructose 3-phosphate,C6H13O9P,Diabetic cardiomyopathy,NA,NA,NA,NA
Fructose,cpd:C22502,alpha-D-Fructofuranose;alpha-D-Fructose,C6H12O6,NA,NA,NA,5.3.1.5,R00307
O-Acetylcholine,cpd:C01996,Acetylcholine;O-Acetylcholine,C7H16NO2,Glycerophospholipid metabolism;cAMP signaling pathway;Neuroactive ligand-receptor interaction;Synaptic vesicle cycle;Cholinergic synapse;Taste transduction;Regulation of actin cytoskeleton;Insulin secretion;Salivary secretion;Gastric acid secretion;Pancreatic secretion;Bile secretion;Pathways of neurodegeneration - multiple diseases;Nicotine addiction,NA,Compounds with biological roles [BR:br08001]; Hormones and transmitters;  Neurotransmitters;   Acetylcholine;    C01996  Acetylcholine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS;    S01EB Parasympathomimetics;     S01EB09 Acetylcholine;      C01996  Acetylcholine;Drug groups [BR:br08330]; Cardiovascular agent;  DG01532  Nicotinic cholinergic receptor agonist;   DG01133  Acetylcholine;    C01996  Acetylcholine; Neuropsychiatric agent;  DG01490  Muscarinic cholinergic receptor agonist;   DG01133  Acetylcholine;    C01996  Acetylcholine; Ophthalmic agent;  DG03201  Intraocular pressure lowering agent;   DG01133  Acetylcholine;    C01996  Acetylcholine; Metabolizing enzyme substrate;  DG02974  ACHE substrate;   DG01133  Acetylcholine;    C01996  Acetylcholine,2.3.1.6;3.1.1.7;3.1.1.8,R01023 R01026
Phenylalanine,cpd:C00079,L-Phenylalanine;(S)-alpha-Amino-beta-phenylpropionic acid,C9H11NO2,"Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Cyanoamino acid metabolism;D-Amino acid metabolism;Phenylpropanoid biosynthesis;Tropane, piperidine and pyridine alkaloid biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of various alkaloids;Biosynthesis of various other secondary metabolites;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;ABC transporters;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","Phenylalanine biosynthesis, chorismate => phenylpyruvate => phenylalanine;Monolignol biosynthesis, phenylalanine/tyrosine => monolignol;Flavanone biosynthesis, phenylalanine => naringenin;Ditryptophenaline biosynthesis, tryptophan + phenylalanine => ditryptophenaline;Phenylalanine biosynthesis, chorismate => arogenate => phenylalanine",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00079  Phenylalanine (Phe);Risk category of Japanese OTC drugs [BR:br08312(D00021)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Phenylalanine;    D00021  Phenylalanine (USP/INN);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00021)]; Chemicals;  D00021  L-Phenylalanine,1.4.1.20;1.4.3.2;1.11.1.21;1.13.12.9;1.14.14.40;1.14.16.1;1.14.16.7;2.3.1.53;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.28;2.6.1.57;2.6.1.58;2.6.1.64;2.6.1.70;2.6.1.-;3.4.17.23;4.1.1.28;4.1.1.53;4.1.1.109;4.2.1.51;4.2.1.91;4.3.1.24;4.3.1.25;5.1.1.11;5.4.3.10;5.4.3.11;6.1.1.20;6.3.2.40;6.3.2.-,R00686 R00688 R00689 R00690 R00691 R00692 R00693 R00694;R00695 R00697 R00698 R00699 R01375 R01376 R01795 R03660;R06744 R07211 R08463 R08652 R08690 R09535 R09578 R09579;R10286 R10287 R10495 R10499 R10729 R11068 R11918 R12413;R12540 R12543
Phenylalanine,cpd:C00355,"3,4-Dihydroxy-L-phenylalanine;L-Dopa;3-Hydroxy-L-tyrosine;L-beta-(3,4-Dihydroxyphenyl)alanine;Levodopa;Dihydroxy-L-phenylalanine",C9H11NO4,Tyrosine metabolism;Isoquinoline alkaloid biosynthesis;Betalain biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Dopaminergic synapse;Prolactin signaling pathway;Parkinson disease;Cocaine addiction;Amphetamine addiction;Alcoholism,"Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline;Betacyanin biosynthesis, L-tyrosine => amaranthin","Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00355  3,4-Dihydroxy-L-phenylalanine; Hormones and transmitters;  Neurotransmitters;   Amino acids;    C00355  Dopa;Prodrugs [br08324.html]; C00355;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00059)]; N NERVOUS SYSTEM;  N04 ANTI-PARKINSON DRUGS;   N04B DOPAMINERGIC AGENTS;    N04BA Dopa and dopa derivatives;     N04BA01 Levodopa;      D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00059)]; Antiparkinson Agents;  Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors;   Levodopa;    D00059  Levodopa (JP18/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D00059)]; 1  Agents affecting nervous system and sensory organs;  11  Agents affecting central nervous system;   116  Antiparkinsonian agents;    1164  Levodopas;     D00059  Levodopa (JP18/USP/INN);Drug groups [BR:br08330(D00059)]; Neuropsychiatric agent;  DG01472  Dopamine agonist;   D00059  Levodopa;  DG01967  Antiparkinson agent;   D00059  Levodopa;Drug classes [BR:br08332(D00059)]; Neuropsychiatric agent;  DG01967  Antiparkinson agent;   D00059  Levodopa;Target-based classification of drugs [BR:br08310(D00059)]; G Protein-coupled receptors;  Rhodopsin family;   Dopamine;    DRD;     D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00059)]; Chemicals;  D00059  Levodopa;New drug approvals in Europe [br08329.html(D00059)]; European public assessment reports (EPAR) authorised medicine;  D00059;Prodrugs [br08324.html(D00059)]; D00059",1.10.3.1;1.11.2.6;1.13.11.29;1.13.11.30;1.13.11.-;1.13.12.15;1.14.16.2;1.14.18.1;1.14.-.-;2.6.1.49;4.1.1.25;4.1.1.28;4.1.1.107;4.3.1.22,R00031 R00045 R00731 R01815 R02075 R02076 R02077 R02078;R02080 R03672 R07212 R08443 R08827 R08836 R08846 R08920;R11916 R12541 R12611 R13031 R13032
Phenylalanine,cpd:C02057,Phenylalanine;alpha-Amino-beta-phenylpropionic acid,C9H11NO2,NA,NA,NA,NA,NA
Phenylalanine,cpd:C02265,D-Phenylalanine;D-alpha-Amino-beta-phenylpropionic acid,C9H11NO2,Phenylalanine metabolism;D-Amino acid metabolism;Metabolic pathways;Taste transduction,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C02265  D-Phenylalanine,1.4.5.1;2.3.1.36;2.6.1.21;5.1.1.11,R00686 R01374 R01582 R03903
Phenylalanine,cpd:C03519,N-Acetyl-L-phenylalanine,C11H13NO3,Phenylalanine metabolism;Metabolic pathways,NA,NA,2.3.1.53,R00693
Phenylalanine,cpd:C03709,N-Adenylyl-L-phenylalanine,C19H23N6O8P,NA,NA,NA,NA,NA
Phenylalanine,cpd:C05620,N-Acetyl-D-phenylalanine,C11H13NO3,D-Amino acid metabolism;Metabolic pathways,NA,NA,2.3.1.36,R03903
Phenylalanine,cpd:C08273,"2,5-Dihydrophenylalanine;L-2,5-Dihydrophenylalanine",C9H13NO2,NA,NA,NA,NA,NA
Phenylalanine,cpd:C11217,p-Fluorophenylalanine,C9H10FNO2,NA,NA,NA,NA,NA
Phenylalanine,cpd:C11221,Formylmethionyl-leucyl-phenylalanine methyl ester;FMLP OMe,C22H33N3O5S,Neutrophil extracellular trap formation,NA,NA,NA,NA
Phenylalanine,cpd:C11341,N-Acetylphenylalanine beta-naphthyl ester;N-Acetyl-DL-phenylalanine beta-naphthyl ester,C21H19NO3,NA,NA,NA,NA,NA
Phenylalanine,cpd:C11596,FMLP;N-Formyl-L-methionyl-L-leucyl-L-phenylalanine,C21H31N3O5S,Staphylococcus aureus infection,NA,NA,NA,NA
Phenylalanine,cpd:C11615,Pristinamycin IA;Vernamycin B alpha;Mikamycin B;4-[4-(Dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1;Streptogramin B,C45H54N8O10,Nonribosomal peptide structures,NA,NA,NA,NA
Phenylalanine,cpd:C11616,Pristinamycin IB;Vernamycin B beta;Efepristin;4-[N-Methyl-4-(methylamino)-L-phenylalanine]virginiamycin S1,C44H52N8O10,NA,NA,NA,NA,NA
Phenylalanine,cpd:C11617,Pristinamycin IC;Vernamycin B gamma;2-D-Alanine-4-[4-(dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1,C44H52N8O10,NA,NA,NA,NA,NA
Phenylalanine,cpd:C12033,4-Aminophenylalanine;p-Aminophenylalanine,C9H12N2O2,NA,NA,NA,NA,NA
Phenylalanine,cpd:C17235,L-Homophenylalanine,C10H13NO2,"Phenylalanine, tyrosine and tryptophan biosynthesis;Glucosinolate biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism",NA,NA,1.14.13.-;2.6.1.-,R08655 R08690 R10503
Phenylalanine,cpd:C18619,4-Dimethylamino-L-phenylalanine,C11H16N2O2,NA,NA,NA,NA,NA
Phenylalanine,cpd:C19712,N-Hydroxy-L-phenylalanine;2-(Hydroxyamino)-3-phenylpropanoate,C9H11NO3,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.40,R09579 R09580
Phenylalanine,cpd:C19715,"N,N-Dihydroxy-L-phenylalanine",C9H11NO4,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.40,R09580 R09581
Phenylalanine,cpd:C20487,L-beta-Phenylalanine;(R)-3-Amino-3-phenylpropanoate,C9H11NO2,NA,NA,NA,5.4.3.10,R10286
Phenylalanine,cpd:C20488,D-beta-Phenylalanine;(S)-3-Amino-3-phenylpropanoate;(S)-beta-Phenylalanine,C9H11NO2,NA,NA,NA,5.4.3.11,R10287
Phenylalanine,cpd:C20807,3-Hydroxy-L-phenylalanine;3-Tyrosine,C9H11NO3,NA,NA,NA,1.14.16.7,R10729 R12543
Phenylalanine,cpd:C20895,"(2S,3S)-3-Methylphenylalanine",C10H13NO2,NA,NA,NA,2.6.1.57;2.6.1.107,R10845
D-lyxose,cpd:C00476,D-Lyxose,C5H10O5,Pentose and glucuronate interconversions,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C00476  D-Lyxose,5.3.1.15,R01898
D-lyxose,cpd:C02204,alpha-D-Lyxose,C5H10O5,NA,NA,NA,NA,NA
Glycerol monostearate NIST,NA,NA,NA,NA,NA,NA,NA,NA
Hexacosanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
lactose,cpd:C00052,UDP-alpha-D-galactose;UDP-D-galactose;UDP-galactose;UDP-D-galactopyranose;UDP-alpha-D-galactopyranose,C15H24N2O17P2,Galactose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Teichoic acid biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,"Nucleotide sugar biosynthesis, galactose => UDP-galactose;Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P",NA,1.1.1.-;2.4.1.22;2.4.1.23;2.4.1.37;2.4.1.38;2.4.1.44;2.4.1.46;2.4.1.47;2.4.1.50;2.4.1.62;2.4.1.74;2.4.1.86;2.4.1.87;2.4.1.90;2.4.1.96;2.4.1.122;2.4.1.123;2.4.1.137;2.4.1.156;2.4.1.167;2.4.1.179;2.4.1.205;2.4.1.228;2.4.1.234;2.4.1.241;2.4.1.272;2.4.1.274;2.4.1.275;2.4.1.294;2.4.1.303;2.4.1.304;2.4.1.309;2.4.1.343;2.4.1.-;2.7.7.10;2.7.7.12;2.7.7.64;2.7.8.6;2.7.8.18;5.1.3.2;5.4.99.9,R00291 R00501 R00502 R00503 R00504 R00505 R00506 R00809;R00853 R00854 R00955 R01192 R01205 R01500 R01535 R01928;R01997 R02691 R02791 R03354 R03380 R03486 R03679 R03981;R04016 R04322 R04334 R04431 R04469 R04495 R04531 R04548;R04610 R04631 R04644 R05080 R05107 R05110 R05111 R06808;R09753 R09755 R10240 R10432 R10433 R10436 R10440 R10804;R10865 R11599 R11714 R13152
lactose,cpd:C00124,D-Galactose;D-Galactopyranose,C6H12O6,Galactose metabolism;Metabolic pathways;Bacterial chemotaxis;Phosphotransferase system (PTS);Carbohydrate digestion and absorption;Mineral absorption,"Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P",Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C00124  D-Galactose,1.1.1.21;1.1.1.48;1.1.1.120;1.1.1.121;1.1.1.359;1.1.1.360;1.1.3.9;2.4.1.388;2.4.1.389;2.7.1.204;3.1.3.94;3.2.1.22;3.2.1.23;3.2.1.46;3.2.1.108;5.1.3.3,R01093 R01094 R01095 R01096 R01097 R01098 R01099 R01101;R01103 R01104 R01105 R01194 R01329 R01678 R02926 R03355;R03617 R03618 R03634 R04019 R04470 R04633 R05112 R05549;R05961 R05994 R06010 R06070 R06091 R06093 R06094 R06096;R06098 R06099 R06142 R06152 R06202 R07807 R08544 R10619;R10622 R11171 R12979 R13002 R13179
lactose,cpd:C00243,Lactose;1-beta-D-Galactopyranosyl-4-D-glucopyranose;beta-D-Gal-(1->4)-D-Glc;Milk sugar,C12H22O11,Galactose metabolism;Metabolic pathways;ABC transporters;Phosphotransferase system (PTS);Carbohydrate digestion and absorption,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C00243  Lactose; Milk sugar;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00046)]; Chemicals;  D00046  Anhydrous lactose,1.1.99.13;2.4.1.22;2.7.1.207;3.2.1.23;3.2.1.108;3.2.1.140,R00503 R01100 R01678 R01680 R04393 R05166
lactose,cpd:C00446,alpha-D-Galactose 1-phosphate;alpha-D-Galactopyranose 1-phosphate,C6H13O9P,Galactose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars,"Nucleotide sugar biosynthesis, galactose => UDP-galactose;Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P",NA,2.4.1.211;2.4.1.247;2.7.1.6;2.7.7.10;2.7.7.12;2.7.7.32;2.7.7.64;3.1.3.94,R00502 R00955 R01092 R02329 R05326 R06057 R09632 R10622
lactose,cpd:C00962,beta-D-Galactose,C6H12O6,NA,NA,NA,3.2.1.23;3.2.1.62;3.2.1.108,R01100 R06114 R12970
lactose,cpd:C00984,alpha-D-Galactose,C6H12O6,Galactose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars,"Nucleotide sugar biosynthesis, galactose => UDP-galactose;Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P",Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D04291)]; V VARIOUS;  V04 DIAGNOSTIC AGENTS;   V04C OTHER DIAGNOSTIC AGENTS;    V04CE Tests for liver functional capacity;     V04CE01 Galactose;      D04291  Galactose (NF);Risk category of Japanese OTC drugs [BR:br08312(D04291)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Galactose;    D04291  Galactose (NF),2.7.1.6;5.1.3.3,R01092 R10619
lactose,cpd:C01018,6-Deoxy-D-galactose;D-Fucose,C6H12O5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C01018  D-Fucose,NA,NA
lactose,cpd:C01019,L-Fucose;L-Fucopyranose;6-Deoxy-L-galactose,C6H12O5,Fructose and mannose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of nucleotide sugars;Two-component system;Quorum sensing;C-type lectin receptor signaling pathway,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C01019  L-Fucose,1.1.1.122;2.7.1.52;3.2.1.51;3.2.1.63;5.3.1.3;5.3.1.25,R03161 R03162 R03163 R04270 R06118 R08926 R13144
lactose,cpd:C01067,D-Galactose 6-sulfate,C6H12O9S,NA,NA,NA,NA,NA
lactose,cpd:C01074,N-Acetylgalactosamine;N-Acetylchondrosamine;2-Acetamido-2-deoxygalactose;GalNAc,NA,Amoebiasis,NA,NA,3.2.1.35,R07824
lactose,cpd:C01113,D-Galactose 6-phosphate;6-Phospho-D-galactose,C6H13O9P,Galactose metabolism;Metabolic pathways;Phosphotransferase system (PTS),NA,NA,2.7.1.204;3.2.1.85;5.3.1.26,R03240 R03255 R03256 R06110 R11171
lactose,cpd:C01132,N-Acetyl-D-galactosamine;N-Acetyl-D-chondrosamine;2-Acetamido-2-deoxy-D-galactose,C8H15NO6,Galactose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars;Phosphotransferase system (PTS),NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C01132  N-Acetyl-D-galactosamine,1.1.3.29;2.7.1.157;2.7.1.162;2.7.1.-;3.2.1.49;3.2.1.52,R03492 R04183 R04184 R04586 R05963 R05966 R06001 R06004;R08366 R08967 R12963 R12975 R12976
lactose,cpd:C01582,Galactose,C6H12O6,NA,NA,NA,3.2.1.-,R03616
lactose,cpd:C01825,L-Galactose,C6H12O6,Ascorbate and aldarate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ascorbate biosynthesis, plants, fructose-6P => ascorbate",Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C01825  L-Galactose,1.1.1.122;1.1.1.316;1.1.1.-;3.1.3.93,R07674 R07675 R12156
lactose,cpd:C01970,beta-Lactose;beta-D-Lactose,C12H22O11,NA,NA,NA,NA,NA
lactose,cpd:C02097,dTDP-galactose;dTDP-D-galactose,C16H26N2O16P2,NA,NA,NA,1.1.1.186;2.7.7.32;5.1.3.2,R02329 R02984 R03826 R07150
lactose,cpd:C02262,D-Galactosamine;D-Chondrosamine;2-Amino-2-deoxy-D-galactose,C6H13NO5,Galactose metabolism;Metabolic pathways;Phosphotransferase system (PTS),NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C02262  D-Galactosamine,2.7.1.-,R08367
lactose,cpd:C02280,GDP-L-galactose;GDP-beta-L-galactose,C16H25N5O16P2,Ascorbate and aldarate metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars,"Ascorbate biosynthesis, plants, fructose-6P => ascorbate",NA,2.7.7.69;5.1.3.18;5.1.3.-,R00889 R07673 R07678
lactose,cpd:C02781,2-Deoxy-D-galactose,C6H12O5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C02781  2-Deoxy-D-galactose,NA,NA
lactose,cpd:C02985,L-Fucose 1-phosphate;6-Deoxy-L-galactose 1-phosphate;beta-L-Fucose 1-phosphate,C6H13O8P,Fructose and mannose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.7.1.52;2.7.7.30,R01951 R03161
lactose,cpd:C03348,"3,6-Dideoxy-L-galactose;Colitose;3,6-Dideoxy-L-xylo-hexose",C6H12O4,NA,NA,NA,NA,NA
lactose,cpd:C03384,D-Galactose 1-phosphate,C6H13O9P,NA,NA,NA,NA,NA
lactose,cpd:C03611,Galactose oligosaccharide,C6H11O5R,ABC transporters,NA,NA,NA,NA
lactose,cpd:C04346,"dTDP-4-amino-4,6-dideoxy-D-galactose;dTDP-4-amino-4,6-dideoxy-alpha-D-galactose",C16H27N3O14P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.3.1.210;2.6.1.59,R04438 R10142
lactose,cpd:C04648,"alpha-L-Fucosyl-1,2-beta-D-galactoside;Glycoprotein alpha-L-fucosyl-(1,2)-D-galactose;Glycolipid alpha-L-fucosyl-1,2-beta-D-galactose;alpha-L-Fucosyl-(1->2)-D-galactosyl-R",C12H21O10R,NA,NA,NA,2.4.1.37;2.4.1.40;2.4.1.69,R04081 R04423 R04548
lactose,cpd:C04724,alpha-D-Mannosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-alpha-D-galactosyl-diphosphoundecaprenol;alpha-D-Man-(1->4)-alpha-L-Rha-(1->3)-alpha-D-Gal-PP-Und;D-Mannosyl-L-rhamnosyl-D-galactose-1-diphospholipid,C73H122O21P2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C04724  alpha-D-Mannosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-alpha-D-galactosyl-diphosphoundecaprenol,2.4.1.60;2.4.1.-,R04581 R08858
lactose,cpd:C04739,UDP-N-acetyl-6-(alpha-D-galactose-1-phospho)-alpha-D-glucosamine;UDP-N-acetyl-6-(D-galactose-1-phospho)-D-glucosamine,C23H38N3O25P3,NA,NA,NA,2.7.8.18,R00504
lactose,cpd:C04808,alpha-D-Abequosyl-(1->3)-alpha-D-mannosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-alpha-D-galactosyl-diphosphoundecaprenol;alpha-D-Abe-(1->3)-alpha-D-Man-(1->4)-alpha-L-Rha-(1->3)-alpha-D-Gal-PP-Und;D-Abequosyl-D-mannosyl-rhamnosyl-D-galactose-1-diphospholipid,C79H132O24P2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C04808  alpha-D-Abequosyl-(1->3)-alpha-D-mannosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-alpha-D-galactosyl-diphosphoundecaprenol,2.4.1.60,R04581
lactose,cpd:C04839,"3-O-(3,6-Anhydro-alpha-D-galactopyranosyl)-D-galactose 4-O-sulfate",C12H20O13S,NA,NA,NA,NA,NA
lactose,cpd:C04866,"alpha-D-Galactosyl-(1,3)-[alpha-L-fucosyl-(1,2)]-D-galactoside;Glycoprotein alpha-D-galactosyl-(1,3)-[alpha-L-fucosyl-(1,2)]-D-galactose;alpha-D-Galactosyl-(1->3)-[alpha-L-fucosyl(1->2)]-D-galactosyl-R",C18H31O15R,NA,NA,NA,2.4.1.37,R04548
lactose,cpd:C04926,"alpha-N-Acetylneuraminyl-2,3-beta-D-galactose-1,3-(alpha-N-acetylneuraminyl-2,6)-N-acetyl-D-galactosaminyl-R;N-Acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-[N-acetyl-alpha-neuraminyl-(2->6)]-N-acetyl-D-galactosaminyl-R",C36H58N3O27R,NA,NA,NA,2.4.3.7,R04635
lactose,cpd:C05136,"GDP-3,6-dideoxy-D-galactose",C16H25N5O14P2,NA,NA,NA,NA,NA
lactose,cpd:C05394,3-Keto-beta-D-galactose,C6H10O6,NA,NA,NA,3.2.1.23,R04783 R06144
lactose,cpd:C05396,Lactose 6'-phosphate,C12H23O14P,Galactose metabolism;Metabolic pathways;Phosphotransferase system (PTS),NA,NA,2.7.1.207;3.2.1.85,R03256 R04393
lactose,cpd:C05403,3-Ketolactose,C12H20O11,NA,NA,NA,1.1.99.13;3.2.1.23,R01680 R04783
lactose,cpd:C06471,"Abequose;3,6-Dideoxy-D-galactose;3,6-Dideoxy-D-xylo-hexose;3-Deoxy-D-fucose",C6H12O4,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C06471  Abequose,NA,NA
lactose,cpd:C06474,"3,6-Anhydrogalactose;3,6-Anhydro-D-galactose",C6H10O5,NA,NA,"Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C06474  3,6-Anhydrogalactose",NA,NA
lactose,cpd:C06483,"N-Acetyl-alpha-D-galactosaminyl-(1,3)-[alpha-L-fucosyl-(1,2)]-D-galactoside;Glycoprotein-N-Acetyl-alpha-D-galactosaminyl-(1,3)-[alpha-L-fucosyl-(1,2)]-D-galactose",C20H34NO15R,NA,NA,NA,2.4.1.40,R04423
lactose,cpd:C07285,Arabino-galactose,C11H20O10,NA,NA,NA,NA,NA
lactose,cpd:C11907,"dTDP-4-oxo-6-deoxy-D-glucose;dTDP-4-dehydro-6-deoxy-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-glucopyranose;dTDP-4-oxo-6-deoxy-alpha-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-galactose;dTDP-4-dehydro-6-deoxy-D-galactose;dTDP-6-deoxy-D-xylo-hexos-4-ulose;dTDP-6-deoxy-D-xylo-4-hexulose;4,6-Dideoxy-4-oxo-dTDP-D-glucose",C16H24N2O15P2,Streptomycin biosynthesis;Polyketide sugar unit biosynthesis;Acarbose and validamycin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-rhamnose biosynthesis;dTDP-6-deoxy-D-allose biosynthesis;dTDP-beta-L-noviose biosynthesis;dTDP-D-mycaminose biosynthesis;dTDP-D-desosamine biosynthesis;dTDP-L-mycarose biosynthesis;dTDP-L-oleandrose biosynthesis;dTDP-L-megosamine biosynthesis;dTDP-L-olivose biosynthesis;dTDP-D-forosamine biosynthesis;dTDP-D-angolosamine biosynthesis,NA,1.1.1.266;1.1.1.-;2.6.1.33;2.6.1.59;4.2.1.46;4.2.1.159;5.1.3.13;5.1.3.27;5.3.2.3;5.3.2.4,R02772 R02773 R04438 R05518 R05687 R06424 R06428 R06437;R06513 R06514 R08935 R09904
lactose,cpd:C12446,"dTDP-D-oliose;dTDP-2,6-dideoxy-D-galactose",C16H26N2O14P2,NA,NA,NA,2.4.1.-,R06717
lactose,cpd:C14830,GDP-4-keto-6-L-deoxygalactose,C16H23N5O15P2,NA,NA,NA,1.1.1.271,R07059 R07060
lactose,cpd:C15478,"D-Fucosamine;2-Amino-2,6-dideoxy-D-galactose",C6H13NO4,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C15478  D-Fucosamine,NA,NA
lactose,cpd:C15480,"N-Acetyl-D-fucosamine;2-Acetamido-2,6-dideoxy-D-galactose",C8H15NO5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C15480  N-Acetyl-D-fucosamine,NA,NA
lactose,cpd:C15926,beta-L-Galactose 1-phosphate;L-Galactose 1-phosphate,C6H13O9P,Ascorbate and aldarate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ascorbate biosynthesis, plants, fructose-6P => ascorbate",NA,2.7.7.69;3.1.3.93,R07674 R07678
lactose,cpd:C20415,"dTDP-4-acetamido-4,6-dideoxy-alpha-D-galactose;dTDP-Fuc4NAc",C18H29N3O15P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.3.1.210;2.4.1.325,R10142 R10303
lactose,cpd:C21317,"NDP-2-amino-4-oxo-2,6-dideoxy-D-galactose",C11H20NO13P2R,Biosynthesis of enediyne antibiotics;Biosynthesis of secondary metabolites,NA,NA,NA,R11432 R11433
lactose,cpd:C21318,"NDP-2-amino-2,6-dideoxy-D-galactose",C11H22NO13P2R,Biosynthesis of enediyne antibiotics;Biosynthesis of secondary metabolites,NA,NA,2.1.1.-,R11433 R11434
lactose,cpd:C21319,"NDP-2-methylamino-2,6-dideoxy-D-galactose",C12H24NO13P2R,Biosynthesis of enediyne antibiotics;Biosynthesis of secondary metabolites,NA,NA,2.1.1.-,R11434
lactose,cpd:C22261,"UDP-2-acetamido-2,6-dideoxy-alpha-D-galactose;UDP-N-acetyl-alpha-D-fucosamine;UDP-D-FucNAc",C17H27N3O16P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,NA,R12555
lactose,cpd:C22270,"UDP-2,6-dideoxy-2-acetamidino-beta-L-galactose;UDP-L-FucNAm",C17H28N4O15P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,UDP-L-FucNAm biosynthesis,NA,NA,R12584
lactose,cpd:C22492,beta-D-Glucosyl-(1->4)-D-galactose,C12H22O11,NA,NA,NA,2.4.1.388,R12979
lactose,cpd:C22575,"UDP-2-acetamido-4-amino-2,4,6-trideoxy-D-galactose",C17H28N4O15P2,O-Antigen nucleotide sugar biosynthesis,NA,NA,NA,R13087
L-glutamic acid,cpd:C00025,L-Glutamate;L-Glutamic acid;L-Glutaminic acid;Glutamate,C5H9NO4,"Arginine biosynthesis;Alanine, aspartate and glutamate metabolism;Arginine and proline metabolism;Carbapenem biosynthesis;Histidine metabolism;Taurine and hypotaurine metabolism;D-Amino acid metabolism;Glutathione metabolism;Neomycin, kanamycin and gentamicin biosynthesis;Glyoxylate and dicarboxylate metabolism;Butanoate metabolism;C5-Branched dibasic acid metabolism;Porphyrin metabolism;Nitrogen metabolism;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;ABC transporters;Two-component system;FoxO signaling pathway;Phospholipase D signaling pathway;Neuroactive ligand-receptor interaction;Ferroptosis;Gap junction;Circadian entrainment;Long-term potentiation;Synaptic vesicle cycle;Retrograde endocannabinoid signaling;Glutamatergic synapse;GABAergic synapse;Long-term depression;Taste transduction;Proximal tubule bicarbonate reclamation;Protein digestion and absorption;Amyotrophic lateral sclerosis;Huntington disease;Spinocerebellar ataxia;Pathways of neurodegeneration - multiple diseases;Cocaine addiction;Amphetamine addiction;Nicotine addiction;Alcoholism;Central carbon metabolism in cancer","Proline biosynthesis, glutamate => proline;GABA (gamma-Aminobutyrate) shunt;Ornithine biosynthesis, glutamate => ornithine;Histidine degradation, histidine => N-formiminoglutamate => glutamate;Glutathione biosynthesis, glutamate => glutathione;Heme biosynthesis, plants and bacteria, glutamate => heme;Photorespiration;Methylaspartate cycle;Ornithine biosynthesis, mediated by LysW, glutamate => ornithine;Arginine biosynthesis, glutamate => acetylcitrulline => arginine;Arginine succinyltransferase pathway, arginine => glutamate;Proline degradation, proline => glutamate",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00025  Glutamic acid (Glu); Hormones and transmitters;  Neurotransmitters;   Amino acids;    C00025  Glutamate;Risk category of Japanese OTC drugs [BR:br08312(D00007)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Glutamic acid;    D00007  Glutamic acid (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00007)]; Chemicals;  D00007  L-Glutamic acid,1.2.1.88;1.4.1.2;1.4.1.3;1.4.1.4;1.4.1.13;1.4.1.14;1.4.3.11;1.4.7.1;1.5.1.9;1.5.1.10;1.5.3.18;1.5.99.5;1.14.11.76;2.1.1.21;2.1.2.5;2.3.1.1;2.3.1.14;2.3.1.35;2.3.2.2;2.3.2.-;2.4.2.14;2.5.1.140;2.6.1.1;2.6.1.2;2.6.1.3;2.6.1.4;2.6.1.5;2.6.1.6;2.6.1.7;2.6.1.9;2.6.1.11;2.6.1.13;2.6.1.16;2.6.1.17;2.6.1.19;2.6.1.22;2.6.1.23;2.6.1.24;2.6.1.26;2.6.1.27;2.6.1.29;2.6.1.33;2.6.1.34;2.6.1.36;2.6.1.38;2.6.1.39;2.6.1.42;2.6.1.44;2.6.1.48;2.6.1.49;2.6.1.52;2.6.1.55;2.6.1.57;2.6.1.59;2.6.1.65;2.6.1.67;2.6.1.72;2.6.1.75;2.6.1.76;2.6.1.79;2.6.1.80;2.6.1.81;2.6.1.82;2.6.1.83;2.6.1.85;2.6.1.86;2.6.1.87;2.6.1.89;2.6.1.90;2.6.1.92;2.6.1.93;2.6.1.94;2.6.1.95;2.6.1.98;2.6.1.102;2.6.1.103;2.6.1.104;2.6.1.106;2.6.1.107;2.6.1.109;2.6.1.110;2.6.1.111;2.6.1.114;2.6.1.116;2.6.1.118;2.6.1.120;2.6.1.122;2.6.1.123;2.6.1.-;2.7.2.11;3.4.17.21;3.4.19.9;3.4.19.13;3.4.19.14;3.4.19.16;3.5.1.2;3.5.1.38;3.5.1.55;3.5.1.65;3.5.1.68;3.5.1.87;3.5.1.94;3.5.1.96;3.5.1.118;3.5.1.123;3.5.1.129;3.5.2.9;3.5.3.8;4.1.1.15;4.1.3.27;4.2.1.168;4.3.2.10;4.3.3.6;5.1.1.3;5.4.3.9;5.4.99.1;6.1.1.17;6.1.1.24;6.2.1.39;6.2.1.68;6.3.1.2;6.3.1.6;6.3.1.11;6.3.1.17;6.3.1.18;6.3.2.2;6.3.2.12;6.3.2.17;6.3.2.18;6.3.2.31;6.3.2.32;6.3.2.33;6.3.2.34;6.3.2.41;6.3.2.42;6.3.2.53;6.3.2.60;6.3.2.-;6.3.4.2;6.3.4.12;6.3.4.24;6.3.5.1;6.3.5.2;6.3.5.3;6.3.5.4;6.3.5.5;6.3.5.6;6.3.5.7;6.3.5.9;6.3.5.10;6.3.5.11;6.3.5.12;6.3.5.13;6.3.5.-,R00021 R00093 R00114 R00239 R00243 R00245 R00248 R00250;R00251 R00253 R00254 R00256 R00257 R00258 R00259 R00260;R00261 R00262 R00263 R00355 R00372 R00411 R00457 R00494;R00525 R00573 R00575 R00578 R00609 R00667 R00668 R00684;R00694 R00707 R00708 R00734 R00768 R00894 R00895 R00908;R00942 R00986 R01072 R01090 R01155 R01161 R01214 R01231;R01339 R01585 R01586 R01648 R01654 R01684 R01716 R01939;R01956 R02040 R02077 R02199 R02237 R02274 R02282 R02283;R02285 R02287 R02313 R02315 R02433 R02619 R02700 R02772;R02773 R02929 R02930 R03053 R03120 R03189 R03207 R03243;R03266 R03651 R03905 R03916 R03952 R03970 R03971 R04028;R04029 R04051 R04171 R04173 R04188 R04212 R04217 R04234;R04241 R04242 R04269 R04338 R04438 R04463 R04467 R04475;R04529 R04558 R04776 R05052 R05085 R05197 R05207 R05224;R05225 R05507 R05578 R05815 R06423 R06426 R06586 R06631;R06634 R06977 R07275 R07276 R07277 R07396 R07414 R07419;R07456 R07613 R07643 R07659 R08244 R08855 R08897 R08903;R08905 R08906 R08931 R08956 R09195 R09399 R09400 R09401;R09495 R09594 R09598 R09599 R09778 R09824 R09825 R09875;R10086 R10089 R10094 R10141 R10153 R10460 R10677 R10678;R10679 R10687 R10688 R10693 R10698 R10772 R10845 R10902;R10929 R10932 R10991 R10993 R11021 R11118 R11269 R11270;R11285 R11291 R11297 R11298 R11299 R11395 R11409 R11475;R11515 R11561 R11607 R11627 R11705 R11792 R11793 R11794;R11795 R11960 R11963 R12214 R12251 R12272 R12352 R12410;R12412 R12590 R12606 R12663 R12688 R12728 R12730 R12906;R12936 R12939 R13098 R13148
L-glutamic acid,cpd:C00449,"N6-(L-1,3-Dicarboxypropyl)-L-lysine;Saccharopine;L-Saccharopine;N-[(S)-5-Amino-5-carboxypentyl]-L-glutamic acid",C11H20N2O6,Lysine biosynthesis;Lysine degradation;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of amino acids,"Lysine biosynthesis, AAA pathway, 2-oxoglutarate => 2-aminoadipate => lysine;Lysine degradation, lysine => saccharopine => acetoacetyl-CoA",NA,1.5.1.7;1.5.1.8;1.5.1.9;1.5.1.10;1.5.3.18,R00715 R00716 R02313 R02315 R09495
L-glutamic acid,cpd:C00624,N-Acetyl-L-glutamate;N-Acetyl-L-glutamic acid,C7H11NO5,Arginine biosynthesis;D-Amino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids,"Ornithine biosynthesis, glutamate => ornithine;Arginine biosynthesis, glutamate => acetylcitrulline => arginine",NA,2.3.1.1;2.3.1.35;2.7.2.8;5.1.1.25,R00259 R02282 R02649 R13097 R13098
L-glutamic acid,cpd:C01046,N-Methyl-L-glutamate;N-Methyl-L-glutamic acid,C6H11NO4,Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.5.99.5;2.1.1.21,R00609 R01586
L-glutamic acid,cpd:C01425,Glutamyl-glutamic acid;L-alpha-Glutamyl-L-glutamic acid;Glu-Glu,C10H16N2O7,NA,NA,NA,NA,NA
L-glutamic acid,cpd:C03066,3-Hydroxy-L-glutamate;3-Hydroxy-L-glutamic acid,C5H9NO5,NA,NA,NA,4.1.1.16,R04135
L-glutamic acid,cpd:C03079,4-Hydroxy-L-glutamate;4-Hydroxy-L-glutamic acid,C5H9NO5,NA,NA,NA,2.6.1.23,R03266
L-leucine,cpd:C00123,L-Leucine;2-Amino-4-methylvaleric acid;(2S)-alpha-2-Amino-4-methylvaleric acid;(2S)-alpha-Leucine,C6H13NO2,"Valine, leucine and isoleucine degradation;Valine, leucine and isoleucine biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from histidine and purine;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;ABC transporters;mTOR signaling pathway;Protein digestion and absorption;Mineral absorption;Shigellosis;Central carbon metabolism in cancer","Leucine degradation, leucine => acetoacetate + acetyl-CoA",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00123  Leucine (Leu);Risk category of Japanese OTC drugs [BR:br08312(D00030)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Leucine;    D00030  Leucine (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00030)]; Chemicals;  D00030  L-Leucine,1.4.1.9;1.14.13.-;2.3.1.66;2.6.1.6;2.6.1.42;2.6.1.67;3.5.1.64;5.4.3.7;6.1.1.4;6.3.2.47,R01088 R01089 R01090 R01091 R02552 R03657 R08411 R08664;R10944
L-leucine,cpd:C02155,Glycyl-leucine;Glycyl-L-leucine,C8H16N2O3,NA,NA,NA,NA,NA
L-leucine,cpd:C02710,N-Acetyl-L-leucine,C8H15NO3,NA,NA,NA,2.3.1.66,R01089
L-leucine,cpd:C04301,N(alpha)-t-Butoxycarbonyl-L-leucine,C11H21NO4,NA,NA,NA,NA,NA
L-leucine,cpd:C04335,N(alpha)-Benzyloxycarbonyl-L-leucine,C14H19NO4,NA,NA,NA,3.5.1.64,R02552
L-leucine,cpd:C11332,Leucyl-leucine,C12H24N2O3,NA,NA,NA,NA,NA
L-leucine,cpd:C11333,N-Acetyl-leucyl-leucine,C14H26N2O4,NA,NA,NA,NA,NA
L-leucine,cpd:C20964,Dapdiamide C;3-{[(2E)-4-Amino-4-oxobut-2-enoyl]amino}-L-alanyl-L-leucine,C13H22N4O5,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Dapdiamides biosynthesis, L-2,3-diaminopropanoate => dapdiamide A/B/C",Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C20964,6.3.2.47,R10944
L-serine,cpd:C00065,L-Serine;L-2-Amino-3-hydroxypropionic acid;L-3-Hydroxy-alanine;Serine,C3H7NO3,"Glycine, serine and threonine metabolism;Monobactam biosynthesis;Cysteine and methionine metabolism;Cyanoamino acid metabolism;D-Amino acid metabolism;Glycerophospholipid metabolism;Sphingolipid metabolism;Glyoxylate and dicarboxylate metabolism;Methane metabolism;Sulfur metabolism;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Vancomycin resistance;ABC transporters;Sphingolipid signaling pathway;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","Serine biosynthesis, glycerate-3P => serine;Cysteine biosynthesis, serine => cysteine;Methionine degradation;Ceramide biosynthesis;Cysteine biosynthesis, homocysteine + serine => cysteine;Formaldehyde assimilation, serine pathway;Photorespiration;Nocardicin A biosynthesis, L-pHPG + arginine + serine => nocardicin A;Cycloserine biosynthesis, arginine/serine => cycloserine;Staphyloferrin B biosynthesis, L-serine => staphyloferrin B;Betaine degradation, bacteria, betaine => pyruvate",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00065  Serine (Ser);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00016)]; Chemicals;  D00016  L-Serine,1.1.1.276;1.1.1.387;1.4.1.7;2.1.2.1;2.3.1.30;2.3.1.50;2.6.1.45;2.6.1.51;2.7.1.80;2.7.1.225;2.7.1.226;2.7.8.4;2.7.8.8;2.7.8.29;2.7.8.38;2.8.1.4;3.1.3.3;3.1.4.13;4.1.1.-;4.2.1.20;4.2.1.22;4.2.1.50;4.2.1.122;4.3.1.17;4.3.1.19;5.1.1.10;5.1.1.18;6.1.1.11;6.2.1.72;6.3.2.14,R00220 R00581 R00582 R00584 R00585 R00586 R00588 R00589;R00590 R00674 R00891 R00945 R01281 R01289 R01290 R01800;R02378 R02563 R02722 R02817 R03662 R03923 R04942 R06126;R07376 R07377 R07644 R08218 R09099 R10255 R10441 R10880;R10984 R10985 R10986 R11667 R12342 R12344 R12757 R12779;R12781 R13249
L-serine,cpd:C00979,O-Acetyl-L-serine;O3-Acetyl-L-serine,C5H9NO4,Cysteine and methionine metabolism;Zeatin biosynthesis;Sulfur metabolism;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Sulfur relay system,"Cysteine biosynthesis, serine => cysteine;Cycloserine biosynthesis, arginine/serine => cycloserine",NA,2.3.1.30;2.5.1.47;2.5.1.49;2.5.1.50;2.5.1.51;2.5.1.52;2.5.1.53;2.5.1.65;2.5.1.118;2.5.1.119;2.5.1.134;2.5.1.144;2.6.99.3,R00586 R00897 R03131 R03132 R03133 R03134 R03601 R04091;R04859 R10305 R10461 R10839 R10840
L-serine,cpd:C01005,O-Phospho-L-serine;L-O-Phosphoserine;3-Phosphoserine;Dexfosfoserine;3-Phospho-L-serine,C3H8NO6P,"Glycine, serine and threonine metabolism;Cysteine and methionine metabolism;Methane metabolism;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids","Serine biosynthesis, glycerate-3P => serine;Staphyloferrin B biosynthesis, L-serine => staphyloferrin B",NA,2.5.1.47;2.5.1.65;2.5.1.76;2.5.1.113;2.5.1.140;2.6.1.52;2.7.1.80;2.7.1.225;2.7.1.226;2.8.5.1;3.1.3.3;6.1.1.27,R00582 R00584 R04173 R07274 R08576 R09530 R10610 R11705;R12092 R12342 R12344
L-serine,cpd:C02189,[Protein]-L-serine;Protein serine;Protein L-serine,C4H6N2O3R2,Mucin type O-glycan biosynthesis;Mannose type O-glycan biosynthesis;Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate;Glycosaminoglycan biosynthesis - heparan sulfate / heparin;Metabolic pathways,"O-glycan biosynthesis, mucin type core;Glycosaminoglycan biosynthesis, linkage tetrasaccharide;O-glycan biosynthesis, mannose type (core M3)",NA,2.4.1.41;2.4.1.109;2.4.1.221;2.4.1.255;2.4.1.376;2.4.2.26;2.4.2.33;2.4.2.63;2.7.11.35;3.2.1.97;3.2.1.169,R03356 R04072 R04527 R05907 R05925 R06140 R07620 R09295;R09304 R09315 R09672 R09676 R13188
L-serine,cpd:C02703,L-Serine O-sulfate,C3H7NO6S,NA,NA,NA,4.3.1.10,R00532
L-serine,cpd:C02737,"Phosphatidylserine;Phosphatidyl-L-serine;1,2-Diacyl-sn-glycerol 3-phospho-L-serine;3-O-sn-Phosphatidyl-L-serine;O3-Phosphatidyl-L-serine;L-1-Phosphatidylserine",C8H12NO10PR2,"Glycine, serine and threonine metabolism;Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Efferocytosis;Leishmaniasis;Amoebiasis;Systemic lupus erythematosus","Phosphatidylethanolamine (PE) biosynthesis, PA => PS => PE","Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C02737  Phosphatidylserine;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP03 Glycerophosphoserines;   GP0301 Diacylglycerophosphoserines;    C02737  1,2-Diacyl-sn-glycerol 3-phospho-L-serine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; A ALIMENTARY TRACT AND METABOLISM;  A05 BILE AND LIVER THERAPY;   A05B LIVER THERAPY, LIPOTROPICS;    A05BA Liver therapy;     A05BA10 Phospholipids;      C02737  Phosphatidylserine",2.3.1.-;2.7.8.8;2.7.8.29;3.1.1.32;3.1.1.111;4.1.1.65,R01800 R02055 R04034 R07376 R07377 R09035
L-serine,cpd:C03015,O-Carbamoyl-L-serine,C4H8N2O4,NA,NA,NA,4.3.1.13,R00213
L-serine,cpd:C03872,L-Serine-phosphoethanolamine;Serine phosphoethanolamine,C5H13N2O6P,Glycerophospholipid metabolism,NA,NA,2.7.8.4;3.1.4.13,R02563 R02817
L-serine,cpd:C04128,Low-density lipoprotein L-serine,C4H6N2O3R2,NA,NA,NA,2.7.11.29,R04403
L-serine,cpd:C04204,"N-(2,3-Dihydroxybenzoyl)-L-serine;2,3-Dihydroxy-N-benzoyl-L-serine;2,3-Dihydroxybenzoylserine",C10H11NO6,NA,NA,NA,NA,NA
L-serine,cpd:C04565,Low-density lipoprotein O-phospho-L-serine,C4H7N2O6PR2,NA,NA,NA,2.7.11.29,R04403
L-serine,cpd:C04776,Peptide beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-L-serine;T antigen,C18H29N3O13R2,Mucin type O-glycan biosynthesis;Metabolic pathways,NA,NA,3.2.1.97,R04527
L-serine,cpd:C04800,"D-Glucuronyl-N-acetyl-1,3-beta-D-galactosaminylproteoglycan;[Protein]-3-O-(beta-D-GlcA-(1->3)-beta-D-GalNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-serine",C41H63N3O34R2,NA,NA,NA,2.4.1.175,R04603
L-serine,cpd:C04825,3-beta-D-Galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein;[Protein]-3-O-(beta-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-xylosyl)-L-serine,C21H34N2O17R2,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate;Glycosaminoglycan biosynthesis - heparan sulfate / heparin;Metabolic pathways,NA,NA,2.4.1.135,R04607
L-serine,cpd:C04903,"3-beta-D-Glucuronosyl-3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein;beta-D-Glucuronyl-1,3-D-galactosylproteoglycan;[Protein]-3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-serine",C27H42N2O23R2,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate;Glycosaminoglycan biosynthesis - heparan sulfate / heparin;Metabolic pathways,NA,NA,2.4.1.135;2.4.1.223,R04607 R07397
L-serine,cpd:C04913,"N-Acetyl-beta-D-galactosaminyl-1,4-beta-D-glucuronyl-N-acetyl-1,3-beta-D-galactosaminylproteoglycan;[Protein]-3-O-(beta-D-GalNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-GalNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-serine",C49H76N4O39R2,NA,NA,NA,2.4.1.175,R04603
L-serine,cpd:C05821,"Enterochelin;Enterobactin;Tri-(2,3-dihydroxy-N-benzoyl-L-serine)-ester;Tri-(N-(2,3-dihydroxybenzoyl)-L-serine)-ester",C30H27N3O15,Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Biosynthesis of secondary metabolites,NA,Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C05821,2.4.1.369;3.1.1.107;6.3.2.14,R07644 R12469 R12473
L-serine,cpd:C06395,omega-Agatoxin IVC;[Protein]-L-serine,C4H6N2O3R2,NA,NA,NA,5.1.1.16,R05175
L-serine,cpd:C15656,alpha-N-Acetyl-D-glucosaminyl-(1->4)-beta-D-glucuronosyl-(1->3)-beta-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-xylosylproteoglycan;[Protein]-3-O-(alpha-D-GlcNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-serine,C35H55N3O28R2,Glycosaminoglycan biosynthesis - heparan sulfate / heparin;Metabolic pathways,NA,NA,2.4.1.223,R07397
L-serine,cpd:C19802,[Protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine;[Protein]-3-O-(N-acetyl-beta-D-glucosaminyl)-L-serine,C12H19N3O8R2,NA,NA,NA,2.4.1.255;3.2.1.169,R09672 R09676
L-serine,cpd:C20466,"2,3-Bis-(O-geranylgeranyl)-sn-glycero-1-phospho-L-serine",C46H78NO8P,Glycerophospholipid metabolism;Biosynthesis of secondary metabolites,NA,NA,2.7.8.38,R10255
L-serine,cpd:C20628,"2,3-Bis-(O-phytanyl)-sn-glycero-1-phospho-L-serine",C46H94NO8P,NA,NA,NA,2.7.8.38,R10441
L-serine,cpd:C20639,O-Ureido-L-serine;(2S)-2-Amino-3-[(carbamoylamino)oxy]propanoate;(2S)-2-Amino-3-(carbamoylamino)oxypropanoic acid,C4H9N3O4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cycloserine biosynthesis, arginine/serine => cycloserine",NA,2.6.99.3;5.1.1.19,R10461 R10488
L-serine,cpd:C21171,[Wnt]-O-(9Z)-hexadec-9-enoyl-L-serine,C20H34N2O4R2,NA,NA,NA,2.3.1.250;3.1.1.98,R11201 R11202
L-serine,cpd:C21172,[Wnt]-L-serine,C4H6N2O3R2,NA,NA,NA,2.3.1.250;3.1.1.98,R11201 R11202
L-serine,cpd:C22185,"N-(2,3-Dihydroxybenzoyl)-L-serine trimer;O-3-{O-3-[N-(2,3-Dihydroxybenzoyl)-L-seryl]-N-(2,3-dihydroxybenzoyl)-L-seryl}-N-(2,3-dihydroxybenzoyl)-L-serine",C30H29N3O16,NA,NA,NA,3.1.1.107,R12473
L-serine,cpd:C22186,"Triglucosyl-(2,3-dihydroxybenzoylserine)3;O-3-{O-3-[N-(2,3-Dihydroxybenzoyl)-C-5-deoxy-beta-D-glucosyl-L-seryl]-N-(2,3-dihydroxybenzoyl)-C-5-deoxy-beta-D-glucosyl-L-seryl}-N-(2,3-dihydroxybenzoyl)-C-5-deoxy-beta-D-glucosyl-L-serine",C48H59N3O31,NA,NA,NA,3.1.1.107,R12474
L-serine,cpd:C22188,"Monoglucosyl-(2,3-dihydroxybenzoylserine)3;O-3-{O-3-[N-(2,3-Dihydroxybenzoyl)-C-5-deoxy-beta-D-glucosyl-L-seryl]-N-(2,3-dihydroxybenzoyl)-L-seryl}-N-(2,3-dihydroxybenzoyl)-L-serine",C36H39N3O21,NA,NA,NA,3.1.1.107,R12476
L-serine,cpd:C22227,[Sulfatase]-L-serine,C3H6N2O2R2,NA,NA,NA,1.1.98.7,R12569
L-serine,cpd:C22692,[Protein]-O-phospho-L-serine,C4H7N2O6PR2,NA,NA,NA,2.7.11.35,R13188
Octacosanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
Tricosanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
Alanine,cpd:C00041,L-Alanine;L-2-Aminopropionic acid;L-alpha-Alanine,C3H7NO2,"Alanine, aspartate and glutamate metabolism;Cysteine and methionine metabolism;Taurine and hypotaurine metabolism;Selenocompound metabolism;D-Amino acid metabolism;Carbon fixation in photosynthetic organisms;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Vancomycin resistance;ABC transporters;Sulfur relay system;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","C4-dicarboxylic acid cycle, NAD - malic enzyme type;Fumiquinazoline biosynthesis, tryptophan + alanine + anthranilate => fumiquinazoline",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00041  Alanine (Ala);Risk category of Japanese OTC drugs [BR:br08312(D00012)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Alanine;    D00012  Alanine (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00012)]; Chemicals;  D00012  L-Alanine,1.4.1.1;1.5.1.17;2.3.1.47;2.6.1.2;2.6.1.12;2.6.1.15;2.6.1.18;2.6.1.30;2.6.1.37;2.6.1.40;2.6.1.41;2.6.1.43;2.6.1.44;2.6.1.46;2.6.1.47;2.6.1.51;2.6.1.56;2.6.1.58;2.6.1.66;2.6.1.71;2.6.1.77;2.6.1.84;2.6.1.96;2.6.1.99;2.6.1.108;2.6.1.113;2.6.1.115;2.6.1.119;2.8.1.7;2.8.1.9;3.5.1.28;3.7.1.3;4.1.1.12;4.1.1.64;4.4.1.16;5.1.1.1;6.1.1.7;6.2.1.67;6.3.2.8;6.3.2.49;6.3.2.-,R00258 R00369 R00396 R00397 R00398 R00400 R00401 R00453;R00576 R00585 R00692 R00863 R00907 R00987 R01215 R01261;R01712 R02050 R02271 R02293 R02668 R02970 R03001 R03038;R03193 R03210 R03502 R03599 R03854 R03936 R04112 R04152;R04187 R05652 R07460 R08197 R08714 R08872 R09048 R09254;R10124 R10178 R10180 R10992 R11038 R11064 R11528 R11583;R12343 R12417 R12419 R12622 R12725 R12727
Alanine,cpd:C00065,L-Serine;L-2-Amino-3-hydroxypropionic acid;L-3-Hydroxy-alanine;Serine,C3H7NO3,"Glycine, serine and threonine metabolism;Monobactam biosynthesis;Cysteine and methionine metabolism;Cyanoamino acid metabolism;D-Amino acid metabolism;Glycerophospholipid metabolism;Sphingolipid metabolism;Glyoxylate and dicarboxylate metabolism;Methane metabolism;Sulfur metabolism;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Vancomycin resistance;ABC transporters;Sphingolipid signaling pathway;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","Serine biosynthesis, glycerate-3P => serine;Cysteine biosynthesis, serine => cysteine;Methionine degradation;Ceramide biosynthesis;Cysteine biosynthesis, homocysteine + serine => cysteine;Formaldehyde assimilation, serine pathway;Photorespiration;Nocardicin A biosynthesis, L-pHPG + arginine + serine => nocardicin A;Cycloserine biosynthesis, arginine/serine => cycloserine;Staphyloferrin B biosynthesis, L-serine => staphyloferrin B;Betaine degradation, bacteria, betaine => pyruvate",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00065  Serine (Ser);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00016)]; Chemicals;  D00016  L-Serine,1.1.1.276;1.1.1.387;1.4.1.7;2.1.2.1;2.3.1.30;2.3.1.50;2.6.1.45;2.6.1.51;2.7.1.80;2.7.1.225;2.7.1.226;2.7.8.4;2.7.8.8;2.7.8.29;2.7.8.38;2.8.1.4;3.1.3.3;3.1.4.13;4.1.1.-;4.2.1.20;4.2.1.22;4.2.1.50;4.2.1.122;4.3.1.17;4.3.1.19;5.1.1.10;5.1.1.18;6.1.1.11;6.2.1.72;6.3.2.14,R00220 R00581 R00582 R00584 R00585 R00586 R00588 R00589;R00590 R00674 R00891 R00945 R01281 R01289 R01290 R01800;R02378 R02563 R02722 R02817 R03662 R03923 R04942 R06126;R07376 R07377 R07644 R08218 R09099 R10255 R10441 R10880;R10984 R10985 R10986 R11667 R12342 R12344 R12757 R12779;R12781 R13249
Alanine,cpd:C00079,L-Phenylalanine;(S)-alpha-Amino-beta-phenylpropionic acid,C9H11NO2,"Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Cyanoamino acid metabolism;D-Amino acid metabolism;Phenylpropanoid biosynthesis;Tropane, piperidine and pyridine alkaloid biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of various alkaloids;Biosynthesis of various other secondary metabolites;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;ABC transporters;Protein digestion and absorption;Mineral absorption;Central carbon metabolism in cancer","Phenylalanine biosynthesis, chorismate => phenylpyruvate => phenylalanine;Monolignol biosynthesis, phenylalanine/tyrosine => monolignol;Flavanone biosynthesis, phenylalanine => naringenin;Ditryptophenaline biosynthesis, tryptophan + phenylalanine => ditryptophenaline;Phenylalanine biosynthesis, chorismate => arogenate => phenylalanine",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00079  Phenylalanine (Phe);Risk category of Japanese OTC drugs [BR:br08312(D00021)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Phenylalanine;    D00021  Phenylalanine (USP/INN);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00021)]; Chemicals;  D00021  L-Phenylalanine,1.4.1.20;1.4.3.2;1.11.1.21;1.13.12.9;1.14.14.40;1.14.16.1;1.14.16.7;2.3.1.53;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.28;2.6.1.57;2.6.1.58;2.6.1.64;2.6.1.70;2.6.1.-;3.4.17.23;4.1.1.28;4.1.1.53;4.1.1.109;4.2.1.51;4.2.1.91;4.3.1.24;4.3.1.25;5.1.1.11;5.4.3.10;5.4.3.11;6.1.1.20;6.3.2.40;6.3.2.-,R00686 R00688 R00689 R00690 R00691 R00692 R00693 R00694;R00695 R00697 R00698 R00699 R01375 R01376 R01795 R03660;R06744 R07211 R08463 R08652 R08690 R09535 R09578 R09579;R10286 R10287 R10495 R10499 R10729 R11068 R11918 R12413;R12540 R12543
Alanine,cpd:C00082,L-Tyrosine;(S)-3-(p-Hydroxyphenyl)alanine;(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid;Tyrosine,C9H11NO3,"Ubiquinone and other terpenoid-quinone biosynthesis;Monobactam biosynthesis;Tyrosine metabolism;Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Novobiocin biosynthesis;Cyanoamino acid metabolism;Methane metabolism;Thiamine metabolism;Phenylpropanoid biosynthesis;Isoquinoline alkaloid biosynthesis;Betalain biosynthesis;Glucosinolate biosynthesis;Aminoacyl-tRNA biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of vancomycin group antibiotics;Biosynthesis of enediyne antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Dopaminergic synapse;Melanogenesis;Prolactin signaling pathway;Protein digestion and absorption;Parkinson disease;Cocaine addiction;Amphetamine addiction;Alcoholism;Central carbon metabolism in cancer","Tyrosine biosynthesis, chorismate => HPP => tyrosine;Monolignol biosynthesis, phenylalanine/tyrosine => monolignol;Tyrosine biosynthesis, chorismate => arogenate => tyrosine;Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline;Thyroid hormone biosynthesis, tyrosine => triiodothyronine/thyroxine;Tyrosine degradation, tyrosine => homogentisate;Thiamine biosynthesis, prokaryotes, AIR (+ DXP/tyrosine) => TMP/TPP;Cyanogenic glycoside biosynthesis, tyrosine => dhurrin;C-1027 beta-amino acid moiety biosynthesis, tyrosine => 3-chloro-4,5-dihydroxy-beta-phenylalanyl-PCP;Maduropeptin beta-hydroxy acid moiety biosynthesis, tyrosine => 3-(4-hydroxyphenyl)-3-oxopropanoyl-PCP;Puromycin biosynthesis, ATP => puromycin;Methanofuran biosynthesis;Betacyanin biosynthesis, L-tyrosine => amaranthin",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00082  Tyrosine (Tyr);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00022)]; Chemicals;  D00022  L-Tyrosine,1.2.1.101;1.3.1.43;1.3.1.78;1.3.1.79;1.4.1.20;1.4.3.2;1.10.3.1;1.11.1.8;1.11.2.6;1.14.14.36;1.14.16.1;1.14.16.2;1.14.18.1;1.14.-.-;1.21.1.1;2.1.1.304;2.5.1.122;2.5.1.147;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.57;2.6.1.58;2.6.1.103;4.1.1.25;4.1.1.28;4.1.1.108;4.1.99.2;4.1.99.19;4.1.99.24;4.3.1.23;4.3.1.25;5.4.3.6;6.1.1.1;6.3.2.24;6.3.2.25,R00031 R00728 R00729 R00730 R00731 R00732 R00733 R00734;R00735 R00736 R00737 R00739 R01795 R01815 R02078 R02918;R03539 R04730 R05671 R06626 R06751 R07211 R07212 R08825;R09254 R09521 R09830 R10059 R10246 R10671 R10964 R10968;R11366 R11917 R12150 R12161 R12235 R12540 R12541 R12611;R12759 R13031
Alanine,cpd:C00099,beta-Alanine;3-Aminopropionic acid;3-Aminopropanoate,C3H7NO2,Pyrimidine metabolism;beta-Alanine metabolism;Propanoate metabolism;Pantothenate and CoA biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors;Neuroactive ligand-receptor interaction;Protein digestion and absorption,"Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate;Pantothenate biosynthesis, valine/L-aspartate => pantothenate;Pantothenate biosynthesis, 2-oxoisovalerate/spermine => pantothenate",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00099  beta-Alanine;  Amines;   Biogenic amines;    C00099  beta-Alanine,1.2.1.3;1.2.1.5;1.2.1.19;1.5.1.26;2.6.1.18;2.6.1.19;2.6.1.55;2.6.1.120;2.8.3.-;3.4.13.4;3.4.13.5;3.4.13.18;3.4.13.20;3.5.1.6;3.5.1.21;3.5.1.22;3.5.1.100;3.5.3.17;4.1.1.11;4.1.1.15;6.3.2.1;6.3.2.11;6.3.2.23;6.3.2.36;6.3.2.44,R00489 R00904 R00905 R00906 R00907 R00908 R00909 R00910;R00911 R00912 R00913 R00914 R00915 R00916 R00917 R01164;R01166 R02473 R02474 R02741 R03286 R03288 R03935 R09379;R09648 R10821
Alanine,cpd:C00133,D-Alanine;D-2-Aminopropionic acid;D-Ala,C3H7NO2,D-Amino acid metabolism;Peptidoglycan biosynthesis;Teichoic acid biosynthesis;Metabolic pathways;Vancomycin resistance;Cationic antimicrobial peptide (CAMP) resistance;Taste transduction,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00133  D-Alanine,1.4.3.3;1.4.3.19;2.1.2.7;2.3.1.263;2.3.2.14;2.6.1.21;3.1.1.103;3.4.13.22;3.4.17.8;5.1.1.1;6.1.1.13;6.1.2.1;6.3.2.4;6.3.2.16;6.3.2.35,R00399 R00401 R01147 R01148 R01149 R01150 R01225 R01344;R02718 R04369 R04611 R05861 R07651 R08850 R09588 R09595;R11965 R12557 R12812 R12863 R12867 R12871 R12873 R12875;R12904
Alanine,cpd:C00328,L-Kynurenine;3-Anthraniloyl-L-alanine,C10H12N2O3,Tryptophan metabolism;Metabolic pathways;Biosynthesis of cofactors;African trypanosomiasis,"Tryptophan metabolism, tryptophan => kynurenine => 2-aminomuconate;NAD biosynthesis, tryptophan => quinolinate => NAD",NA,1.14.13.9;2.6.1.7;2.6.1.63;3.5.1.9;3.7.1.3,R00987 R01956 R01957 R01959 R01960 R12688 R12692
Alanine,cpd:C00355,"3,4-Dihydroxy-L-phenylalanine;L-Dopa;3-Hydroxy-L-tyrosine;L-beta-(3,4-Dihydroxyphenyl)alanine;Levodopa;Dihydroxy-L-phenylalanine",C9H11NO4,Tyrosine metabolism;Isoquinoline alkaloid biosynthesis;Betalain biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Dopaminergic synapse;Prolactin signaling pathway;Parkinson disease;Cocaine addiction;Amphetamine addiction;Alcoholism,"Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline;Betacyanin biosynthesis, L-tyrosine => amaranthin","Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00355  3,4-Dihydroxy-L-phenylalanine; Hormones and transmitters;  Neurotransmitters;   Amino acids;    C00355  Dopa;Prodrugs [br08324.html]; C00355;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00059)]; N NERVOUS SYSTEM;  N04 ANTI-PARKINSON DRUGS;   N04B DOPAMINERGIC AGENTS;    N04BA Dopa and dopa derivatives;     N04BA01 Levodopa;      D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00059)]; Antiparkinson Agents;  Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors;   Levodopa;    D00059  Levodopa (JP18/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D00059)]; 1  Agents affecting nervous system and sensory organs;  11  Agents affecting central nervous system;   116  Antiparkinsonian agents;    1164  Levodopas;     D00059  Levodopa (JP18/USP/INN);Drug groups [BR:br08330(D00059)]; Neuropsychiatric agent;  DG01472  Dopamine agonist;   D00059  Levodopa;  DG01967  Antiparkinson agent;   D00059  Levodopa;Drug classes [BR:br08332(D00059)]; Neuropsychiatric agent;  DG01967  Antiparkinson agent;   D00059  Levodopa;Target-based classification of drugs [BR:br08310(D00059)]; G Protein-coupled receptors;  Rhodopsin family;   Dopamine;    DRD;     D00059  Levodopa (JP18/USP/INN) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00059)]; Chemicals;  D00059  Levodopa;New drug approvals in Europe [br08329.html(D00059)]; European public assessment reports (EPAR) authorised medicine;  D00059;Prodrugs [br08324.html(D00059)]; D00059",1.10.3.1;1.11.2.6;1.13.11.29;1.13.11.30;1.13.11.-;1.13.12.15;1.14.16.2;1.14.18.1;1.14.-.-;2.6.1.49;4.1.1.25;4.1.1.28;4.1.1.107;4.3.1.22,R00031 R00045 R00731 R01815 R02075 R02076 R02077 R02078;R02080 R03672 R07212 R08443 R08827 R08836 R08846 R08920;R11916 R12541 R12611 R13031 R13032
Alanine,cpd:C00506,L-Cysteate;L-Cysteic acid;3-Sulfoalanine;2-Amino-3-sulfopropionic acid,C3H7NO5S,Cysteine and methionine metabolism;Taurine and hypotaurine metabolism;Metabolic pathways;Neuroactive ligand-receptor interaction,NA,NA,2.5.1.76;2.6.1.1;4.1.1.15;4.1.1.29;4.1.1.122;4.4.1.10;4.4.1.25,R00901 R01682 R02433 R02434 R07634 R08699 R09530
Alanine,cpd:C00606,3-Sulfino-L-alanine;L-Cysteinesulfinic acid;3-Sulphino-L-alanine;3-Sulfinoalanine,C3H7NO4S,Cysteine and methionine metabolism;Taurine and hypotaurine metabolism;Metabolic pathways,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00606  3-Sulfino-L-alanine,1.4.1.-;1.13.11.20;2.6.1.1;4.1.1.12;4.1.1.15;4.1.1.29,R00863 R00893 R02434 R02466 R02618 R02619
Alanine,cpd:C00716,Serine;2-Amino-3-hydroxypropionic acid;3-Hydroxyalanine,C3H7NO3,Bacterial chemotaxis,NA,NA,4.3.1.15,R00223 R02818
Alanine,cpd:C00993,D-Alanyl-D-alanine;D-Ala-D-Ala,C6H12N2O3,D-Amino acid metabolism;Peptidoglycan biosynthesis;Metabolic pathways;Vancomycin resistance,NA,Compounds with biological roles [BR:br08001]; Peptides;  Peptides;   Dipeptides;    C00993  D-Alanyl-D-alanine,3.4.13.22;6.3.2.4;6.3.2.10,R01150 R04573 R04617 R07651
Alanine,cpd:C01073,N-Acetyl-beta-alanine,C5H9NO3,beta-Alanine metabolism,NA,NA,3.5.1.21,R00909
Alanine,cpd:C01162,3-(Pyrazol-1-yl)-L-alanine;beta-Pyrazol-1-ylalanine,C6H9N3O2,NA,NA,NA,2.5.1.51;4.2.1.50,R02378 R03134
Alanine,cpd:C01212,UDP-N-acetylmuramoyl-L-alanine;UDP-N-acetyl-alpha-D-muramoyl-L-alanine,C23H36N4O20P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,NA,6.3.2.8;6.3.2.9;6.3.2.53,R02783 R03193 R12272
Alanine,cpd:C01314,"(S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]-(S)-alanine",C16H20N2O6S,NA,NA,NA,NA,NA
Alanine,cpd:C01316,"(S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxoprolyl]-(S)-alanine benzyl ester",C25H28N2O7S,NA,NA,NA,NA,NA
Alanine,cpd:C01401,Alanine;2-Aminopropionic acid;2-Aminopropanoic acid,C3H7NO2,Cyanoamino acid metabolism;Metabolic pathways,NA,Risk category of Japanese OTC drugs [BR:br08312]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Alanine;    C01401  Alanine,3.5.5.1,R03542 R05840
Alanine,cpd:C01513,Lupinate;Lupinic acid;3-[N6-(4-Hydroxyisopentenyl)adeninyl]-L-alanine;(S)-2-Amino-3-{[(E)-4-hydroxy-3-methylbut-2-enylamino]purin-9-yl}propanoic acid,C13H18N6O3,Zeatin biosynthesis;Biosynthesis of secondary metabolites,NA,NA,2.5.1.50,R03133
Alanine,cpd:C01536,Tyrosine;3-(p-Hydroxyphenyl)alanine;2-Amino-3-(p-hydroxyphenyl)propionic acid,C9H11NO3,NA,NA,NA,NA,NA
Alanine,cpd:C01718,Kynurenine;3-Anthraniloylalanine,C10H12N2O3,NA,NA,NA,NA,NA
Alanine,cpd:C02057,Phenylalanine;alpha-Amino-beta-phenylpropionic acid,C9H11NO2,NA,NA,NA,NA,NA
Alanine,cpd:C02065,Protein alanine,C4H6N2O2R2,NA,NA,NA,NA,NA
Alanine,cpd:C02207,beta-Alanopine;N-(D-1-Carboxyethyl)-beta-alanine,C6H11NO4,NA,NA,NA,1.5.1.26,R00906
Alanine,cpd:C02218,Dehydroalanine;2-Aminoacrylate;2-Aminoprop-2-enoate,C3H5NO2,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,1.11.1.8;4.1.99.1;4.1.99.2;4.3.1.17;4.3.3.8;4.4.1.4,R00590 R03208 R03901 R03953 R08698 R08699 R11100 R12758;R12759 R13116
Alanine,cpd:C02265,D-Phenylalanine;D-alpha-Amino-beta-phenylpropionic acid,C9H11NO2,Phenylalanine metabolism;D-Amino acid metabolism;Metabolic pathways;Taste transduction,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C02265  D-Phenylalanine,1.4.5.1;2.3.1.36;2.6.1.21;5.1.1.11,R00686 R01374 R01582 R03903
Alanine,cpd:C02487,(Ac)2-L-Lys-D-Ala;(Ac)2-L-lysyl-D-alanine,C13H23N3O5,NA,NA,NA,NA,NA
Alanine,cpd:C02512,3-Cyano-L-alanine;L-3-Cyanoalanine;L-beta-Cyanoalanine,C4H6N2O2,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,2.3.2.2;3.5.5.4;4.1.1.-;4.2.1.65;4.4.1.9,R00486 R01267 R02846 R03524 R03970 R06614
Alanine,cpd:C02634,3-Chloro-D-alanine,C3H6ClNO2,NA,NA,NA,4.5.1.2,R01031
Alanine,cpd:C02635,3-Chloro-L-alanine,C3H6ClNO2,NA,NA,NA,4.5.1.5,R01032 R04003
Alanine,cpd:C02638,3-Fluoro-D-alanine;(S)-3-Fluoroalanine,C3H6FNO2,NA,NA,NA,NA,NA
Alanine,cpd:C02642,3-Ureidopropionate;3-Ureidopropanoate;beta-Ureidopropionic acid;N-Carbamoyl-beta-alanine,C4H8N2O3,Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Metabolic pathways,"Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate",NA,3.5.1.6;3.5.2.2,R00905 R02269
Alanine,cpd:C02721,N-Methyl-L-alanine,C4H9NO2,NA,NA,NA,1.4.1.17,R01584
Alanine,cpd:C02999,N-Acetylmuramoyl-Ala;N-Acetyl-D-muramoyl-L-alanine,C14H24N2O9,NA,NA,NA,3.5.1.28,R04112
Alanine,cpd:C03210,"Alanopine;2,2'-Iminodipropanoate;meso-N-(1-Carboxyethyl)-alanine",C6H11NO4,NA,NA,NA,1.5.1.17,R00398
Alanine,cpd:C03326,(Ac)2-L-Lys-D-Ala-D-Ala;(Ac)2-L-lysyl-D-alanyl-D-alanine,C16H28N4O6,NA,NA,NA,NA,NA
Alanine,cpd:C03401,"L-2,3-Diaminopropanoate;L-2,3-Diaminopropionate;L-2,3-Diaminopropionic acid;L-2,3-Diaminopropanoic acid;3-Amino-L-alanine;(S)-2,3-Diaminopropanoate;(2S)-2,3-Diaminopropanoic acid",C3H8N2O2,Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Staphyloferrin B biosynthesis, L-serine => staphyloferrin B;Dapdiamides biosynthesis, L-2,3-diaminopropanoate => dapdiamide A/B/C","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C03401  (2S)-2,3-Diaminopropanoic acid",1.5.1.51;2.3.1.58;6.3.2.46;6.3.2.54;6.3.2.55,R04211 R10940 R11655 R12308 R12311
Alanine,cpd:C03450,(3-Arylcarbonyl)-alanine,C10H11NO3,NA,NA,NA,NA,NA
Alanine,cpd:C03519,N-Acetyl-L-phenylalanine,C11H13NO3,Phenylalanine metabolism;Metabolic pathways,NA,NA,2.3.1.53,R00693
Alanine,cpd:C03584,3-(Uracil-1-yl)-L-alanine;Willardiine,C7H9N3O4,NA,NA,NA,2.5.1.53,R03131
Alanine,cpd:C03709,N-Adenylyl-L-phenylalanine,C19H23N6O8P,NA,NA,NA,NA,NA
Alanine,cpd:C03738,gamma-L-Glutamyl-D-alanine;L-gamma-Glutamyl-D-alanine,C8H14N2O5,NA,NA,NA,2.3.2.14,R01149
Alanine,cpd:C03790,N-(Carboxymethyl)-D-alanine;Strombine,C5H9NO4,NA,NA,NA,1.5.1.22,R00368
Alanine,cpd:C03803,Ribosomal-protein L-alanine;Ribosomal-protein N-terminal-L-alanine,C3H7N2OR,NA,NA,NA,2.3.1.266;2.3.1.267,R04316
Alanine,cpd:C04111,3-(Phosphoacetylamido)-L-alanine,C5H11N2O7P,NA,NA,NA,NA,NA
Alanine,cpd:C04209,"3-(Carboxycarbonylamino)-L-alanine;N3-Oxalyl-L-2,3-diaminopropanoate;L-alpha-Amino-beta-oxalylaminopropionic acid;beta-ODAP",C5H8N2O5,NA,NA,NA,2.3.1.58,R04211
Alanine,cpd:C04341,Ribosomal-protein N-acetyl-L-alanine,C5H9N2O2R,NA,NA,NA,2.3.1.266;2.3.1.267,R04316
Alanine,cpd:C04446,"3-(3,4-Dihydroxypyridin-1-yl)-L-alanine",C8H11N2O4,NA,NA,NA,2.5.1.52,R04091
Alanine,cpd:C04544,gamma-L-Glutamyl-L-cysteinyl-beta-alanine,C11H19N3O6S,NA,NA,NA,6.3.2.23,R02741
Alanine,cpd:C04702,UDPMurNAc(oyl-L-Ala-D-gamma-Glu-L-Lys-D-Ala-D-Ala);UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine;UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanine,C40H65N9O26P2,Peptidoglycan biosynthesis;Metabolic pathways;beta-Lactam resistance;Vancomycin resistance,NA,NA,2.3.2.10;2.7.8.13;3.4.17.8;6.3.2.10,R04573 R04611 R04613 R05629
Alanine,cpd:C04804,"UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimeloyl-D-alanine;UDP-N-acetylmuramoyl-L-Ala-D-gamma-Glu-6-carboxy-L-Lys-D-Ala;UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-6-carboxy-L-lysyl-D-alanine",C38H60N8O27P2,NA,NA,NA,3.4.17.8,R08850
Alanine,cpd:C04851,MurAc(oyl-L-Ala-D-gamma-Glu-L-Lys-D-Ala-D-Ala)-diphospho-undecaprenol;Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine,C86H143N7O21P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C04851  MurAc(oyl-L-Ala-D-gamma-Glu-L-Lys-D-Ala-D-Ala)-diphospho-undecaprenol,2.4.1.227;2.7.8.13,R05629 R05662
Alanine,cpd:C04882,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine;UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine;UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine",C41H65N9O28P2,Lysine biosynthesis;Peptidoglycan biosynthesis;Metabolic pathways,NA,NA,2.7.8.13;3.4.17.8;6.3.2.10,R04617 R05630 R08850
Alanine,cpd:C04894,UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-N6-(L-alanyl)-L-lysyl-D-alanyl-D-alanine;UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-N6-(L-alanyl)-L-lysyl-D-alanyl-D-alanine,C43H70N10O27P2,NA,NA,NA,2.3.2.10,R04613
Alanine,cpd:C04904,N-Acetyl-D-glucosaminyl-N-acetylmuramoyl-L-Ala-D-glutamyl-6-carboxy-L-lysyl-D-alanine,C37H61N7O21,NA,NA,NA,NA,NA
Alanine,cpd:C05620,N-Acetyl-D-phenylalanine,C11H13NO3,D-Amino acid metabolism;Metabolic pathways,NA,NA,2.3.1.36,R03903
Alanine,cpd:C05672,2-Amino-3-phosphonopropanoate;Phosphonoalanine,C3H8NO5P,Phosphonate and phosphinate metabolism;Metabolic pathways,NA,NA,2.6.1.-,R04051
Alanine,cpd:C05705,Selenocysteine seleninic acid;Selenocysteine seleninate;3-Seleninoalanine,C3H7NO4Se,NA,NA,NA,NA,R04933
Alanine,cpd:C05711,gamma-Glutamyl-beta-cyanoalanine,C9H13N3O5,Cyanoamino acid metabolism,NA,NA,2.3.2.2,R03970
Alanine,cpd:C05893,"Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine;GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-diphosphoundecaprenol;GlcNAc-(1->4)-MurNAc(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-diphosphoundecaprenol;beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-diphospho-ditrans,octacis-undecaprenol",C94H156N8O26P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C05893  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine,2.3.2.10;2.4.1.227;2.4.99.28;6.3.5.13;6.3.5.-,R05030 R05662 R06178 R08779 R08855 R12330
Alanine,cpd:C05894,"Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-D-alanyl-D-alanine;beta-D-GlcNAc-(1->4)-MurNAc-L-Ala-gamma-D-O-P-Glu-L-Lys-D-Ala-D-Ala-diphospho-ditrans,octacis-undecaprenol",C94H157N9O25P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C05894  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-D-alanyl-D-alanine,2.3.2.16;6.3.5.13;6.3.5.-,R05030 R08776 R08855 R12331
Alanine,cpd:C05895,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)5-D-alanyl-D-alanine,C104H172N14O30P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C05895  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)5-D-alanyl-D-alanine,2.3.2.18,R08778
Alanine,cpd:C05897,"Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine",C87H143N7O23P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C05897  Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine",2.4.1.227;2.7.8.13,R05032 R05630
Alanine,cpd:C05898,"Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine",C95H156N8O28P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C05898  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine",2.4.1.227;2.4.99.28,R04519 R05032
Alanine,cpd:C06420,D-Tyrosine;(R)-3-(p-Hydroxyphenyl)alanine;(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid,C9H11NO3,NA,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C06420  D-Tyrosine,NA,NA
Alanine,cpd:C06432,UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanine;UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-L-lysyl-D-alanine,C37H60N8O25P2,Vancomycin resistance,NA,NA,3.4.17.8,R04611
Alanine,cpd:C06457,Bialaphos;Bilanafos;2-Amino-4-(methylphosphino)butyrylalanylalanine;gamma-(Hydroxymethylphosphinyl)-L-alpha-aminobutyryl-L-alanyl-L-alanine;Phosphinothricin tripeptide,C11H22N3O6P,Phosphonate and phosphinate metabolism;Biosynthesis of secondary metabolites,NA,Pesticides [BR:br08007]; Pesticides;  Herbicides;   Organophosphorus herbicides;    C06457  Bialaphos,NA,R08876 R11481
Alanine,cpd:C08263,beta-Alaninebetaine;beta-Alanine betaine;Propiobetaine;Trimethylalanine,C6H13NO2,NA,NA,NA,NA,NA
Alanine,cpd:C08273,"2,5-Dihydrophenylalanine;L-2,5-Dihydrophenylalanine",C9H13NO2,NA,NA,NA,NA,NA
Alanine,cpd:C08291,3-Methylamino-L-alanine,C4H10N2O2,NA,NA,NA,NA,NA
Alanine,cpd:C10644,Atalanine,C34H30N2O9,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from tryptophan and anthranilic acid;   Acridone alkaloids;    C10644  Atalanine,NA,NA
Alanine,cpd:C11217,p-Fluorophenylalanine,C9H10FNO2,NA,NA,NA,NA,NA
Alanine,cpd:C11221,Formylmethionyl-leucyl-phenylalanine methyl ester;FMLP OMe,C22H33N3O5S,Neutrophil extracellular trap formation,NA,NA,NA,NA
Alanine,cpd:C11341,N-Acetylphenylalanine beta-naphthyl ester;N-Acetyl-DL-phenylalanine beta-naphthyl ester,C21H19NO3,NA,NA,NA,NA,NA
Alanine,cpd:C11345,"1,2,4-Triazole-3-alanine;Triazolealanine",C5H8N4O2,NA,NA,NA,NA,NA
Alanine,cpd:C11596,FMLP;N-Formyl-L-methionyl-L-leucyl-L-phenylalanine,C21H31N3O5S,Staphylococcus aureus infection,NA,NA,NA,NA
Alanine,cpd:C11615,Pristinamycin IA;Vernamycin B alpha;Mikamycin B;4-[4-(Dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1;Streptogramin B,C45H54N8O10,Nonribosomal peptide structures,NA,NA,NA,NA
Alanine,cpd:C11616,Pristinamycin IB;Vernamycin B beta;Efepristin;4-[N-Methyl-4-(methylamino)-L-phenylalanine]virginiamycin S1,C44H52N8O10,NA,NA,NA,NA,NA
Alanine,cpd:C11617,Pristinamycin IC;Vernamycin B gamma;2-D-Alanine-4-[4-(dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1,C44H52N8O10,NA,NA,NA,NA,NA
Alanine,cpd:C12033,4-Aminophenylalanine;p-Aminophenylalanine,C9H12N2O2,NA,NA,NA,NA,NA
Alanine,cpd:C15311,"N,N-Bis(2-chloroethyl)-DL-alanine hydrochloride",C7H13Cl2NO2. HCl,NA,NA,NA,NA,NA
Alanine,cpd:C16632,alpha-Fluoro-beta-alanine;3-Amino-2-fluoropropionic acid,C3H6FNO2,Drug metabolism - other enzymes,NA,NA,3.5.1.6,R08228
Alanine,cpd:C16734,Thyroglobulin dehydroalanine;[Thyroglobulin]-aminoacrylate,C4H4N2O2R2,NA,NA,NA,1.11.1.8,R08522 R08523
Alanine,cpd:C17235,L-Homophenylalanine,C10H13NO2,"Phenylalanine, tyrosine and tryptophan biosynthesis;Glucosinolate biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism",NA,NA,1.14.13.-;2.6.1.-,R08655 R08690 R10503
Alanine,cpd:C17541,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)-D-alanyl-D-alanine;Und-PP-MurNAc-(GlcNAc)-L-Ala-D-isoglutaminyl-L-Lys-(Gly)-D-Ala-D-Ala,C96H160N10O26P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C17541  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)-D-alanyl-D-alanine,2.3.2.16;2.3.2.17,R08776 R08777
Alanine,cpd:C17542,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)3-D-alanyl-D-alanine;Und-PP-MurNAc-(GlcNAc)-L-Ala-D-isoglutaminyl-L-Lys-(Gly)3-D-Ala-D-Ala,C100H166N12O28P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C17542  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-isoglutaminyl-L-lysyl-(glycyl)3-D-alanyl-D-alanine,2.3.2.17;2.3.2.18,R08777 R08778
Alanine,cpd:C17549,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl-L-alanyl)-D-alanyl-D-alanine,C100H166N10O28P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C17549  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl-L-alanyl)-D-alanyl-D-alanine,2.3.2.-,R08780
Alanine,cpd:C17550,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl)-D-alanyl-D-alanine,C97H161N9O27P2,Peptidoglycan biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C17550  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl)-D-alanyl-D-alanine,2.3.2.10;2.3.2.-,R08779 R08780
Alanine,cpd:C18619,4-Dimethylamino-L-phenylalanine,C11H16N2O2,NA,NA,NA,NA,NA
Alanine,cpd:C19712,N-Hydroxy-L-phenylalanine;2-(Hydroxyamino)-3-phenylpropanoate,C9H11NO3,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.40,R09579 R09580
Alanine,cpd:C19715,"N,N-Dihydroxy-L-phenylalanine",C9H11NO4,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.40,R09580 R09581
Alanine,cpd:C19779,beta-Alaninamide;beta-Alanine amide;3-Aminopropionamide,C3H8N2O,NA,NA,NA,3.5.1.100,R09648
Alanine,cpd:C20487,L-beta-Phenylalanine;(R)-3-Amino-3-phenylpropanoate,C9H11NO2,NA,NA,NA,5.4.3.10,R10286
Alanine,cpd:C20488,D-beta-Phenylalanine;(S)-3-Amino-3-phenylpropanoate;(S)-beta-Phenylalanine,C9H11NO2,NA,NA,NA,5.4.3.11,R10287
Alanine,cpd:C20807,3-Hydroxy-L-phenylalanine;3-Tyrosine,C9H11NO3,NA,NA,NA,1.14.16.7,R10729 R12543
Alanine,cpd:C20892,3-(5-Oxoisoxazolin-2-yl)-L-alanine;beta-(Isoxazolin-5-on-2-yl)-L-alanine,C6H8N2O4,NA,NA,NA,2.5.1.118,R10839
Alanine,cpd:C20893,3-(5-Oxoisoxazolin-4-yl)-L-alanine;beta-(Isoxazolin-5-on-4-yl)-L-alanine,C6H8N2O4,NA,NA,NA,2.5.1.119,R10840
Alanine,cpd:C20895,"(2S,3S)-3-Methylphenylalanine",C10H13NO2,NA,NA,NA,2.6.1.57;2.6.1.107,R10845
Alanine,cpd:C20966,3-{[(2E)-4-Amino-4-oxobut-2-enoyl]amino}-L-alanine,C7H11N3O4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Dapdiamides biosynthesis, L-2,3-diaminopropanoate => dapdiamide A/B/C",NA,6.3.2.47;6.3.5.-,R10942 R10943 R10944 R12352
Alanine,cpd:C20967,"N(beta)-Epoxysuccinamoyl-DAP;N(beta)-Epoxysuccinamoyl-diaminopropionate;3-({[(2R,3R)-3-Carbamoyloxiran-2-yl]carbonyl}amino)-L-alanine",C7H11N3O5,NA,NA,NA,6.3.2.47,R10941
Alanine,cpd:C21741,[Sulfatase]-3-oxo-L-alanine;[Sulfatase]-(S)-formylglycine;[Sulfatase]-(S)-Calpha-formylglycine;[Sulfatase]-FGly,C3H4N2O2R2,NA,NA,NA,1.1.98.7;1.8.3.7,R11878 R12569
Alanine,cpd:C21861,[Protein]-dehydroalanine,C4H4N2O2R2,NA,NA,NA,2.4.2.60;4.4.1.37,R10685 R12061 R12062 R12065 R12066
Ethanol,cpd:C00132,Methanol;Methyl alcohol;CH3OH,CH4O,Butanoate metabolism;Methane metabolism;Indole alkaloid biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism;Degradation of aromatic compounds,"Methane oxidation, methanotroph, methane => formaldehyde;Methanogenesis, methanol => methane",NA,1.1.1.244;1.1.2.7;1.1.2.10;1.1.3.13;1.1.99.37;1.2.98.1;1.11.1.6;1.11.1.7;1.11.1.21;1.13.11.8;1.13.11.-;1.14.13.25;1.14.14.117;1.14.18.3;2.1.1.90;2.1.1.246;2.3.1.152;2.3.1.232;3.1.1.11;3.1.1.44;3.1.1.59;3.1.1.61;3.1.1.78;3.1.1.82;3.1.1.85;3.1.1.95;3.1.1.97;3.1.1.100;3.1.1.114;3.1.1.122;3.1.1.-;3.1.6.16;3.3.2.14,R00602 R00605 R00608 R00614 R01142 R01143 R01144 R01145;R01146 R02362 R02624 R03551 R04280 R04384 R04409 R04608;R05825 R06250 R06685 R06729 R08149 R08150 R08974 R08975;R09061 R09098 R09273 R09274 R09337 R09518 R09553 R09725;R09846 R10319 R10320 R10545 R10681 R10705 R10983 R11166;R11189 R13238 R13239
Ethanol,cpd:C00157,"Phosphatidylcholine;Lecithin;Phosphatidyl-N-trimethylethanolamine;1,2-Diacyl-sn-glycero-3-phosphocholine;Choline phosphatide;3-sn-Phosphatidylcholine",C10H18NO8PR2,Glycerophospholipid metabolism;Arachidonic acid metabolism;Linoleic acid metabolism;alpha-Linolenic acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Retrograde endocannabinoid signaling;Choline metabolism in cancer,"Phosphatidylcholine (PC) biosynthesis, choline => PC;Phosphatidylcholine (PC) biosynthesis, PE => PC","Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C00157  Phosphatidylcholine; Lecithin;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP01 Glycerophosphocholines;   GP0101 Diacylglycerophosphocholines;    C00157  1,2-Diacyl-sn-glycero-3-phosphocholine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; A ALIMENTARY TRACT AND METABOLISM;  A05 BILE AND LIVER THERAPY;   A05B LIVER THERAPY, LIPOTROPICS;    A05BA Liver therapy;     A05BA10 Phospholipids;      C00157  Phosphatidylcholine",2.1.1.16;2.1.1.71;2.3.1.23;2.3.1.43;2.3.1.62;2.3.1.83;2.3.1.135;2.7.8.2;2.7.8.24;2.7.8.27;3.1.1.4;3.1.1.5;3.1.1.32;3.1.4.3;3.1.4.4,R01309 R01310 R01312 R01313 R01314 R01315 R01316 R01317;R01318 R01319 R01320 R01321 R02114 R04227 R04514 R05794;R07064 R07377 R07859 R07860 R08387 R08969
Ethanol,cpd:C00189,Ethanolamine;Aminoethanol;2-Hydroxyethylamine,C2H7NO,Glycerophospholipid metabolism;Metabolic pathways;Retrograde endocannabinoid signaling,"Phosphatidylethanolamine (PE) biosynthesis, ethanolamine => PE",Compounds with biological roles [BR:br08001]; Peptides;  Amines;   Biogenic amines;    C00189  Ethanolamine,1.4.3.8;2.6.-.-;2.7.1.82;2.7.8.29;2.7.8.-;3.1.3.75;3.1.4.2;3.1.4.4;3.1.4.39;3.1.4.46;3.5.1.60;3.5.1.99;4.1.1.-;4.3.1.7;4.3.3.-;4.99.1.-,R00749 R01468 R01469 R01470 R02041 R02051 R04248 R04362;R05381 R06870 R07376 R07385 R07386 R07388 R09536 R11062;R12757
Ethanol,cpd:C00346,Ethanolamine phosphate;O-Phosphorylethanolamine;Phosphoethanolamine;O-Phosphoethanolamine,C2H8NO4P,Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Glycerophospholipid metabolism;Sphingolipid metabolism;Metabolic pathways;Cationic antimicrobial peptide (CAMP) resistance;Sphingolipid signaling pathway,"Phosphatidylethanolamine (PE) biosynthesis, ethanolamine => PE;Sphingosine degradation",NA,2.1.1.103;2.7.1.82;2.7.7.14;3.1.3.75;3.1.4.3;3.1.4.13;3.1.4.-;4.1.2.27;4.1.2.-;4.2.3.2,R00748 R01468 R02037 R02038 R02052 R02464 R02817 R06516;R06870 R07380 R07381
Ethanol,cpd:C00350,Phosphatidylethanolamine;(3-Phosphatidyl)ethanolamine;(3-Phosphatidyl)-ethanolamine;Cephalin;O-(1-beta-Acyl-2-acyl-sn-glycero-3-phospho)ethanolamine;1-Acyl-2-acyl-sn-glycero-3-phosphoethanolamine;L-1-Phosphatidylethanolamine,C7H12NO8PR2,Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Autophagy - other;Autophagy - yeast;Autophagy - animal;Retrograde endocannabinoid signaling;Pathogenic Escherichia coli infection;Kaposi sarcoma-associated herpesvirus infection,"Phosphatidylcholine (PC) biosynthesis, PE => PC;Phosphatidylethanolamine (PE) biosynthesis, ethanolamine => PE;Phosphatidylethanolamine (PE) biosynthesis, PA => PS => PE","Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C00350  Phosphatidylethanolamine;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0201 Diacylglycerophosphoethanolamines;    C00350  1-Acyl-2-acyl-sn-glycero-3-phosphoethanolamine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; A ALIMENTARY TRACT AND METABOLISM;  A05 BILE AND LIVER THERAPY;   A05B LIVER THERAPY, LIPOTROPICS;    A05BA Liver therapy;     A05BA10 Phospholipids;      C00350  Phosphatidylethanolamine",2.1.1.17;2.3.1.23;2.3.1.40;2.7.8.1;2.7.8.29;2.7.8.42;2.7.8.43;2.7.8.-;2.7.-.-;3.1.1.4;3.1.1.32;3.1.4.3;3.1.4.4;4.1.1.65,R02051 R02052 R02053 R02054 R02055 R02056 R02057 R04480;R04864 R05923 R05924 R07376 R08107 R11062 R11204 R11205;R11555 R11556 R11557 R12202 R12351 R12702
Ethanol,cpd:C00469,Ethanol;Ethyl alcohol;Methylcarbinol,C2H6O,Glycolysis / Gluconeogenesis;Pyruvate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Inflammatory mediator regulation of TRP channels;Alcoholic liver disease;Alcoholism;Chemical carcinogenesis - reactive oxygen species,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00068)]; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AX Other antiseptics and disinfectants;     D08AX08 Ethanol;      D00068  Alcohol (USP) &lt;JP/US&gt;; V VARIOUS;  V03 ALL OTHER THERAPEUTIC PRODUCTS;   V03A ALL OTHER THERAPEUTIC PRODUCTS;    V03AB Antidotes;     V03AB16 Ethanol;      D00068  Alcohol (USP) &lt;JP/US&gt;;    V03AZ Nerve depressants;     V03AZ01 Ethanol;      D00068  Alcohol (USP) &lt;JP/US&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00068)]; 2  Agents affecting individual organs;  26  Epidermides;   261  Antimicrobial agents;    2615  Alcohols;     D00068  Alcohol (USP); Anhydrous ethanol (JP18); 4  Agents affecting cellular function;  42  Antineoplastics;   429  Miscellaneous;    4291  Other Antitumors;     D00068  Alcohol (USP); Anhydrous ethanol (JP18);Classification of Japanese OTC drugs [BR:br08313(D00068)]; Agents for integumentary system;  54 Disinfectants (incl. special bandages);   D00068  Alcohol (USP);Risk category of Japanese OTC drugs [BR:br08312(D00068)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Ethanol;    D00068  Alcohol (USP); Third-class OTC drugs;  Inorganic and organic chemicals;   Ethanol;    D00068  Alcohol (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00068)]; Chemicals;  D00068  Anhydrous ethanol,1.1.1.1;1.1.1.2;1.1.1.71;1.1.2.7;1.1.2.8;1.1.5.5;1.1.99.36;2.3.1.152;2.3.1.268;3.1.1.67;3.1.1.113;3.5.1.75,R00746 R00754 R02359 R02682 R04410 R05198 R09127 R09479;R09552 R11957 R12515
Ethanol,cpd:C00556,Benzyl alcohol;alpha-Hydroxytoluene;Benzenemethanol;Phenylmethanol;Phenylcarbinol;Hydroxymethylbenzene,C7H8O,Toluene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Toluene degradation, toluene => benzoate","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00077)]; P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS;  P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS;   P03A ECTOPARASITICIDES, INCL. SCABICIDES;    P03AX Other ectoparasiticides, incl. scabicides;     P03AX06 Benzyl alcohol;      D00077  Benzyl alcohol (JP18/NF/INN);Risk category of Japanese OTC drugs [BR:br08312(D00077)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Benzyl alcohol;    D00077  Benzyl alcohol (JP18/NF/INN);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00077)]; Chemicals;  D00077  Benzyl alcohol;New drug approvals in the USA [br08319.html(D00077)]; New molecular entities and new therapeutic biological products;  D00077;New drug approvals in the USA, Europe and Japan [br08328.html(D00077)]; Approval dates by FDA, EMA and PMDA;  D00077",1.1.1.90;1.14.13.-;1.14.15.26;2.3.1.196;2.3.1.224;3.1.1.70;3.5.1.58;3.5.1.64,R01763 R02550 R02551 R02552 R03612 R09528 R10473
Ethanol,cpd:C00570,CDP-ethanolamine;Cytidine diphosphate ethanolamine,C11H20N4O11P2,Glycerophospholipid metabolism;Metabolic pathways,"Phosphatidylethanolamine (PE) biosynthesis, ethanolamine => PE",NA,2.7.7.14;2.7.8.1;2.7.8.4;2.7.8.48,R01503 R02038 R02057 R02563 R06364 R07384
Ethanol,cpd:C00928,Mercaptoethanol;2-Mercaptoethanol;Thioglycol,C2H6OS,NA,NA,NA,NA,NA
Ethanol,cpd:C00955,Indole-3-ethanol;Tryptophol,C10H11NO,Tryptophan metabolism,NA,NA,1.1.1.190;1.1.1.191,R02679 R02680
Ethanol,cpd:C01210,N-Methylethanolamine phosphate,C3H10NO4P,Glycerophospholipid metabolism,NA,NA,2.1.1.103;2.7.7.57,R02037 R03375 R06868
Ethanol,cpd:C01233,sn-Glycero-3-phosphoethanolamine;Glycerophosphoethanolamine,C5H14NO6P,Glycerophospholipid metabolism;Ether lipid metabolism;Metabolic pathways,NA,NA,3.1.1.5;3.1.4.2;3.1.4.46;3.3.2.2,R01470 R03415 R03416 R03417
Ethanol,cpd:C01241,Phosphatidyl-N-methylethanolamine,C8H14NO8PR2,Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,"Phosphatidylcholine (PC) biosynthesis, PE => PC",NA,2.1.1.16;2.1.1.17;2.1.1.71,R02056 R03424
Ethanol,cpd:C01279,4-Amino-5-hydroxymethyl-2-methylpyrimidine;Toxopyrimidine;4-Amino-2-methyl-5-pyrimidinemethanol;HMP,C6H9N3O,Thiamine metabolism;Metabolic pathways;Biosynthesis of cofactors;ABC transporters,"Thiamine salvage pathway, HMP/HET => TMP",NA,2.7.1.49;3.5.99.2;3.5.99.-,R02133 R03471 R09993
Ethanol,cpd:C01678,Cysteamine;2-Aminoethanethiol;beta-Aminoethanethiol;beta-Mercaptoethylamine;Mercaptamine;Thioethanolamine,C2H7NS,Taurine and hypotaurine metabolism;Metabolic pathways,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amines;   Biogenic amines;    C01678  Cysteamine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D03634)]; A ALIMENTARY TRACT AND METABOLISM;  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;    A16AA Amino acids and derivatives;     A16AA04 Mercaptamine;      D03634  Cysteamine (USAN); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01X OTHER OPHTHALMOLOGICALS;    S01XA Other ophthalmologicals;     S01XA21 Mercaptamine;      D03634  Cysteamine (USAN);New drug approvals in Europe [br08329.html(D03634)]; European public assessment reports (EPAR) authorised medicine;  D03634,1.13.11.19;2.3.1.11;3.5.1.92,R02467 R02973 R03668
Ethanol,cpd:C02390,Methylazoxymethanol;CH3-N(O)=N-CH2OH,C2H6N2O2,NA,NA,NA,2.4.1.171,R03547
Ethanol,cpd:C02452,"(-)-Perillyl alcohol;Perillyl alcohol;(S)-Perillyl alcohol;[(4S)-4-(Prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol;p-Mentha-1,8-dien-7-ol;(-)-Perillylalcohol",C10H16O,Monoterpenoid biosynthesis;Limonene degradation;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C02452  Perillyl alcohol;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C02452  Perillyl alcohol,1.1.1.144;1.14.14.52;1.17.99.8,R02470 R03945 R12591
Ethanol,cpd:C02735,Phenylethanolamine;2-Amino-1-phenylethanol,C8H11NO,NA,NA,NA,2.1.1.28,R04033
Ethanol,cpd:C02909,(2-Naphthyl)methanol;2-Naphthalenemethanol;2-Hydroxymethylnaphthalene,C11H10O,Naphthalene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.1;1.14.12.12;1.14.13.-,R06926 R06927 R06930
Ethanol,cpd:C03351,3-Hydroxybenzyl alcohol;3-Hydroxybenzenemethanol,C7H8O2,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.97;1.14.13.-,R04136 R07665
Ethanol,cpd:C03486,CDP-N-methylethanolamine,C12H22N4O11P2,NA,NA,NA,2.7.7.57,R03375
Ethanol,cpd:C03537,S-Acetylthioethanolamine,C4H9NOS,NA,NA,NA,2.3.1.11,R03668
Ethanol,cpd:C03711,N-Methylphenylethanolamine;alpha-[(Methylamino)methyl]-benzyl alcohol,C9H13NO,NA,NA,NA,2.1.1.28,R04033
Ethanol,cpd:C03872,L-Serine-phosphoethanolamine;Serine phosphoethanolamine,C5H13N2O6P,Glycerophospholipid metabolism,NA,NA,2.7.8.4;3.1.4.13,R02563 R02817
Ethanol,cpd:C03947,"Glycerol 1,2-cyclic phosphate;1,3,2-Dioxaphospholane-4-methanol",C3H7O5P,NA,NA,NA,3.1.4.42,R02648
Ethanol,cpd:C04080,N-(Long-chain-acyl)ethanolamine,C3H6NO2R,NA,NA,NA,3.5.1.60,R02041
Ethanol,cpd:C04227,Octopamine;1-(4-Hydroxyphenyl)-2-aminoethanol;p-Hydroxyphenylethanolamine,C8H11NO2,Neuroactive ligand-receptor interaction,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; C CARDIOVASCULAR SYSTEM;  C01 CARDIAC THERAPY;   C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES;    C01CA Adrenergic and dopaminergic agents;     C01CA18 Octopamine;      C04227  Octopamine;Drug groups [BR:br08330]; Cardiovascular agent;  DG01703  Cardiotonic;   DG01702  Phenethylamine cardiotonic;    DG00225  Octopamine;     C04227  Octopamine;   DG01699  Catecholamine cardiotonic;    DG00225  Octopamine;     C04227  Octopamine,4.2.1.87,R03358
Ethanol,cpd:C04308,Phosphatidyl-N-dimethylethanolamine,C9H16NO8PR2,Glycerophospholipid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,"Phosphatidylcholine (PC) biosynthesis, PE => PC",NA,2.1.1.16;2.1.1.71,R01320 R03424
Ethanol,cpd:C04438,1-Acyl-sn-glycero-3-phosphoethanolamine;L-2-Lysophosphatidylethanolamine,C6H13NO7PR,Glycerophospholipid metabolism,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0205 Monoacylglycerophosphoethanolamines;    C04438  1-Acyl-sn-glycero-3-phosphoethanolamine,2.3.1.23;3.1.1.4;3.1.1.5,R02053 R03416 R04480
Ethanol,cpd:C04475,1-Alkyl-2-acylglycerophosphoethanolamine;1-Radyl-2-acyl-sn-glycero-3-phosphoethanolamine;1-Organyl-2-acyl-sn-glycero-3-phosphoethanolamine;O-1-Alkyl-2-acyl-sn-glycero-3-phosphoethanolamine;2-Acyl-1-alkyl-sn-glycero-3-phosphoethanolamine;Plasmanylethanolamine,C6H12NO7PR2,Ether lipid metabolism;Metabolic pathways,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0202 1-alkyl,2-acylglycerophosphoethanolamines;    C04475  2-Acyl-1-alkyl-sn-glycero-3-phosphoethanolamine",1.14.19.77;2.3.1.148;2.7.8.1,R04571 R04721 R06364
Ethanol,cpd:C04476,1-Alkyl-sn-glycero-3-phosphoethanolamine,C5H13NO6PR,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0206 Monoalkylglycerophosphoethanolamines;    C04476  1-Alkyl-sn-glycero-3-phosphoethanolamine,3.1.4.39,R04362
Ethanol,cpd:C04515,(3S)-3-Hydroxyacyl-N-acylthioethanolamine,C6H9NO3SR2,NA,NA,NA,NA,NA
Ethanol,cpd:C04548,Synephrine;(+/-)-Synephrine;1-(4-Hydroxyphenyl)-2-(methylamino)ethanol,C9H13NO2,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07148)]; C CARDIOVASCULAR SYSTEM;  C01 CARDIAC THERAPY;   C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES;    C01CA Adrenergic and dopaminergic agents;     C01CA08 Oxedrine;      D07148  Oxedrine (BAN); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01G DECONGESTANTS AND ANTIALLERGICS;    S01GA Sympathomimetics used as decongestants;     S01GA06 Oxedrine;      D07148  Oxedrine (BAN);Drug groups [BR:br08330(D07148)]; Cardiovascular agent;  DG01703  Cardiotonic;   DG01702  Phenethylamine cardiotonic;    DG00217  Oxedrine;     D07148  Oxedrine;  DG01456  Adrenergic receptor agonist;   DG01450  alpha-Adrenergic receptor agonist;    DG00217  Oxedrine;     D07148  Oxedrine,NA,NA
Ethanol,cpd:C04635,1-(1-Alkenyl)-sn-glycero-3-phosphoethanolamine;1-Alkenylglycerophosphoethanolamine,C7H15NO6PR,Ether lipid metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0207 1Z-alkenylglycerophosphoethanolamines;    C04635  1-(1-Alkenyl)-sn-glycero-3-phosphoethanolamine,2.3.1.121;3.1.1.4;3.1.4.39;3.1.4.-;3.3.2.2,R03415 R04413 R07379 R07380 R07388
Ethanol,cpd:C04756,O-1-Alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine;Phosphatidalethanolamine;Plasmenylethanolamine;Ethanolamineplasmalogen;2-Acyl-1-(1-alkenyl)-sn-glycero-3-phosphoethanolamine;1-Alkenyl-2-acylglycerophosphoethanolamine,C8H14NO7PR2,Ether lipid metabolism;Metabolic pathways,NA,"Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C04756  Plasmenylethanolamine;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0203 1-(1Z-alkenyl),2-acylglycerophosphoethanolamines;    C04756  2-Acyl-1-(1-alkenyl)-sn-glycero-3-phosphoethanolamine",1.14.19.77;2.3.1.121;2.6.-.-;2.7.8.1;3.1.1.4;3.1.4.3;3.1.4.4,R04413 R04571 R07379 R07381 R07384 R07385 R07386
Ethanol,cpd:C05209,1-Alkyl-2-lyso-sn-glycero-3-phosphoethanolamine;1-Organyl-2-lyso-sn-glycero-3-phosphoethanolamine;1-Radyl-2-lyso-sn-glycero-3-phosphoethanolamine,C5H13NO6PR,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0206 Monoalkylglycerophosphoethanolamines;    C05209  1-Alkyl-2-lyso-sn-glycero-3-phosphoethanolamine,2.3.1.147;2.3.1.148,R04720 R04721
Ethanol,cpd:C05210,1-Alkyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine;1-Organyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine,C25H43NO7PR,NA,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0202 1-alkyl,2-acylglycerophosphoethanolamines;    C05210  1-Alkyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine",2.3.1.147,R04720
Ethanol,cpd:C05562,1H-Imidazole-4-methanol;Imidazole-4-methanol,C4H6N2O,NA,NA,NA,NA,NA
Ethanol,cpd:C05675,Diacylglyceryl-2-aminoethylphosphonate;Diacylglycerophosphonoethanolamine,C7H12NO7PR2,Phosphonate and phosphinate metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP17 Glycerophosphonoethanolamines;   GP1701 Diacylglycerophosphonoethanolamines;    C05675  Diacylglycerophosphonoethanolamine,2.7.8.1,R04920 R04923
Ethanol,cpd:C05853,Phenylethyl alcohol;Phenethyl alcohol;2-Phenylethanol,C8H10O,Phenylalanine metabolism,NA,NA,1.1.1.90,R02611
Ethanol,cpd:C05973,2-Acyl-sn-glycero-3-phosphoethanolamine;L-1-Lysophosphatidylethanolamine;O-(2-Acyl-sn-glycero-3-phospho)-ethanolamine,C6H13NO7PR,Glycerophospholipid metabolism,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0205 Monoacylglycerophosphoethanolamines;    C05973  2-Acyl-sn-glycero-3-phosphoethanolamine,2.3.1.40;3.1.1.5;3.1.1.32,R02054 R03417 R04864
Ethanol,cpd:C06044,4-Hydroxyphenylethanol;Tyrosol,C8H10O2,Tyrosine metabolism;Metabolic pathways,NA,NA,1.1.1.90;2.4.1.-,R04304 R05083
Ethanol,cpd:C06062,Ceramide phosphoethanolamine,C21H42N2O6PR,Sphingolipid metabolism,NA,Lipids [BR:br08002]; SP  Sphingolipids;  SP03 Phosphosphingolipids;   SP0302 Ceramide phosphoethanolamines;    C06062  Ceramide phosphoethanolamine,2.7.8.48,R01503
Ethanol,cpd:C06317,Vanillyl alcohol;4-Hydroxy-3-methoxy-benzenemethanol;4-Hydroxy-3-methoxybenzyl alcohol;4-Hydroxy-3-methoxybenzenemethanol,C8H10O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.1.3.38,R02877
Ethanol,cpd:C06639,"2,2-Bis(4'-chlorophenyl)ethanol;DDOH",C14H12Cl2O,NA,NA,NA,NA,R05251 R05477 R05478 R05481
Ethanol,cpd:C06753,2-Chloroethanol;Ethylene chlorohydrin;Glycol chlorohydrin,C2H5ClO,Chloroalkane and chloroalkene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.1.2.7;1.1.2.8;3.8.1.5,R05284 R05285 R09128
Ethanol,cpd:C06771,Triethanolamine;Trolamine,C6H15NO3,Glycerophospholipid metabolism,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00215)]; D DERMATOLOGICALS;  D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS;   D03A CICATRIZANTS;    D03AX Other cicatrizants;     D03AX12 Trolamine;      D00215  Trolamine (NF),4.3.3.-,R05382
Ethanol,cpd:C06772,Diethanolamine,C4H11NO2,Glycerophospholipid metabolism,NA,NA,4.3.3.-,R05381 R05382
Ethanol,cpd:C07112,1-Phenylethanol;Methylphenyl carbinol;alpha-Methylbenzyl alcohol,C8H10O,NA,NA,NA,1.17.-.-,R05495
Ethanol,cpd:C07397,"Quetiapine;2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol",C21H25N3O2S,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08456)]; N NERVOUS SYSTEM;  N05 PSYCHOLEPTICS;   N05A ANTIPSYCHOTICS;    N05AH Diazepines, oxazepines, thiazepines and oxepines;     N05AH04 Quetiapine;      D08456  Quetiapine (INN);Drug groups [BR:br08330(D08456)]; Neuropsychiatric agent;  DG01478  Dopamine antagonist;   DG01474  Dopamine D2-receptor antagonist;    DG00899  Quetiapine;     D08456  Quetiapine;  DG03200  Antipsychotic agent;   DG03064  Atypical antipsychotic;    DG00899  Quetiapine;     D08456  Quetiapine; Anti-allergic agent;  DG01557  Histamine receptor antagonist;   DG01482  Histamine receptor H1 antagonist;    DG00899  Quetiapine;     D08456  Quetiapine; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00899  Quetiapine;     D08456  Quetiapine;Target-based classification of drugs [BR:br08310(D08456)]; G Protein-coupled receptors;  Rhodopsin family;   Dopamine;    DRD2;     D08456  Quetiapine (INN);   Serotonin;    HTR2A;     D08456  Quetiapine (INN);Drug metabolizing enzymes and transporters [br08309.html(D08456)]; Drug metabolizing enzymes;  D08456",NA,NA
Ethanol,cpd:C07427,Perphenazine;4-(3-(2-Chlorophenothiazin-10-YL)propyl)-1-piperazineethanol,C21H26ClN3OS,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00503)]; N NERVOUS SYSTEM;  N05 PSYCHOLEPTICS;   N05A ANTIPSYCHOTICS;    N05AB Phenothiazines with piperazine structure;     N05AB03 Perphenazine;      D00503  Perphenazine (JP18/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00503)]; Antiemetics;  Antiemetics, Other;   Perphenazine;    D00503  Perphenazine (JP18/USP/INN); Antipsychotics;  1st Generation/Typical;   Perphenazine;    D00503  Perphenazine (JP18/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D00503)]; 1  Agents affecting nervous system and sensory organs;  11  Agents affecting central nervous system;   117  Psychotropics;    1172  Phenothiazines;     D00503  Perphenazine (JP18/USP/INN);Drug groups [BR:br08330(D00503)]; Neuropsychiatric agent;  DG01478  Dopamine antagonist;   DG01474  Dopamine D2-receptor antagonist;    DG00875  Perphenazine;     D00503  Perphenazine;  DG03200  Antipsychotic agent;   DG01905  Phenothiazine antipsychotics;    DG00875  Perphenazine;     D00503  Perphenazine; Metabolizing enzyme substrate;  DG01644  CYP2D6 substrate;   DG00875  Perphenazine;    D00503  Perphenazine;Target-based classification of drugs [BR:br08310(D00503)]; G Protein-coupled receptors;  Rhodopsin family;   Dopamine;    DRD2;     D00503  Perphenazine (JP18/USP/INN) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00503)]; Chemicals;  D00503  Perphenazine;  D00503  Perphenazine tablets;Drug metabolizing enzymes and transporters [br08309.html(D00503)]; Drug metabolizing enzymes;  D00503;Pharmacogenomic biomarkers [br08341.html(D00503)]; Polymorphisms and mutations affecting drug response;  D00503",NA,NA
Ethanol,cpd:C07490,"Trichloroethanol;2,2,2-Trichloroethanol",C2H3Cl3O,Chloroalkane and chloroalkene degradation;Metabolism of xenobiotics by cytochrome P450;Microbial metabolism in diverse environments;Hypnotics,NA,NA,1.1.1.1;1.1.-.-;1.14.13.25;1.14.14.-;2.4.1.17,R07105 R07106 R07107 R09148 R09149
Ethanol,cpd:C07911,"Phenylpropanolamine;(+/-)-Phenylpropanolamine;(R*,S*)-(+/-)-alpha-(1-Aminoethyl)benzenemethanol;(+/-)-Norephedrine",C9H13NO,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08368)]; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01B NASAL DECONGESTANTS FOR SYSTEMIC USE;    R01BA Sympathomimetics;     R01BA01 Phenylpropanolamine;      D08368  Phenylpropanolamine (INN);Drug groups [BR:br08330(D08368)]; Cardiovascular agent;  DG01456  Adrenergic receptor agonist;   DG01041  Phenylpropanolamine;    D08368  Phenylpropanolamine; Metabolizing enzyme inhibitor;  DG01634  CYP1A2 inhibitor;   DG01041  Phenylpropanolamine;    D08368  Phenylpropanolamine;Target-based classification of drugs [BR:br08310(D08368)]; G Protein-coupled receptors;  Rhodopsin family;   Adrenaline;    ADRA1;     D08368  Phenylpropanolamine (INN);    ADRA2;     D08368  Phenylpropanolamine (INN);    ADRB;     D08368  Phenylpropanolamine (INN);Drug metabolizing enzymes and transporters [br08309.html(D08368)]; Drug metabolizing enzymes;  D08368;Narcotics and psychotropics in Japan [br08308.html(D08368)]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  D08368,NA,NA
Ethanol,cpd:C08681,"Elatine;Aconitane-4-methanol, 20-ethyl-7,8-(methylenebis(oxy))-, 1,6,14,16-tetramethoxy-2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoate(ester), (1-alpha,6-beta,14-alpha,16-beta)-",C38H50N2O10,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08681  Elatine,NA,NA
Ethanol,cpd:C10354,2-Hydroxymethylanthraquinone;Anthraquinone-2-methanol,C15H10O3,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1304 Anthracenes and phenanthrenes;    C10354  2-Hydroxymethylanthraquinone;Phytochemical compounds [BR:br08003]; Polyketides;  Anthraquinones;   Anthraquinone type;    C10354  2-Hydroxymethylanthraquinone,NA,NA
Ethanol,cpd:C11348,(S)-1-Phenylethanol;(S)-1-Phenethyl alcohol,C8H10O,Ethylbenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.311;1.14.12.12;1.17.99.2,R05352 R05425 R05426 R05745
Ethanol,cpd:C11695,"Anandamide;Arachidonylethanolamide;N-(5Z,8Z,11Z,14Z-Eicosatetraenoyl)-ethanolamine;AEA",C22H37NO2,Neuroactive ligand-receptor interaction;Axon regeneration;Thermogenesis;Retrograde endocannabinoid signaling;Inflammatory mediator regulation of TRP channels,NA,"Lipids [BR:br08002]; FA  Fatty acyls;  FA08 Fatty amides;   FA0804 N-acyl ethanolamines (endocannabinoids);    C11695  N-(5Z,8Z,11Z,14Z-Eicosatetraenoyl)-ethanolamine",3.5.1.99,R09536
Ethanol,cpd:C11882,"Abietinol;Abietol;Abieta-7,13-dien-18-ol;((1R,4aR,4bR,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl)methanol",C20H32O,Diterpenoid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010405 Abietane diterpenoids;     C11882  Abietinol,1.14.14.144;1.14.14.145,R06351 R06354 R10077 R12122
Ethanol,cpd:C13482,Phosphodimethylethanolamine,C4H12NO4P,Glycerophospholipid metabolism,NA,NA,2.1.1.103,R06868 R06869
Ethanol,cpd:C13638,1-(4'-Hydroxyphenyl)ethanol;4-Hydroxy-alpha-methyl-benzenemethanol;4-(1-Hydroxyethyl)phenol,C8H10O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.1.1.-;1.14.13.-,R06890 R06891
Ethanol,cpd:C13785,TRAM-3;(2-Chlorophenyl)diphenylmethanol,C19H15ClO,NA,NA,NA,NA,NA
Ethanol,cpd:C13828,"8,11,14-Eicosatrienoylethanolamide;N-(8Z,11Z,14Z-Eicosatrienoyl)-ethanolamine",C22H39NO2,NA,NA,"Lipids [BR:br08002]; FA  Fatty acyls;  FA08 Fatty amides;   FA0804 N-acyl ethanolamines (endocannabinoids);    C13828  N-(8Z,11Z,14Z-Eicosatrienoyl)-ethanolamine",NA,NA
Ethanol,cpd:C13829,"7,10,13,16-Docosatetraenoylethanolamine;N-(7Z,10Z,13Z,16Z-Docosatetraenoyl)-ethanolamine",C24H41NO2,NA,NA,"Lipids [BR:br08002]; FA  Fatty acyls;  FA08 Fatty amides;   FA0804 N-acyl ethanolamines (endocannabinoids);    C13829  N-(7Z,10Z,13Z,16Z-docosatetraenoyl)-ethanolamine",NA,NA
Ethanol,cpd:C13877,1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine,C39H76NO8P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0201 Diacylglycerophosphoethanolamines;    C13877  1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine,NA,NA
Ethanol,cpd:C13878,1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphonoethanolamine,C39H76NO7P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP17 Glycerophosphonoethanolamines;   GP1701 Diacylglycerophosphonoethanolamines;    C13878  1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphonoethanolamine,NA,NA
Ethanol,cpd:C13896,sn-Caldarchaeo-1-phosphoethanolamine,C88H178NO9P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP18 Di-glycerol tetraether phospholipids (caldarchaeols);   C13896  sn-Caldarchaeo-1-phosphoethanolamine,NA,NA
Ethanol,cpd:C13897,sn-Caldito-1-phosphoethanolamine,C94H190NO15P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP19 Glycerol-nonitol tetraether phospholipids;   C13897  sn-Caldito-1-phosphoethanolamine,NA,NA
Ethanol,cpd:C14089,1-Hydroxymethylnaphthalene;1-Naphthalenemethanol,C11H10O,Naphthalene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.1;1.14.13.-,R06916 R06917
Ethanol,cpd:C14596,Ethamoxytriphetol;4-Methoxy-alpha-[4-[2-(diethylamino)ethoxy]phenyl]-alpha-phenylbenzeneethanol,C27H33NO3,NA,NA,NA,NA,NA
Ethanol,cpd:C14672,p-Chlorobenzhydrol;(4-Chlorophenyl)phenylmethanol,C13H11ClO,NA,NA,NA,NA,NA
Ethanol,cpd:C14687,2-Ethoxyethanol,C4H10O2,NA,NA,NA,NA,NA
Ethanol,cpd:C14689,"Diethylene glycol;2,2'-Oxydiethanol;1,5-Dihydroxy-3-oxapentane",C4H10O3,NA,NA,NA,NA,NA
Ethanol,cpd:C14869,"Trichloroethanol glucuronide;Urochloralic acid;2,2,2-Trichloroethyl beta-D-glucopyranosiduronic acid",C8H11Cl3O7,Metabolism of xenobiotics by cytochrome P450,NA,NA,2.4.1.17,R07106
Ethanol,cpd:C15008,"1,2,3,4,4a,9,10,10a-Octahydro-6-hydroxy-7-isopropyl-1,4a-dimethyl-1-phenanthrenemethanol",C20H30O2,NA,NA,NA,NA,NA
Ethanol,cpd:C15028,"alpha-Ethyl-alpha,beta-diphenyl-2-pyridineethanol",C21H21NO,NA,NA,NA,NA,NA
Ethanol,cpd:C15067,4-Chloro-alpha-[4-[2-(diethylamino)ethoxy]phenyl]-alpha-phenylbenzeneethanol,C26H30ClNO2,NA,NA,NA,NA,NA
Ethanol,cpd:C15161,"2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-7-hydroxy-2H-1-benzopyran-8-methanol diacetate",C25H28O6,NA,NA,NA,NA,NA
Ethanol,cpd:C15360,"Evadol hydrochloride;2-Amino-1,2-bis(p-methoxyphenyl)ethanol hydrochloride;beta-Amino-4-methoxy-alpha-(4-methoxyphenyl)benzeneethanol hydrochloride",C16H19NO3. HCl,NA,NA,NA,NA,NA
Ethanol,cpd:C15427,"2-Amino-1,2-bis(p-chlorophenyl)ethanol",C14H13Cl2NO,NA,NA,NA,NA,NA
Ethanol,cpd:C15458,"(alphaS,betaS)-alpha-Ethyl-alpha-(4-methoxyphenyl)-beta-phenyl-2-pyridineethanol",C22H23NO2,NA,NA,NA,NA,NA
Ethanol,cpd:C16512,Palmitoylethanolamide;Palmidrol,C18H37NO2,Neuroactive ligand-receptor interaction,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA08 Fatty amides;   FA0804 N-acyl ethanolamines (endocannabinoids);    C16512  Palmitoylethanolamide,NA,NA
Ethanol,cpd:C18215,Bis(4-hydroxyphenyl)methanol,C13H12O3,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.1.-.-;1.14.-.-,R09102 R09103
Ethanol,cpd:C18863,2-(Octylthio)ethanol;2-Hydroxyethyl octyl sulphide,C10H22OS,NA,NA,Pesticides [BR:br08007]; Pesticides;  Insecticides;   Others;    C18863  2-(Octylthio)ethanol,NA,NA
Ethanol,cpd:C19247,"HC Blue No.1;2,2'-[[4-(Methylamino)-3-nitrophenyl]imino]bisethanol",C11H17N3O4,NA,NA,NA,NA,NA
Ethanol,cpd:C19258,Methylazoxymethanol acetate,C4H8N2O3,NA,NA,NA,NA,NA
Ethanol,cpd:C19278,N-Nitrosodiethanolamine,C4H10N2O3,NA,NA,NA,NA,NA
Ethanol,cpd:C19332,2-(1-Aziridinyl)ethanol;1-Aziridineethanol,C4H9NO,NA,NA,NA,NA,NA
Ethanol,cpd:C19355,2-Butoxyethanol,C6H14O2,NA,NA,NA,NA,NA
Ethanol,cpd:C19429,"HC Blue No. 2;2,2'-[[4-[(2-Hydroxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol",C12H19N3O5,NA,NA,NA,NA,NA
Ethanol,cpd:C19430,HC Red No. 3;2-[(4-Amino-2-nitrophenyl)amino]-ethanol,C8H11N3O3,NA,NA,NA,NA,NA
Ethanol,cpd:C19431,HC Yellow No. 4;2-[[2-(2-Hydroxyethoxy)-4-nitrophenyl]amino]-ethanol,C10H14N2O5,NA,NA,NA,NA,NA
Ethanol,cpd:C19561,7-Hydroxymethyl-12-methylbenz[a]anthracene;12-Methylbenz[a]anthracene-7-methanol,C20H16O,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,1.14.14.-;2.8.2.14,R09441 R09444
Ethanol,cpd:C19580,alpha-[3-[(Hydroxymethyl)nitrosoamino]propyl]-3-pyridinemethanol,C10H15N3O3,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,1.14.14.1;1.14.14.-,R09425 R09432
Ethanol,cpd:C19581,alpha-[3-(Nitrosoamino)propyl]-3-pyridinemethanol,C9H13N3O2,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,NA,R09432 R09436
Ethanol,cpd:C19800,(3-Phenoxyphenyl)methanol;3-Phenoxybenzenemethanol,C13H12O2,NA,NA,NA,3.1.1.88,R09724
Ethanol,cpd:C19912,N-Arachidonoyl-phosphatidylethanolamine,C25H41NO7PR2,Retrograde endocannabinoid signaling,NA,NA,NA,NA
Ethanol,cpd:C20305,"1,2-Dichloroethanol",C2H4Cl2O,Chemical carcinogenesis - DNA adducts,NA,NA,NA,NA
Ethanol,cpd:C20441,Furfuryl alcohol;2-Furancarbinol;2-Furanmethanol,C5H6O2,Furfural degradation;Microbial metabolism in diverse environments,NA,NA,1.1.1.-,R10217
Ethanol,cpd:C20792,Oleoylethanolamide;OEA,C20H39NO2,cAMP signaling pathway,NA,NA,NA,NA
Ethanol,cpd:C21068,[5-(Aminomethyl)furan-3-yl]methyl phosphate;5-(Aminomethyl)-3-furanmethanol phosphate,C6H10NO5P,Methane metabolism;Metabolic pathways;Biosynthesis of cofactors,Methanofuran biosynthesis,NA,2.6.1.108;2.7.4.31,R11038 R11039
Ethanol,cpd:C21069,[5-(Aminomethyl)furan-3-yl]methyl diphosphate;5-(Aminomethyl)-3-furanmethanol diphosphate,C6H11NO8P2,Methane metabolism;Metabolic pathways;Biosynthesis of cofactors,Methanofuran biosynthesis,NA,2.5.1.131;2.7.4.31,R11039 R11040
Ethanol,cpd:C21173,PEtN-KDO2-lipid A;7-O-Ethanolaminephospho-alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-lipid A,C112H208N3O42P3,Lipopolysaccharide biosynthesis,NA,Lipids [BR:br08002]; SL  Saccharolipids;  SL02 Acylaminosugar glycans;   C21173  PEtN-KDO2-lipid A,2.7.8.42,R11204
Ethanol,cpd:C21174,PEtN-KDO2-lipid IV(A);7-O-Ethanolaminephospho-alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-lipid IV(A),C86H160N3O40P3,NA,NA,Lipids [BR:br08002]; SL  Saccharolipids;  SL02 Acylaminosugar glycans;   C21174  PEtN-KDO2-lipid IV(A),2.7.8.42,R11205
Ethanol,cpd:C21420,"(3,4-Dimethoxyphenyl)methanol;Veratryl alcohol;3,4-Dimethoxybenzyl alcohol",C9H12O3,NA,NA,NA,1.11.1.14,R11502
Ethanol,cpd:C21421,"(3,4-Dimethoxyphenyl)methanol radical",C9H11O3,NA,NA,NA,1.11.1.14,R11502
Ethanol,cpd:C21480,"1-Octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine",C43H78NO8P,Ferroptosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0201 Diacylglycerophosphoethanolamines;    C21480  1-Octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine",NA,NA
Ethanol,cpd:C21481,"1-Octadecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoethanolamine",C45H82NO8P,Ferroptosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0201 Diacylglycerophosphoethanolamines;    C21481  1-Octadecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoethanolamine",NA,NA
Ethanol,cpd:C21482,"1-Octadecanoyl-2-(15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine;18:0/15-HETE-PE",C43H78NO9P,Ferroptosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP20 Oxidized glycerophospholipids;   GP2002 Oxidized glycerophosphoethanolamines;    C21482  1-Octadecanoyl-2-(15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine",NA,NA
Ethanol,cpd:C21483,"1-Octadecanoyl-2-(15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine;18:0/15-HpETE-PE",C43H78NO10P,Ferroptosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP20 Oxidized glycerophospholipids;   GP2002 Oxidized glycerophosphoethanolamines;    C21483  1-Octadecanoyl-2-(15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine",NA,NA
Ethanol,cpd:C21484,1-Octadecanoyl-sn-glycero-3-phosphoethanolamine,C23H48NO7P,Ferroptosis,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP02 Glycerophosphoethanolamines;   GP0205 Monoacylglycerophosphoethanolamines;    C21484  1-Octadecanoyl-sn-glycero-3-phosphoethanolamine,NA,NA
Ethanol,cpd:C21521,"Deglymidodrine;Desglymidodrine;DMAE;2-Amino-1-(2,5-dimethoxyphenyl)ethanol",C10H15NO3,NA,NA,Prodrugs [br08324.html]; C21521,NA,NA
Ethanol,cpd:C21568,"4-Hydroxy-2,2'-bipyrrole-5-methanol",C9H10N2O2,Prodigiosin biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Prodigiosin biosynthesis, L-proline => prodigiosin;Undecylprodigiosin biosynthesis, L-proline => undecylprodigiosin",NA,NA,R11667 R11668 R11669
Ethanol,cpd:C22012,"[(4S)-4-(5,5-Dimethylcyclohex-1-en-1-yl)-cyclohex-1-en-1-yl]methanol",C15H24O,NA,NA,NA,1.14.14.160,R12227 R12228
Ethanol,cpd:C22272,(+)-Perillyl alcohol;(R)-Perillyl alcohol;[(4R)-4-(Prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol,C10H16O,NA,NA,NA,1.17.99.8,R12592
Ethanol,cpd:C22778,"11-Hydroxytetrahydrocannabinol;11-Hydroxy-delta9-tetrahydrocannabinol;(6aR,10aR)-6a,7,8,10a-Tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6H-dibenzo[b,d]pyran-9-methanol",C21H30O3,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22778,NA,NA
Glucose,cpd:C00029,UDP-glucose;UDPglucose;UDP-D-glucose;Uridine diphosphate glucose;UDP-alpha-D-glucose,C15H24N2O17P2,"Pentose and glucuronate interconversions;Galactose metabolism;Ascorbate and aldarate metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Neomycin, kanamycin and gentamicin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Teichoic acid biosynthesis;Glycerolipid metabolism;Zeatin biosynthesis;Biosynthesis of ansamycins;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars","Glucuronate pathway (uronate pathway);Ascorbate biosynthesis, animals, glucose-1P => ascorbate;Nucleotide sugar biosynthesis, glucose => UDP-glucose;Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P;Glycogen biosynthesis, glucose-1P => glycogen/starch",Compounds with biological roles [BR:br08001]; Vitamins and cofactors;  Cofactors;   Coenzymes;    C00029  UDP-glucose,1.1.1.22;1.1.1.-;2.4.1.11;2.4.1.12;2.4.1.13;2.4.1.14;2.4.1.15;2.4.1.34;2.4.1.35;2.4.1.52;2.4.1.53;2.4.1.58;2.4.1.63;2.4.1.66;2.4.1.71;2.4.1.73;2.4.1.78;2.4.1.80;2.4.1.81;2.4.1.85;2.4.1.91;2.4.1.103;2.4.1.104;2.4.1.105;2.4.1.106;2.4.1.111;2.4.1.114;2.4.1.115;2.4.1.116;2.4.1.117;2.4.1.118;2.4.1.120;2.4.1.121;2.4.1.126;2.4.1.127;2.4.1.128;2.4.1.136;2.4.1.158;2.4.1.160;2.4.1.170;2.4.1.171;2.4.1.172;2.4.1.173;2.4.1.176;2.4.1.177;2.4.1.178;2.4.1.181;2.4.1.183;2.4.1.185;2.4.1.186;2.4.1.188;2.4.1.192;2.4.1.193;2.4.1.194;2.4.1.195;2.4.1.196;2.4.1.202;2.4.1.203;2.4.1.208;2.4.1.209;2.4.1.210;2.4.1.215;2.4.1.218;2.4.1.219;2.4.1.220;2.4.1.237;2.4.1.238;2.4.1.239;2.4.1.240;2.4.1.242;2.4.1.245;2.4.1.249;2.4.1.263;2.4.1.271;2.4.1.276;2.4.1.284;2.4.1.286;2.4.1.295;2.4.1.296;2.4.1.297;2.4.1.298;2.4.1.301;2.4.1.305;2.4.1.310;2.4.1.314;2.4.1.315;2.4.1.323;2.4.1.324;2.4.1.330;2.4.1.336;2.4.1.337;2.4.1.338;2.4.1.350;2.4.1.354;2.4.1.357;2.4.1.358;2.4.1.360;2.4.1.363;2.4.1.364;2.4.1.365;2.4.1.366;2.4.1.367;2.4.1.368;2.4.1.369;2.4.1.-;2.7.7.9;2.7.7.12;2.7.7.64;2.7.8.19;2.7.8.31;3.6.1.9;3.6.1.45;3.13.1.1;4.2.1.76;5.1.3.2,R00286 R00287 R00289 R00291 R00292 R00293 R00766 R00806;R00836 R00955 R01005 R01240 R01304 R01497 R01722 R01912;R01994 R01995 R02113 R02118 R02158 R02179 R02256 R02380;R02388 R02594 R02689 R02709 R02716 R02737 R02889 R02897;R02932 R02951 R03094 R03118 R03190 R03213 R03267 R03297;R03526 R03547 R03548 R03558 R03565 R03573 R03574 R03588;R03594 R03605 R03625 R03680 R03681 R03686 R03710 R03797;R03996 R04005 R04071 R04108 R04127 R04179 R04296 R04359;R04377 R04491 R04577 R04579 R04948 R05083 R05164 R05324;R05325 R05769 R05775 R05882 R06047 R06048 R06534 R06535;R06536 R06546 R06547 R06594 R06611 R06795 R06803 R06804;R06805 R06810 R06812 R06813 R06819 R07260 R07266 R07332;R07333 R07338 R07339 R07340 R07426 R07574 R07575 R07718;R07720 R07729 R07740 R07753 R07874 R07875 R07877 R07878;R07879 R07911 R07912 R07913 R07914 R07923 R08006 R08007;R08013 R08021 R08075 R08076 R08128 R08164 R08369 R08533;R08534 R08661 R08668 R08687 R08813 R08814 R08816 R08822;R08830 R08839 R08859 R09641 R09757 R09758 R09759 R09804;R09857 R10037 R10063 R10096 R10262 R10263 R10264 R10265;R10293 R10294 R10295 R10434 R10594 R10607 R10638 R10639;R10807 R10834 R10835 R10850 R10988 R10989 R10990 R11241;R11271 R11272 R11306 R11939 R12036 R12045 R12047 R12088;R12160 R12290 R12382 R12383 R12384 R12385 R12386 R12387;R12388 R12389 R12469 R12470 R12471 R12807 R12916 R12995
Glucose,cpd:C00031,D-Glucose;Grape sugar;Dextrose;Glucose;D-Glucopyranose,C6H12O6,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Streptomycin biosynthesis;Neomycin, kanamycin and gentamicin biosynthesis;Indole alkaloid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;ABC transporters;Two-component system;Phosphotransferase system (PTS);HIF-1 signaling pathway;FoxO signaling pathway;Meiosis - yeast;Efferocytosis;AMPK signaling pathway;Taste transduction;Insulin signaling pathway;Insulin secretion;Prolactin signaling pathway;Glucagon signaling pathway;Type II diabetes mellitus;Insulin resistance;Non-alcoholic fatty liver disease;AGE-RAGE signaling pathway in diabetic complications;Carbohydrate digestion and absorption;Bile secretion;Mineral absorption;Biofilm formation - Vibrio cholerae;Central carbon metabolism in cancer;Diabetic cardiomyopathy",NA,"Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C00031  D-Glucose;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00009)]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CX Other irrigating solutions;     B05CX01 Glucose;      D00009  Glucose (JP18) &lt;JP&gt;; V VARIOUS;  V04 DIAGNOSTIC AGENTS;   V04C OTHER DIAGNOSTIC AGENTS;    V04CA Tests for diabetes;     V04CA02 Glucose;      D00009  Glucose (JP18) &lt;JP&gt;;  V06 GENERAL NUTRIENTS;   V06D OTHER NUTRIENTS;    V06DC Carbohydrates;     V06DC01 Glucose;      D00009  Glucose (JP18) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00009)]; 3  Agents affecting metabolism;  32  Nutrients, tonics;   323  Saccharide preparations;    3231  Glucoses;     D00009  Glucose (JP18); Purified glucose (JP18);Risk category of Japanese OTC drugs [BR:br08312(D00009)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Glucose;    D00009  Glucose (JP18);Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  964  Saccharide preparations and blood substitutes;   9641  Dextrose and preparations;    C00031  D-Glucose;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00009)]; Chemicals;  D00009  Glucose;  D00009  Purified glucose;  D00009  Glucose injection",1.1.1.118;1.1.1.119;1.1.1.121;1.1.1.359;1.1.1.360;1.1.1.432;1.1.3.10;1.1.5.2;1.1.5.9;1.1.99.28;1.1.99.35;2.3.1.72;2.3.1.90;2.3.1.91;2.3.1.92;2.3.1.103;2.3.1.143;2.3.1.152;2.3.1.-;2.4.1.8;2.4.1.9;2.4.1.10;2.4.1.20;2.4.1.22;2.4.1.25;2.4.1.31;2.4.1.64;2.4.1.99;2.4.1.230;2.4.1.245;2.4.1.279;2.4.1.281;2.7.1.1;2.7.1.2;2.7.1.41;2.7.1.42;2.7.1.61;2.7.1.62;2.7.1.63;2.7.1.142;2.7.1.147;2.7.1.199;3.1.1.33;3.1.3.9;3.1.3.10;3.1.3.58;3.1.4.48;3.1.6.3;3.2.1.3;3.2.1.10;3.2.1.20;3.2.1.21;3.2.1.22;3.2.1.23;3.2.1.26;3.2.1.28;3.2.1.39;3.2.1.42;3.2.1.45;3.2.1.48;3.2.1.58;3.2.1.74;3.2.1.86;3.2.1.93;3.2.1.104;3.2.1.105;3.2.1.107;3.2.1.108;3.2.1.117;3.2.1.118;3.2.1.122;3.2.1.125;3.2.1.126;3.2.1.147;3.2.1.175;3.2.1.182;3.2.1.186;3.2.1.188;3.2.1.189;3.2.1.205;3.2.1.206;3.2.1.207;3.2.1.208;3.2.1.216;3.2.1.220;3.2.1.-;4.2.99.22;4.2.99.23,R00010 R00015 R00028 R00049 R00063 R00299 R00300 R00301;R00302 R00303 R00304 R00305 R00306 R00308 R00327 R00337;R00503 R00534 R00550 R00725 R00801 R00837 R00838 R00839;R00850 R00874 R00952 R00953 R00960 R01006 R01100 R01101;R01139 R01444 R01460 R01498 R01555 R01718 R01790 R01791;R02185 R02558 R02595 R02727 R02738 R02887 R02985 R03075;R03323 R03527 R03604 R03703 R03801 R03802 R03820 R04006;R04094 R04194 R04333 R04409 R04410 R04411 R04498 R04503;R04949 R04998 R05061 R05140 R05141 R05142 R05196 R05804;R05980 R05981 R06040 R06053 R06056 R06058 R06059 R06067;R06069 R06079 R06080 R06087 R06091 R06103 R06104 R06105;R06106 R06107 R06108 R06109 R06112 R06113 R06114 R06115;R06135 R06204 R06620 R07147 R07264 R08404 R08432 R08514;R08819 R08823 R08946 R09039 R09723 R09941 R09943 R10411;R10494 R10525 R10530 R10580 R10581 R11215 R11306 R11682;R11791 R11942 R12208 R12209 R12250 R12983 R12997 R13178;R13191
Glucose,cpd:C00092,D-Glucose 6-phosphate;Glucose 6-phosphate;Robison ester,C6H13O9P,"Starch and sucrose metabolism;Streptomycin biosynthesis;Neomycin, kanamycin and gentamicin biosynthesis;Inositol phosphate metabolism;Biosynthesis of various antibiotics;Biosynthesis of terpenoids and steroids;Metabolic pathways;Biosynthesis of secondary metabolites;Two-component system;Phosphotransferase system (PTS);Insulin secretion;Prolactin signaling pathway;Thyroid hormone synthesis;Insulin resistance;Carbohydrate digestion and absorption;Biofilm formation - Vibrio cholerae;Central carbon metabolism in cancer;Diabetic cardiomyopathy","Glycogen degradation, glycogen => glucose-6P;Kanosamine biosynthesis, glucose 6-phosphate => kanosamine",NA,1.1.1.49;1.1.1.200;1.1.1.361;1.1.1.363;1.1.1.388;1.1.98.2;2.4.1.15;2.4.1.36;2.4.1.216;2.4.1.347;2.7.1.1;2.7.1.2;2.7.1.61;2.7.1.63;2.7.1.142;2.7.1.147;2.7.1.232;3.1.3.9;3.1.3.58;3.2.1.26;3.2.1.86;3.2.1.93;3.2.1.122;3.5.-.-;4.2.3.124;5.3.1.9;5.4.2.2;5.4.2.5;5.4.2.6;5.5.1.4,R00299 R00303 R00725 R00771 R00834 R00835 R00836 R00837;R00838 R00839 R00850 R01139 R02168 R02185 R03921 R05767;R05804 R06043 R06044 R06112 R06113 R06115 R06125 R07324;R08125 R08404 R08617 R08639 R09550 R10519 R10520 R11310;R11783 R12746
Glucose,cpd:C00103,D-Glucose 1-phosphate;alpha-D-Glucose 1-phosphate;Cori ester;D-Glucose alpha-1-phosphate,C6H13O9P,Glycolysis / Gluconeogenesis;Pentose and glucuronate interconversions;Galactose metabolism;Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Streptomycin biosynthesis;Polyketide sugar unit biosynthesis;Acarbose and validamycin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Glycerolipid metabolism;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars;Glucagon signaling pathway,"Ascorbate biosynthesis, animals, glucose-1P => ascorbate;Nucleotide sugar biosynthesis, glucose => UDP-glucose;Trehalose biosynthesis, D-glucose 1P => trehalose;Galactose degradation, Leloir pathway, galactose => alpha-D-glucose-1P;dTDP-L-rhamnose biosynthesis;Glycogen biosynthesis, glucose-1P => glycogen/starch;Glycogen degradation, glycogen => glucose-6P",NA,2.4.1.1;2.4.1.7;2.4.1.20;2.4.1.30;2.4.1.31;2.4.1.49;2.4.1.97;2.4.1.139;2.4.1.231;2.4.1.321;2.4.1.329;2.4.1.333;2.4.1.342;2.4.1.352;2.4.1.359;2.4.1.388;2.4.1.389;2.4.1.392;2.7.1.10;2.7.1.41;2.7.1.42;2.7.1.62;2.7.1.106;2.7.7.9;2.7.7.12;2.7.7.24;2.7.7.27;2.7.7.33;2.7.7.34;2.7.7.36;2.7.7.64;2.7.7.69;2.7.7.78;3.1.3.10;3.1.4.51;3.6.1.9;3.6.1.21;3.6.1.45;3.6.1.-;5.4.2.2;5.4.2.5,R00287 R00289 R00304 R00550 R00803 R00947 R00948 R00949;R00951 R00952 R00953 R00954 R00955 R00956 R00957 R00959;R00960 R01233 R01660 R01821 R02111 R02328 R02888 R03116;R04180 R05512 R06018 R06022 R06034 R06050 R06056 R06058;R06061 R06185 R07265 R08514 R08515 R08639 R09752 R10832;R10987 R11128 R11530 R11959 R12243 R12607 R12979 R13002;R13125
Glucose,cpd:C00140,N-Acetyl-D-glucosamine;N-Acetylchitosamine;2-Acetamido-2-deoxy-D-glucose;GlcNAc,C8H15NO6,Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars;ABC transporters;Phosphotransferase system (PTS),NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C00140  N-Acetyl-D-glucosamine,1.1.3.29;2.3.1.3;2.4.1.90;2.4.1.211;2.4.1.280;2.4.1.320;2.7.1.59;2.7.1.162;2.7.1.193;2.7.1.-;3.1.4.45;3.2.1.14;3.2.1.50;3.2.1.52;3.2.1.169;3.2.2.11;3.5.1.33;5.1.3.8,R00022 R01200 R01201 R01203 R01204 R01205 R01206 R01207;R01266 R04373 R05199 R05326 R06055 R06057 R06081 R06141;R07809 R07816 R08968 R09323 R09672 R09673 R09942 R10829;R10831 R11316 R11317 R12973
Glucose,cpd:C00221,beta-D-Glucose;beta-D-Glucopyranose,C6H12O6,Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism,NA,NA,1.1.1.47;1.1.3.4;1.1.3.5;2.3.1.213;2.7.1.1;2.7.1.2;2.7.1.63;2.7.1.147;3.2.1.21;3.2.1.23;3.2.1.62;3.2.1.85;3.2.1.106;3.2.1.205;3.2.1.216;4.3.3.5;5.1.3.3;5.1.3.44,R00026 R01520 R01521 R01522 R01600 R01602 R02187 R03256;R04783 R05979 R06077 R06092 R06110 R06144 R09086 R09568;R10035 R10039 R10040 R10236 R11791 R12664 R12969 R12983;R13051 R13052 R13065 R13081
Glucose,cpd:C00267,alpha-D-Glucose,C6H12O6,"Glycolysis / Gluconeogenesis;Fructose and mannose metabolism;Galactose metabolism;Amino sugar and nucleotide sugar metabolism;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of nucleotide sugars;Proximal tubule bicarbonate reclamation","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Nucleotide sugar biosynthesis, glucose => UDP-glucose;UDP-N-acetyl-D-glucosamine biosynthesis, eukaryotes, glucose => UDP-GlcNAc;UDP-N-acetyl-D-glucosamine biosynthesis, prokaryotes, glucose => UDP-GlcNAc",NA,1.1.1.21;1.1.3.41;2.4.1.231;2.7.1.1;2.7.1.2;2.7.1.63;2.7.1.147;3.1.3.9;3.1.3.10;3.2.1.3;3.2.1.10;3.2.1.20;3.2.1.23;3.2.1.26;3.2.1.33;3.2.1.48;3.2.1.58;3.2.1.108;3.2.1.219;5.1.3.3;5.3.1.5,R00307 R00802 R00878 R00947 R01602 R01678 R01718 R01786;R01787 R01788 R02109 R02189 R03115 R06078 R06080 R06084;R06088 R06098 R06158 R06199 R07265 R09085 R11620 R13126;R13204
Glucose,cpd:C00329,D-Glucosamine;Chitosamine;2-Amino-2-deoxy-D-glucose,C6H13NO5,Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars;Phosphotransferase system (PTS),NA,"Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C00329  D-Glucosamine;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D04334)]; M MUSCULO-SKELETAL SYSTEM;  M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;   M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;    M01AX Other antiinflammatory and antirheumatic agents, non-steroids;     M01AX05 Glucosamine;      D04334  Glucosamine (USAN/INN)",1.1.3.-;2.3.1.3;2.7.1.1;2.7.1.8;2.7.1.147;2.7.1.-;3.2.1.165;3.5.1.33;3.10.1.1,R01200 R01204 R01961 R01962 R01963 R01964 R01965 R01966;R02631 R06225 R08715 R12594
Glucose,cpd:C00394,GDP-glucose;GDP-D-glucose;GDP-alpha-D-glucose,C16H25N5O16P2,Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.4.1.29;2.4.1.36;2.7.7.34;2.7.7.69;2.7.7.78;3.2.1.42;3.6.1.-,R00337 R00954 R01233 R02168 R02890 R09752 R12607
Glucose,cpd:C00498,ADP-glucose;ADP-alpha-D-glucose;Adenosine diphosphoglucose,C16H25N5O15P2,Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,"Trehalose biosynthesis, D-glucose 1P => trehalose;Glycogen biosynthesis, glucose-1P => glycogen/starch",NA,2.4.1.13;2.4.1.21;2.4.1.113;2.4.1.213;2.4.1.242;2.4.1.245;2.4.1.268;2.4.1.342;2.4.1.347;2.7.7.27;2.7.7.36;3.6.1.21,R00948 R00951 R02420 R02421 R05328 R08515 R08676 R08946;R09665 R11530 R11783
Glucose,cpd:C00501,CDP-glucose;CDP-D-Glucose,C15H25N3O16P2,Starch and sucrose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.7.7.33;4.2.1.45,R00956 R02426
Glucose,cpd:C00586,2-Deoxy-D-glucose;2-Deoxy-D-arabino-hexose;D-arabino-2-Deoxyhexose,C6H12O5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C00586  2-Deoxy-D-glucose,3.1.3.68;3.2.1.112,R02587 R02588
Glucose,cpd:C00663,beta-D-Glucose 1-phosphate,C6H13O9P,Starch and sucrose metabolism,NA,NA,2.4.1.8;2.4.1.64;2.4.1.216;2.4.1.230;2.4.1.279;2.4.1.282;2.4.1.332;2.4.1.334;5.4.2.6,R01555 R02727 R02728 R05767 R06040 R06044 R06053 R07264;R09941 R10098 R11127 R11140 R11310
Glucose,cpd:C00668,alpha-D-Glucose 6-phosphate,C6H13O9P,"Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Galactose metabolism;Amino sugar and nucleotide sugar metabolism;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of cofactors;Biosynthesis of nucleotide sugars;AMPK signaling pathway;Glucagon signaling pathway","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Pentose phosphate pathway (Pentose phosphate cycle);Nucleotide sugar biosynthesis, glucose => UDP-glucose;UDP-N-acetyl-D-glucosamine biosynthesis, eukaryotes, glucose => UDP-GlcNAc;UDP-N-acetyl-D-glucosamine biosynthesis, prokaryotes, glucose => UDP-GlcNAc",NA,2.4.1.15;2.7.1.1;2.7.1.2;2.7.1.63;2.7.1.147;2.7.1.199;3.1.3.9;3.2.1.26;5.1.3.15;5.3.1.9;5.4.2.2;5.4.2.5,R00959 R01786 R01788 R02189 R02737 R02738 R02739 R02740;R06102 R06226 R09085 R13199
Glucose,cpd:C00718,"Amylose;Amylose chain;(1,4-alpha-D-Glucosyl)n;(1,4-alpha-D-Glucosyl)n+1;(1,4-alpha-D-Glucosyl)n-1;4-{(1,4)-alpha-D-Glucosyl}(n-1)-D-glucose;1,4-alpha-D-Glucan",(C6H10O5)n,Starch and sucrose metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,"Trehalose biosynthesis, D-glucose 1P => trehalose;Glycogen biosynthesis, glucose-1P => glycogen/starch",NA,2.4.1.1;2.4.1.2;2.4.1.4;2.4.1.11;2.4.1.18;2.4.1.21;2.4.1.25;2.4.1.242;2.4.99.16;3.2.1.33,R00292 R01821 R01823 R02109 R02110 R02111 R02121 R02421;R05196 R07261 R09994
Glucose,cpd:C00842,dTDP-glucose;dTDP-D-glucose;dTDP-alpha-D-glucose,C16H26N2O16P2,Streptomycin biosynthesis;Polyketide sugar unit biosynthesis;Acarbose and validamycin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-rhamnose biosynthesis,NA,1.1.1.-;2.7.7.24;4.2.1.46;5.1.3.2,R02328 R02983 R02984 R06513 R11471
Glucose,cpd:C01009,UDP-2-deoxyglucose,C15H24N2O16P2,NA,NA,NA,NA,NA
Glucose,cpd:C01158,1-O-Galloyl-beta-D-glucose;1-Galloyl-beta-glucose;beta-Glucogallin;1-Galloyl-beta-D-glucose,C13H16O10,Biosynthesis of various plant secondary metabolites;Biosynthesis of phenylpropanoids,NA,NA,2.3.1.90;2.3.1.143;2.4.1.136,R00049 R03297 R04498
Glucose,cpd:C01172,beta-D-Glucose 6-phosphate,C6H13O9P,Glycolysis / Gluconeogenesis;Pentose phosphate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;AMPK signaling pathway;Glucagon signaling pathway,"Pentose phosphate pathway (Pentose phosphate cycle);Pentose phosphate pathway, oxidative phase, glucose 6P => ribulose 5P;Entner-Doudoroff pathway, glucose-6P => glyceraldehyde-3P + pyruvate",NA,1.1.1.49;1.1.1.363;1.1.1.388;2.7.1.1;2.7.1.2;2.7.1.63;2.7.1.147;3.2.1.86;5.1.3.15;5.3.1.9;5.4.2.6,R01600 R02187 R02728 R02736 R02739 R03321 R05133 R05134;R09086 R10907
Glucose,cpd:C01175,1-O-Sinapoyl-beta-D-glucose;1-O-Sinapoyl beta-D-glucoside,C17H22O10,Phenylpropanoid biosynthesis;Biosynthesis of secondary metabolites,NA,Phytochemical compounds [BR:br08003]; Phenylpropanoids;  Monolignols;   Sinapate derivatives;    C01175  1-O-Sinapoyl-beta-D-glucose,2.3.1.91;2.3.1.92;2.3.1.103;2.4.1.120;2.4.1.126;2.4.1.299,R00063 R02380 R03075 R03323 R10261 R10298 R10299
Glucose,cpd:C01219,CDP-4-dehydro-6-deoxy-D-glucose,C15H23N3O15P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.17.1.1;4.2.1.45,R02426 R03391 R03392
Glucose,cpd:C01231,"alpha-D-Glucose 1,6-bisphosphate;alpha-D-Glucose 1,6-biphosphate;D-Glucose 1,6-bisphosphate",C6H14O12P2,Starch and sucrose metabolism;Metabolic pathways,NA,NA,2.7.1.10;2.7.1.41;2.7.1.106,R00949 R00960 R01660
Glucose,cpd:C01518,Nigerose;Sakebiose;3-O-alpha-D-Glucopyranosyl-D-glucose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C01518  Nigerose,2.4.1.279;2.4.1.334,R09941 R11140
Glucose,cpd:C02048,Laminaribiose;Laminariaceae;3-beta-D-Glucosyl-D-glucose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C02048  Laminaribiose,2.4.1.31,R00953
Glucose,cpd:C02130,Acetyl-maltose;6-O-Acetyl-alpha-D-glucopyranosyl-(1->4)-D-glucose,C14H24O12,NA,NA,NA,2.3.1.79,R01556
Glucose,cpd:C02264,D-Glucose oxime,C6H13NO6,NA,NA,NA,NA,NA
Glucose,cpd:C02522,6-Deoxy-D-glucose;D-Quinovose;6-Deoxy-D-glucopyranose;D-Chinovose;D-Glucomethylose;Isorhamnose;D-Epifucose;Isorhodeose,C6H12O5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Deoxy sugars;    C02522  D-Quinovose,NA,NA
Glucose,cpd:C02655,6-Acetyl-D-glucose,C8H14O7,NA,NA,NA,3.1.1.33,R00327
Glucose,cpd:C02779,2-Dehydro-D-glucose,C6H10O6,NA,NA,NA,1.1.3.10;1.1.3.-,R00302 R04048
Glucose,cpd:C02827,D-Glucose 6-sulfate,C6H12O9S,NA,NA,NA,3.1.6.3,R00534
Glucose,cpd:C03018,Oligoglycosylglucose,OH(C6H10O5)n,NA,NA,Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00084)]; Chemicals;  D00084  Dextrin,3.2.1.123,R04118
Glucose,cpd:C03367,6-alpha-Maltosylglucose,C18H32O16,NA,NA,NA,NA,NA
Glucose,cpd:C03598,"CDP-3,6-dideoxy-D-glucose;CDP-paratose;CDP-alpha-D-paratose;CDP-3,6-dideoxy-alpha-D-ribo-hexose",C15H25N3O14P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.342;5.1.3.10,R04265 R04266
Glucose,cpd:C03799,Polyprenylphosphate-glucose,C11H21O9P(C5H8)n,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR00 Other Prenol lipids;   C03799  Polyprenylphosphate-glucose,2.4.1.78,R03190
Glucose,cpd:C03811,alpha-D-Glucose 3-phosphate,C6H13O9P,NA,NA,NA,NA,NA
Glucose,cpd:C04089,UDP-4-dehydro-6-deoxy-D-glucose;UDP-4-keto-6-deoxy-D-glucose;UDP-4-oxo-6-deoxy-D-glucose;UDP-4-dehydro-6-deoxy-alpha-D-glucose,C15H22N2O16P2,Amino sugar and nucleotide sugar metabolism;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.-;4.2.1.76;5.1.3.-,R00293 R03879 R08704
Glucose,cpd:C04101,"1-O,6-O-Digalloyl-beta-D-glucose",C20H20O14,NA,NA,NA,2.3.1.90,R00049
Glucose,cpd:C04197,Indole-3-acetyl-beta-1-D-glucoside;1-O-(Indol-3-yl)acetyl-beta-D-glucose,C16H19NO7,NA,NA,NA,2.3.1.72;2.4.1.121,R03094 R04333
Glucose,cpd:C04268,"dTDP-4-amino-4,6-dideoxy-D-glucose;dTDP-4-amino-4,6-dideoxy-alpha-D-glucose;dTDP-viosamine;dTDP-4-amino-4,6-dideoxy-alpha-D-glucopyranose",C16H27N3O14P2,Polyketide sugar unit biosynthesis;Acarbose and validamycin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,"dTDP-D-desosamine biosynthesis;Acarbose biosynthesis, sedoheptulopyranose-7P => acarbose",NA,1.14.15.-;2.3.1.209;2.4.-.-;2.6.1.33;4.3.1.30,R02773 R08583 R10174 R11247 R11468
Glucose,cpd:C04275,"1,2-Bis-O-sinapoyl-beta-D-glucose;1,2-Bis-O-sinapoyl-beta-D-glucoside",C28H32O14,NA,NA,NA,2.3.1.103,R00063
Glucose,cpd:C04297,"CDP-4-dehydro-3,6-dideoxy-D-glucose;CDP-3,6-dideoxy-D-erythro-hexos-4-ulose;CDP-4-dehydro-3,6-dideoxy-alpha-D-glucose",C15H23N3O14P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.341;1.1.1.342;1.17.1.1;4.2.1.-;5.1.3.-,R03391 R03392 R04265 R08708 R08711
Glucose,cpd:C04360,"1-O,2-O,6-O-Trigalloyl-beta-D-glucose;1,2,6-Trigalloylglucose",C27H24O18,NA,NA,NA,NA,NA
Glucose,cpd:C04473,3-alpha-D-Galactosyl-[lipopolysaccharide glucose],NA,NA,NA,NA,2.4.1.44,R01997
Glucose,cpd:C04516,"1,2,3,6-Tetrakis-O-galloyl-beta-D-glucose;1,2,3,6-Tetra-O-galloyl-beta-D-glucose",C34H28O22,NA,NA,NA,2.3.1.143,R04498
Glucose,cpd:C04534,"6-Phospho-beta-D-glucosyl-(1,4)-D-glucose;Cellobiose 6'-phosphate;Cellobiose 6-phosphate",C12H23O14P,Starch and sucrose metabolism;Phosphotransferase system (PTS),NA,NA,2.7.1.85;2.7.1.205;3.2.1.86,R00839 R01441 R11172
Glucose,cpd:C04566,Membrane-derived-oligosaccharide D-glucose,NA,NA,NA,NA,2.7.8.20,R04511
Glucose,cpd:C04576,"Pentagalloylglucose;1,2,3,4,6-Pentakis-O-galloyl-beta-D-glucose;Pentagalloyl-beta-D-glucose",C41H32O26,Biosynthesis of various plant secondary metabolites;Biosynthesis of phenylpropanoids,NA,Phytochemical compounds [BR:br08003]; Others;  Tannins and galloyl derivatives;   Ellagitannins;    C04576  Pentagalloylglucose;Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C04576,2.3.1.143,R04498
Glucose,cpd:C04613,"UDP-2-acetamido-4-dehydro-2,6-dideoxyglucose;UDP-2-acetamido-2,6-dideoxy-alpha-D-xylo-hexos-4-ulose;UDP-2-acetamido-2,6-dideoxy-alpha-D-xylo-hex-4-ulose;UDP-2-acetamido-2,6-dideoxy-alpha-D-xylohex-4-ulose;UDP-4-keto-6-deoxy-GlcNAc",C17H25N3O16P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Teichoic acid biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.426;1.1.1.-;2.6.1.34;2.6.1.-;4.2.1.135;5.1.3.-,R04529 R10266 R12554 R12555 R12556 R12760 R12906 R13087
Glucose,cpd:C04630,"UDP-2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-glucose;UDP-4-amino-4,6-dideoxy-N-acetyl-alpha-D-glucosamine;UDP-N-acetylbacillosamine",C17H28N4O15P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.3.1.203;2.6.1.34,R04529 R10099 R12557
Glucose,cpd:C04645,6-(D-Glucose-1-phospho)-D-mannosylglycoprotein;Glycoprotein 6-(D-glucose-1-phospho)-D-mannose,C12H22O14PR,NA,NA,NA,2.7.8.19;3.1.4.51,R04179 R04180
Glucose,cpd:C04725,"Oligosaccharide containing 6-methyl-D-glucose units;1,4-alpha-D-Glucooligosaccharide containing 6-O-methyl-D-glucose units",(C19H32O15)n,NA,NA,NA,2.1.1.18,R04396
Glucose,cpd:C04794,3-(4-Deoxy-beta-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine;3-(4-Deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose,C14H21NO11,NA,NA,NA,4.2.2.1,R02465
Glucose,cpd:C04809,Membrane-derived-oligosaccharide 6-(glycerophospho)-D-glucose,NA,NA,NA,NA,2.7.8.20,R04511
Glucose,cpd:C05402,Melibiose;6-O-(alpha-D-Galactopyranosyl)-D-glucopyranose;D-Gal-alpha1->6D-Glucose,C12H22O11,Galactose metabolism;Metabolic pathways;ABC transporters,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C05402  Melibiose,3.2.1.22;3.2.1.26,R01101 R02410 R05549
Glucose,cpd:C05404,D-Gal alpha 1->6D-Gal alpha 1->6D-Glucose;D-Gal-alpha1->6D-Gal-alpha1->6D-Glucose;Manninotriose,C18H32O16,Galactose metabolism;Metabolic pathways,NA,NA,3.2.1.22;3.2.1.26,R03635 R05549
Glucose,cpd:C06018,"dTDP-4-acetamido-4,6-dideoxy-D-glucose;dTDP-4-acetamido-4,6-dideoxy-alpha-D-glucose;dTDP-N-acetylviosamine",C18H29N3O15P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.3.1.209;2.6.1.33,R02772 R10174
Glucose,cpd:C06369,2-Deoxy-D-glucose 6-phosphate,C6H13O8P,NA,NA,NA,3.1.3.68,R02587
Glucose,cpd:C06478,"3,6-Anhydroglucose;3,6-Anhydro-D-glucose",C6H10O5,NA,NA,"Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C06478  3,6-Anhydroglucose",NA,NA
Glucose,cpd:C06620,"dTDP-3,4-dioxo-2,6-dideoxy-D-glucose;dTDP-3,4-didehydro-2,6-dideoxy-alpha-D-glucose",C16H22N2O14P2,Polyketide sugar unit biosynthesis;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-mycarose biosynthesis;dTDP-L-oleandrose biosynthesis;dTDP-L-megosamine biosynthesis;dTDP-L-olivose biosynthesis;dTDP-D-forosamine biosynthesis;dTDP-D-angolosamine biosynthesis,NA,1.1.1.384;1.1.1.-;2.6.1.-;4.2.1.159,R05518 R05526 R06443 R06631 R08927 R11034 R11051
Glucose,cpd:C08193,Aurothioglucose,C6H11AuO5S,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00991)]; M MUSCULO-SKELETAL SYSTEM;  M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;   M01C SPECIFIC ANTIRHEUMATIC AGENTS;    M01CB Gold preparations;     M01CB04 Aurothioglucose;      D00991  Aurothioglucose (USP);Drug groups [BR:br08330(D00991)]; Anti-inflammatory;  DG01985  Disease modifying anti-rheumatic drug (DMARD);   DG01912  Gold preparations;    D00991  Aurothioglucose,NA,NA
Glucose,cpd:C08245,6-O-beta-D-Xylopyranosyl-D-glucose;Primeverose,C11H20O10,NA,NA,NA,NA,NA
Glucose,cpd:C10243,"1,2,3,4-Tetragalloyl-alpha-D-glucose",C34H28O22,NA,NA,"Phytochemical compounds [BR:br08003]; Others;  Tannins and galloyl derivatives;   Ellagitannins;    C10243  1,2,3,4-Tetragalloyl-alpha-D-glucose",NA,NA
Glucose,cpd:C10433,1-Caffeoyl-beta-D-glucose,C15H18O9,NA,NA,NA,NA,NA
Glucose,cpd:C11907,"dTDP-4-oxo-6-deoxy-D-glucose;dTDP-4-dehydro-6-deoxy-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-glucopyranose;dTDP-4-oxo-6-deoxy-alpha-D-glucose;dTDP-4-dehydro-6-deoxy-alpha-D-galactose;dTDP-4-dehydro-6-deoxy-D-galactose;dTDP-6-deoxy-D-xylo-hexos-4-ulose;dTDP-6-deoxy-D-xylo-4-hexulose;4,6-Dideoxy-4-oxo-dTDP-D-glucose",C16H24N2O15P2,Streptomycin biosynthesis;Polyketide sugar unit biosynthesis;Acarbose and validamycin biosynthesis;O-Antigen nucleotide sugar biosynthesis;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-rhamnose biosynthesis;dTDP-6-deoxy-D-allose biosynthesis;dTDP-beta-L-noviose biosynthesis;dTDP-D-mycaminose biosynthesis;dTDP-D-desosamine biosynthesis;dTDP-L-mycarose biosynthesis;dTDP-L-oleandrose biosynthesis;dTDP-L-megosamine biosynthesis;dTDP-L-olivose biosynthesis;dTDP-D-forosamine biosynthesis;dTDP-D-angolosamine biosynthesis,NA,1.1.1.266;1.1.1.-;2.6.1.33;2.6.1.59;4.2.1.46;4.2.1.159;5.1.3.13;5.1.3.27;5.3.2.3;5.3.2.4,R02772 R02773 R04438 R05518 R05687 R06424 R06428 R06437;R06513 R06514 R08935 R09904
Glucose,cpd:C11908,"3,6-Dideoxy-3-oxo-dTDP-D-glucose;dTDP-3-oxo-6-deoxy-D-glucose;dTDP-3-oxo-6-deoxy-alpha-D-glucose;dTDP-3-dehydro-6-deoxy-alpha-D-glucopyranose;dTDP-6-deoxy-D-ribo-hexos-3-ulose",C16H24N2O15P2,Polyketide sugar unit biosynthesis;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-mycaminose biosynthesis,NA,2.6.1.89;5.3.2.4,R06423 R06424
Glucose,cpd:C11909,"dTDP-3-oxo-4,6-dideoxy-D-glucose;dTDP-3-oxo-4,6-dideoxy-alpha-D-glucose;dTDP-3-dehydro-4,6-dideoxy-alpha-D-glucopyranose",C16H24N2O14P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-desosamine biosynthesis,NA,2.6.1.106;4.3.1.30,R06426 R08583
Glucose,cpd:C11910,"dTDP-3-amino-3,4,6-trideoxy-D-glucose;dTDP-3-amino-3,4,6-trideoxy-alpha-D-glucose",C16H27N3O13P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-desosamine biosynthesis,NA,2.1.1.234;2.6.1.106,R06426 R06427
Glucose,cpd:C11911,"dTDP-D-desosamine;dTDP-3-dimethylamino-3,4,6-trideoxy-D-glucose;dTDP-alpha-D-desosamine;dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucose;dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucopyranose",C18H31N3O13P2,"Biosynthesis of 12-, 14- and 16-membered macrolides;Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars",dTDP-D-desosamine biosynthesis,NA,2.1.1.234;2.4.1.277;2.4.1.278;2.4.1.-,R05531 R06427 R06457 R06460 R06461 R10876
Glucose,cpd:C11922,"dTDP-4-oxo-2,6-dideoxy-D-glucose;dTDP-4-oxo-2,6-dideoxy-alpha-D-glucose;dTDP-4-dehydro-2,6-dideoxy-alpha-D-glucose;dTDP-4-keto-2,6-dideoxy-D-glucose",C16H24N2O14P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-olivose biosynthesis;dTDP-D-forosamine biosynthesis,NA,1.1.1.384;4.2.1.164;5.1.3.-,R05526 R06446 R08597 R08930
Glucose,cpd:C11923,"dTDP-D-olivose;dTDP-2,6-dideoxy-D-glucose;dTDP-alpha-D-olivose",C16H26N2O14P2,NA,NA,NA,2.4.1.-,R06446 R06660 R06662 R06664 R06668 R06716 R09345 R09351;R09352
Glucose,cpd:C11925,"dTDP-3-amino-3,6-dideoxy-D-glucose",C16H27N3O14P2,Polyketide sugar unit biosynthesis;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-mycaminose biosynthesis,NA,2.1.1.235;2.3.1.-;2.6.1.89,R06423 R06439 R12549
Glucose,cpd:C12067,2-Deoxy-2-dimethylamino-alpha-D-Glucose,C8H17NO5,NA,NA,NA,NA,NA
Glucose,cpd:C12210,UDP-3-ketoglucose;UDP-3-keto-D-glucose,C15H22N2O17P2,"Neomycin, kanamycin and gentamicin biosynthesis;Biosynthesis of ansamycins;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars",NA,NA,1.1.1.-;2.6.1.-,R06586 R06594
Glucose,cpd:C12212,Kanosamine;D-Kanosamine;3-Amino-3-deoxy-D-glucose,C6H13NO5,Biosynthesis of various antibiotics;Biosynthesis of ansamycins;Metabolic pathways;Biosynthesis of secondary metabolites,"Kanosamine biosynthesis, glucose 6-phosphate => kanosamine",Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C12212,2.7.1.179;3.1.3.92,R06587 R06588 R10547
Glucose,cpd:C12318,"dTDP-3-amino-2,3,6-trideoxy-4-keto-D-glucose;dTDP-3-amino-2,3,6-trideoxy-D-threo-hexopyranos-4-ulose;dTDP-3-amino-4-oxo-2,3,6-trideoxy-D-glucose",C16H25N3O13P2,Staurosporine biosynthesis;Polyketide sugar unit biosynthesis;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-megosamine biosynthesis,NA,2.1.1.-;2.6.1.-,R06627 R06631 R11045 R11138
Glucose,cpd:C15479,"D-Quinovosamine;2-Amino-2,6-dideoxy-D-glucose",C6H13NO4,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C15479  D-Quinovosamine,NA,NA
Glucose,cpd:C15481,"N-Acetyl-D-quinovosamine;2-Acetamido-2,6-dideoxy-D-glucose",C8H15NO5,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Amino sugars;    C15481  N-Acetyl-D-quinovosamine,NA,NA
Glucose,cpd:C15541,NDP-glucose;NDP-D-glucose;NDP-alpha-D-glucose,C11H21O15P2R,NA,NA,NA,2.4.1.13;2.4.1.242;2.4.1.245;2.4.1.266,R07256 R07261 R09663 R10525
Glucose,cpd:C15548,2-alpha-D-Glucosyl-D-glucose;Kojibiose;alpha-D-Glucopyranosyl-(1->2)-D-glucopyranose,C12H22O11,NA,NA,NA,2.4.1.230;3.2.1.216,R07264 R12983
Glucose,cpd:C15906,Glucose-dependent insulinotropic peptide;Gastric inhibitory peptide;GIP,NA,NA,NA,Compounds with biological roles [BR:br08001]; Hormones and transmitters;  Peptide hormones;   Incretin;    C15906  Gastric inhibitory peptide;Bioactive peptides [BR:br08005]; Non-endocrine glands secretion peptides;  Gut peptide;   C15906  Gastric inhibitory polypeptide,NA,NA
Glucose,cpd:C15970,Abscisic acid glucose ester;Abscisic acid-beta-D-glucopyranosyl ester;beta-D-Glucopyranosyl abscisate,C21H30O9,Carotenoid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0103 C15 isoprenoids (sesquiterpenes);    PR010305 Cyclofarnesane sesquiterpenoids;     C15970  Abscisic acid glucose ester,2.4.1.263;3.2.1.175,R07575 R09723
Glucose,cpd:C16827,p-Coumaroyl-D-glucose;1-O-(4-Coumaroyl)-beta-D-glucose;1-O-(4-Hydroxycinnamoyl)-beta-D-glucose,C15H18O8,NA,NA,NA,2.3.1.213;2.4.1.126,R08534 R10236
Glucose,cpd:C17087,"dTDP-(3R)-amino-3,6-dideoxy-D-glucose;dTDP-3-amino-3,6-dideoxy-D-allose",C16H27N3O14P2,NA,NA,NA,NA,NA
Glucose,cpd:C17093,"dTDP-3-amino-4,6-dideoxy-3,4-dehydroglucose",C16H25N3O13P2,NA,NA,NA,NA,NA
Glucose,cpd:C17139,"dTDP-3,4-dioxo-2,6-dideoxy-L-glucose",C16H22N2O14P2,NA,NA,NA,NA,R08591
Glucose,cpd:C17326,"CDP-4-dehydro-3,6-dideoxy-D-glucose epimer",C15H23N3O14P2,Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.-;5.1.3.-,R08708 R08709 R08710
Glucose,cpd:C17458,"Gallotannin;1,3,6-Tri-o-galloyl-beta-D-glucose",C27H24O18,NA,NA,NA,NA,NA
Glucose,cpd:C17759,1-O-Feruloyl-beta-D-glucose;1-Feruloyl-D-glucose,C16H20O9,NA,NA,NA,2.3.1.-;2.4.1.120;2.4.1.126,R08819 R08823 R08839
Glucose,cpd:C18029,"dTDP-3-oxo-2,6-dideoxy-D-glucose;dTDP-(2,6-dideoxy-alpha-D-erythro-hexopyranos-3-ulos-1-yl) ester",C16H24N2O14P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-angolosamine biosynthesis,NA,NA,R08927 R08928
Glucose,cpd:C18032,"dTDP-4-oxo-2,3,6-trideoxy-D-glucose;dTDP-[(2R,6R)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl] ester;dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-hexopyranose",C16H24N2O13P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-forosamine biosynthesis,NA,2.6.1.110;4.2.1.164,R08930 R08931
Glucose,cpd:C18033,"dTDP-4-amino-2,3,4,6-tetradeoxy-D-glucose;dTDP-[(2R,5S,6R)-5-aminotetrahydro-6-methyl-2H-pyran-2-yl] ester;dTDP-4-amino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranose",C16H27N3O12P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-D-forosamine biosynthesis,NA,2.1.1.324;2.6.1.110,R08931 R08932 R11452
Glucose,cpd:C18035,"dTDP-3-methyl-4-oxo-2,6-dideoxy-D-glucose;dTDP-(2,6-dideoxy-3-C-methyl-alpha-D-threo-hexopyranos-4-ulos-1-yl) ester",C17H26N2O14P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-mycarose biosynthesis,NA,2.1.1.-;5.1.3.-,R08933 R08934
Glucose,cpd:C19632,Kojibiose;2-O-alpha-D-Glucopyranosyl-D-glucose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C19632  Kojibiose,NA,NA
Glucose,cpd:C20470,1-O-Vanilloyl-beta-D-glucose,C14H18O9,NA,NA,NA,2.4.1.300,R10259 R10296 R10297
Glucose,cpd:C20577,6-Tuliposide A;6-O-(4-Hydroxy-2-methylenebutanoyl)-D-glucose,C11H18O8,NA,NA,NA,4.2.99.22,R10494
Glucose,cpd:C20668,3-Dehydro-D-glucose 6-phosphate,C6H11O9P,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Kanosamine biosynthesis, glucose 6-phosphate => kanosamine",NA,1.1.1.361;2.6.1.104,R10519 R10698
Glucose,cpd:C20829,Sulfoquinovose;6-Deoxy-6-sulfo-D-glucopyranose;6-Deoxy-6-sulfo-D-glucose,C6H12O8S,NA,NA,NA,1.1.1.390;1.14.14.181,R11036 R13017
Glucose,cpd:C20978,Glucoselysine,C12H24N2O7,Phosphotransferase system (PTS),NA,NA,NA,NA
Glucose,cpd:C20979,Glucoselysine-6-phosphate,C12H25N2O10P,Phosphotransferase system (PTS),NA,NA,NA,NA
Glucose,cpd:C21073,"dTDP-3-N,N-dimethylamino-2,3,6-trideoxy-4-keto-D-glucose;dTDP-3-N,N-dimethylamino-4-oxo-2,3,6-trideoxy-D-glucose",C18H29N3O13P2,Polyketide sugar unit biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,dTDP-L-megosamine biosynthesis,NA,2.1.1.-;5.1.3.-,R11045 R11046
Glucose,cpd:C21186,"6-Tuliposide B;6-O-[(3S)-3,4-Dihydroxy-2-methylenebutanoyl]-D-glucose",C11H18O9,NA,NA,NA,4.2.99.23,R11215
Glucose,cpd:C21348,"dTDP-4-hydroxyamino-4,6-dideoxy-alpha-D-glucose",C16H27N3O15P2,Polyketide sugar unit biosynthesis;Biosynthesis of enediyne antibiotics;Biosynthesis of secondary metabolites,NA,NA,1.14.15.-;2.4.1.-,R11417 R11468
Glucose,cpd:C21395,"dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-D-glucose;dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranose",C17H29N3O12P2,NA,NA,NA,2.1.1.324,R11452 R11453
Glucose,cpd:C22097,(1->6)-alpha-D-Glucan containing a (1->3)-alpha-D-glucose branch,(C18H30O15)n,NA,NA,NA,2.4.1.362,R12349
Glucose,cpd:C22230,(1->6)-alpha-D-Glucan containing a (1->2)-alpha-D-glucose branch,(C18H30O15)n,NA,NA,NA,2.4.1.373,R12528
Glucose,cpd:C22247,"UDP-2-acetamido-4-(D-alanylamino)-2,4,6-trideoxy-alpha-D-glucopyranose;UDP-2-acetamido-4-(D-alanylamino)-2,4,6-trideoxy-alpha-D-glucose",C20H33N5O16P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,5.1.3.-,R12557 R12558
Glucose,cpd:C22257,"dTDP-3-acetamido-3,6-dideoxy-alpha-D-glucose;dTDP-D-Qui3NAc",C18H29N3O15P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,2.3.1.-,R12549
Glucose,cpd:C22260,"UDP-2-acetamido-2,6-dideoxy-beta-L-glucose;UDP-L-QuiNAc",C17H27N3O16P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,5.1.3.-,R12551
Glucose,cpd:C22262,"UDP-2-acetamido-2,6-dideoxy-alpha-D-glucose;UDP-N-acetyl-alpha-D-quinovosamine;UDP-N-acetyl-6-deoxy-alpha-D-glucosamine;UDP-D-QuiNAc",C17H27N3O16P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.426;1.1.1.-,R12556 R12760
Glucose,cpd:C22430,Phenyllactylglucose,C15H20O8,"Tropane, piperidine and pyridine alkaloid biosynthesis;Biosynthesis of secondary metabolites",NA,NA,2.3.1.-;2.4.1.-,R08432 R12916
Glucose,cpd:C22508,6-Dehydro-D-glucose;6-Oxo-Glc;6-Oxo-D-quinovose,C6H10O6,NA,NA,NA,1.1.1.432;1.14.14.181,R12997 R13017
Glucose,cpd:C22635,3-Dehydro-D-glucopyranose;3-Dehydro-D-glucose,C6H10O6,NA,NA,NA,3.2.1.218,R13128
Isocaproate,cpd:C00233,4-Methyl-2-oxopentanoate;2-Oxoisocaproate;alpha-Ketoisocaproate,C6H10O3,"Valine, leucine and isoleucine degradation;Valine, leucine and isoleucine biosynthesis;Lipoic acid metabolism;Glucosinolate biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Leucine degradation, leucine => acetoacetate + acetyl-CoA;Leucine biosynthesis, 2-oxoisovalerate => 2-oxoisocaproate",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00233  2-Oxoisocaproate,1.1.1.85;1.2.1.25;1.2.4.4;1.2.7.7;1.4.1.9;2.6.1.6;2.6.1.42;2.6.1.67,R01088 R01090 R01651 R01652 R01702 R07601 R08566 R10052
Isocaproate,cpd:C02504,alpha-Isopropylmalate;(2S)-2-Isopropylmalate;(2S)-2-Hydroxy-2-isopropylsuccinic acid;2-Isopropylmalic acid;3-Carboxy-3-hydroxy-4-methylpentanoate;3-Carboxy-3-hydroxyisocaproate;(2S)-2-Isopropylmalic acid,C7H12O5,"Valine, leucine and isoleucine biosynthesis;Pyruvate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Leucine biosynthesis, 2-oxoisovalerate => 2-oxoisocaproate",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C02504  (2S)-2-Isopropylmalic acid,2.3.3.13;4.2.1.33,R01213 R03968 R10170
Isocaproate,cpd:C03264,(R)-2-Hydroxyisocaproate;D-2-Hydroxyisocaproate;(R)-2-Hydroxy-4-methylpentanoate;(2R)-2-Hydroxy-4-methylpentanoic acid;D-Leucate,C6H12O3,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C03264  (2R)-2-Hydroxy-4-methylpentanoic acid,2.8.3.24,R11462
Isocaproate,cpd:C03467,beta-Ketoisocaproate;beta-Ketoisocaproic acid;3-Oxo-4-methylpentanoate;4-Methyl-3-oxopentanoic acid,C6H10O3,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C03467  3-Oxo-4-methylpentanoic acid,NA,NA
Isocaproate,cpd:C04411,"(2R,3S)-3-Isopropylmalate;3-Isopropylmalate;3-Carboxy-2-hydroxy-4-methylpentanoate;2-D-threo-Hydroxy-3-carboxy-isocaproate",C7H12O5,"Valine, leucine and isoleucine biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Leucine biosynthesis, 2-oxoisovalerate => 2-oxoisocaproate",NA,1.1.1.85;4.2.1.33,R04001 R04426 R10052 R10170
Isocaproate,cpd:C14663,Testosterone isocaproate;17beta-Hydroxyandrost-4-ene-3-one 4-methylvalerate,C25H38O3,NA,NA,NA,NA,NA
Isocaproate,cpd:C21399,Isocaproate;4-Methylpentanoate,C6H12O2,NA,NA,NA,2.8.3.24,R11462
1-Hexacosanol NIST,NA,NA,NA,NA,NA,NA,NA,NA
3-3-hydroxyphenylpropionic acid,NA,NA,NA,NA,NA,NA,NA,NA
3-4-hydroxyphenylpropionic acid,NA,NA,NA,NA,NA,NA,NA,NA
3-hydroxybutyric acid,cpd:C00188,L-Threonine;2-Amino-3-hydroxybutyric acid,C4H9NO3,"Glycine, serine and threonine metabolism;Monobactam biosynthesis;Valine, leucine and isoleucine biosynthesis;D-Amino acid metabolism;Porphyrin metabolism;Aminoacyl-tRNA biosynthesis;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of amino acids;ABC transporters;Protein digestion and absorption;Mineral absorption","Threonine biosynthesis, aspartate => homoserine => threonine;Isoleucine biosynthesis, threonine => 2-oxobutanoate => isoleucine",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Common amino acids;    C00188  Threonine (Thr);Risk category of Japanese OTC drugs [BR:br08312(D00041)]; Third-class OTC drugs;  Inorganic and organic chemicals;   L-Threonine;    D00041  Threonine (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00041)]; Chemicals;  D00041  L-Threonine,1.1.1.103;2.2.1.8;2.7.1.177;2.7.7.87;3.4.-.-;4.1.2.5;4.1.2.48;4.2.3.1;4.3.1.19;5.1.1.6;6.1.1.3;6.2.1.70;6.3.2.-,R00751 R00996 R01465 R01466 R01467 R03663 R06531 R07247;R08323 R10463 R10888 R10891 R10892 R12772 R12774
3-hydroxybutyric acid,cpd:C00820,D-Threonine;D-2-Amino-3-hydroxybutyric acid,C4H9NO3,D-Amino acid metabolism;Metabolic pathways,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00820  D-Threonine,4.1.2.42;5.1.1.6,R01467 R08195
3-hydroxybutyric acid,cpd:C01089,(R)-3-Hydroxybutanoate;(R)-3-Hydroxybutanoic acid;(R)-3-Hydroxybutyric acid;D-beta-Hydroxybutyric acid,C4H8O3,Butanoate metabolism;Metabolic pathways;cAMP signaling pathway,"Ketone body biosynthesis, acetyl-CoA => acetoacetate/3-hydroxybutyrate/acetone",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Hydroxycarboxylic acids;    C01089  (R)-3-Hydroxybutanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C01089  (R)-3-Hydroxybutanoic acid,1.1.1.30;3.1.1.22,R00048 R01361
4-guanidinobutyric acid,cpd:C01035,4-Guanidinobutanoate;4-Guanidinobutyric acid,C5H11N3O2,Arginine and proline metabolism;Metabolic pathways,NA,NA,1.2.1.54;2.1.4.1;3.5.1.4;3.5.3.7,R01989 R01990 R03177 R03180
5-Trimethylsilyloxy-n-valeric acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
benzoic acid,cpd:C00108,Anthranilate;Anthranilic acid;o-Aminobenzoic acid;Vitamin L1;2-Aminobenzoate,C7H7NO2,"Tryptophan metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Phenazine biosynthesis;Dioxin degradation;Aminobenzoate degradation;Biosynthesis of various alkaloids;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Biosynthesis of amino acids;Benzoic acid family","Tryptophan biosynthesis, chorismate => tryptophan;Carbazole degradation, carbazole => 2-oxopent-4-enoate + anthranilate;Anthranilate degradation, anthranilate => catechol;Aurachin biosynthesis, anthranilate => aurachin A;Fumiquinazoline biosynthesis, tryptophan + alanine + anthranilate => fumiquinazoline",NA,1.4.-.-;1.7.1.17;1.13.11.23;1.14.12.1;1.14.13.35;1.14.14.8;2.1.1.111;2.1.1.277;2.3.1.113;2.3.1.144;2.4.2.18;3.5.1.9;3.7.1.3;3.7.1.13;4.1.1.24;4.1.3.27;6.2.1.32;6.3.2.40;6.3.2.-,R00823 R00825 R00980 R00982 R00983 R00984 R00985 R00986;R00987 R00988 R00989 R00990 R00991 R01073 R02453 R05365;R07734 R08473 R08477 R09517 R10451 R10495 R12035 R12417
benzoic acid,cpd:C00156,4-Hydroxybenzoate;Hydroxybenzoic acid;4-Hydroxybenzoic acid;Hydroxybenzenecarboxylic acid,C7H6O3,Ubiquinone and other terpenoid-quinone biosynthesis;Benzoate degradation;Bisphenol degradation;Toluene degradation;Aminobenzoate degradation;Folate biosynthesis;Biosynthesis of phenylpropanoids;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Biosynthesis of cofactors;Benzoic acid family,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol;Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",Dietary phytochemicals [br08012.html]; Flavonoids;  C00156,1.2.1.7;1.2.1.28;1.2.1.64;1.2.1.96;1.13.11.41;1.13.-.-;1.14.13.2;1.14.13.33;1.14.13.64;1.14.14.92;1.14.19.55;1.14.99.15;1.14.99.-;2.4.1.194;2.4.2.54;2.5.1.39;2.5.1.93;3.1.1.-;3.1.2.23;3.2.1.-;3.8.1.6;4.1.1.61;4.1.1.123;4.1.3.40;6.2.1.27;6.2.1.50,R01238 R01293 R01294 R01295 R01296 R01297 R01298 R01299;R01300 R01301 R01302 R01303 R01304 R01305 R01306 R01307;R01308 R05000 R05603 R05615 R05616 R06889 R07273 R09039;R09040 R09105 R11102 R11608 R11872 R12013 R12015
benzoic acid,cpd:C00180,Benzoate;Benzoic acid;Benzenecarboxylic acid;Phenylformic acid;Dracylic acid,C7H6O2,Benzoate degradation;Dioxin degradation;Toluene degradation;Aminobenzoate degradation;Biosynthesis of various alkaloids;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Toluene degradation, toluene => benzoate;Biphenyl degradation, biphenyl => 2-oxopent-4-enoate + benzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",Therapeutic category of drugs in Japan [BR:br08301(D00038)]; 7  Agents not mainly for therapeutic purpose;  73  Public health agents;   731  Antiseptics;    7319  Others;     D00038  Benzoic acid (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00038)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP); Third-class OTC drugs;  Inorganic and organic chemicals;   Benzoic acid;    D00038  Benzoic acid (JP18/USP);Animal drugs in Japan [BR:br08331]; 99  Agents for not mainly purpose of therapeutic;  992  Amphoteric soap and preparations;   9929  Other agents for disinfections;    C00180  Benzoate;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00038)]; Chemicals;  D00038  Benzoic acid,1.2.1.7;1.2.1.28;1.14.12.10;1.14.13.-;1.14.14.92;2.1.1.273;3.1.1.1;3.1.1.84;3.5.1.4;3.5.1.32;3.5.1.40;3.5.5.1;3.6.1.7;3.6.1.20;3.7.1.8;6.2.1.25,R01295 R01419 R01420 R01421 R01422 R01423 R01424 R01425;R01426 R01427 R02606 R05590 R05591 R05621 R05622 R06727;R06728 R07188 R07835 R08838 R09088 R10447
benzoic acid,cpd:C00196,"2,3-Dihydroxybenzoate;2,3-Dihydroxybenzoic acid",C7H6O4,Benzoate degradation;Aminobenzoate degradation;Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,NA,NA,1.3.1.28;1.13.11.14;1.13.11.28;1.14.13.35;1.14.99.23;4.1.1.46;6.2.1.71;6.3.2.14,R00821 R00980 R01504 R01505 R01506 R01507 R01508 R07644;R12777
benzoic acid,cpd:C00230,"3,4-Dihydroxybenzoate;3,4-Dihydroxybenzoic acid;Protocatechuate;Protocatechuic acid",C7H6O4,"Benzoate degradation;Phenylalanine, tyrosine and tryptophan biosynthesis;Toluene degradation;Polycyclic aromatic hydrocarbon degradation;Aminobenzoate degradation;Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds","Phthalate degradation, phthalate => protocatechuate;Terephthalate degradation, terephthalate => 3,4-dihydroxybenzoate;Phthalate degradation, phthalate => protocatechuate",Dietary phytochemicals [br08012.html]; Flavonoids;  C00230,1.3.1.53;1.13.11.3;1.13.11.8;1.14.12.8;1.14.12.-;1.14.13.2;1.14.13.23;1.14.13.33;1.14.13.64;1.14.13.82;1.14.13.-;1.14.19.55;2.1.1.341;2.1.1.382;4.1.1.55;4.1.1.63;4.1.1.69;4.2.1.118;6.2.1.62,R00822 R01296 R01298 R01627 R01628 R01629 R01630 R01631;R01632 R01633 R01634 R01635 R01636 R01637 R05274 R05280;R07668 R10136 R11197 R11198 R12018 R12019 R12575 R12576
benzoic acid,cpd:C00568,4-Aminobenzoate;ABEE;4-Aminobenzoic acid;p-Aminobenzoate,C7H7NO2,Aminobenzoate degradation;Folate biosynthesis;Biosynthesis of phenylpropanoids;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02456)]; D DERMATOLOGICALS;  D02 EMOLLIENTS AND PROTECTIVES;   D02B PROTECTIVES AGAINST UV-RADIATION;    D02BA Protectives against UV-radiation for topical use;     D02BA01 Aminobenzoic acid;      D02456  Aminobenzoic acid (USP);Drug groups [BR:br08330(D02456)]; Neuropsychiatric agent;  DG02030  Anesthetics;   DG01675  Local anesthetic;    DG01674  Esterified local anesthetic;     DG00379  Aminobenzoic acid;      D02456  Aminobenzoic acid;Target-based classification of drugs [BR:br08310(D02456)]; Ion channels;  Voltage-gated ion channels;   Sodium channels;    SCN1A;     D02456  Aminobenzoic acid (USP);    SCN2A;     D02456  Aminobenzoic acid (USP);    SCN3A;     D02456  Aminobenzoic acid (USP);    SCN4A;     D02456  Aminobenzoic acid (USP);    SCN5A;     D02456  Aminobenzoic acid (USP);    SCN8A;     D02456  Aminobenzoic acid (USP);    SCN9A;     D02456  Aminobenzoic acid (USP);    SCN10A;     D02456  Aminobenzoic acid (USP);    SCN11A;     D02456  Aminobenzoic acid (USP),1.7.1.-;1.14.12.-;1.14.13.27;1.14.99.68;2.4.2.54;2.5.1.15;4.1.1.24;4.1.3.38,R01860 R02561 R02562 R03066 R03067 R05277 R05280 R05553;R10337 R12675
benzoic acid,cpd:C00587,3-Hydroxybenzoate;3-Hydroxybenzoic acid;m-Hydroxybenzoic acid,C7H6O3,"Benzoate degradation;Phenylalanine, tyrosine and tryptophan biosynthesis;Toluene degradation;Polycyclic aromatic hydrocarbon degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds",NA,NA,1.2.1.7;1.2.1.28;1.2.1.64;1.14.13.23;1.14.13.24;1.14.99.23;4.1.1.55;4.1.3.45;6.2.1.37,R01427 R01508 R01628 R02589 R05375 R07666 R07667 R09589;R10597
benzoic acid,cpd:C00628,"2,5-Dihydroxybenzoate;2,5-Dihydroxybenzoic acid;Gentisic acid;Hydroquinonecarboxylic acid;Gentisate",C7H6O4,Tyrosine metabolism;Benzoate degradation;Naphthalene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Salicylate degradation, salicylate => gentisate",NA,1.2.1.29;1.2.3.1;1.13.11.4;1.14.13.24;1.14.13.172;4.1.1.62,R02489 R02589 R02655 R02656 R02657 R07686 R07709 R07710
benzoic acid,cpd:C00805,Salicylate;o-Hydroxybenzoic acid;Salicylic acid,C7H6O3,Dioxin degradation;Polycyclic aromatic hydrocarbon degradation;Naphthalene degradation;Biosynthesis of various alkaloids;Biosynthesis of siderophore group nonribosomal peptides;Biosynthesis of phenylpropanoids;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Plant hormone signal transduction;Bile secretion,"Naphthalene degradation, naphthalene => salicylate;Salicylate degradation, salicylate => gentisate","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00097)]; D DERMATOLOGICALS;  D01 ANTIFUNGALS FOR DERMATOLOGICAL USE;   D01A ANTIFUNGALS FOR TOPICAL USE;    D01AE Other antifungals for topical use;     D01AE12 Salicylic acid;      D00097  Salicylic acid (JP18/USP) &lt;JP&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BC Antiinflammatory agents, non-steroids;     S01BC08 Salicylic acid;      D00097  Salicylic acid (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00097)]; 2  Agents affecting individual organs;  26  Epidermides;   265  Antiparasitic dermatosis agents;    2652  Salicylic acids for external use;     D00097  Salicylic acid (JP18/USP);   266  Emollients;    2661  Organic acids;     D00097  Salicylic acid (JP18/USP);Classification of Japanese OTC drugs [BR:br08313(D00097)]; Agents for integumentary system;  56 Purulent skin remedies;   D00097  Salicylic acid (JP18/USP);  58 Ringworm drugs;   D00097  Salicylic acid (JP18/USP);  59 Skin emollient (incl. pus extrusion);   D00097  Salicylic acid (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00097)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Salicylic acid;    D00097  Salicylic acid (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Salicylic acid;    D00097  Salicylic acid (JP18/USP);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  951  Antimicrobials for dermatologic use;   9519  Other antimicrobials for dermatologic use;    C00805  Salicylate;  956  Bath and disinfectants preparations;   9562  Disinfectants preparations;    C00805  Salicylate; 99  Agents for not mainly purpose of therapeutic;  992  Amphoteric soap and preparations;   9929  Other agents for disinfections;    C00805  Salicylate;Drug groups [BR:br08330(D00097)]; Transporter inhibitor;  DG02883  SLC22A7 inhibitor;   D00097  Salicylic acid;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00097)]; Chemicals;  D00097  Salicylic acid;  D00097  Salicylic acid spirit;  D00097  Salicylic acid adhesive plaster;Drug metabolizing enzymes and transporters [br08309.html(D00097)]; Drug transporters;  D00097",1.2.1.65;1.2.1.-;1.14.13.1;1.14.13.172;1.14.13.-;2.1.1.274;3.1.1.55;3.7.1.-;4.1.1.91;4.1.1.-;4.2.99.21;6.2.1.61;6.2.1.65,R00818 R02941 R02942 R05360 R05537 R06602 R06603 R06925;R07695 R07709 R07710 R08838 R09539 R10448 R12640 R12642;R12805
benzoic acid,cpd:C01424,"Gallate;Gallic acid;3,4,5-Trihydroxybenzoic acid;3,4,5-Trihydroxybenzoate;Pyrogallol-5-carboxylic acid",C7H6O5,Aminobenzoate degradation;Biosynthesis of various plant secondary metabolites;Biosynthesis of phenylpropanoids;Microbial metabolism in diverse environments,NA,Phytochemical compounds [BR:br08003]; Others;  Tannins and galloyl derivatives;   Galloyl derivatives;    C01424  Gallate;Dietary phytochemicals [br08012.html]; Flavonoids;  C01424,1.13.11.3;1.13.11.8;1.13.11.57;2.1.1.341;2.4.1.136;3.1.1.20;4.1.1.59,R00053 R01637 R03247 R03297 R03549 R03550 R03551 R09271;R09565 R12886
benzoic acid,cpd:C01454,Toluate;p-Toluate;p-Toluic acid;4-Methylbenzoic acid;Toluenecarboxylic acid;Crithminic acid,C8H8O2,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Xylene degradation, xylene => methylbenzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.2.1.7;1.2.1.28;1.14.12.-,R05289 R05290 R05291
benzoic acid,cpd:C01839,"Orsellinate;o-Orsellinic acid;2,4-Dihydroxy-6-methylbenzoic acid;2,4-Dihydroxy-6-methylbenzoate;4,6-Dihydroxy-o-toluic acid",C8H8O4,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1301 Monocyclic aromatic polyketides;    C01839  Orsellinic acid,3.1.1.40;4.1.1.58,R00054 R02831
benzoic acid,cpd:C02236,4-Sulfobenzoate;4-Sulfobenzoic acid,C7H6O5S,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.2.1.62;1.14.12.8,R01636 R05272
benzoic acid,cpd:C02357,2-Chlorobenzoate;2-Chlorobenzoic acid;o-Chlorobenzoic acid,C7H5ClO2,Fluorobenzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.13,R01033
benzoic acid,cpd:C02359,2-Fluorobenzoate;2-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10,R08100 R08101
benzoic acid,cpd:C02363,3-Ethoxybenzoate;3-Ethoxybenzoic acid,C9H10O3,NA,NA,NA,NA,NA
benzoic acid,cpd:C02364,3-Fluorobenzoate;3-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10,R08108 R08109
benzoic acid,cpd:C02370,4-Chlorobenzoate;4-Chlorobenzoic acid,C7H5ClO2,Fluorobenzoate degradation;Dioxin degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Biphenyl degradation, biphenyl => 2-oxopent-4-enoate + benzoate",NA,1.2.-.-;3.7.1.8;3.8.1.6;6.2.1.33,R01307 R03932 R05252 R05359 R05472
benzoic acid,cpd:C02371,4-Fluorobenzoate;4-Fluorobenzoic acid,C7H5FO2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.12.10;6.2.1.33,R08110 R08117
benzoic acid,cpd:C02519,4-Methoxybenzoate;4-Methoxybenzoic acid;4-Anisic acid,C8H8O3,Benzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.99.15,R01306
benzoic acid,cpd:C02657,6-Methylsalicylate;6-Methylsalicylic acid;2-Hydroxy-6-methylbenzoic acid;6-Methyl-2-hydroxybenzenecarboxylate,C8H8O3,Biosynthesis of enediyne antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"3,6-Dimethylsalicylyl-CoA biosynthesis, malonyl-CoA => 6-methylsalicylate => 3,6-dimethylsalicylyl-CoA",Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1301 Monocyclic aromatic polyketides;    C02657  6-Methylsalicylic acid,2.3.1.165;4.1.1.52;6.2.1.-,R03567 R07253 R11370
benzoic acid,cpd:C03005,N-Methylanthranilate;N-Methylanthranilic acid;2-(Methylamino)benzoic acid,C8H9NO2,Biosynthesis of various alkaloids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of secondary metabolites,NA,NA,2.1.1.111;6.2.1.32,R00984 R07416
benzoic acid,cpd:C03057,2-Carboxybenzaldehyde;Phthalaldehydic acid;o-Formylbenzoic acid;2-Formylbenzoic acid;2-Formylbenzoate,C8H6O3,Polycyclic aromatic hydrocarbon degradation;Microbial metabolism in diverse environments,NA,NA,1.2.1.78;4.1.2.34,R03465 R05643 R07713
benzoic acid,cpd:C03141,N-Benzoylanthranilate;2-Benzoylaminobenzoic acid,C14H11NO3,NA,NA,NA,2.3.1.144,R02453
benzoic acid,cpd:C03444,p-Chloromercuribenzoate;p-Chloromercuribenzoic acid;PCMB,C7H5ClHgO2,NA,NA,NA,NA,NA
benzoic acid,cpd:C05653,Formylanthranilate;N-Formylanthranilate;2-(Formylamino)-benzoic acid,C8H7NO3,Tryptophan metabolism;Metabolic pathways,NA,NA,1.13.11.47;3.5.1.9;3.7.1.3,R00988 R03936 R04915 R05719
benzoic acid,cpd:C06332,N-Acetylanthranilate;2-(Acetylamino)-benzoic acid;N-Acetylanthranilic acid,C9H9NO3,Biosynthesis of various alkaloids;Biosynthesis of alkaloids derived from shikimate pathway,NA,NA,1.13.11.48,R05155 R05720 R08478
benzoic acid,cpd:C06670,"2,4-Dichlorobenzoate;2,4-Dichlorobenzoic acid",C7H4Cl2O2,Fluorobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,6.2.1.-,R05451
benzoic acid,cpd:C06672,Vanillate;Vanillic acid;4-Hydroxy-3-methoxybenzoate;4-Hydroxy-3-methoxybenzoic acid,C8H8O4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C06672,1.2.1.67;1.2.3.9;1.14.13.82;2.1.1.341;2.1.1.382;2.4.1.300,R05273 R05274 R05699 R07668 R09278 R10136 R10259 R10296;R10297
benzoic acid,cpd:C07211,m-Methylbenzoate;m-Toluic Acid;beta-Bethylbenzoic acid;m-Toluylic acid,C8H8O2,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Xylene degradation, xylene => methylbenzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.2.1.7;1.2.1.28;1.14.12.-,R05664 R05665
benzoic acid,cpd:C07215,o-Toluate;o-Methylbenzoate;o-Toluic Acid;2-Methylbenzoic acid,C8H8O2,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Xylene degradation, xylene => methylbenzoate;Benzoate degradation, benzoate => catechol / methylbenzoate => methylcatechol",NA,1.2.1.7;1.2.1.28;1.14.12.-,R05428 R05663
benzoic acid,cpd:C07659,Sulfathalidine;Phthalylsulfathiazole;2-[[[4-[(2-Thiazolylamino)sulfonyl]phenyl]amino]carbonyl]benzoic acid,C17H13N3O5S2,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02440)]; A ALIMENTARY TRACT AND METABOLISM;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07A INTESTINAL ANTIINFECTIVES;    A07AB Sulfonamides;     A07AB02 Phthalylsulfathiazole;      D02440  Phthalylsulfathiazole (INN);Drug groups [BR:br08330(D02440)]; Antibacterial;  DG01787  Sulfonamide antibacterial;   DG01784  Short-acting sulfonamide;    D02440  Phthalylsulfathiazole;Antimicrobials [BR:br08307(D02440)]; Antibacterials;  Folic acid biosynthesis inhibitor;   Short-acting sulfonamide;    D02440  Phthalylsulfathiazole (INN);Prodrugs [br08324.html(D02440)]; D02440;Prodrugs [br08324.html]; C07659",NA,NA
benzoic acid,cpd:C08171,"Sodium thiosalicylate;2-Mercapto-benzoic acid, monosodium salt",C7H5O2S. Na,NA,NA,"Drug groups [BR:br08330(D00971)]; Anti-inflammatory;  DG01504  Nonsteroidal anti-inflammatory drug (NSAID);   DG01909  Anti-inflammatory drug, salicylic acid derivatives;    DG01920  Thiosalicylic acid;     D00971  Sodium thiosalicylate",NA,NA
benzoic acid,cpd:C08478,"Dianthramine;2,2'-Iminobis(4-hydroxybenzoic acid)",C14H11NO6,NA,NA,NA,NA,NA
benzoic acid,cpd:C09822,Cyclohexane-1-carboxylate;Cyclohexanecarboxylic acid;Hexahydrobenzoic acid,C7H12O2,Benzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Benzoate degradation, cyclohexanecarboxylic acid =>pimeloyl-CoA",NA,6.2.1.-,R05620
benzoic acid,cpd:C10804,2-(Hydroxymethyl)benzoic acid;2-Hydroxymethylbenzoic acid,C8H8O3,NA,NA,NA,NA,NA
benzoic acid,cpd:C11083,"Assert;Imazamethabenz;Imazamethabenz-methyl;2-[4,5-Dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-4(or 5)-methylbenzoic acid methyl ester",NA,NA,NA,NA,NA,NA
benzoic acid,cpd:C12107,3-Amino-5-hydroxybenzoate;AHBA;3-Amino-5-hydroxybenzoic acid;3-Ahba,C7H7NO3,Biosynthesis of ansamycins;Biosynthesis of secondary metabolites,NA,NA,4.2.1.144;6.2.1.74,R06595 R12789
benzoic acid,cpd:C12110,"Gabaculine;3-Amino-2,3-dihydrobenzoic acid",C7H9NO2,NA,NA,NA,NA,NA
benzoic acid,cpd:C12115,"3-Amino-4-hydroxybenzoate;3-Amino-4-hydroxybenzoic acid;3,4-AHBA",C7H7NO3,Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Grixazone biosynthesis, aspartate 4-semialdehyde => grixazone B;Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,1.10.3.15;1.14.13.249;4.1.99.20,R08650 R10469 R10720 R12912
benzoic acid,cpd:C13425,3-Hexaprenyl-4-hydroxybenzoate;3-Hexaprenyl-4-hydroxybenzoic acid,C37H54O3,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR02 Quinones and hydroquinones;   PR0201 Ubiquinones;    C13425  3-Hexaprenyl-4-hydroxybenzoate,1.14.13.-;2.5.1.39,R05616 R06865
benzoic acid,cpd:C13705,5-Nitro-2-(3-phenylpropylamino)benzoic acid;NPPB,C16H16N2O4,NA,NA,NA,NA,NA
benzoic acid,cpd:C14095,2-Hydroxy-3-carboxybenzalpyruvate;3-(3-Carboxy-3-oxo-1-propenyl)-2-hydroxy-benzoic acid,C11H8O6,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,4.2.1.-;5.3.99.-,R06922 R06923
benzoic acid,cpd:C14100,4-Formylsalicylic acid;4-Formyl-2-hydroxybenzoic acid,C8H6O4,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,NA,R06929
benzoic acid,cpd:C14103,4-Methylsalicylate;m-Cresotic acid;2-Hydroxy-4-methylbenzoic acid,C8H8O3,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,1.14.13.1,R06938 R06939
benzoic acid,cpd:C14109,4-Hydroxymethylsalicylate;2-Hydroxy-4-hydroxymethylbenzoic acid,C8H8O4,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,1.2.1.-;1.14.13.1,R06935 R06936
benzoic acid,cpd:C14274,4-Heptyloxybenzoic acid,C14H20O3,NA,NA,NA,NA,NA
benzoic acid,cpd:C14535,4-t-Butylbenzoic acid;p-tert-Butylbenzoic acid,C11H14O2,NA,NA,NA,NA,NA
benzoic acid,cpd:C14935,m-(beta-Acetyl-alpha-ethyl-p-hydroxyphenethyl)benzoic acid,C19H20O4,NA,NA,NA,NA,NA
benzoic acid,cpd:C16234,o-Nitrobenzoate;2-Nitrobenzoic acid,C7H5NO4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.7.1.-,R07727
benzoic acid,cpd:C16235,o-Hydroxylaminobenzoate;2-Hydroxylaminobenzoic acid,C7H7NO3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.4.-.-;1.7.1.-;5.4.99.-,R07727 R07730 R07734
benzoic acid,cpd:C18090,Tricaine;3-Aminobenzoic acid;m-Aminobenzoate,C9H11NO2,NA,NA,NA,NA,NA
benzoic acid,cpd:C18625,4-Nitrobenzoate;4-Nitrobenzoic acid;p-Nitrobenzoic acid,C7H5NO4,NA,NA,NA,1.14.99.68,R12675
benzoic acid,cpd:C18767,"2,3,6-TBA;2,3,6-Trichlorobenzoic acid",C7H3Cl3O2,NA,NA,"Pesticides [BR:br08007]; Pesticides;  Herbicides;   Benzoic acid herbicides;    C18767  2,3,6-TBA",NA,NA
benzoic acid,cpd:C20772,3-[(1-Carboxyvinyl)oxy]benzoate;3-[(1-Carboxyethenyl)oxy]benzoic acid,C10H8O5,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Menaquinone biosynthesis, futalosine pathway;Menaquinone biosynthesis, modified futalosine pathway",NA,2.5.1.120;4.2.1.151,R10666 R10667
benzoic acid,cpd:C22041,Acifluorfen;5-[2-Chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoic acid,C14H7ClF3NO5,NA,NA,Pesticides [BR:br08007]; Pesticides;  Herbicides;   Diphenyl ether herbicide;    C22041  Acifluorfen,NA,NA
benzoic acid,cpd:C22425,3-Amino-2-hydroxy-4-methoxybenzoate;3-Amino-2-hydroxy-4-methoxybenzoic acid,C8H9NO4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,2.1.1.380;6.7.1.1,R12928 R12943
benzoic acid,cpd:C22455,"3-Amino-2,4-dihydroxybenzoate;3-Amino-2,4-dihydroxybenzoic acid",C7H7NO4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",NA,1.14.13.249;2.1.1.380,R12912 R12928
caprylic acid,cpd:C06423,Octanoic acid;Caprylic acid;Octylic acid;Octanoate,C8H16O2,Fatty acid biosynthesis;Lipoic acid metabolism;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from terpenoid and polyketide;Metabolic pathways;Biosynthesis of cofactors,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C06423  Caprylate; Octanoate; Lipids;  Fatty acids;   Saturated fatty acids;    C06423  Caprylic acid (8:0);Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C06423  Octanoic acid;Phytochemical compounds [BR:br08003]; Fatty acids related compounds;  Fatty acids;   Saturated fatty acids;    C06423  Octanoic acid,3.1.2.21;6.3.1.20,R08157 R08509 R12429
DL-3-aminoisobutyric acid,NA,NA,NA,NA,NA,NA,NA,NA
L-Aspartic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
L-glutamic acid dehydrated,NA,NA,NA,NA,NA,NA,NA,NA
L-threonineM,NA,NA,NA,NA,NA,NA,NA,NA
methylmalonic acid,cpd:C02170,Methylmalonate;Methylmalonic acid,C4H6O4,"Pyrimidine metabolism;Valine, leucine and isoleucine degradation;Propanoate metabolism;Metabolic pathways",NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C02170  Methylmalonic acid,1.2.1.3;1.2.3.1;3.1.2.17;3.5.1.95;3.5.2.1;6.2.1.-,R02764 R03383 R03869 R03870 R03871 R03872 R10778
myo-inositol,cpd:C00137,myo-Inositol;D-myo-Inositol;1D-myo-Inositol;L-myo-Inositol;1L-myo-Inositol;meso-Inositol;Inositol;Dambose;Cyclohexitol;Meat sugar;Bios I,C6H12O6,Galactose metabolism;Ascorbate and aldarate metabolism;Streptomycin biosynthesis;Inositol phosphate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of nucleotide sugars;ABC transporters;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol",Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Sugar alcohols;    C00137  myo-Inositol;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08079)]; A ALIMENTARY TRACT AND METABOLISM;  A11 VITAMINS;   A11H OTHER PLAIN VITAMIN PREPARATIONS;    A11HA Other plain vitamin preparations;     A11HA07 Inositol;      D08079  Inositol (NF);Risk category of Japanese OTC drugs [BR:br08312(D08079)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Inositol;    D08079  Inositol (NF),1.1.1.18;1.13.99.1;2.1.1.39;2.1.1.40;2.1.1.129;2.3.1.72;2.4.1.67;2.4.1.82;2.4.1.123;2.7.1.64;2.7.8.11;3.1.3.25;3.1.4.44;3.2.1.22,R01183 R01184 R01185 R01186 R01187 R01188 R01189 R01190;R01192 R01193 R01194 R01802 R02411 R03418 R04333 R06042;R06071 R06093 R06214 R07279 R07343
myo-inositol,cpd:C01177,Inositol 1-phosphate;myo-Inositol 1-phosphate;1D-myo-Inositol 1-phosphate;D-myo-Inositol 1-phosphate;1D-myo-Inositol 1-monophosphate,C6H13O9P,Inositol phosphate metabolism;Metabolic pathways;ABC transporters;Phosphatidylinositol signaling system,NA,NA,3.1.3.25;3.1.3.64;3.1.4.3;3.1.4.11;3.1.4.43;4.6.1.13,R01185 R03330 R03331 R03332 R03333
myo-inositol,cpd:C01194,"1-Phosphatidyl-D-myo-inositol;1-Phosphatidyl-1D-myo-inositol;1-Phosphatidyl-myo-inositol;Phosphatidyl-1D-myo-inositol;(3-Phosphatidyl)-1-D-inositol;1,2-Diacyl-sn-glycero-3-phosphoinositol;Phosphatidylinositol",C11H17O13PR2,Inositol phosphate metabolism;Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Glycerophospholipid metabolism;Lipoarabinomannan (LAM) biosynthesis;Metabolic pathways;Phosphatidylinositol signaling system;Autophagy - other;Autophagy - yeast;Autophagy - animal;Salmonella infection;Tuberculosis,"GPI-anchor biosynthesis, core oligosaccharide;Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4","Compounds with biological roles [BR:br08001]; Lipids;  Phospholipids;   Glycerophospholipids;    C01194  Phosphatidylinositol;Lipids [BR:br08002]; GP  Glycerophospholipids;  GP06 Glycerophosphoinositols;   GP0601 Diacylglycerophosphoinositols;    C01194  1,2-Diacyl-sn-glycero-3-phosphoinositol;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; A ALIMENTARY TRACT AND METABOLISM;  A05 BILE AND LIVER THERAPY;   A05B LIVER THERAPY, LIPOTROPICS;    A05BA Liver therapy;     A05BA10 Phospholipids;      C01194  1-Phosphatidyl-D-myo-inositol",2.3.1.-;2.4.1.198;2.4.1.345;2.7.1.67;2.7.1.137;2.7.1.150;2.7.1.154;2.7.8.11;3.1.1.52;3.1.1.118;3.1.3.64;3.1.3.67;3.1.3.-;3.1.4.3;3.1.4.11;4.6.1.13,R01802 R02654 R03332 R03360 R03361 R03362 R03363 R03364;R05916 R09034 R10951 R11680 R11702 R12038 R12795
myo-inositol,cpd:C01204,"Phytic acid;Phytate;myo-Inositol hexakisphosphate;1D-myo-Inositol 1,2,3,4,5,6-hexakisphosphate;D-myo-Inositol 1,2,3,4,5,6-hexakisphosphate;myo-Inositol 1,2,3,4,5,6-hexakisphosphate;Inositol 1,2,3,4,5,6-hexakisphosphate;1D-myo-Inositol hexakisphosphate",C6H18O24P6,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4)P3 => phytate",Risk category of Japanese OTC drugs [BR:br08312]; Third-class OTC drugs;  Inorganic and organic chemicals;   Phytin;    C01204  Phytic acid,2.7.1.158;2.7.4.21;2.7.4.24;3.1.3.8;3.1.3.26;3.1.3.62;3.1.3.72;3.6.1.52,R03371 R03372 R05202 R05779 R05799 R07583 R09087
myo-inositol,cpd:C01220,"1D-myo-Inositol 1,4-bisphosphate;D-myo-Inositol 1,4-bisphosphate;myo-Inositol 1,4-bisphosphate;Inositol 1,4-bisphosphate",C6H14O12P2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,NA,NA,3.1.3.56;3.1.3.57;3.1.4.11,R03393 R03394 R10952
myo-inositol,cpd:C01225,sn-Glycero-3-phospho-1-inositol;1-(sn-Glycero-3-phospho)-1D-myo-inositol,C9H19O11P,NA,NA,NA,3.1.4.43;3.1.4.44,R01193 R03331
myo-inositol,cpd:C01235,alpha-D-Galactosyl-(1->3)-1D-myo-inositol;O-alpha-D-Galactosyl-(1->3)-1D-myo-inositol;3-O-alpha-D-Galactosyl-1D-myo-inositol;1-alpha-D-Galactosyl-myo-inositol;Galactinol,C12H22O11,Galactose metabolism;Metabolic pathways,NA,NA,2.4.1.67;2.4.1.82;2.4.1.123;3.2.1.22,R01192 R01194 R02411 R03418
myo-inositol,cpd:C01243,"1D-myo-Inositol 1,3,4-trisphosphate;D-myo-Inositol 1,3,4-trisphosphate;Inositol 1,3,4-trisphosphate",C6H15O15P3,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol;Inositol phosphate metabolism, Ins(1,3,4)P3 => phytate",NA,2.7.1.159;3.1.3.56;3.1.3.57;3.1.3.66,R03427 R03428 R03429 R03430 R10950
myo-inositol,cpd:C01245,"D-myo-Inositol 1,4,5-trisphosphate;1D-myo-Inositol 1,4,5-trisphosphate;Inositol 1,4,5-trisphosphate;Ins(1,4,5)P3",C6H15O15P3,"Inositol phosphate metabolism;Metabolic pathways;MAPK signaling pathway;ErbB signaling pathway;Ras signaling pathway;Calcium signaling pathway;cGMP-PKG signaling pathway;cAMP signaling pathway;Chemokine signaling pathway;NF-kappa B signaling pathway;HIF-1 signaling pathway;Phosphatidylinositol signaling system;Sphingolipid signaling pathway;Phospholipase D signaling pathway;Oocyte meiosis;Adrenergic signaling in cardiomyocytes;Vascular smooth muscle contraction;VEGF signaling pathway;Apelin signaling pathway;Osteoclast differentiation;Gap junction;Platelet activation;Neutrophil extracellular trap formation;NOD-like receptor signaling pathway;C-type lectin receptor signaling pathway;Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Fc gamma R-mediated phagocytosis;Long-term potentiation;Neurotrophin signaling pathway;Retrograde endocannabinoid signaling;Glutamatergic synapse;Cholinergic synapse;Serotonergic synapse;Dopaminergic synapse;Long-term depression;Taste transduction;Phototransduction - fly;Inflammatory mediator regulation of TRP channels;Insulin secretion;GnRH signaling pathway;Estrogen signaling pathway;Melanogenesis;Thyroid hormone synthesis;Thyroid hormone signaling pathway;Oxytocin signaling pathway;Glucagon signaling pathway;Renin secretion;Aldosterone synthesis and secretion;Relaxin signaling pathway;Cortisol synthesis and secretion;Parathyroid hormone synthesis, secretion and action;GnRH secretion;AGE-RAGE signaling pathway in diabetic complications;Cushing syndrome;Growth hormone synthesis, secretion and action;Endocrine and other factor-regulated calcium reabsorption;Salivary secretion;Gastric acid secretion;Pancreatic secretion;Alzheimer disease;Parkinson disease;Huntington disease;Spinocerebellar ataxia;Pathways of neurodegeneration - multiple diseases;Vibrio cholerae infection;Shigellosis;Yersinia infection;Chagas disease;African trypanosomiasis;Amoebiasis;Human cytomegalovirus infection;Kaposi sarcoma-associated herpesvirus infection;Epstein-Barr virus infection;Human immunodeficiency virus 1 infection;Pathways in cancer;Glioma;Non-small cell lung cancer;Hepatocellular carcinoma;PD-L1 expression and PD-1 checkpoint pathway in cancer;Lipid and atherosclerosis","Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4",NA,2.7.1.127;2.7.1.151;3.1.3.56;3.1.3.62;3.1.4.11,R03394 R03433 R03434 R03435 R05800 R10065
myo-inositol,cpd:C01272,"1D-myo-Inositol 1,3,4,5-tetrakisphosphate;D-myo-Inositol 1,3,4,5-tetrakisphosphate;Inositol 1,3,4,5-tetrakisphosphate",C6H16O18P4,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4;Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol",NA,2.7.1.127;2.7.1.151;2.7.1.159;3.1.3.56;3.1.3.62,R03428 R03430 R03433 R03434 R10953
myo-inositol,cpd:C01277,"1-Phosphatidyl-1D-myo-inositol 4-phosphate;Phosphatidylinositol 4-phosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate)",C11H18O16P2R2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system;Legionellosis,"Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4","Lipids [BR:br08002]; GP  Glycerophospholipids;  GP07 Glycerophosphoinositol monophosphates;   GP0701 Diacylglycerophosphoinositol monophosphates;    C01277  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate)",2.7.1.67;2.7.1.68;2.7.1.154;3.1.3.36;3.1.3.64;3.1.3.-;3.1.4.11,R03361 R03469 R04404 R05795 R06875 R10952 R11680
myo-inositol,cpd:C01284,"1D-myo-Inositol 1,3,4,5,6-pentakisphosphate;D-myo-Inositol 1,3,4,5,6-pentakisphosphate;Inositol 1,3,4,5,6-pentakisphosphate",C6H17O21P5,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4)P3 => phytate",NA,2.7.1.134;2.7.1.140;2.7.1.151;2.7.1.158,R03478 R03479 R05202 R05801 R10065 R10953
myo-inositol,cpd:C01288,N-Acetyl-D-glucosaminylphosphatidylinositol;6-(N-Acetyl-alpha-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol,C19H30NO18PR2,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C01288  N-Acetyl-D-glucosaminylphosphatidylinositol,2.4.1.198;3.5.1.89,R02654 R03482
myo-inositol,cpd:C03365,5-O-Methyl-myo-inositol;1D-5-O-Methyl-myo-inositol;Sequoyitol,C7H14O6,NA,NA,NA,1.1.1.143,R03497
myo-inositol,cpd:C03546,myo-Inositol 4-phosphate;D-myo-Inositol 4-phosphate;1D-myo-Inositol 4-phosphate;1D-myo-Inositol 4-monophosphate;Inositol 4-phosphate,C6H13O9P,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,NA,NA,3.1.3.25;3.1.3.57,R01186 R03393
myo-inositol,cpd:C03659,D-Bornesitol;(-)-Bornesitol;1-O-Methyl-myo-inositol;1D-1-O-Methyl-myo-inositol,C7H14O6,Inositol phosphate metabolism,NA,NA,2.1.1.40,R01188
myo-inositol,cpd:C03660,L-Bornesitol;(+)-Bornesitol;3-O-Methyl-myo-inositol;1D-3-O-Methyl-myo-inositol,C7H14O6,Inositol phosphate metabolism,NA,NA,2.1.1.39,R01189
myo-inositol,cpd:C03868,Indole-3-acetyl-myo-inositol;Indol-3-ylacetyl-myo-inositol;Indole-3-ylacetyl-myo-inositol,C16H19NO7,NA,NA,NA,2.3.1.72;2.4.1.156;2.4.2.34,R04333 R04334 R04335
myo-inositol,cpd:C04006,1D-myo-Inositol 3-phosphate;D-myo-Inositol 3-phosphate;myo-Inositol 3-phosphate;Inositol 3-phosphate;1D-myo-Inositol 3-monophosphate;D-myo-Inositol 3-monophosphate;myo-Inositol 3-monophosphate;Inositol 3-monophosphate;1L-myo-Inositol 1-phosphate;L-myo-Inositol 1-phosphate,C6H13O9P,Streptomycin biosynthesis;Inositol phosphate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol",NA,2.4.1.250;2.7.1.64;2.7.7.74;2.7.8.34;2.7.8.39;3.1.3.25;3.1.3.66;5.5.1.4,R01187 R04372 R07279 R07324 R09634 R09669 R09670 R10464
myo-inositol,cpd:C04062,"D-myo-Inositol 1,3-bisphosphate;1D-myo-Inositol 1,3-bisphosphate;myo-Inositol 1,3-bisphosphate;Inositol 1,3-bisphosphate",C6H14O12P2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,NA,NA,3.1.3.64;3.1.3.66,R03330 R10950
myo-inositol,cpd:C04063,"D-myo-Inositol 3,4-bisphosphate;1D-myo-Inositol 3,4-bisphosphate;Inositol 3,4-bisphosphate",C6H14O12P2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol",NA,3.1.3.57;3.1.3.66,R03427 R04372
myo-inositol,cpd:C04064,"D-myo-Inositol 4,5-bisphosphate",C6H14O12P2,NA,NA,NA,NA,NA
myo-inositol,cpd:C04248,6-(alpha-D-Glucosaminyl)-1-phosphatidyl-1D-myo-inositol;D-Glucosaminylphosphatidylinositol,C17H28NO17PR2,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C04248  6-(alpha-D-Glucosaminyl)-1-phosphatidyl-1D-myo-inositol,3.1.4.50;3.5.1.89;4.6.1.14,R03482 R07398 R07635
myo-inositol,cpd:C04299,"D-myo-Inositol 1,2-cyclic phosphate;1D-myo-Inositol 1,2-cyclic phosphate",C6H11O8P,NA,NA,NA,3.1.4.43;4.6.1.13,R03333 R03364
myo-inositol,cpd:C04477,"1D-myo-Inositol 1,3,4,6-tetrakisphosphate;D-myo-Inositol 1,3,4,6-tetrakisphosphate;Inositol 1,3,4,6-tetrakisphosphate",C6H16O18P4,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,"Inositol phosphate metabolism, Ins(1,3,4)P3 => phytate",NA,2.7.1.140;2.7.1.159,R03429 R03478
myo-inositol,cpd:C04520,"1D-myo-Inositol 3,4,5,6-tetrakisphosphate;D-myo-Inositol 3,4,5,6-tetrakisphosphate;Inositol 3,4,5,6-tetrakisphosphate",C6H16O18P4,Inositol phosphate metabolism;Metabolic pathways,NA,NA,2.7.1.134,R03479
myo-inositol,cpd:C04549,"1-Phosphatidyl-1D-myo-inositol 3-phosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3'-phosphate)",C11H18O16P2R2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system;Autophagy - other;Autophagy - yeast;Autophagy - animal;Endocytosis;Phagosome;Alzheimer disease;Amyotrophic lateral sclerosis;Huntington disease;Spinocerebellar ataxia;Pathways of neurodegeneration - multiple diseases;Shigellosis;Salmonella infection;Tuberculosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP07 Glycerophosphoinositol monophosphates;   GP0701 Diacylglycerophosphoinositol monophosphates;    C04549  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3'-phosphate)",2.7.1.137;2.7.1.150;2.7.1.154;3.1.3.64;3.1.3.66;3.1.3.67;3.1.3.-,R03362 R03363 R04504 R05802 R07299 R12124
myo-inositol,cpd:C04563,"D-myo-Inositol 1,2,4,5,6-pentakisphosphate;1D-myo-Inositol 1,2,4,5,6-pentakisphosphate;myo-Inositol 1,2,4,5,6-pentakisphosphate;Inositol 1,2,4,5,6-pentakisphosphate",C6H17O21P5,Inositol phosphate metabolism;Metabolic pathways,NA,NA,3.1.3.8;3.1.3.62,R03371 R13243
myo-inositol,cpd:C04579,"Inositol 1,2,3,5,6-pentakisphosphate;myo-Inositol 1,2,3,5,6-pentakisphosphate;1D-myo-Inositol 1,2,3,5,6-pentakisphosphate;1L-myo-Inositol 1,2,3,4,5-pentakisphosphate",C6H17O21P5,Inositol phosphate metabolism;Metabolic pathways,NA,NA,3.1.3.26,R03372
myo-inositol,cpd:C04611,Indol-3-ylacetyl-myo-inositol L-arabinoside,C21H27NO11,NA,NA,NA,2.4.2.34,R04335
myo-inositol,cpd:C04637,"1-Phosphatidyl-D-myo-inositol 4,5-bisphosphate;1-Phosphatidyl-1D-myo-inositol 4,5-bisphosphate;Phosphatidyl-myo-inositol 4,5-bisphosphate;Phosphatidylinositol-4,5-bisphosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate)",C11H19O19P3R2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system;Phospholipase D signaling pathway;Endocytosis;PI3K-Akt signaling pathway;Focal adhesion;Fc gamma R-mediated phagocytosis;Leukocyte transendothelial migration;Cholinergic synapse;Regulation of actin cytoskeleton;GnRH secretion;Shigellosis;Yersinia infection,"Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4","Lipids [BR:br08002]; GP  Glycerophospholipids;  GP08 Glycerophosphoinositol bisphosphates;   GP0801 Diacylglycerophosphoinositol bisphosphates;    C04637  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate)",2.7.1.68;2.7.1.149;2.7.1.153;3.1.3.36;3.1.3.67;3.1.3.78;3.1.4.11,R03435 R03469 R04404 R04513 R04545 R05803 R08981
myo-inositol,cpd:C04695,5-O-(Indol-3-ylacetyl-myo-inositol) D-galactoside,C22H29NO12,NA,NA,NA,2.4.1.156,R04334
myo-inositol,cpd:C05981,"Phosphatidylinositol-3,4,5-trisphosphate;1-Phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4',5'-bisphosphate)",C11H20O22P4R2,Inositol phosphate metabolism;Metabolic pathways;EGFR tyrosine kinase inhibitor resistance;ErbB signaling pathway;Ras signaling pathway;Chemokine signaling pathway;FoxO signaling pathway;Phosphatidylinositol signaling system;Sphingolipid signaling pathway;Phospholipase D signaling pathway;Autophagy - animal;Endocytosis;mTOR signaling pathway;PI3K-Akt signaling pathway;AMPK signaling pathway;Apoptosis;Longevity regulating pathway;Longevity regulating pathway - worm;Longevity regulating pathway - multiple species;Cellular senescence;VEGF signaling pathway;Focal adhesion;Platelet activation;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Fc gamma R-mediated phagocytosis;Neurotrophin signaling pathway;Regulation of actin cytoskeleton;Insulin signaling pathway;Progesterone-mediated oocyte maturation;Prolactin signaling pathway;Thyroid hormone signaling pathway;Relaxin signaling pathway;Insulin resistance;Aldosterone-regulated sodium reabsorption;Carbohydrate digestion and absorption;Alzheimer disease;Shigellosis;Salmonella infection;Yersinia infection;Chagas disease;Toxoplasmosis;Hepatitis C;Measles;Human cytomegalovirus infection;Influenza A;Human papillomavirus infection;Human T-cell leukemia virus 1 infection;Kaposi sarcoma-associated herpesvirus infection;Herpes simplex virus 1 infection;Epstein-Barr virus infection;Human immunodeficiency virus 1 infection;Pathways in cancer;Chemical carcinogenesis - receptor activation;Chemical carcinogenesis - reactive oxygen species;Colorectal cancer;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer;Breast cancer;Hepatocellular carcinoma;Gastric cancer;Choline metabolism in cancer;PD-L1 expression and PD-1 checkpoint pathway in cancer;Diabetic cardiomyopathy;Lipid and atherosclerosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP09 Glycerophosphoinositol trisphosphates;   GP0901 Diacylglycerophosphoinositol trisphosphates;    C05981  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4',5'-bisphosphate)",2.7.1.153;3.1.3.36;3.1.3.67;3.1.3.86,R04504 R04513 R04545 R09827
myo-inositol,cpd:C06155,myo-Inositol 5-phosphate;1D-myo-Inositol 5-phosphate,C6H13O9P,NA,NA,NA,NA,NA
myo-inositol,cpd:C06352,4-O-Methyl-myo-inositol;1D-4-O-Methyl-myo-inositol,C7H14O6,NA,NA,NA,2.1.1.129,R01190
myo-inositol,cpd:C06353,6-O-Methyl-myo-inositol;1D-6-O-Methyl-myo-inositol,C7H14O6,NA,NA,NA,NA,NA
myo-inositol,cpd:C11174,"1-Diphosinositol pentakisphosphate;D-myo-Inositol, 2,3,4,5,6-pentakis(dihydrogen phosphate) 1-(trihydrogen diphosphate);Diphospho-myo-inositol pentakisphosphate;1D-myo-Inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate",C6H19O27P7,Phosphatidylinositol signaling system,NA,NA,2.7.4.21;2.7.4.24,R05799 R10548
myo-inositol,cpd:C11524,Diphospho-myo-inositol polyphosphate,NA,NA,NA,NA,3.6.1.52,R05777
myo-inositol,cpd:C11525,myo-Inositol polyphosphate,NA,NA,NA,NA,3.6.1.52,R05777
myo-inositol,cpd:C11526,"5-PP-InsP5;5-Diphosphoinositol pentakisphosphate;1D-myo-Inositol 5-diphosphate pentakisphosphate;1D-myo-Inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate",C6H19O27P7,Phosphatidylinositol signaling system,NA,NA,2.7.4.21;2.7.4.24;3.6.1.52,R05779 R08964 R09087
myo-inositol,cpd:C11554,"1-Phosphatidyl-1D-myo-inositol 3,4-bisphosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4'-bisphosphate)",C11H19O19P3R2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system;Regulation of actin cytoskeleton;Progesterone-mediated oocyte maturation;Salmonella infection,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP08 Glycerophosphoinositol bisphosphates;   GP0801 Diacylglycerophosphoinositol bisphosphates;    C11554  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4'-bisphosphate)",2.7.1.154;3.1.3.36;3.1.3.64;3.1.3.66;3.1.3.86,R05795 R06875 R07299 R09827
myo-inositol,cpd:C11555,"1D-myo-Inositol 1,4,5,6-tetrakisphosphate;D-myo-Inositol 1,4,5,6-tetrakisphosphate;Inositol 1,4,5,6-tetrakisphosphate",C6H16O18P4,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system,NA,NA,2.7.1.151,R05800 R05801
myo-inositol,cpd:C11556,"1-Phosphatidyl-1D-myo-inositol 3,5-bisphosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',5'-bisphosphate)",C11H19O19P3R2,Inositol phosphate metabolism;Metabolic pathways;Calcium signaling pathway;Phosphatidylinositol signaling system;Endocytosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP08 Glycerophosphoinositol bisphosphates;   GP0801 Diacylglycerophosphoinositol bisphosphates;    C11556  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',5'-bisphosphate)",2.7.1.150;3.1.3.95;3.1.3.-,R05802 R10928 R12124
myo-inositol,cpd:C11557,"1-Phosphatidyl-1D-myo-inositol 5-phosphate;1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-5'-phosphate)",C11H18O16P2R2,Inositol phosphate metabolism;Metabolic pathways;Phosphatidylinositol signaling system;Shigellosis,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP07 Glycerophosphoinositol monophosphates;   GP0701 Diacylglycerophosphoinositol monophosphates;    C11557  1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-5'-phosphate)",2.7.1.149;2.7.1.150;3.1.3.78;3.1.3.95,R05803 R08981 R10928 R10951
myo-inositol,cpd:C13888,1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol,C43H81O13P,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP06 Glycerophosphoinositols;   GP0601 Diacylglycerophosphoinositols;    C13888  1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol,NA,NA
myo-inositol,cpd:C15585,myo-Inositol phosphate,NA,NA,NA,NA,3.1.3.25,R07343
myo-inositol,cpd:C15658,6-(alpha-D-Glucosaminyl)-1D-myo-inositol,C12H23NO10,Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Metabolic pathways,NA,NA,3.1.4.50,R07398
myo-inositol,cpd:C15990,"1L-myo-Inositol 1,2,3,4,6-pentakisphosphate;myo-Inositol 1,2,3,4,6-pentakisphosphate",C6H17O21P5,NA,NA,NA,3.1.3.72,R07583
myo-inositol,cpd:C15991,myo-Inositol pentakisphosphate,C6H17O21P5,NA,NA,NA,NA,NA
myo-inositol,cpd:C16070,"6-(alpha-D-Glucosaminyl)-1D-myo-inositol 1,2-cyclic phosphate",C12H22NO12P,NA,NA,NA,4.6.1.14,R07635
myo-inositol,cpd:C18058,1D-myo-Inositol bisdiphosphate tetrakisphosphate,NA,NA,NA,NA,NA,NA
myo-inositol,cpd:C19702,1-O-(2-Amino-2-deoxy-alpha-D-glucopyranosyl)-1D-myo-inositol,C12H23NO10,NA,NA,NA,3.5.1.103;3.5.1.115;6.3.1.13,R09591 R09651 R10617
myo-inositol,cpd:C19703,1-O-[2-(L-Cysteinamido)-2-deoxy-alpha-D-glucopyranosyl]-1D-myo-inositol;Desacetylmycothiol,C15H28N2O11S,NA,NA,NA,2.3.1.189;6.3.1.13,R09591 R09622
myo-inositol,cpd:C19761,1-O-(2-Acetamido-2-deoxy-alpha-D-glucopyranosyl)-1D-myo-inositol 3-phosphate,C14H26NO14P,NA,NA,NA,2.4.1.250;3.1.3.-,R09634 R12125
myo-inositol,cpd:C19784,1-O-(2-Acetamido-2-deoxy-alpha-D-glucopyranosyl)-1D-myo-inositol;1-O-[2-(Acetylamino)-2-deoxy-alpha-D-glucopyranosyl]-D-myo-inositol;1-(2-Acetamido-2-deoxy-alpha-D-glucopyranosyl)-1D-myo-inositol,C14H25NO11,NA,NA,NA,3.1.3.-;3.5.1.103,R09651 R12125
myo-inositol,cpd:C19794,CDP-1L-myo-inositol,C15H25N3O16P2,Inositol phosphate metabolism;Metabolic pathways,NA,NA,2.7.7.74;2.7.8.34,R09669 R09670
myo-inositol,cpd:C19799,"Bis(1L-myo-inositol)-3,1'-phosphate 1-phosphate",C12H24O17P2,Inositol phosphate metabolism;Metabolic pathways,NA,NA,2.7.8.34,R09670
myo-inositol,cpd:C20642,1-Archaetidyl-1D-myo-inositol 3-phosphate;1-Saturated archaetidyl-1D-myo-inositol 3-phosphate;Archaetidylinositol phosphate,C49H100O14P2,NA,NA,NA,2.7.8.39,R10464
myo-inositol,cpd:C20690,"1D-myo-Inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate",C6H20O30P8,Phosphatidylinositol signaling system,NA,NA,2.7.4.21;2.7.4.24,R08964 R10548
myo-inositol,cpd:C21606,2-O-(alpha-D-Mannosyl)-1-phosphatidyl-1D-myo-inositol;2-O-alpha-D-Mannosyl-1-phosphatidyl-1D-myo-inositol,C17H27O18PR2,Lipoarabinomannan (LAM) biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C21606  2-O-alpha-D-Mannosyl-1-phosphatidyl-1D-myo-inositol,2.3.1.265;2.4.1.345;2.4.1.346,R11702 R11703 R11782
myo-inositol,cpd:C21607,"2,6-Di-O-alpha-D-mannosyl-1-phosphatidyl-1D-myo-inositol",C23H37O23PR2,Lipoarabinomannan (LAM) biosynthesis;Metabolic pathways,NA,"Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C21607  2,6-Di-O-alpha-D-mannosyl-1-phosphatidyl-1D-myo-inositol",2.3.1.265;2.4.1.346,R11703 R11781
myo-inositol,cpd:C21608,2-O-(6-O-Acyl-alpha-D-mannosyl)-6-O-alpha-D-mannosyl-1-phosphatidyl-1D-myo-inositol,C24H36O24PR3,Lipoarabinomannan (LAM) biosynthesis;Metabolic pathways;Tuberculosis,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C21608  2-O-(6-O-Acyl-alpha-D-mannosyl)-6-O-alpha-D-mannosyl-1-phosphatidyl-1D-myo-inositol,2.3.1.265;2.4.1.346,R11704 R11781
myo-inositol,cpd:C21609,2-O-(6-O-Acyl-alpha-D-mannosyl)-1-phosphatidyl-1D-myo-inositol,C18H26O19PR3,Lipoarabinomannan (LAM) biosynthesis;Metabolic pathways,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP15 Glycerophosphoinositolglycans;   GP1501 Diacylglycerophosphoinositolglycans;    C21609  2-O-(6-O-Acyl-alpha-D-mannosyl)-1-phosphatidyl-1D-myo-inositol,2.3.1.265;2.4.1.346,R11704 R11782
myo-inositol,cpd:C22088,"Bis(myo-inositol) 1,3'-phosphate",C12H23O14P,NA,NA,NA,2.4.1.361,R12338 R12339
myo-inositol,cpd:C22089,"2-O-(beta-D-Mannosyl-(1->2)-beta-D-mannosyl)-bis(myo-inositol) 1,3'-phosphate;2-(O-beta-D-Mannosyl-1,2-O-beta-D-mannosyl)-di-myo-inositol-1,3'-phosphate;MMDIP",C24H43O24P,NA,NA,NA,2.4.1.361,R12338 R12340
myo-inositol,cpd:C22090,"2-O-(beta-D-Mannosyl)-bis(myo-inositol) 1,3'-phosphate;2-(O-beta-D-Mannosyl)-di-myo-inositol-1,3'-phosphate;MDIP",C18H33O19P,NA,NA,NA,2.4.1.361,R12339 R12340
myo-inositol,cpd:C22400,2-Acyl-sn-glycero-3-phospho-1D-myo-inositol,C10H18O12PR,NA,NA,Lipids [BR:br08002]; GP  Glycerophospholipids;  GP06 Glycerophosphoinositols;   GP0605 Monoacylglycerophosphoinositols;    C22400  2-Acyl-sn-glycero-3-phospho-1D-myo-inositol,3.1.1.118,R12795
myo-inositol,cpd:C22851,"1D-myo-Inositol 1,2,5,6-tetrakisphosphate",C6H16O18P4,NA,NA,NA,3.1.3.62,R13243 R13244
myo-inositol,cpd:C22852,"1D-myo-Inositol 1,2,6-trisphosphate",C6H15O15P3,NA,NA,NA,3.1.3.62,R13244 R13245
myo-inositol,cpd:C22853,"1D-myo-Inositol 1,2-bisphosphate",C6H14O12P2,NA,NA,NA,3.1.3.62,R13245 R13246
myo-inositol,cpd:C22854,1D-myo-Inositol 2-phosphate,C6H13O9P,NA,NA,NA,3.1.3.62,R13246
phenylethylamine,cpd:C02455,1-Phenylethylamine;alpha-Phenylethylamine;alpha-Methylbenzylamine,C8H11N,NA,NA,NA,NA,NA
phenylethylamine,cpd:C05332,Phenethylamine;2-Phenylethylamine;beta-Phenylethylamine;Phenylethylamine,C8H11N,Phenylalanine metabolism;Metabolic pathways,NA,Compounds with biological roles [BR:br08001]; Peptides;  Amines;   Biogenic amines;    C05332  Phenethylamine,1.4.3.4;1.4.3.21;1.4.9.2;3.5.1.85;4.1.1.28;4.1.1.53,R00699 R02612 R02613 R07301
phenylethylamine,cpd:C06746,N-(2-Phenylethyl)-acetamide;N-Acetylphenylethylamine;N-Acetyl-2-phenylethylamine,C10H13NO,NA,NA,NA,3.5.1.85,R07301
phenylethylamine,cpd:C15411,"beta-Chloro-alpha-phenylbenzeneethanamine hydrochloride;2-Chloro-1,2-diphenylethylamine hydrochloride",C14H14ClN. HCl,NA,NA,NA,NA,NA
pimelic acid,cpd:C00666,"LL-2,6-Diaminoheptanedioate;LL-2,6-Diaminopimelate;LL-2,6-Diaminopimelic acid;(2S,6S)-2,6-Diaminoheptanedioic acid",C7H14N2O4,Lysine biosynthesis;D-Amino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of amino acids,"Lysine biosynthesis, succinyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, acetyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, DAP aminotransferase pathway, aspartate => lysine","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C00666  (2S,6S)-2,6-Diaminoheptanedioic acid",2.6.1.83;3.5.1.18;3.5.1.47;5.1.1.7,R02733 R02734 R02735 R07613
pimelic acid,cpd:C00680,"meso-2,6-Diaminoheptanedioate;meso-2,6-Diaminopimelate;meso-2,6-Diaminopimelic acid;meso-Diaminoheptanedioate",C7H14N2O4,Lysine biosynthesis;D-Amino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Biosynthesis of amino acids,"Lysine biosynthesis, succinyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, acetyl-DAP pathway, aspartate => lysine;Lysine biosynthesis, DAP dehydrogenase pathway, aspartate => lysine;Lysine biosynthesis, DAP aminotransferase pathway, aspartate => lysine",NA,1.4.1.16;4.1.1.20;5.1.1.7;6.3.2.13,R00451 R02735 R02755 R02788
pimelic acid,cpd:C02656,Pimelate;Pimelic acid;Heptanedioic acid;6-Carboxyhexanoate,C7H12O4,Biotin metabolism;Metabolic pathways;Biosynthesis of cofactors,"Biotin biosynthesis, BioW pathway, pimelate => pimeloyl-CoA => biotin",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Dicarboxylic acids;    C02656  Pimelate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C02656  Heptanedioic acid,6.2.1.14,R03209
pimelic acid,cpd:C04462,N-Succinyl-2-L-amino-6-oxoheptanedioate;N-Succinyl-L-2-amino-6-oxoheptanedioate;N-Succinyl-L-2-amino-6-oxopimelate;N-Succinyl-2-amino-6-oxo-L-pimelic acid;N-Succinyl-epsilon-keto-L-aminopimelic acid;(S)-2-(Succinylamino)-6-oxoheptanedioate,C11H15NO8,Lysine biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of amino acids,"Lysine biosynthesis, succinyl-DAP pathway, aspartate => lysine",NA,2.3.1.117;2.6.1.17,R04365 R04475
p-Toluic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
putrescine,cpd:C00134,"Putrescine;1,4-Butanediamine;1,4-Diaminobutane;Tetramethylenediamine;Butane-1,4-diamine",C4H12N2,"Arginine and proline metabolism;D-Amino acid metabolism;Glutathione metabolism;Tropane, piperidine and pyridine alkaloid biosynthesis;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Metabolic pathways;Biosynthesis of secondary metabolites;ABC transporters;Efferocytosis;Protein digestion and absorption","Polyamine biosynthesis, arginine => agmatine => putrescine => spermidine;Polyamine biosynthesis, arginine => ornithine => putrescine;GABA biosynthesis, eukaryotes, putrescine => GABA;GABA biosynthesis, prokaryotes, putrescine => GABA",Compounds with biological roles [BR:br08001]; Peptides;  Amines;   Biogenic amines;    C00134  Putrescine,1.4.3.10;1.4.3.22;1.5.1.43;1.5.3.13;1.5.3.17;2.1.1.53;2.1.3.6;2.3.1.57;2.3.1.138;2.3.1.-;2.5.1.16;2.5.1.44;2.5.1.45;2.6.1.29;2.6.1.82;2.6.1.113;3.5.1.53;3.5.1.62;3.5.3.11;4.1.1.17;4.1.1.116;6.3.1.11,R00018 R00670 R01151 R01152 R01153 R01154 R01155 R01156;R01157 R01399 R01919 R01920 R01944 R07414 R08714 R09074;R09077 R09079 R09256 R09257 R12304
putrescine,cpd:C00436,N-Carbamoylputrescine,C5H13N3O,Arginine and proline metabolism;Metabolic pathways,NA,Phytochemical compounds [BR:br08003]; Amino acid related compounds;  Others;   Amines;    C00436  N-Carbamoylputrescine,2.1.3.6;3.5.1.53;3.5.3.12,R01152 R01399 R01416
putrescine,cpd:C02714,N-Acetylputrescine,C6H14N2O,Arginine and proline metabolism;Metabolic pathways,"GABA biosynthesis, eukaryotes, putrescine => GABA",NA,1.4.3.4;2.3.1.57;3.5.1.62,R01154 R01156 R04025
putrescine,cpd:C02723,N-Methylputrescine,C5H14N2,"Tropane, piperidine and pyridine alkaloid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites",NA,NA,1.4.3.21;1.4.3.22;2.1.1.53,R01153 R04027 R05334
putrescine,cpd:C03002,N-Caffeoylputrescine,C13H18N2O3,NA,NA,NA,2.3.1.138,R01944
putrescine,cpd:C10497,Feruloylputrescine;Subaphyllin,C14H20N2O3,Arginine and proline metabolism;Metabolic pathways,NA,NA,2.3.1.-,R09257
putrescine,cpd:C15699,gamma-L-Glutamylputrescine,C9H19N3O3,Arginine and proline metabolism;Metabolic pathways,"GABA biosynthesis, prokaryotes, putrescine => GABA",NA,1.4.3.-;6.3.1.11,R07414 R07415
putrescine,cpd:C18326,p-Coumaroylputrescine,C13H18N2O2,Arginine and proline metabolism;Metabolic pathways,NA,NA,2.3.1.-,R09256
4-hydroxy-3-methoxybenzoic acid,cpd:C06672,Vanillate;Vanillic acid;4-Hydroxy-3-methoxybenzoate;4-Hydroxy-3-methoxybenzoic acid,C8H8O4,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C06672,1.2.1.67;1.2.3.9;1.14.13.82;2.1.1.341;2.1.1.382;2.4.1.300,R05273 R05274 R05699 R07668 R09278 R10136 R10259 R10296;R10297
5-aminovaleric acid 1,cpd:C00431,5-Aminopentanoate;5-Aminopentanoic acid;5-Aminovaleric acid,C5H11NO2,Lysine degradation;Arginine and proline metabolism;D-Amino acid metabolism;Metabolic pathways;Microbial metabolism in diverse environments,"Lysine degradation, bacteria, L-lysine => succinate;Lysine degradation, bacteria, L-lysine => glutarate => succinate/acetyl-CoA",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C00431  5-Aminopentanoic acid,1.2.1.19;1.4.1.12;1.21.4.1;2.6.1.48;3.5.1.30;3.5.1.63,R02273 R02274 R02276 R02825 R12215
behenic acid,cpd:C08281,Docosanoic acid;Docosanoate;Behenic acid,C22H44O2,"Cutin, suberine and wax biosynthesis;Biosynthesis of unsaturated fatty acids",NA,Compounds with biological roles [BR:br08001]; Lipids;  Fatty acids;   Saturated fatty acids;    C08281  Behenic acid (22:0);Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C08281  Docosanoic acid;Phytochemical compounds [BR:br08003]; Fatty acids related compounds;  Fatty acids;   Saturated fatty acids;    C08281  Behenic acid,1.14.-.-;3.1.2.-,R08184 R09454
ciliatine,cpd:C03557,2-Aminoethylphosphonate;(2-Aminoethyl)phosphonate;Ciliatine,C2H8NO3P,Phosphonate and phosphinate metabolism;Metabolic pathways;Microbial metabolism in diverse environments;ABC transporters,NA,NA,1.1.99.-;1.14.11.46;2.3.1.280;2.6.1.37;2.7.7.14;2.7.7.107;4.99.1.-,R04152 R04247 R04248 R04249 R04250 R04252 R10724 R11479
ciliatine,cpd:C05673,CMP-2-aminoethylphosphonate;CMPciliatine,C11H20N4O10P2,Phosphonate and phosphinate metabolism;Metabolic pathways,NA,NA,2.7.7.14;2.7.7.107;2.7.8.1;2.7.8.-,R04247 R04920 R04921
ciliatine,cpd:C05681,Ceramide 2-aminoethylphosphonate;Ceramide ciliatine,C21H42N2O5PR,Phosphonate and phosphinate metabolism;Sphingolipid metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; SP  Sphingolipids;  SP04 Phosphonosphingolipids;   C05681  Ceramide 2-aminoethylphosphonate,2.7.8.-,R04921
D-mannitol,cpd:C00392,Mannitol;D-Mannitol,C6H14O6,Fructose and mannose metabolism;Metabolic pathways;ABC transporters;Phosphotransferase system (PTS),NA,"Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Sugar alcohols;    C00392  Mannitol;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00062)]; A ALIMENTARY TRACT AND METABOLISM;  A06 DRUGS FOR CONSTIPATION;   A06A DRUGS FOR CONSTIPATION;    A06AD Osmotically acting laxatives;     A06AD16 Mannitol;      D00062  Mannitol (USP) &lt;JP/US&gt;; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05B I.V. SOLUTIONS;    B05BC Solutions producing osmotic diuresis;     B05BC01 Mannitol;      D00062  Mannitol (USP) &lt;JP/US&gt;;   B05C IRRIGATING SOLUTIONS;    B05CX Other irrigating solutions;     B05CX04 Mannitol;      D00062  Mannitol (USP) &lt;JP/US&gt;; R RESPIRATORY SYSTEM;  R05 COUGH AND COLD PREPARATIONS;   R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;    R05CB Mucolytics;     R05CB16 Mannitol;      D00062  Mannitol (USP) &lt;JP/US&gt;; V VARIOUS;  V04 DIAGNOSTIC AGENTS;   V04C OTHER DIAGNOSTIC AGENTS;    V04CX Other diagnostic agents;     V04CX04 Mannitol;      D00062  Mannitol (USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00062)]; Respiratory Tract/Pulmonary Agents;  Cystic Fibrosis Agents;   Cystic Fibrosis Agents, Other;    Mannitol;     D00062  Mannitol (USP);Therapeutic category of drugs in Japan [BR:br08301(D00062)]; 2  Agents affecting individual organs;  21  Cardiovascular agents;   219  Miscellaneous;    2190  Miscellaneous;     D00062  Mannitol (USP); D-Mannitol (JP18);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00062)]; Chemicals;  D00062  D-Mannitol;  D00062  D-Mannitol injection;New drug approvals in Europe [br08329.html(D00062)]; European public assessment reports (EPAR) authorised medicine;  D00062",1.1.1.11;1.1.1.67;1.1.1.138;1.1.1.255;1.1.2.2;1.1.3.40;2.7.1.197;3.1.3.22,R00865 R00868 R00870 R02167 R02704 R05698 R07135
D-mannitol,cpd:C00644,D-Mannitol 1-phosphate,C6H15O9P,Fructose and mannose metabolism;Metabolic pathways;Phosphotransferase system (PTS),NA,NA,1.1.1.17;1.1.1.224;2.7.1.197;3.1.3.22,R00758 R01817 R02167 R02703 R02704
D-mannitol,cpd:C16538,"1,5-Anhydro-D-mannitol",C6H12O5,NA,NA,NA,1.1.1.292,R08194
Dodecanedioic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
Hexanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
Octadecanenitrile NIST,NA,NA,NA,NA,NA,NA,NA,NA
palatinose,cpd:C01742,Palatinose;Isomaltulose;6-O-alpha-D-Glucopyranosyl-D-fructofuranose,C12H22O11,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Oligosaccharides;   Disaccharides;    C01742  Palatinose,3.2.1.219;5.4.99.11,R00810 R13126
Pentacosanoic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
Pentanedioic acid NIST,NA,NA,NA,NA,NA,NA,NA,NA
tagatose,cpd:C00795,D-Tagatose;lyxo-Hexulose,C6H12O6,Galactose metabolism;Metabolic pathways,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C00795  D-Tagatose,1.1.1.16;1.1.1.407;2.7.1.101;5.1.3.31,R02927 R02928 R10818 R11638
tagatose,cpd:C01097,D-Tagatose 6-phosphate,C6H13O9P,Galactose metabolism;Metabolic pathways,NA,NA,1.1.1.251;2.7.1.11;2.7.1.56;2.7.1.101;2.7.1.144;3.5.99.-;5.1.3.40;5.3.1.26,R02927 R03236 R03237 R03238 R03239 R03240 R05571 R08365;R11623
tagatose,cpd:C01721,L-Fuculose;6-Deoxy-L-tagatose,C6H12O5,Fructose and mannose metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,2.7.1.51;5.3.1.3;5.3.1.25,R03163 R03241
tagatose,cpd:C03785,"D-Tagatose 1,6-bisphosphate",C6H14O12P2,Galactose metabolism;Metabolic pathways,NA,NA,2.7.1.11;2.7.1.56;2.7.1.144;2.7.1.234;4.1.2.40,R01069 R03236 R03237 R03238 R03239 R12940
tagatose,cpd:C06312,L-Tagatose 6-phosphate,C6H13O9P,NA,NA,NA,NA,NA
tagatose,cpd:C21523,L-Tagatose,C6H12O6,NA,NA,NA,1.1.1.406,R11637
tagatose,cpd:C22459,D-Tagatopyranose 1-phosphate;D-Tagatose 1-phosphate,C6H13O9P,NA,NA,NA,2.7.1.234,R12940
talose,cpd:C01222,GDP-4-dehydro-6-deoxy-D-mannose;GDP-4-dehydro-6-deoxy-D-talose;GDP-4-oxo-6-deoxy-D-mannose;GDP-4-dehydro-D-rhamnose;GDP-4-keto-6-deoxy-D-mannose;GDP-4-dehydro-alpha-D-rhamnose;GDP-4-dehydro-6-deoxy-alpha-D-mannose,C16H23N5O15P2,Fructose and mannose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.135;1.1.1.187;1.1.1.271;1.1.1.281;2.6.1.102;4.2.1.47;4.2.1.168,R00888 R03396 R03397 R03398 R03399 R05692 R07059 R10460;R11409
talose,cpd:C02977,GDP-6-deoxy-D-talose;GDP-6-deoxy-alpha-D-talose,C16H25N5O15P2,Fructose and mannose metabolism;Amino sugar and nucleotide sugar metabolism;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.135;1.1.1.187,R03396 R03398
talose,cpd:C03187,dTDP-6-deoxy-beta-L-talose;dTDP-beta-L-pneumose,C16H26N2O15P2,Polyketide sugar unit biosynthesis;O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of nucleotide sugars,NA,NA,1.1.1.134;1.1.1.339;1.1.1.344;5.1.3.25,R02776 R10190 R10279
talose,cpd:C06467,D-Talose;D-talo-Hexose,C6H12O6,NA,NA,Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Aldoses;    C06467  D-Talose,NA,NA
talose,cpd:C08235,Digitalose;beta-D-Digitalopyranose,C7H14O5,NA,NA,NA,NA,NA
talose,cpd:C20768,"UDP-2-acetamido-2,6-dideoxy-beta-L-talose;UDP-N-acetyl-beta-L-pneumosamine",C17H27N3O16P2,O-Antigen nucleotide sugar biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,UDP-L-FucNAm biosynthesis,NA,1.1.1.367;5.1.3.28,R10665 R10676 R12552
talose,cpd:C21058,6-Deoxy-D-talose;6-Deoxy-D-talopyranose,C6H12O5,NA,NA,NA,NA,NA
1-Butanol,cpd:C06142,1-Butanol;n-Butanol;Butan-1-ol,C4H10O,Butanoate metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA05 Fatty alcohols;   C06142  1-Butanol,1.1.1.-;1.1.2.9;1.1.5.11;1.14.13.230,R03544 R03545 R11343 R11344 R11448
1-Butanol,cpd:C17146,4-Guanidino-1-butanol,C5H13N3O,NA,NA,NA,NA,NA
1-Butanol,cpd:C19574,4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol;NNAL,C10H15N3O2,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,1.1.1.146;1.1.1.184;1.3.1.20;1.14.14.1;1.14.14.-;2.4.1.17,R09420 R09424 R09425 R09426 R09427 R09430
1-Butanol,cpd:C19603,4-(Methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanol;NNAL-N-oxide,C10H15N3O3,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,NA,R09430
1-Butanol,cpd:C19605,4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronide;NNAL-O-glucuronide,C16H23N3O8,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,2.4.1.17,R09426
"3,7-Dimethyluric acid",cpd:C16360,"3,7-Dimethyluric acid",C7H8N4O3,Caffeine metabolism,NA,"Phytochemical compounds [BR:br08003]; Alkaloids;  Others;   Purine alkaloids;    C16360  3,7-Dimethyluric acid",1.17.3.2,R07978
Acetate,cpd:C00033,Acetate;Acetic acid;Ethanoic acid,C2H4O2,Glycolysis / Gluconeogenesis;Taurine and hypotaurine metabolism;Phosphonate and phosphinate metabolism;Glycosaminoglycan biosynthesis - heparan sulfate / heparin;Pyruvate metabolism;Glyoxylate and dicarboxylate metabolism;C5-Branched dibasic acid metabolism;Methane metabolism;Carbon fixation pathways in prokaryotes;Zeatin biosynthesis;Sulfur metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Degradation of aromatic compounds;Cholinergic synapse;Alcoholic liver disease;Carbohydrate digestion and absorption;Protein digestion and absorption,"Methanogenesis, acetate => methane;Phosphate acetyltransferase-acetate kinase pathway, acetyl-CoA => acetate","Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C00033  Acetate; Ethanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C00033  Acetic acid;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00010)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;   G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;    G01AD Organic acids;     G01AD02 Acetic acid;      D00010  Acetic acid, glacial (USP) &lt;JP/US&gt;; S SENSORY ORGANS;  S02 OTOLOGICALS;   S02A ANTIINFECTIVES;    S02AA Antiinfectives;     S02AA10 Acetic acid;      D00010  Acetic acid, glacial (USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00010)]; Antibacterials;  Antibacterials, Other;   Acetic Acid;    D00010  Acetic acid, glacial (USP); Dermatological Agents;  Topical Anti-infectives;   Antibacterials, dermatological;    Acetic Acid;     D00010  Acetic acid, glacial (USP);Therapeutic category of drugs in Japan [BR:br08301(D00010)]; 2  Agents affecting individual organs;  26  Epidermides;   264  Analgesics, anti-itchings, astringents, anti-inflammatory agents;    2649  Others;     D00010  Acetic acid, glacial (USP); Acetic acid (JP18/NF); Glacial acetic acid (JP18);   266  Emollients;    2661  Organic acids;     D00010  Acetic acid, glacial (USP); Acetic acid (JP18/NF); Glacial acetic acid (JP18); 7  Agents not mainly for therapeutic purpose;  71  Dispensing medicines;   714  Flavorings, deodorants, coloring agents;    7149  Others;     D00010  Acetic acid, glacial (USP); Acetic acid (JP18/NF); Glacial acetic acid (JP18);   719  Miscellaneous;    7190  Miscellaneous;     D00010  Acetic acid, glacial (USP); Acetic acid (JP18/NF); Glacial acetic acid (JP18);Risk category of Japanese OTC drugs [BR:br08312(D00010)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Acetic acid;    D00010  Acetic acid, glacial (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00010)]; Chemicals;  D00010  Acetic acid;  D00010  Glacial acetic acid",1.1.1.318;1.1.1.319;1.2.1.3;1.2.1.4;1.2.1.5;1.2.1.-;1.2.5.1;1.2.5.2;1.2.99.6;1.13.11.50;1.13.12.4;1.14.13.54;1.14.14.32;2.1.1.152;2.3.1.187;2.5.1.47;2.5.1.48;2.5.1.49;2.5.1.50;2.5.1.51;2.5.1.52;2.5.1.53;2.5.1.65;2.5.1.118;2.5.1.119;2.5.1.134;2.5.1.144;2.6.99.3;2.7.2.1;2.7.2.12;2.7.2.15;2.8.3.1;2.8.3.3;2.8.3.8;2.8.3.10;2.8.3.11;2.8.3.12;2.8.3.14;2.8.3.18;2.8.3.19;2.8.3.-;3.1.1.2;3.1.1.6;3.1.1.7;3.1.1.8;3.1.1.33;3.1.1.41;3.1.1.47;3.1.1.53;3.1.1.54;3.1.1.55;3.1.1.56;3.1.1.58;3.1.1.66;3.1.1.71;3.1.1.80;3.1.1.94;3.1.1.105;3.1.1.106;3.1.1.112;3.1.1.113;3.1.1.114;3.1.2.1;3.1.2.16;3.5.1.4;3.5.1.14;3.5.1.15;3.5.1.16;3.5.1.17;3.5.1.21;3.5.1.25;3.5.1.29;3.5.1.33;3.5.1.41;3.5.1.47;3.5.1.48;3.5.1.51;3.5.1.62;3.5.1.63;3.5.1.66;3.5.1.76;3.5.1.85;3.5.1.89;3.5.1.103;3.5.1.104;3.5.1.105;3.5.1.108;3.5.1.112;3.5.1.113;3.5.1.114;3.5.1.125;3.5.1.135;3.5.1.136;3.5.1.-;3.6.1.7;3.6.1.20;3.7.1.1;3.7.1.6;3.7.1.24;3.7.1.25;3.11.1.2;4.1.1.88;4.1.3.4;4.1.3.6;4.1.3.22;4.1.3.26;4.2.99.24;6.2.1.1;6.2.1.13;6.2.1.22;6.2.1.35,R00227 R00229 R00235 R00315 R00316 R00317 R00318 R00319;R00320 R00321 R00322 R00324 R00325 R00326 R00327 R00338;R00362 R00393 R00458 R00488 R00628 R00651 R00669 R00710;R00711 R00743 R00897 R00909 R00928 R01019 R01026 R01156;R01179 R01200 R01241 R01287 R01308 R01323 R01359 R01426;R01649 R01810 R01987 R02026 R02059 R02276 R02333 R02733;R02942 R02955 R03062 R03131 R03132 R03133 R03134 R03145;R03153 R03217 R03482 R03601 R03884 R04000 R04043 R04056;R04057 R04091 R04141 R04146 R04174 R04397 R04449 R04450;R04452 R04490 R04525 R04587 R04727 R04769 R04859 R04945;R05138 R05168 R05219 R05336 R05508 R05509 R05677 R05880;R05917 R06241 R06893 R07183 R07300 R07301 R07342 R07513;R07832 R08090 R08206 R08517 R08518 R08600 R08601 R08874;R08876 R08895 R08901 R08944 R09107 R09475 R09483 R09651;R09721 R09801 R09931 R10248 R10249 R10289 R10305 R10343;R10398 R10401 R10461 R10553 R10600 R10614 R10705 R10839;R10840 R11116 R11283 R11693 R11694 R11889 R11903 R12347;R12390 R12391 R12392 R12515 R12516 R12635 R12671 R12926;R13046 R13218
Acetate,cpd:C00036,Oxaloacetate;Oxalacetic acid;Oxaloacetic acid;2-Oxobutanedioic acid;2-Oxosuccinic acid;keto-Oxaloacetate,C4H4O5,"Glycolysis / Gluconeogenesis;Citrate cycle (TCA cycle);Alanine, aspartate and glutamate metabolism;Benzoate degradation;D-Amino acid metabolism;Pyruvate metabolism;Glyoxylate and dicarboxylate metabolism;Methane metabolism;Carbon fixation in photosynthetic organisms;Carbon fixation pathways in prokaryotes;Degradation of flavonoids;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Two-component system;Glucagon signaling pathway;Proximal tubule bicarbonate reclamation;Central carbon metabolism in cancer","Gluconeogenesis, oxaloacetate => fructose-6P;Citrate cycle (TCA cycle, Krebs cycle);Citrate cycle, first carbon oxidation, oxaloacetate => 2-oxoglutarate;Citrate cycle, second carbon oxidation, 2-oxoglutarate => oxaloacetate;Glyoxylate cycle;CAM (Crassulacean acid metabolism), dark;C4-dicarboxylic acid cycle, phosphoenolpyruvate carboxykinase type;C4-dicarboxylic acid cycle, NAD - malic enzyme type;C4-dicarboxylic acid cycle, NADP - malic enzyme type;Reductive citrate cycle (Arnon-Buchanan cycle);Formaldehyde assimilation, serine pathway;Dicarboxylate-hydroxybutyrate cycle;Incomplete reductive citrate cycle, acetyl-CoA => oxoglutarate;Methylaspartate cycle",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00036  Oxaloacetate; 2-Oxosuccinate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C00036  2-Oxobutanedioic acid,1.1.1.37;1.1.1.38;1.1.1.40;1.1.1.82;1.1.1.299;1.1.5.4;1.1.99.7;1.4.1.21;1.4.3.1;1.4.3.2;1.4.3.15;1.4.3.16;2.1.3.1;2.3.3.1;2.3.3.2;2.3.3.3;2.3.3.5;2.3.3.8;2.3.3.16;2.6.1.1;2.6.1.12;2.6.1.21;2.6.1.31;2.6.1.35;2.6.1.57;2.6.1.70;2.6.1.78;2.6.1.-;3.1.1.44;3.5.1.3;3.7.1.1;4.1.1.31;4.1.1.32;4.1.1.38;4.1.1.49;4.1.1.112;4.1.3.6;4.1.3.13;4.1.3.17;4.1.3.34;4.2.1.32;4.2.1.81;4.3.1.16;4.3.1.20;4.3.1.27;5.3.2.2;6.4.1.1;7.2.4.2,R00217 R00338 R00339 R00340 R00341 R00342 R00343 R00344;R00345 R00346 R00347 R00348 R00350 R00351 R00352 R00353;R00354 R00355 R00357 R00359 R00360 R00361 R00362 R00363;R00373 R00400 R00431 R00477 R00493 R00695 R00726 R00930;R00931 R01144 R01257 R01447 R01713 R01731 R03735 R05053;R05758 R07164 R07165 R09683 R12212 R13023 R13076 R13206;R13207 R13222
Acetate,cpd:C00164,Acetoacetate;3-Oxobutanoic acid;beta-Ketobutyric acid;Acetoacetic acid,C4H6O3,"Valine, leucine and isoleucine degradation;Lysine degradation;Tyrosine metabolism;Styrene degradation;Butanoate metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Two-component system","Leucine degradation, leucine => acetoacetate + acetyl-CoA;Tyrosine degradation, tyrosine => homogentisate;Ketone body biosynthesis, acetyl-CoA => acetoacetate/3-hydroxybutyrate/acetone",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   3-Oxocarboxylic acids;    C00164  Acetoacetate; 3-Oxobutanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C00164  3-Oxobutanoic acid,1.1.1.30;1.1.99.24;1.8.1.5;2.3.1.247;2.8.3.5;2.8.3.8;2.8.3.9;3.1.2.11;3.7.1.2;4.1.1.4;4.1.3.4;4.2.1.27;6.2.1.16;6.4.1.6,R00410 R01357 R01358 R01359 R01360 R01361 R01364 R01365;R01366 R01367 R03225 R05713 R05735 R10564
Acetate,cpd:C00284,EDTA;Ethylenediaminetetraacetic acid;Edetic acid;Ethylenediaminetetraacetate,C10H16N2O8,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00052)]; V VARIOUS;  V03 ALL OTHER THERAPEUTIC PRODUCTS;   V03A ALL OTHER THERAPEUTIC PRODUCTS;    V03AB Antidotes;     V03AB03 Edetates;      D00052  Edetic acid (NF/INN);Drug groups [BR:br08330(D00052)]; Vitamin and mineral;  DG01692  Chelator;   DG01152  Edetate;    D00052  Edetic acid,1.14.14.33,R11454 R11456
Acetate,cpd:C00544,"Homogentisate;Homogentisic acid;2,5-Dihydroxyphenylacetic acid;2,5-Dihydroxyphenylacetate",C8H8O4,Ubiquinone and other terpenoid-quinone biosynthesis;Tyrosine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,"Tyrosine degradation, tyrosine => homogentisate;Tocopherol/tocotorienol biosynthesis, homogentisate + phytyl/geranylgeranyl-PP => tocopherol/tocotorienol;Plastoquinone biosynthesis, homogentisate + solanesyl-PP => plastoquinol",NA,1.13.11.5;1.13.11.27;1.13.12.-;1.14.13.18;1.14.13.63;1.14.13.-;2.5.1.115;2.5.1.116;2.5.1.117;4.1.1.-,R02514 R02515 R02516 R02517 R02518 R02519 R02520 R02521;R05450 R07500 R08782 R10708
Acetate,cpd:C00548,"Phenyl acetate;Acetylphenol;Acetic acid,phenyl ester",C8H8O2,NA,NA,NA,3.1.1.2,R01241
Acetate,cpd:C00581,Guanidinoacetate;Guanidinoacetic acid;Glycocyamine;N-Amidinoglycine;Guanidoacetic acid,C3H7N3O2,"Glycine, serine and threonine metabolism;Arginine and proline metabolism;Metabolic pathways",Creatine pathway,NA,2.1.1.2;2.1.4.1;2.7.3.1;3.5.3.2,R00565 R00775 R01883 R02575
Acetate,cpd:C00642,4-Hydroxyphenylacetate;4-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C00642,1.2.1.5;1.2.1.29;1.2.1.39;1.2.1.53;1.2.3.13;1.14.13.18;1.14.14.9;4.1.1.83;6.2.1.-,R00042 R02514 R02516 R02695 R02697 R02698 R02699 R06790;R07312 R13086
Acetate,cpd:C00719,"Betaine;Trimethylaminoacetate;Glycine betaine;N,N,N-Trimethylglycine;Trimethylammonioacetate",C5H11NO2,"Glycine, serine and threonine metabolism;Metabolic pathways;ABC transporters","Betaine biosynthesis, choline => betaine;Betaine metabolism, animals, betaine => glycine;Betaine degradation, bacteria, betaine => pyruvate","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07523)]; A ALIMENTARY TRACT AND METABOLISM;  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS;    A16AA Amino acids and derivatives;     A16AA06 Betaine;      D07523  Betaine (JAN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D07523)]; Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment;  Betaine;   D07523  Betaine (JAN);Therapeutic category of drugs in Japan [BR:br08301(D07523)]; 3  Agents affecting metabolism;  39  Other agents affecting metabolism;   399  Miscellaneous;    3999  Others;     D07523  Betaine (JAN);Risk category of Japanese OTC drugs [BR:br08312(D07523)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Betaine;    D07523  Betaine (JAN);New drug approvals in Europe [br08329.html(D07523)]; European public assessment reports (EPAR) authorised medicine;  D07523;New drug approvals in Japan [br08318.html(D07523)]; Drugs with new active ingredients;  D07523;New drug approvals in the USA, Europe and Japan [br08328.html(D07523)]; Approval dates by FDA, EMA and PMDA;  D07523",1.1.3.17;1.2.1.8;1.13.11.90;1.14.13.251;1.21.4.4;2.1.1.5;2.1.1.157;2.1.1.161;2.1.1.162;2.1.1.376,R02565 R02566 R02821 R07228 R07244 R08211 R08212 R10061;R10062 R12614 R12787 R13016
Acetate,cpd:C00849,Ethyl acetate,C4H8O2,NA,NA,NA,2.3.1.268;3.1.1.113,R11957 R12515
Acetate,cpd:C00954,Indole-3-acetate;Indole-3-acetic acid;(Indol-3-yl)acetate;Indoleacetate;Indoleacetic acid;(1H-indol-3-yl)acetate;IAA,C10H9NO2,Tryptophan metabolism;Biosynthesis of plant hormones;Metabolic pathways;Plant hormone signal transduction,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from tryptophan and anthranilic acid;   Indole alkaloids;    C00954  Indole-3-acetate;Pesticides [BR:br08007]; Pesticides;  Plant growth regulators;   Auxins;    C00954  Indole-3-acetate,1.2.1.3;1.2.3.7;1.13.11.-;1.14.11.-;1.14.13.168;1.14.13.235;2.1.1.278;2.4.1.121;2.5.1.-;3.5.1.4;3.5.1.134;3.5.1.-;3.5.5.1;4.1.1.115;6.2.1.75;6.3.2.20,R02678 R02681 R03092 R03093 R03094 R03095 R03096 R03097;R08609 R10181 R10452 R11730 R12303 R12501 R12513 R12968
Acetate,cpd:C01036,"4-Maleylacetoacetate;4-Maleylacetoacetic acid;(2Z)-4,6-Dioxooct-2-enedioic acid",C8H8O6,Tyrosine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Tyrosine degradation, tyrosine => homogentisate","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C01036  (2Z)-4,6-Dioxooct-2-enedioic acid",1.13.11.5;5.2.1.2,R02519 R03181
Acetate,cpd:C01061,"4-Fumarylacetoacetate;4-Fumarylacetoacetic acid;Fumarylacetoacetate;(2E)-4,6-Dioxooct-2-enedioic acid",C8H8O6,Tyrosine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Tyrosine degradation, tyrosine => homogentisate","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C01061  (2E)-4,6-Dioxooct-2-enedioic acid",3.7.1.2;5.2.1.2,R01364 R03181
Acetate,cpd:C01161,"3,4-Dihydroxyphenylacetate;3,4-Dihydroxyphenylacetic acid;Homoprotocatechuate",C8H8O4,Tyrosine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Dopaminergic synapse;Cocaine addiction;Amphetamine addiction;Alcoholism,"Homoprotocatechuate degradation, homoprotocatechuate => 2-oxohept-3-enedioate",Dietary phytochemicals [br08012.html]; Flavonoids;  C01161,1.2.1.5;1.2.1.29;1.2.1.39;1.13.11.15;1.14.12.9;1.14.14.9;2.1.1.6,R02698 R03299 R03300 R03302 R03303 R03304 R03306 R13085
Acetate,cpd:C01278,"2-Carboxy-2,5-dihydro-5-oxofuran-2-acetate;5-Carboxy-2,5-dihydro-2-oxofuran-5-acetate;4-Carboxymuconolactone;gamma-Carboxymuconolactone",C7H6O6,Benzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,4.1.1.44;5.5.1.2,R03307 R03470
Acetate,cpd:C01757,"Triacetate;3,5-Dioxo-hexanoic acid",C6H8O4,NA,NA,NA,3.1.1.38,R03702
Acetate,cpd:C01812,Haloacetate,C2H3O2X,NA,NA,NA,3.8.1.3,R02336
Acetate,cpd:C01857,Thioacetate;Thioacetic acid,C2H4OS,NA,NA,NA,2.3.1.10,R01850
Acetate,cpd:C01963,Tolylacetate;p-Cresyl acetate;p-Tolyacetate,C9H10O2,NA,NA,NA,NA,NA
Acetate,cpd:C01983,(R)-Mandelate;(R)-2-Hydroxy-2-phenylacetic acid;(R)-2-Hydroxy-2-phenylacetate;(R)-Mandelic acid,C8H8O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CA Antiinfectives;     B05CA06 Mandelic acid;      C01983  (R)-Mandelate; J ANTIINFECTIVES FOR SYSTEMIC USE;  J01 ANTIBACTERIALS FOR SYSTEMIC USE;   J01X OTHER ANTIBACTERIALS;    J01XX Other antibacterials;     J01XX06 Mandelic acid;      C01983  (R)-Mandelate,1.1.1.379;3.5.1.86;5.1.2.2,R03790 R03791 R05783
Acetate,cpd:C01984,(S)-Mandelate;(S)-2-Hydroxy-2-phenylacetic acid;(S)-2-Hydroxy-2-phenylacetate;(S)-Mandelic acid,C8H8O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CA Antiinfectives;     B05CA06 Mandelic acid;      C01984  (S)-Mandelate; J ANTIINFECTIVES FOR SYSTEMIC USE;  J01 ANTIBACTERIALS FOR SYSTEMIC USE;   J01X OTHER ANTIBACTERIALS;    J01XX Other antibacterials;     J01XX06 Mandelic acid;      C01984  (S)-Mandelate,1.1.1.-;1.1.99.31;1.14.16.6;5.1.2.2,R03791 R03792 R03793 R03794 R07664
Acetate,cpd:C02137,alpha-Oxo-benzeneacetic acid;Benzoylformate;Benzoylformic acid;Phenylglyoxylic acid;Phenylglyoxylate;2-Oxo-2-phenylacetate,C8H6O3,Phenylalanine metabolism;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.1.1.379;1.1.1.-;1.1.99.31;1.2.1.58;3.1.2.25;4.1.1.7,R01764 R02450 R03790 R03792 R03793 R07294 R07664
Acetate,cpd:C02181,Phenoxyacetate;Phenoxyacetic acid,C8H8O3,NA,NA,NA,NA,NA
Acetate,cpd:C02222,2-Maleylacetate;4-Oxohex-2-enedioate;Maleylacetate,C6H6O5,Chlorocyclohexane and chlorobenzene degradation;Benzoate degradation;Fluorobenzoate degradation;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.2.1.61;1.3.1.32;1.13.11.37;3.1.1.45;3.1.1.92,R02988 R02989 R03891 R03892 R03893 R05236 R05355 R05420;R06838 R07781 R08120 R08121
Acetate,cpd:C02362,2-Oxosuccinamate;2-Oxosuccinamic acid;gamma-Aminooxaloacetate;Oxaloacetamide,C4H5NO4,"Alanine, aspartate and glutamate metabolism;Metabolic pathways",NA,NA,2.6.1.14;3.5.1.3,R00348 R01346
Acetate,cpd:C02595,Thien-2-ylacetate;2-Thiopheneacetic acid;2-Thienylacetic acid,C6H6O2S,NA,NA,NA,NA,NA
Acetate,cpd:C02752,Triacetate lactone;4-Hydroxy-6-methyl-2-pyrone,C6H6O3,NA,NA,NA,3.1.1.38,R03702 R06510
Acetate,cpd:C02821,Cortisol 21-acetate;Hydrocortisone acetate;Cortell,C23H32O6,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C02821  Cortisol 21-acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00165)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC03 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA02 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA01 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AA Corticosteroids, weak (group I);     D07AA02 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XA Corticosteroids, weak, other combinations;     D07XA01 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB09 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA02 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB03 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA01 Hydrocortisone;      D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;USP drug classification [BR:br08302(D00165)]; Dermatological Agents;  Dermatitis and Pruitus Agents;   Glucocorticoids, Low Potency;    Hydrocortisone;     D00165  Hydrocortisone acetate (JP18/USP); Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Hydrocortisone;   D00165  Hydrocortisone acetate (JP18/USP); Inflammatory Bowel Disease Agents;  Glucocorticoids;   Hydrocortisone;    D00165  Hydrocortisone acetate (JP18/USP);Classification of Japanese OTC drugs [BR:br08313(D00165)]; Agents for  urogenital organs and anus;  30 Hemorrhoid drugs for external use;   D00165  Hydrocortisone acetate (JP18/USP); Agents for integumentary system;  57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches);   D00165  Hydrocortisone acetate (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00165)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Hydrocortisone acetate;    D00165  Hydrocortisone acetate (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Hydrocortisone acetate;    D00165  Hydrocortisone acetate (JP18/USP);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  953  Analgesics, anti-itchings, astringents and antiinflammatory agents;   9539  Other analgesics, anti-itchings, astringents and inflammatory agents;    C02821  Hydrocortisone acetate;Drug groups [BR:br08330(D00165)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00012  Hydrocortisone;     D00165  Hydrocortisone acetate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG00012  Hydrocortisone;    D00165  Hydrocortisone acetate;Drug classes [BR:br08332(D00165)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00165  Hydrocortisone acetate;Target-based classification of drugs [BR:br08310(D00165)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00165  Hydrocortisone acetate (JP18/USP) &lt;US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00165)]; Chemicals;  D00165  Hydrocortisone acetate;Drug metabolizing enzymes and transporters [br08309.html(D00165)]; Drug metabolizing enzymes;  D00165;Rx-to-OTC switch list in the USA [br08315.html(D00165)]; D00165",2.3.1.27,R02837
Acetate,cpd:C02835,Imidazole-4-acetate;Imidazoleacetic acid;4-Imidazoleacetate,C5H6N2O2,Histidine metabolism;Metabolic pathways,NA,NA,1.2.1.3;1.14.13.5;6.3.4.8,R04065 R04066 R04068
Acetate,cpd:C02975,Ethyl 3-oxohexanoate;Ethyl butyrylacetate,C8H14O3,NA,NA,NA,1.1.1.279;1.1.1.280,R04105 R04106
Acetate,cpd:C03027,Testosterone acetate,C21H30O3,NA,NA,Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0202 C19 steroids (androgens) and derivatives;    C03027  Testosterone acetate,1.14.13.54;1.14.99.4,R02210 R02212
Acetate,cpd:C03076,4-Bromophenylacetate;4-Bromophenylacetic acid,C8H7BrO2,NA,NA,NA,NA,NA
Acetate,cpd:C03077,4-Chlorophenylacetate;4-Chlorophenylacetic acid,C8H7ClO2,Tyrosine metabolism;Dioxin degradation;Microbial metabolism in diverse environments,NA,NA,1.14.12.9;3.5.5.5,R03306 R04140 R05473 R05474
Acetate,cpd:C03166,Phosphoguanidinoacetate;Guanidinoacetate phosphate,C3H8N3O5P,Arginine and proline metabolism;Metabolic pathways,NA,NA,2.7.3.1,R02575
Acetate,cpd:C03173,S-Methylthioglycolate;(Methylsulfanyl)acetic acid;(Methylthio)acetic acid;(Methylsulfanyl)acetate,C3H6O2S,NA,NA,NA,2.1.1.3,R04153
Acetate,cpd:C03198,(S)-4-Hydroxymandelate;(S)-2-Hydroxy-2-(4-hydroxyphenyl)acetate;L-4-Hydroxymandelate;L-p-Hydroxymandelate,C8H8O4,Monobactam biosynthesis;Aminobenzoate degradation;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,NA,NA,1.1.3.19;1.1.3.46;1.1.99.31;1.13.11.46;1.14.16.6;5.1.2.2,R02673 R03794 R04160 R04161 R06632 R06633
Acetate,cpd:C03214,2-Amino-3-oxobutanoate;2-Amino-acetoacetate,C4H7NO3,NA,NA,NA,NA,NA
Acetate,cpd:C03235,4-Hydroxypheoxyacetate,C8H8O4,NA,NA,NA,NA,NA
Acetate,cpd:C03392,Dimethylsulfonioacetate,C4H9O2S,NA,NA,NA,2.1.1.3,R04153
Acetate,cpd:C03500,Ethyl 3-oxobutanoate;Ethyl acetoacetate,C6H10O3,NA,NA,NA,NA,NA
Acetate,cpd:C03508,L-2-Amino-3-oxobutanoic acid;L-2-Amino-3-oxobutanoate;L-2-Amino-acetoacetate;(S)-2-Amino-3-oxobutanoic acid,C4H7NO3,"Glycine, serine and threonine metabolism;Metabolic pathways",NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C03508  L-2-Amino-3-oxobutanoic acid,1.1.1.103;1.1.1.381;2.3.1.29,R00371 R01465 R03758 R10851
Acetate,cpd:C03586,"2-Oxo-2,3-dihydrofuran-5-acetate;3-Oxoadipate enol-lactone;4,5-Dihydro-5-oxofuran-2-acetate;5-Oxo-4,5-dihydrofuran-2-acetate",C6H6O4,Benzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Catechol ortho-cleavage, catechol => 3-oxoadipate",NA,3.1.1.24;4.1.1.44;5.3.3.4,R02991 R03470 R04260 R06990
Acetate,cpd:C03590,4-Hydroxyphenylglyoxylate;4-Hydroxybenzoylformate;4-Hydroxyphenylglyoxylic acid;2-(4-Hydroxyphenyl)-2-oxoacetate,C8H6O4,Monobactam biosynthesis;Aminobenzoate degradation;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,NA,NA,1.1.3.46;1.1.99.31;2.6.1.72;2.6.1.103;4.1.1.7,R02672 R04160 R04234 R06626 R06633
Acetate,cpd:C03601,Chloramphenicol 3-acetate,C13H14Cl2N2O6,NA,NA,NA,2.3.1.28,R03065
Acetate,cpd:C03664,"2,4-Dichlorophenoxyacetate;2,4-Dichlorophenoxyacetic acid;2,4-D",C8H6Cl2O3,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,"Endocrine disrupting compounds [BR:br08006]; Pesticides and herbicides;  Phenoxy herbicides;   C03664  2,4-Dichlorophenoxyacetate;Pesticides [BR:br08007]; Pesticides;  Herbicides;   Phenoxy herbicides;    C03664  2,4-Dichlorophenoxyacetate",1.14.11.-;1.97.1.-,R05419 R05505
Acetate,cpd:C03707,Monoterpenol acetate ester,C2H3O2R,NA,NA,NA,2.3.1.69,R03017
Acetate,cpd:C03716,Oxaloacetate 4-methyl ester,C5H6O5,NA,NA,NA,3.1.1.44,R01144
Acetate,cpd:C03768,4-Substituted phenylacetate,C8H7O2R,NA,NA,NA,NA,NA
Acetate,cpd:C03837,4-Methylumbelliferyl acetate,C12H10O4,NA,NA,NA,3.1.1.56,R04141
Acetate,cpd:C03981,2-Hydroxyethylenedicarboxylate;enol-Oxaloacetate;enol-Oxaloacetic acid;2-Hydroxybut-2-enedioic acid,C4H4O5,Pyruvate metabolism,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C03981  2-Hydroxybut-2-enedioic acid,4.1.1.78;4.1.1.-;5.3.2.2,R00219 R00363 R04177
Acetate,cpd:C04105,"2,5-Dihydro-5-oxofuran-2-acetate;2-Oxo-2,5-dihydrofuran-5-acetate;Muconolactone;5-Oxo-2,5-dihydrofuran-2-acetate;4-Carboxymethyl-4-hydroxyisocrotonolactone",C6H6O4,NA,NA,NA,5.3.3.4;5.5.1.1,R03959 R04260
Acetate,cpd:C04437,1-(5-Phosphoribosyl)imidazole-4-acetate,C10H15N2O9P,Histidine metabolism,NA,Glycosides [BR:br08021]; N-glycosides;  C04437  1-(5-Phosphoribosyl)imidazole-4-acetate,6.3.4.8,R04068 R04479
Acetate,cpd:C04522,"2-Chloro-2,5-dihydro-5-oxofuran-2-acetate;5-Chloro-2,5-dihydro-2-oxofuran-5-acetate;2-Chloro-5-oxo-2,5-dihydrofuran-2-acetate;(2R)-2-Chloro-2,5-dihydro-5-oxofuran-2-acetate;(+)-4-Chloromuconolactone",C6H5ClO4,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments,NA,NA,5.5.1.7,R04259 R04500
Acetate,cpd:C04553,"3-Carboxy-2,5-dihydro-5-oxofuran-2-acetate;4-Carboxy-2,5-dihydro-2-oxofuran-5-acetate",C7H6O6,Benzoate degradation;Microbial metabolism in diverse environments,NA,NA,5.5.1.5,R03308
Acetate,cpd:C04625,"2,4-Dichloro-2,5-dihydro-5-oxofuran-2-acetate;3,5-Dichloro-2,5-dihydro-2-oxofuran-5-acetate",C6H4Cl2O4,NA,NA,NA,5.5.1.11,R04345 R10097
Acetate,cpd:C05131,(1-Ribosylimidazole)-4-acetate,C10H14N2O6,Histidine metabolism,NA,NA,NA,R04479
Acetate,cpd:C05133,4-Imidazolone-5-acetate;Imidazolone acetate;(5-Hydroxyimidazole)-4-acetate;5-Hydroxy-4-imidazoleacetate,C5H6N2O3,Histidine metabolism;Metabolic pathways,NA,NA,1.14.13.5;3.5.2.-,R04066 R04214
Acetate,cpd:C05151,12-O-Tetradecanoylphorbol 13-acetate;TPA;Phorbol 12-myristate 13-acetate;12-Tetradecanoylphorbol 13-acetate;PMA,C36H56O8,Neutrophil extracellular trap formation,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010433 Tigliane and ingenane diterpenoids;     C05151  12-O-Tetradecanoylphorbol 13-acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Tiglianes;    C05151  12-O-Tetradecanoylphorbol 13-acetate,NA,NA
Acetate,cpd:C05322,7-O-Acetylsalutaridinol;Salutaridinol acetate;Salutaridinol 7-O-acetate,C21H25NO5,Isoquinoline alkaloid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Morphine biosynthesis, (S)-reticuline => morphine",Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from tyrosine;   Isoquinoline alkaloids;    C05322  7-O-Acetylsalutaridinol,2.3.1.150;4.2.99.24,R04723 R04769
Acetate,cpd:C05582,Homovanillate;Homovanillic acid;3-Methoxy-4-hydroxyphenylacetate,C9H10O4,Tyrosine metabolism;Metabolic pathways;Dopaminergic synapse,NA,NA,1.2.1.5;2.1.1.6,R03304 R04888 R04889
Acetate,cpd:C05593,3-Hydroxyphenylacetate;3-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.13.63;1.14.14.9,R02515 R02517 R03299 R06791
Acetate,cpd:C05635,5-Hydroxyindoleacetate,C10H9NO3,Tryptophan metabolism;Metabolic pathways;Serotonergic synapse,NA,NA,1.2.1.3;1.2.3.1;2.1.1.4;6.3.2.-,R04903 R04904 R04905 R04906
Acetate,cpd:C05660,5-Methoxyindoleacetate;5-Methoxyindoleacetic acid,C11H11NO3,Tryptophan metabolism,NA,NA,2.1.1.4,R04905
Acetate,cpd:C05682,Phosphonoacetate;Phosphonoacetic acid;Fosfonet,C2H5O5P,Phosphonate and phosphinate metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; J ANTIINFECTIVES FOR SYSTEMIC USE;  J05 ANTIVIRALS FOR SYSTEMIC USE;   J05A DIRECT ACTING ANTIVIRALS;    J05AD Phosphonic acid derivatives;     J05AD02 Fosfonet;      C05682  Phosphonoacetate,1.2.1.-;3.11.1.2,R00318 R04251
Acetate,cpd:C05828,Methylimidazoleacetic acid;Tele-methylimidazoleacetic acid;1-Methyl-4-imidazoleacetic acid;1-Methylimidazole-4-acetate;Methylimidazoleacetate,C6H8N2O2,Histidine metabolism;Metabolic pathways,NA,NA,1.2.1.5,R04996
Acetate,cpd:C05835,2-Formaminobenzoylacetate,C10H9NO4,Tryptophan metabolism,NA,NA,1.13.11.-,R00991 R03097
Acetate,cpd:C05852,2-Hydroxyphenylacetate;2-Hydroxyphenylacetic acid,C8H8O3,Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.13.11.27;1.14.13.-;1.14.14.54,R01372 R05001 R05450 R05487
Acetate,cpd:C06030,Methyloxaloacetate,C5H6O5,C5-Branched dibasic acid metabolism,NA,NA,4.1.1.112,R00995 R04269
Acetate,cpd:C06108,Fluoroacetate;Fluoroacetic acid;Cymonic acid;Gifblaar poison;HFA;UN 2642,C2H3FO2,Drug metabolism - other enzymes,NA,NA,1.2.1.69;3.1.2.29;3.8.1.3,R02857 R07156 R09643
Acetate,cpd:C06207,"2,6-Dihydroxyphenylacetate",C8H8O4,Phenylalanine metabolism,NA,NA,NA,R05001
Acetate,cpd:C06329,2-Chloromaleylacetate,C6H5ClO5,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.32;1.13.11.-;3.1.1.45,R05153 R05355 R05408 R05511
Acetate,cpd:C06550,Arsonoacetate,C2H5AsO5,NA,NA,NA,NA,NA
Acetate,cpd:C06640,Bis(4'-chlorophenyl)acetate;DDA,C14H10Cl2O2,NA,NA,NA,4.1.1.-,R05251 R05376 R05479 R05481
Acetate,cpd:C07086,Phenylacetic acid;Benzylformic acid;Phenylacetate;Benzeneacetic acid,C8H8O2,Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Phenylacetate degradation, phenylaxetate => acetyl-CoA/succinyl-CoA",Prodrugs [br08324.html]; C07086;Narcotics and psychotropics in Japan [br08308.html]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  C07086,1.2.1.5;1.2.1.39;1.14.14.54;3.1.2.-;3.5.1.4;3.5.1.11;3.5.5.1;4.1.1.119;6.2.1.30,R02536 R02537 R02539 R02540 R04103 R05487 R06790 R06791;R07855 R09840 R12504
Acetate,cpd:C07088,4-Chlorophenoxyacetate;4-CPA,C8H7ClO3,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Pesticides [BR:br08007]; Pesticides;  Plant growth regulators;   Auxins;    C07088  4-Chlorophenoxyacetate,1.14.11.-;1.97.1.-,R05493 R05505
Acetate,cpd:C07114,3-Oxo-3-phenylpropanoate;Benzoylacetate;3-Oxo-3-phenylpropionate;3-Oxo-3-phenylpropionic acid,C9H8O3,Ethylbenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,6.2.1.-;6.4.1.8,R05452 R05453
Acetate,cpd:C07159,"2-Oxo-Delta3-4,5,5-trimethylcyclopentenylacetate;2-Oxo-Delta3-4,5,5-trimethylcyclopentenylacetic acid",C10H14O3,NA,NA,NA,NA,NA
Acetate,cpd:C08012,Levomethadyl acetate;LAAM,C23H31NO2,Drug metabolism - cytochrome P450,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D04716)]; N NERVOUS SYSTEM;  N07 OTHER NERVOUS SYSTEM DRUGS;   N07B DRUGS USED IN ADDICTIVE DISORDERS;    N07BC Drugs used in opioid dependence;     N07BC03 Levacetylmethadol;      D04716  Levomethadyl acetate (USAN);Drug groups [BR:br08330(D04716)]; Neuropsychiatric agent;  DG01564  Opioid receptor agonist;   DG01563  mu-Opioid receptor agonist;    DG01000  Levacetylmethadol;     D04716  Levomethadyl acetate; Analgesic;  DG01984  Opioid analgesics;   DG01000  Levacetylmethadol;    D04716  Levomethadyl acetate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG01000  Levacetylmethadol;     D04716  Levomethadyl acetate;Target-based classification of drugs [BR:br08310(D04716)]; G Protein-coupled receptors;  Rhodopsin family;   Opioid;    OPRM1;     D04716  Levomethadyl acetate (USAN);Drug metabolizing enzymes and transporters [br08309.html(D04716)]; Drug metabolizing enzymes;  D04716,1.14.14.-,R08341
Acetate,cpd:C08150,Medroxyprogesterone acetate;6-alpha-Methyl-17-alpha-acetoxyprogesterone;6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate,C24H34O4,Chemical carcinogenesis - receptor activation,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00951)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;    G03AC Progestogens;     G03AC06 Medroxyprogesterone;      D00951  Medroxyprogesterone acetate (JP18/USP) &lt;JP/US&gt;;   G03D PROGESTOGENS;    G03DA Pregnen (4) derivatives;     G03DA02 Medroxyprogesterone;      D00951  Medroxyprogesterone acetate (JP18/USP) &lt;JP/US&gt;; L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L02 ENDOCRINE THERAPY;   L02A HORMONES AND RELATED AGENTS;    L02AB Progestogens;     L02AB02 Medroxyprogesterone;      D00951  Medroxyprogesterone acetate (JP18/USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00951)]; Contraceptives;  Contraceptives, Other;   Medroxyprogesterone;    D00951  Medroxyprogesterone acetate (JP18/USP); Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers);  Progestins;   Medroxyprogesterone;    D00951  Medroxyprogesterone acetate (JP18/USP);Therapeutic category of drugs in Japan [BR:br08301(D00951)]; 2  Agents affecting individual organs;  24  Hormones;   247  Estrogen and progesterone preparations;    2478  Synthetic progestins;     D00951  Medroxyprogesterone acetate (JP18/USP);Drug groups [BR:br08330(D00951)]; Hormonal agent;  DG02004  Progesterone;   DG00458  Medroxyprogesterone;    D00951  Medroxyprogesterone acetate;  DG01666  Progesterone receptor agonist;   DG00458  Medroxyprogesterone;    D00951  Medroxyprogesterone acetate;Drug classes [BR:br08332(D00951)]; Endocrine and hormonal agent;  DG02004  Progesterone;   D00951  Medroxyprogesterone acetate;Target-based classification of drugs [BR:br08310(D00951)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C3 (PGR);     D00951  Medroxyprogesterone acetate (JP18/USP) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00951)]; Chemicals;  D00951  Medroxyprogesterone acetate",NA,NA
Acetate,cpd:C08151,Megestrol acetate,C24H32O4,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C08151  Megestrol acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00952)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;    G03AC Progestogens;     G03AC05 Megestrol;      D00952  Megestrol acetate (USP) &lt;US&gt;;   G03D PROGESTOGENS;    G03DB Pregnadien derivatives;     G03DB02 Megestrol;      D00952  Megestrol acetate (USP) &lt;US&gt;; L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L02 ENDOCRINE THERAPY;   L02A HORMONES AND RELATED AGENTS;    L02AB Progestogens;     L02AB01 Megestrol;      D00952  Megestrol acetate (USP) &lt;US&gt;;USP drug classification [BR:br08302(D00952)]; Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers);  Progestins;   Megestrol;    D00952  Megestrol acetate (USP);Drug groups [BR:br08330(D00952)]; Hormonal agent;  DG02004  Progesterone;   DG00457  Megestrol;    D00952  Megestrol acetate;  DG01666  Progesterone receptor agonist;   DG00457  Megestrol;    D00952  Megestrol acetate;Drug classes [BR:br08332(D00952)]; Endocrine and hormonal agent;  DG02004  Progesterone;   D00952  Megestrol acetate;Target-based classification of drugs [BR:br08310(D00952)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C3 (PGR);     D00952  Megestrol acetate (USP) &lt;US&gt;",NA,NA
Acetate,cpd:C08152,Norethindrone acetate;Norethisterone acetate,C22H28O3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00953)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;    G03AC Progestogens;     G03AC01 Norethisterone;      D00953  Norethindrone acetate (USP) &lt;US&gt;;   G03D PROGESTOGENS;    G03DC Estren derivatives;     G03DC02 Norethisterone;      D00953  Norethindrone acetate (USP) &lt;US&gt;;USP drug classification [BR:br08302(D00953)]; Contraceptives;  Oral Progestins;   Norethindrone;    D00953  Norethindrone acetate (USP); Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers);  Progestins;   Norethindrone;    D00953  Norethindrone acetate (USP);Drug groups [BR:br08330(D00953)]; Hormonal agent;  DG02004  Progesterone;   DG00456  Norethisterone;    D00953  Norethindrone acetate;  DG01666  Progesterone receptor agonist;   DG00456  Norethisterone;    D00953  Norethindrone acetate;Drug classes [BR:br08332(D00953)]; Endocrine and hormonal agent;  DG02004  Progesterone;   D00953  Norethindrone acetate;Target-based classification of drugs [BR:br08310(D00953)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C3 (PGR);     D00953  Norethindrone acetate (USP) &lt;US&gt;",NA,NA
Acetate,cpd:C08173,Cortisone acetate;Cortisyl,C23H30O6,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C08173  Cortisone acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00973)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB10 Cortisone;      D00973  Cortisone acetate (JP18/USP) &lt;JP/US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA03 Cortisone;      D00973  Cortisone acetate (JP18/USP) &lt;JP/US&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00973)]; 2  Agents affecting individual organs;  24  Hormones;   245  Adrenal hormone preparations;    2452  Cortisones;     D00973  Cortisone acetate (JP18/USP);Classification of Japanese OTC drugs [BR:br08313(D00973)]; Agents for integumentary system;  57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches);   D00973  Cortisone acetate (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00973)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Cortisone acetate;    D00973  Cortisone acetate (JP18/USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Cortisone acetate;    D00973  Cortisone acetate (JP18/USP);Drug groups [BR:br08330(D00973)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00509  Cortisone;     D00973  Cortisone acetate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D00973  Cortisone acetate;Drug classes [BR:br08332(D00973)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00973  Cortisone acetate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D00973  Cortisone acetate;Target-based classification of drugs [BR:br08310(D00973)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00973  Cortisone acetate (JP18/USP) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00973)]; Chemicals;  D00973  Cortisone acetate",NA,NA
Acetate,cpd:C08174,Dexamethasone acetate anhydrous,C24H31FO6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07796)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC02 Dexamethasone;      D07796  Dexamethasone 21-acetate; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA09 Dexamethasone;      D07796  Dexamethasone 21-acetate; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AB Corticosteroids, moderately potent (group II);     D07AB19 Dexamethasone;      D07796  Dexamethasone 21-acetate;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XB Corticosteroids, moderately potent, other combinations;     D07XB05 Dexamethasone;      D07796  Dexamethasone 21-acetate;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AA Corticosteroids, combinations for treatment of acne;     D10AA03 Dexamethasone;      D07796  Dexamethasone 21-acetate; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB02 Dexamethasone;      D07796  Dexamethasone 21-acetate; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AD Corticosteroids;     R01AD03 Dexamethasone;      D07796  Dexamethasone 21-acetate; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA01 Dexamethasone;      D07796  Dexamethasone 21-acetate;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB01 Dexamethasone;      D07796  Dexamethasone 21-acetate;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA06 Dexamethasone;      D07796  Dexamethasone 21-acetate;  S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;   S03B CORTICOSTEROIDS;    S03BA Corticosteroids;     S03BA01 Dexamethasone;      D07796  Dexamethasone 21-acetate;Drug groups [BR:br08330(D07796)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00011  Dexamethasone;     D07796  Dexamethasone 21-acetate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00011  Dexamethasone;     D07796  Dexamethasone 21-acetate; Metabolizing enzyme inducer;  DG02853  CYP3A/CYP3A4 inducer;   DG01635  CYP3A4 inducer;    DG00011  Dexamethasone;     D07796  Dexamethasone 21-acetate;Target-based classification of drugs [BR:br08310(D07796)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D07796  Dexamethasone 21-acetate;Drug metabolizing enzymes and transporters [br08309.html(D07796)]; Drug metabolizing enzymes;  D07796",NA,NA
Acetate,cpd:C08179,"Methylprednisolone acetate;6alpha-Methylprednisolone 21-acetate;11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate;M-Predrol",C24H32O6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00979)]; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AA Corticosteroids, weak (group I);     D07AA01 Methylprednisolone;      D00979  Methylprednisolone acetate (JAN/USP) &lt;JP/US&gt;;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AA Corticosteroids, combinations for treatment of acne;     D10AA02 Methylprednisolone;      D00979  Methylprednisolone acetate (JAN/USP) &lt;JP/US&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB04 Methylprednisolone;      D00979  Methylprednisolone acetate (JAN/USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00979)]; Dermatological Agents;  Dermatitis and Pruitus Agents;   Glucocorticoids, High Potency;    Methylprednisolone;     D00979  Methylprednisolone acetate (JAN/USP); Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Methylprednisolone;   D00979  Methylprednisolone acetate (JAN/USP); Inflammatory Bowel Disease Agents;  Glucocorticoids;   Methylprednisolone;    D00979  Methylprednisolone acetate (JAN/USP);Therapeutic category of drugs in Japan [BR:br08301(D00979)]; 2  Agents affecting individual organs;  24  Hormones;   245  Adrenal hormone preparations;    2456  Prednisolones;     D00979  Methylprednisolone acetate (JAN/USP);Drug groups [BR:br08330(D00979)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00410  Methylprednisolone;     D00979  Methylprednisolone acetate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D00979  Methylprednisolone acetate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00410  Methylprednisolone;     D00979  Methylprednisolone acetate;Drug classes [BR:br08332(D00979)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00979  Methylprednisolone acetate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D00979  Methylprednisolone acetate;Target-based classification of drugs [BR:br08310(D00979)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00979  Methylprednisolone acetate (JAN/USP) &lt;JP/US&gt;;Drug metabolizing enzymes and transporters [br08309.html(D00979)]; Drug metabolizing enzymes;  D00979",NA,NA
Acetate,cpd:C08180,Prednisolone acetate;Prednisolone 21-acetate;Pricortin,C23H30O6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00980)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC04 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA01 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA04 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AA Corticosteroids, weak (group I);     D07AA03 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XA Corticosteroids, weak, other combinations;     D07XA02 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB06 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AD Corticosteroids;     R01AD02 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA04 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB02 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA03 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;  S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;   S03B CORTICOSTEROIDS;    S03BA Corticosteroids;     S03BA02 Prednisolone;      D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00980)]; Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Prednisolone;   D00980  Prednisolone acetate (JP18/USP/INN); Ophthalmic Agents;  Ophthalmic Anti-inflammatories;   Glucocorticoids, Ophthalmic;    Prednisolone;     D00980  Prednisolone acetate (JP18/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D00980)]; 1  Agents affecting nervous system and sensory organs;  13  Agents affecting sensory organs;   131  Ophthalmic agents;    1315  Ophthalmic cortisones;     D00980  Prednisolone acetate (JP18/USP/INN);Classification of Japanese OTC drugs [BR:br08313(D00980)]; Agents for  urogenital organs and anus;  30 Hemorrhoid drugs for external use;   D00980  Prednisolone acetate (JP18/USP/INN); Agents for integumentary system;  57 Analgesic, antipruritic, astringent, and anti-inflammatory remedies (incl. gel patches);   D00980  Prednisolone acetate (JP18/USP/INN);Risk category of Japanese OTC drugs [BR:br08312(D00980)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Prednisolone acetate;    D00980  Prednisolone acetate (JP18/USP/INN); Second-class OTC drugs;  Inorganic and organic chemicals;   Prednisolone acetate;    D00980  Prednisolone acetate (JP18/USP/INN);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  953  Analgesics, anti-itchings, astringents and antiinflammatory agents;   9537  Hormone preparations for external use;    C08180  Prednisolone acetate;Drug groups [BR:br08330(D00980)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00093  Prednisolone;     D00980  Prednisolone acetate;Drug classes [BR:br08332(D00980)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00980  Prednisolone acetate;Target-based classification of drugs [BR:br08310(D00980)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00980  Prednisolone acetate (JP18/USP/INN) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00980)]; Chemicals;  D00980  Prednisolone acetate",NA,NA
Acetate,cpd:C08184,Triamcinolone diacetate,C25H31FO8,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00984)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC01 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP); C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA12 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP); D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AB Corticosteroids, moderately potent (group II);     D07AB09 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP);   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XB Corticosteroids, moderately potent, other combinations;     D07XB02 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP); H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB08 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP); R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AD Corticosteroids;     R01AD11 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP);  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;   R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;    R03BA Glucocorticoids;     R03BA06 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA05 Triamcinolone;      D00984  Triamcinolone diacetate (JAN/USP);Drug groups [BR:br08330(D00984)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00010  Triamcinolone;     D00984  Triamcinolone diacetate;Target-based classification of drugs [BR:br08310(D00984)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00984  Triamcinolone diacetate (JAN/USP)",NA,NA
Acetate,cpd:C08186,Fludrocortisone acetate,C23H31FO6,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C08186  Fludrocortisone acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00986)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AA Mineralocorticoids;     H02AA02 Fludrocortisone;      D00986  Fludrocortisone acetate (JP18/USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00986)]; Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Fludrocortisone;   D00986  Fludrocortisone acetate (JP18/USP);Therapeutic category of drugs in Japan [BR:br08301(D00986)]; 2  Agents affecting individual organs;  24  Hormones;   245  Adrenal hormone preparations;    2459  Others;     D00986  Fludrocortisone acetate (JP18/USP);Drug groups [BR:br08330(D00986)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG00506  Fludrocortisone;    D00986  Fludrocortisone acetate;Drug classes [BR:br08332(D00986)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00986  Fludrocortisone acetate;Target-based classification of drugs [BR:br08310(D00986)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C2 (MR);     D00986  Fludrocortisone acetate (JP18/USP) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00986)]; Chemicals;  D00986  Fludrocortisone acetate",NA,NA
Acetate,cpd:C08627,Hopane-29-acetate,C32H54O2,Biosynthesis of various alkaloids;Biosynthesis of terpenoids and steroids;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR04 Hopanoids;   C08627  Hopane-29-acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Triterpenoids (C30);   Hopanes;    C08627  Hopane-29-acetate,NA,R08535
Acetate,cpd:C08630,Lupeol acetate;3-Acetyllupeol,C32H52O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0106 C30 isoprenoids (triterpenes);    PR010614 Lupane triterpenoids;     C08630  Lupeol acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Triterpenoids (C30);   Lupanes;    C08630  Lupeol acetate,NA,NA
Acetate,cpd:C08654,Acetylbrowniine;Browniine 14-acetate,C27H43NO8,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08654  Acetylbrowniine,NA,NA
Acetate,cpd:C08655,"Aconifine;Aconitane-3,8,10,13,14,15-hexol, 20-ethyl-4-(methoxymethyl)-1,6,16-trimethoxy-, 8-acetate 14-benzoate, (1-alpha,3-alpha,6-alpha,14-alpha,15-alpha,16-beta)-",C34H47NO12,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08655  Aconifine,NA,NA
Acetate,cpd:C08679,"Deltaline;Aconitane-6,10-diol, 20-ethyl-4-methyl-7,8-(methylenebis(oxy))-, 1,14,16-trimethoxy-, 6-acetate, (1-alpha,6-beta,14-alpha,16-beta)-",C27H41NO8,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08679  Deltaline,NA,NA
Acetate,cpd:C08867,Hellebrigenin 3-acetate,C26H34O7,NA,NA,Lipids [BR:br08002]; ST  Sterol lipids;  ST01 Sterols;   ST0113 Bufanolides and derivatives;    C08867  Hellebrigenin 3-acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Steroids;   Bufanolide;    C08867  Hellebrigenin 3-acetate,NA,NA
Acetate,cpd:C09059,Alectrol;Orobanchyl acetate,C21H24O7,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Others;    C09059  Alectrol,NA,NA
Acetate,cpd:C09086,Diterpenoid EF-D;12-Deoxy-phorbol-13-alpha-methylbutyrate-20-acetate,C27H38O7,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010433 Tigliane and ingenane diterpenoids;     C09086  Diterpenoid EF-D;Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Tiglianes;    C09086  Diterpenoid EF-D,NA,NA
Acetate,cpd:C09143,"Pedilstatin;12-O-2Z,4E-Octadienoyl-4-deoxyphorbol 13-acetate",C30H40O7,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010433 Tigliane and ingenane diterpenoids;     C09143  Pedilstatin;Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Tiglianes;    C09143  Pedilstatin,NA,NA
Acetate,cpd:C09153,12-O-Palmitoyl-16-hydroxyphorbol 13-acetate;Croton factor F1,C38H60O9,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Tiglianes;    C09153  12-O-Palmitoyl-16-hydroxyphorbol 13-acetate,NA,NA
Acetate,cpd:C09293,Angustibalin;Helenalin 6-acetate,C17H20O5,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Pseudoguaianolide;    C09293  Angustibalin,NA,NA
Acetate,cpd:C09356,Chamissonin diacetate,C19H24O6,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Germacrenes;    C09356  Chamissonin diacetate,NA,NA
Acetate,cpd:C09412,Erioflorin acetate,C21H26O7,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Germacrenes;    C09412  Erioflorin acetate,NA,NA
Acetate,cpd:C09417,Eupachlorin acetate,C22H27ClO8,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Guaianolide;    C09417  Eupachlorin acetate,NA,NA
Acetate,cpd:C09435,Euparotin acetate,C22H26O8,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Guaianolide;    C09435  Euparotin acetate,NA,NA
Acetate,cpd:C09725,Shiromodiol diacetate,C19H30O5,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Sesquiterpenoids (C15);   Others;    C09725  Shiromodiol diacetate,NA,NA
Acetate,cpd:C09764,6-Methoxyaromadendrin 3-O-acetate,C18H16O8,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK12 Flavonoids;   PK1214 Flavanones;    C09764  6-Methoxyaromadendrin 3-O-acetate;Phytochemical compounds [BR:br08003]; Flavonoids;  Flavonoids;   Dihyroflavonols;    C09764  6-Methoxyaromadendrin 3-O-acetate,NA,NA
Acetate,cpd:C09837,"(1S,2R,4S)-(-)-Bornyl acetate",C12H20O2,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010212 Bicyclic monoterpenoids;     C09837  (1S,2R,4S)-(-)-Bornyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C09837  (1S,2R,4S)-(-)-Bornyl acetate",NA,NA
Acetate,cpd:C09861,Geranyl acetate,C12H20O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C09861  Geranyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Linear monoterpenes;    C09861  Geranyl acetate,NA,NA
Acetate,cpd:C09863,Linalyl acetate,C12H20O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010201 Acyclic monoterpenoids;     C09863  Linalyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Linear monoterpenes;    C09863  Linalyl acetate,NA,NA
Acetate,cpd:C09870,(-)-Menthyl acetate;l-Menthyl acetate;Menthyl acetate,C12H22O2,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C09870  (-)-Menthyl acetate,2.3.1.69,R08530
Acetate,cpd:C09909,Thymyl acetate,C12H16O2,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C09909  Thymyl acetate,NA,NA
Acetate,cpd:C09967,Taxifolin 3-O-acetate,C17H14O8,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK12 Flavonoids;   PK1214 Flavanones;    C09967  Taxifolin 3-O-acetate;Phytochemical compounds [BR:br08003]; Flavonoids;  Flavonoids;   Dihyroflavonols;    C09967  Taxifolin 3-O-acetate,NA,NA
Acetate,cpd:C10426,1'-Acetoxychavicol acetate,C13H14O4,NA,NA,Phytochemical compounds [BR:br08003]; Phenylpropanoids;  Monolignols;   Others;    C10426  1'-Acetoxychavicol acetate,NA,NA
Acetate,cpd:C10427,1'-Acetoxyeugenol acetate,C14H16O5,NA,NA,NA,NA,NA
Acetate,cpd:C11149,Dichloroacetate;Dichloroacetic acid,C2H2Cl2O2,Chloroalkane and chloroalkene degradation;Metabolism of xenobiotics by cytochrome P450;Microbial metabolism in diverse environments,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0109 Halogenated fatty acids;    C11149  Dichloroacetic acid,NA,R07103 R07123 R09143
Acetate,cpd:C11150,Trichloroacetate;Trichloroacetic acid;TCA,C2HCl3O2,Chloroalkane and chloroalkene degradation;Metabolism of xenobiotics by cytochrome P450;Microbial metabolism in diverse environments;Chemical carcinogenesis - receptor activation,NA,Pesticides [BR:br08007]; Pesticides;  Herbicides;   Others;    C11150  TCA,1.1.-.-;1.2.1.5;1.14.14.-;3.8.1.-,R07104 R07107 R07123 R09150 R09157 R09158
Acetate,cpd:C11151,Phenylmercury acetate,C8H8HgO2,NA,NA,Pesticides [BR:br08007]; Pesticides;  Fungicides;   Others;    C11151  Phenylmercury acetate,NA,NA
Acetate,cpd:C11338,"Bornyl acetate;(1R,2S,4R)-(+)-Bornyl acetate",C12H20O2,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010212 Bicyclic monoterpenoids;     C11338  Bornyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C11338  (1R,2S,4R)-(+)-Bornyl acetate",2.3.1.69,R08532
Acetate,cpd:C11639,Geniposide pentaacetate;Pentaacetyl geniposide,C27H34O15,NA,NA,NA,NA,NA
Acetate,cpd:C11646,Deoxyloganin tetraacetate,C25H34O13,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11646  Deoxyloganin tetraacetate",NA,NA
Acetate,cpd:C11647,Deoxyloganic acid tetraacetate,C24H32O13,NA,NA,Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11647  Deoxyloganic acid tetraacetate,NA,NA
Acetate,cpd:C11650,8-Epideoxyloganin tetraacetate,C25H34O13,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11650  8-Epideoxyloganin tetraacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11650  8-Epideoxyloganin tetraacetate",NA,NA
Acetate,cpd:C11655,Asperuloside tetraacetate,C26H30O15,NA,NA,NA,NA,NA
Acetate,cpd:C11657,Iridodial glucoside tetraacetate,C24H34O11,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11657  Iridodial glucoside tetraacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11657  Iridodial glucoside tetraacetate",NA,NA
Acetate,cpd:C11658,8-Epiiridodial glucoside tetraacetate,C24H34O11,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11658  8-Epiiridodial glucoside tetraacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11658  8-Epiiridodial glucoside tetraacetate",NA,NA
Acetate,cpd:C11662,7-Epiloganin tetraacetate,C25H34O14,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11662  7-Epiloganin tetraacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11662  7-Epiloganin tetraacetate",NA,NA
Acetate,cpd:C11663,Loganin pentaacetate,C27H36O15,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11663  Loganin pentaacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11663  Loganin pentaacetate",NA,NA
Acetate,cpd:C11664,10-Deoxygeniposide tetraacetate,C25H32O13,NA,NA,Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11664  10-Deoxygeniposide tetraacetate,NA,NA
Acetate,cpd:C11665,7-Deoxygardoside metyl ester tetraacetate,C25H32O13,NA,NA,NA,NA,NA
Acetate,cpd:C11666,11-Hydroxyiridodial glucoside pentaacetate,C26H36O13,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11666  11-Hydroxyiridodial glucoside pentaacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11666  11-Hydroxyiridodial glucoside pentaacetate",NA,NA
Acetate,cpd:C11667,8-epi-11-Hydroxyiridodial glucoside pentaacetate,C26H36O13,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11667  8-epi-11-Hydroxyiridodial glucoside pentaacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11667  8-epi-11-Hydroxyiridodial glucoside pentaacetate",NA,NA
Acetate,cpd:C11668,7-Dehydrologanin tetraacetate,C25H32O14,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11668  7-Dehydrologanin tetraacetate;Glycosides [BR:br08021]; O-glycosides;  Iridoid glycosides;   C11668  7-Dehydrologanin tetraacetate",NA,NA
Acetate,cpd:C11669,Deutzioside pentaacetate,C25H32O14,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010207 Iridoid, 10-alkyliridoid and secoiridoid monoterpenoids;     C11669  Deutzioside pentaacetate",NA,NA
Acetate,cpd:C11896,"Taxa-4(20),11(12)-dien-5alpha-yl acetate",C22H34O2,Diterpenoid biosynthesis;Biosynthesis of secondary metabolites,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010439 Taxane and Abeotaxane diterpenoids;     C11896  Taxa-4(20),11(12)-dien-5alpha-yl acetate",1.14.14.105;2.3.1.162,R06307 R06309
Acetate,cpd:C11898,"Taxa-4(20),11(12)-dien-5alpha-acetoxy-10beta-ol;10beta-Hydroxytaxa-4(20),11-dien-5alpha-yl acetate;5alpha-Acetoxytaxa-4(20),11(12)-dien-10beta-ol",C22H34O3,Diterpenoid biosynthesis;Biosynthesis of secondary metabolites,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010439 Taxane and Abeotaxane diterpenoids;     C11898  Taxa-4(20),11(12)-dien-5alpha-acetoxy-10beta-ol",1.14.13.146;1.14.14.105,R06309 R09867
Acetate,cpd:C12064,Resorcinol monoacetate,C8H8O3,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D02393)]; D DERMATOLOGICALS;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AX Other anti-acne preparations for topical use;     D10AX02 Resorcinol;      D02393  Resorcinol monoacetate (USP); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01A ANTIINFECTIVES;    S01AX Other antiinfectives;     S01AX06 Resorcinol;      D02393  Resorcinol monoacetate (USP),NA,NA
Acetate,cpd:C12282,Polyvinyl acetate,(C4H6O2)n,NA,NA,NA,NA,NA
Acetate,cpd:C12296,Isoamyl acetate;3-Methylbutyl acetate,C7H14O2,NA,NA,NA,3.1.1.112,R12516
Acetate,cpd:C12297,Cyclohexyl acetate,C8H14O2,NA,NA,NA,NA,NA
Acetate,cpd:C12298,"Citronellyl acetate;3,7-Dimethyl-6-octen-1-yl acetate",C12H22O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010201 Acyclic monoterpenoids;     C12298  Citronellyl acetate,NA,NA
Acetate,cpd:C12299,Cinnamyl acetate;3-Phenyl-2-propenyl acetate,C11H12O2,NA,NA,NA,2.3.1.224,R10474
Acetate,cpd:C12300,alpha-Terpinyl acetate;p-Menth-1-en-8-yl acetate,C12H20O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C12300  alpha-Terpinyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C12300  alpha-Terpinyl acetate,NA,NA
Acetate,cpd:C12301,"beta-Terpinyl acetate;Cyclohexanol, 1-methyl-4-(1-methylethenyl)-, 1-acetate",C12H20O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C12301  beta-Terpinyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C12301  beta-Terpinyl acetate,NA,NA
Acetate,cpd:C12302,"gamma-Terpinyl acetate;Cyclohexanol, 1-methyl-4-(1-methylethylidene)-, 1-acetate;p-Menth-4-en-1-yl acetate",C12H20O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C12302  gamma-Terpinyl acetate;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C12302  gamma-Terpinyl acetate,NA,NA
Acetate,cpd:C12303,Phenethyl acetate;2-Phenylethyl acetate,C10H12O2,NA,NA,NA,NA,NA
Acetate,cpd:C12304,Butyl acetate;n-Butyl acetate,C6H12O2,NA,NA,NA,NA,NA
Acetate,cpd:C12325,"3,5-Dihydroxyphenylglyoxylate;2-(3,5-Dihydroxyphenyl)-2-oxoacetate",C8H6O5,Biosynthesis of vancomycin group antibiotics;Biosynthesis of secondary metabolites,NA,NA,1.13.11.80;2.6.1.103,R06624 R06634
Acetate,cpd:C12415,"Methyl nogalonate;Nogalonic acid methyl ester;NAME;Methyl [4,5-dihydroxy-9,10-dioxo-3-(3-oxobutanoyl)-9,10-dihydroanthracen-2-yl]acetate",C21H16O8,Biosynthesis of type II polyketide products;Metabolic pathways;Biosynthesis of secondary metabolites,"Nogalavinone/aklavinone biosynthesis, deoxynogalonate/deoxyaklanonate => nogalavinone/aklavinone",NA,2.1.1.-;5.5.1.23;5.5.1.26,R06675 R06676 R06678 R09328
Acetate,cpd:C12422,"Methyl aklanonate;Aklanonic acid methyl ester;AAME;Methyl [4,5-dihydroxy-9,10-dioxo-3-(3-oxopentanoyl)-9,10-dihydroanthracen-2-yl]acetate",C22H18O8,Biosynthesis of type II polyketide products;Metabolic pathways;Biosynthesis of secondary metabolites,"Nogalavinone/aklavinone biosynthesis, deoxynogalonate/deoxyaklanonate => nogalavinone/aklavinone",NA,2.1.1.288;5.5.1.23,R06680 R06681
Acetate,cpd:C12554,Potassium acetate,C2H3O2. K,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01154)]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05X I.V. SOLUTION ADDITIVES;    B05XA Electrolyte solutions;     B05XA17 Potassium acetate;      D01154  Potassium acetate (JAN/USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D01154)]; Electrolytes/Minerals/Metals/Vitamins;  Electrolyte/Mineral Replacement;   Potassium;    D01154  Potassium acetate (JAN/USP);Therapeutic category of drugs in Japan [BR:br08301(D01154)]; 3  Agents affecting metabolism;  32  Nutrients, tonics;   322  Mineral preparations;    3229  Others;     D01154  Potassium acetate (JAN/USP);Drug groups [BR:br08330(D01154)]; Gastrointestinal agent;  DG02017  Potassium;   D01154  Potassium acetate",NA,NA
Acetate,cpd:C12656,Paramethasone acetate,C24H31FO6,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C12656  Paramethasone acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01229)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB05 Paramethasone;      D01229  Paramethasone acetate (JAN/USAN);Drug groups [BR:br08330(D01229)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00508  Paramethasone;     D01229  Paramethasone acetate;Target-based classification of drugs [BR:br08310(D01229)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D01229  Paramethasone acetate (JAN/USAN)",NA,NA
Acetate,cpd:C12724,Ethynodiol diacetate,C24H32O4,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C12724  Ethynodiol diacetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01294)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03D PROGESTOGENS;    G03DC Estren derivatives;     G03DC06 Etynodiol;      D01294  Ethynodiol diacetate (JAN/USP);Drug groups [BR:br08330(D01294)]; Hormonal agent;  DG02004  Progesterone;   DG00470  Etynodiol;    D01294  Ethynodiol diacetate;  DG01666  Progesterone receptor agonist;   DG00470  Etynodiol;    D01294  Ethynodiol diacetate;Target-based classification of drugs [BR:br08310(D01294)]; Nuclear receptors;  Estrogen like receptors;   Estrogen receptor;    NR3A1 (ESR1);     D01294  Ethynodiol diacetate (JAN/USP);   3-Ketosteroid receptor;    NR3C3 (PGR);     D01294  Ethynodiol diacetate (JAN/USP)",NA,NA
Acetate,cpd:C12729,Chlormadinone acetate,C23H29ClO4,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01299)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03D PROGESTOGENS;    G03DB Pregnadien derivatives;     G03DB06 Chlormadinone;      D01299  Chlormadinone acetate (JP18/USAN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D01299)]; 2  Agents affecting individual organs;  24  Hormones;   247  Estrogen and progesterone preparations;    2478  Synthetic progestins;     D01299  Chlormadinone acetate (JP18/USAN);Animal drugs in Japan [BR:br08331]; 94  Agents for breeding;  941  Hormone preparations (except posterior-pituitary hormone and preparations);   9415  Luteinizing hormone and preparations;    C12729  Chlormadinone acetate;Drug groups [BR:br08330(D01299)]; Antineoplastic;  DG01591  Androgen receptor antagonist;   DG00469  Chlormadinone;    D01299  Chlormadinone acetate; Hormonal agent;  DG02004  Progesterone;   DG00469  Chlormadinone;    D01299  Chlormadinone acetate;  DG01666  Progesterone receptor agonist;   DG00469  Chlormadinone;    D01299  Chlormadinone acetate;Drug classes [BR:br08332(D01299)]; Antineoplastic;  DG01591  Androgen receptor antagonist;   D01299  Chlormadinone acetate; Endocrine and hormonal agent;  DG02004  Progesterone;   D01299  Chlormadinone acetate;Target-based classification of drugs [BR:br08310(D01299)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C3 (PGR);     D01299  Chlormadinone acetate (JP18/USAN) &lt;JP&gt;;    NR3C4 (AR);     D01299  Chlormadinone acetate (JP18/USAN) &lt;JP&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01299)]; Chemicals;  D01299  Chlormadinone acetate,NA,NA
Acetate,cpd:C13081,Retinol acetate;Retinyl acetate;Vitamin A acetate;all-trans-Retinol acetate,C22H32O2,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0109 Retinoids;    C13081  Retinyl acetate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01621)]; A ALIMENTARY TRACT AND METABOLISM;  A11 VITAMINS;   A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;    A11CA Vitamin A, plain;     A11CA01 Retinol (vit A);      D01621  Retinol acetate (JP18); D DERMATOLOGICALS;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AD Retinoids for topical use in acne;     D10AD02 Retinol;      D01621  Retinol acetate (JP18); R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AX Other nasal preparations;     R01AX02 Retinol;      D01621  Retinol acetate (JP18); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01X OTHER OPHTHALMOLOGICALS;    S01XA Other ophthalmologicals;     S01XA02 Retinol;      D01621  Retinol acetate (JP18);Risk category of Japanese OTC drugs [BR:br08312(D01621)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Retinol acetate;    D01621  Retinol acetate (JP18); Second-class OTC drugs;  Inorganic and organic chemicals;   Retinol acetate;    D01621  Retinol acetate (JP18); Third-class OTC drugs;  Inorganic and organic chemicals;   Retinol acetate;    D01621  Retinol acetate (JP18);Drug groups [BR:br08330(D01621)]; Vitamin and mineral;  DG01604  Retinol derivative;   DG00123  Retinol (vit A);    D01621  Retinol acetate; Metabolizing enzyme substrate;  DG02918  CYP2C8 substrate;   DG00123  Retinol (vit A);    D01621  Retinol acetate;Target-based classification of drugs [BR:br08310(D01621)]; Nuclear receptors;  Thyroid hormone like receptors;   Retinoic acid receptor (RAR);    NR1B (RAR);     D01621  Retinol acetate (JP18);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01621)]; Chemicals;  D01621  Retinol acetate;Drug metabolizing enzymes and transporters [br08309.html(D01621)]; Drug metabolizing enzymes;  D01621",NA,NA
Acetate,cpd:C13202,alpha-Tocopherol acetate;Tocopherol acetate,C31H52O3,Vitamin digestion and absorption,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01735)]; A ALIMENTARY TRACT AND METABOLISM;  A11 VITAMINS;   A11H OTHER PLAIN VITAMIN PREPARATIONS;    A11HA Other plain vitamin preparations;     A11HA03 Tocopherol (vit E);      D01735  Tocopherol acetate (JP18) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D01735)]; 3  Agents affecting metabolism;  31  Vitamins;   315  Vitamin E preparations;    3150  Vitamin E preparations;     D01735  Tocopherol acetate (JP18);Classification of Japanese OTC drugs [BR:br08313(D01735)]; Agents for  urogenital organs and anus;  29 Hemorrhoid drugs for internal use;   D01735  Tocopherol acetate (JP18); Nourishing tonics and health supplements;  34 Vitamin E based drugs;   D01735  Tocopherol acetate (JP18);  41 Vitamin EC based drugs;   D01735  Tocopherol acetate (JP18);  43 Vitamin containing supplements;   D01735  Tocopherol acetate (JP18); Agents for integumentary system;  55 Chilblain and chap remedies;   D01735  Tocopherol acetate (JP18); Agents for ophthalmologic use;  62 General eye drops;   D01735  Tocopherol acetate (JP18);Risk category of Japanese OTC drugs [BR:br08312(D01735)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Tocopherol acetate;    D01735  Tocopherol acetate (JP18);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  958  Agents for protective skin;   9582  Vitamin preparations (for external use);    C13202  Tocopherol acetate; 96  Agents affecting metabolism;  962  Vitamin preparations;   9625  Vitamin E and preparations;    C13202  Tocopherol acetate;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01735)]; Chemicals;  D01735  Tocopherol acetate,NA,NA
Acetate,cpd:C13301,Buserelin acetate,C60H86N16O13. C2H4O2,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01831)]; L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L02 ENDOCRINE THERAPY;   L02A HORMONES AND RELATED AGENTS;    L02AE Gonadotropin releasing hormone analogues;     L02AE01 Buserelin;      D01831  Buserelin acetate (JAN/USAN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D01831)]; 2  Agents affecting individual organs;  24  Hormones;   249  Miscellaneous;    2499  Others;     D01831  Buserelin acetate (JAN/USAN);Animal drugs in Japan [BR:br08331]; 94  Agents for breeding;  941  Hormone preparations (except posterior-pituitary hormone and preparations);   9419  Other hormone preparations;    C13301  Buserelin acetate;Drug groups [BR:br08330(D01831)]; Hormonal agent;  DG01494  Gonadotropin-releasing hormone receptor agonist;   DG00729  Buserelin;    D01831  Buserelin acetate;Target-based classification of drugs [BR:br08310(D01831)]; G Protein-coupled receptors;  Rhodopsin family;   Gonadotropin-releasing hormone;    GNRHR;     D01831  Buserelin acetate (JAN/USAN) &lt;JP&gt;,NA,NA
Acetate,cpd:C13636,4-Hydroxyphenyl acetate,C8H8O3,Bisphenol degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.13.84;3.1.1.2,R06892 R06893
Acetate,cpd:C14179,Sulfoacetate;Sulfoacetic acid,C2H4O5S,Taurine and hypotaurine metabolism,NA,NA,1.2.1.73;6.2.1.-,R06980 R13030
Acetate,cpd:C14477,"3,3-Difluoro-5alpha-androstan-17beta-yl acetate;3,3-Difluoroandrostane-17-ol acetate",C21H32F2O2,NA,NA,NA,NA,NA
Acetate,cpd:C14503,"16-Dehydropregnenolone acetate;3beta-Acetyloxy-pregna-5,16-dien-20-one",C23H32O3,NA,NA,NA,NA,NA
Acetate,cpd:C14554,"Deoxycorticosterone acetate;21-Acetoxypregn-4-ene-3,20-dione;Percotol",C23H32O4,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D03698)]; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AA Mineralocorticoids;     H02AA03 Desoxycortone;      D03698  Desoxycorticosterone acetate (USP);Target-based classification of drugs [BR:br08310(D03698)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C2 (MR);     D03698  Desoxycorticosterone acetate (USP)",NA,NA
Acetate,cpd:C14574,"Chlorobenzilate;Ethyl-4,4'-dichlorobenzilate;Ethyl 2-hydroxy-2,2-bis(4-chlorophenyl)acetate",C16H14Cl2O3,NA,NA,Pesticides [BR:br08007]; Obsolete pesticides;  Insecticides;   Acaricides;    C14574  Chlorobenzilate,NA,NA
Acetate,cpd:C14601,Methyl methoxyacetate,C4H8O3,NA,NA,NA,NA,NA
Acetate,cpd:C14610,"(S)-5-Oxo-2,5-dihydrofuran-2-acetate;(+)-Muconolactone",C6H6O4,Benzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Catechol ortho-cleavage, catechol => 3-oxoadipate",NA,5.3.3.4;5.5.1.1,R06989 R06990
Acetate,cpd:C14625,9alpha-Fluoro-6alpha-methylprednisolone 21-acetate,C24H31FO6,NA,NA,NA,NA,NA
Acetate,cpd:C14629,"Fluorometholone 17-acetate;9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 17-acetate;6alpha-Methyl-9alpha-fluoro-17-acetoxy-21-deoxyprednisolone",C24H31FO5,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D04221)]; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA06 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AB Corticosteroids, moderately potent (group II);     D07AB06 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XB Corticosteroids, moderately potent, other combinations;     D07XB04 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;;  D10 ANTI-ACNE PREPARATIONS;   D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE;    D10AA Corticosteroids, combinations for treatment of acne;     D10AA01 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA07 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB05 Fluorometholone;      D04221  Fluorometholone acetate (USP) &lt;US&gt;;USP drug classification [BR:br08302(D04221)]; Ophthalmic Agents;  Ophthalmic Anti-inflammatories;   Glucocorticoids, Ophthalmic;    Fluorometholone;     D04221  Fluorometholone acetate (USP);Drug groups [BR:br08330(D04221)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00294  Fluorometholone;     D04221  Fluorometholone acetate;Drug classes [BR:br08332(D04221)]; Anti-inflammatory;  DG01955  Corticosteroid;   D04221  Fluorometholone acetate;Target-based classification of drugs [BR:br08310(D04221)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D04221  Fluorometholone acetate (USP) &lt;US&gt;",NA,NA
Acetate,cpd:C14635,"16alpha,17alpha-Epoxy-20-oxopregn-5-en-3beta-yl acetate;16alpha,17alpha-Epoxypregnenolone acetate",C23H32O4,NA,NA,NA,NA,NA
Acetate,cpd:C14636,"9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate;Isoflupredone acetate;U-6013",C23H29FO6,NA,NA,NA,NA,NA
Acetate,cpd:C14642,"Melengestrol acetate;17-Hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione acetate;17alpha-Acetoxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione",C25H32O4,NA,NA,NA,NA,NA
Acetate,cpd:C14648,"6alpha-Chloro-17-acetoxyprogesterone;6alpha-Chloro-17-hydroxypregn-4-ene-3,20-dione acetate",C23H31ClO4,NA,NA,NA,NA,NA
Acetate,cpd:C14651,"16alpha,17alpha-Epoxy-3,20-dioxopregn-4-en-21-yl acetate;16,17-Epoxydeoxycorticosterone acetate",C23H30O5,NA,NA,NA,NA,NA
Acetate,cpd:C14658,Pregnenolone acetate;3beta-Hydroxypregn-5-en-20-one acetate,C23H34O3,NA,NA,NA,NA,NA
Acetate,cpd:C14668,"Cortancyl;Prednisone 21-acetate;21-Acetoxy-17alpha-hydroxypregna-1,4-diene-3,11,20-trione",C23H28O6,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08416)]; A ALIMENTARY TRACT AND METABOLISM;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA03 Prednisone;      D08416  Prednisone acetate; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB07 Prednisone;      D08416  Prednisone acetate;Drug groups [BR:br08330(D08416)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00094  Prednisone;     D08416  Prednisone acetate;Target-based classification of drugs [BR:br08310(D08416)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D08416  Prednisone acetate",NA,NA
Acetate,cpd:C14675,"11beta,21-Dihydroxypregn-4-ene-3,20-dione 21-acetate;Corticosterone 21-acetate",C23H32O5,NA,NA,NA,NA,NA
Acetate,cpd:C14695,Nitrilotriacetic acid;Triglycollamic acid;Nitrilotriacetate,C6H9NO6,NA,NA,NA,1.14.14.10,R09798
Acetate,cpd:C14862,2-S-Glutathionyl acetate;S-(Carboxymethyl)glutathione,C12H19N3O8S,Metabolism of xenobiotics by cytochrome P450,NA,NA,NA,R07097 R07124
Acetate,cpd:C14889,"5alpha-Androstane-2beta-fluoro-17beta-ol-3-one acetate;(2beta,5alpha,17beta)-17-(Acetyloxy)-2-fluoro-androstan-3-one",C21H31FO3,NA,NA,NA,NA,NA
Acetate,cpd:C14913,17beta-Hydroxy-4-oxa-5alpha-androstan-3-one acetate,C20H30O4,NA,NA,NA,NA,NA
Acetate,cpd:C14922,"15beta-Hydroxy-7alpha-mercapto-pregn-4-ene-3,20-dione 7-acetate",C23H32O4S,NA,NA,NA,NA,NA
Acetate,cpd:C14924,"3beta,21-Dihydroxy-pregna-5,7,9(11)-trien-20-one diacetate",C25H32O5,NA,NA,NA,NA,NA
Acetate,cpd:C14928,17-[[3-(1-Pyrrolidinyl)propyl]imino]androst-5-en-3beta-ol acetate,C28H44N2O2,NA,NA,NA,NA,NA
Acetate,cpd:C14947,"17-Propylestra-1,3,5(10)-triene-3,17beta-diol diacetate",C25H34O4,NA,NA,NA,NA,NA
Acetate,cpd:C14954,"17-Methylandrosta-4,6-diene-3beta,17beta-diol 3-acetate",C22H32O3,NA,NA,NA,NA,NA
Acetate,cpd:C14955,"17beta-(Acetylthio)estra-1,3,5(10)-trien-3-ol acetate",C22H28O3S,NA,NA,NA,NA,NA
Acetate,cpd:C14974,"3-Methoxy-16-methylestra-1,3,5(10)-triene-16beta,17beta-diol 17-acetate",C22H30O4,NA,NA,NA,NA,NA
Acetate,cpd:C14999,"10-Hydroxyestra-1,4-dien-3-one acetate",C20H26O3,NA,NA,NA,NA,NA
Acetate,cpd:C15023,19-Chloro-3beta-hydroxyandrost-5-en-17-one acetate,C21H29ClO3,NA,NA,NA,NA,NA
Acetate,cpd:C15027,"2,2-Dimethyl-3,4-bis(4-methoxyphenyl)-2H-1-benzopyran-7-ol acetate",C27H26O5,NA,NA,NA,NA,NA
Acetate,cpd:C15046,"Pregna-5,16,20-triene-3beta,20-diol diacetate",C25H34O4,NA,NA,NA,NA,NA
Acetate,cpd:C15050,"2,2-Dimethyl-3-[4-(acetyloxy)phenyl]-4-ethyl-2H-1-benzopyran-7-ol acetate;4-Ethyl-3-(p-hydroxyphenyl)-2,2-dimethyl-2H-1-benzopyran-7-ol diacetate",C23H24O5,NA,NA,NA,NA,NA
Acetate,cpd:C15053,"2,2-Dimethyl-3-(4-methoxyphenyl)-4-propyl-2H-1-benzopyran-7-ol acetate",C23H26O4,NA,NA,NA,NA,NA
Acetate,cpd:C15055,"2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-2H-1-benzopyran-7-ol acetate",C22H24O4,NA,NA,NA,NA,NA
Acetate,cpd:C15056,"2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-benzopyran-7-ol acetate",C20H19FO3,NA,NA,NA,NA,NA
Acetate,cpd:C15059,"2,2,4-Trimethyl-3-(4-methoxyphenyl)-2H-1-benzopyran-7-ol acetate",C21H22O4,NA,NA,NA,NA,NA
Acetate,cpd:C15061,"2,2-Dibutyl-3-(4-methoxyphenyl)-4-methyl-2H-1-benzopyran-7-ol acetate",C27H34O4,NA,NA,NA,NA,NA
Acetate,cpd:C15064,17beta-(Hydroxymethyl)androst-4-en-3-one acetate,C22H32O3,NA,NA,NA,NA,NA
Acetate,cpd:C15068,17beta-Hydroxy-4-oxa-5alpha-androst-1-en-3-one acetate,C20H28O4,NA,NA,NA,NA,NA
Acetate,cpd:C15095,"Coumestrol diacetate;3,9-Diacetoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one",C19H12O7,NA,NA,NA,NA,NA
Acetate,cpd:C15135,3beta-Hydroxy-17-oxoandrost-5-en-19-al acetate,C21H28O4,NA,NA,NA,NA,NA
Acetate,cpd:C15139,D-Homo-17a-oxa-5alpha-androstan-3beta-ol acetate,C21H34O3,NA,NA,NA,NA,NA
Acetate,cpd:C15145,"4,4-Bis[4-(acetyloxy)phenyl]3-hexanone;4,4-Bis(4-hydroxyphenyl)-3-hexanone diacetate",C22H24O5,NA,NA,NA,NA,NA
Acetate,cpd:C15151,17beta-Hydroxy-4-oxa-5alpha-estr-1-en-3-one acetate,C19H26O4,NA,NA,NA,NA,NA
Acetate,cpd:C15157,"3-Acetyl-5alpha-androstane-3beta,17beta-diol 3-acetate",C23H36O4,NA,NA,NA,NA,NA
Acetate,cpd:C15161,"2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-7-hydroxy-2H-1-benzopyran-8-methanol diacetate",C25H28O6,NA,NA,NA,NA,NA
Acetate,cpd:C15166,"5alpha-Androstane-2alpha-fluoro-17beta-ol-3-one acetate;(2alpha,5alpha,17beta)-17-(Acetyloxy)-2-fluoro-androstan-3-one",C21H31FO3,NA,NA,NA,NA,NA
Acetate,cpd:C15180,17beta-Hydroxy-4-mercaptoandrost-4-en-3-one 4-acetate 17-propionate,C24H34O4S,NA,NA,NA,NA,NA
Acetate,cpd:C15185,"21-Acetyloxy-17-hydroxypregna-1,4-diene-3,20-dione;11-Deoxyprednisone acetate",C23H30O5,NA,NA,NA,NA,NA
Acetate,cpd:C15186,"5alpha,17alpha-Pregn-2-en-20-yn-17-ol acetate;17alpha-Ethynyl-5alpha-androst-2-en 17beta-acetate",C23H32O2,NA,NA,NA,NA,NA
Acetate,cpd:C15228,"beta-Estradiol 17-acetate;Estra-1,3,5(10)-triene-3,17beta-diol 17-acetate;17beta-Acetylestradiol",C20H26O3,NA,NA,NA,NA,NA
Acetate,cpd:C15256,"6alpha-Fluoro-17-hydroxycorticosterone 21-acetate;6alpha-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate",C23H31FO6,NA,NA,NA,NA,NA
Acetate,cpd:C15264,17beta-Hydroxy-5alpha-androstane acetate;17beta-Acetoxy-5alpha-androstane,C21H34O2,NA,NA,NA,NA,NA
Acetate,cpd:C15269,"9-Fluoro-11beta,17,21-trihydroxy-2alpha-methylpregn-4-ene-3,20-dione 21-acetate;9-Fluoro-2alpha-methylcortisol 21-acetate",C24H33FO6,NA,NA,NA,NA,NA
Acetate,cpd:C15272,"3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate",C25H38O5,NA,NA,NA,NA,NA
Acetate,cpd:C15275,"21-Acetoxy-11beta,17-dihydroxy-6alpha-methylpregn-4-ene-3,20-dione;17-Hydroxy-6alpha-methylcorticosterone 21-acetate",C24H34O6,NA,NA,NA,NA,NA
Acetate,cpd:C15282,17beta-Hydroxyestr-5(10)-en-3-one acetate;19-Norandrost-5(10)-en-17beta-acetoxy-3-one,C20H28O3,NA,NA,NA,NA,NA
Acetate,cpd:C15284,"6beta,17beta-Dihydroxyandrost-4-en-3-one diacetate;6beta-Hydroxytestosterone diacetate",C23H32O5,NA,NA,NA,NA,NA
Acetate,cpd:C15302,"11beta,17,21-Trihydroxy-2alpha-methylpregn-4-ene-3,20-dione 21-acetate;17-Hydroxy-2alpha-methylcorticosterone 21-acetate;2alpha-Methylcortisol acetate",C24H34O6,NA,NA,NA,NA,NA
Acetate,cpd:C15304,"3beta,19-Dihydroxyandrost-5-en-17-one 3-acetate;3beta-Acetoxy-19-hydroxyandrost-5-en-17-one",C21H30O4,NA,NA,NA,NA,NA
Acetate,cpd:C15305,"9-Chloro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate;9-Chloro-17-hydroxycorticosterone 21-acetate;9alpha-Chlorocortisol acetate",C23H31ClO6,NA,NA,NA,NA,NA
Acetate,cpd:C15310,"6alpha-Fluoro-17-hydroxypregn-4-ene-3,20-dione acetate",C23H31FO4,NA,NA,NA,NA,NA
Acetate,cpd:C15313,"3,17beta-Diacetoxyestra-1,3,5(10)-trien-6-one;3,17beta-Dihydroxyestra-1,3,5(10)-trien-6-one diacetate;6-Oxo-17beta-estradiol diacetate",C22H26O5,NA,NA,NA,NA,NA
Acetate,cpd:C15322,"2alpha,3alpha-(Difluoromethylene)-5alpha-androstan-17beta-ol acetate",C22H32F2O2,NA,NA,NA,NA,NA
Acetate,cpd:C15324,"Androst-4-ene-3beta,17beta-diol diacetate;3beta,17beta-Diacetoxyandrost-4-ene",C23H34O4,NA,NA,NA,NA,NA
Acetate,cpd:C15333,"3alpha-Hydroxy-5beta-pregn-16-ene-11,20-dione 3-acetate",C23H32O4,NA,NA,NA,NA,NA
Acetate,cpd:C15346,"5alpha-Androstane-3beta,17beta-diol diacetate;3beta,17beta-Diacetoxy-5alpha-androstane",C23H36O4,NA,NA,NA,NA,NA
Acetate,cpd:C15372,"11alpha,17beta-Dihydroxyandrost-4-en-3-one diacetate;11alpha-Hydroxytestosterone diacetate",C23H32O5,NA,NA,NA,NA,NA
Acetate,cpd:C15379,"3beta-Hydroxylanostane-7,11-dione acetate",C32H52O4,NA,NA,NA,NA,NA
Acetate,cpd:C15382,"Estra-1,3,5(10)-triene-3,6alpha,17beta-triol triacetate",C24H30O6,NA,NA,NA,NA,NA
Acetate,cpd:C15404,"3beta,17-Dihydroxy-5alpha-pregnane-11,20-dione 3-acetate",C23H34O5,NA,NA,NA,NA,NA
Acetate,cpd:C15414,6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one acetate;6alpha-Fluorotestosterone acetate,C21H29FO3,NA,NA,NA,NA,NA
Acetate,cpd:C15417,3beta-Hydroxy-5alpha-pregnan-20-one acetate;3beta-Acetoxy-5alpha-pregnan-20-one,C23H36O3,NA,NA,NA,NA,NA
Acetate,cpd:C15421,2-Methyl-5alpha-androst-2-en-17beta-ol acetate,C22H34O2,NA,NA,NA,NA,NA
Acetate,cpd:C15423,"Androst-4-ene-3alpha,17beta-diol diacetate;3alpha,17beta-Diacetoxyandrost-4-ene",C23H34O4,NA,NA,NA,NA,NA
Acetate,cpd:C15432,"Flurogestone acetate;9alpha-Fluoro-11-hydroxy,17alpha-acetoxyprogesterone;9-Fluoro-11beta,17-dihydroxypregn-4-ene-3,20-dione 17-acetate",C23H31FO5,NA,NA,NA,NA,NA
Acetate,cpd:C15440,"Estra-1,3,5(10)-triene-3,6beta,17beta-triol triacetate",C24H30O6,NA,NA,NA,NA,NA
Acetate,cpd:C15461,"17beta-Acetyl-1,2,3,4,6alpha,7alpha,10,12,13,14alpha,16,17-dodecahydro-3beta-hydroxy-10beta,13beta-dimethyl-5beta,8beta-etheno-15H-cyclopenta[a]phenanthrene-6,7-dicarboxylic anhydride acetate",C27H32O6,NA,NA,NA,NA,NA
Acetate,cpd:C15513,Benzyl acetate,C9H10O2,NA,NA,NA,1.14.13.92;2.3.1.224,R07201 R10473
Acetate,cpd:C15583,Phenyl acetate,C8H8O2,NA,NA,NA,3.1.1.2,R07342
Acetate,cpd:C15809,Iminoglycine;Iminoacetic acid;2-Iminoacetate,C2H3NO2,Thiamine metabolism;Metabolic pathways;Biosynthesis of cofactors,"Thiamine biosynthesis, prokaryotes, AIR (+ DXP/tyrosine) => TMP/TPP;Thiamine biosynthesis, prokaryotes, AIR (+ DXP/glycine) => TMP/TPP",NA,1.4.3.19;2.5.1.147;2.8.1.10;4.1.99.19,R07463 R10245 R10246 R10247 R12161
Acetate,cpd:C16249,2-Bromomaleylacetate,C6H5BrO5,Fluorobenzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.3.1.32,R07781 R07785
Acetate,cpd:C16418,Pinobanksin 3-O-acetate,C17H14O6,Flavonoid biosynthesis,NA,Lipids [BR:br08002]; PK  Polyketides;  PK12 Flavonoids;   PK1214 Flavanones;    C16418  Pinobanksin 3-O-acetate;Phytochemical compounds [BR:br08003]; Flavonoids;  Flavonoids;   Dihyroflavonols;    C16418  Pinobanksin 3-O-acetate,NA,R08028
Acetate,cpd:C16825,Neomenthyl acetate,C12H22O2,NA,NA,Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C16825  Neomenthyl acetate,2.3.1.69,R08531
Acetate,cpd:C16923,"Bufotalin;3beta,14,16beta-Trihydroxy-5beta-bufa-20,22-dienolide 16-acetate",C26H36O6,NA,NA,Compounds with biological roles [BR:br08001]; Steroids;  24-Carbon atoms;   Bufanolide derivatives;    C16923  Bufotalin;Lipids [BR:br08002]; ST  Sterol lipids;  ST01 Sterols;   ST0113 Bufanolides and derivatives;    C16923  Bufotalin;Natural toxins [BR:br08009]; Venoms;  Frog venoms;   Bufotoxins;    C16923  Bufotalin,NA,NA
Acetate,cpd:C17506,Sugeonyl acetate,C17H24O3,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0103 C15 isoprenoids (sesquiterpenes);    PR010345 Patchoulane sesquiterpenoids;     C17506  Sugeonyl acetate,NA,NA
Acetate,cpd:C17530,Methyl acetate;Devoton;Tereton,C3H6O2,Butanoate metabolism;Metabolic pathways,NA,NA,1.14.13.226;3.1.1.114,R10704 R10705
Acetate,cpd:C17663,3-Phenylpropyl acetate;Hydrocinnamyl acetate,C11H14O2,NA,NA,NA,NA,NA
Acetate,cpd:C17665,2-Phenylpropyl acetate,C11H14O2,NA,NA,NA,NA,NA
Acetate,cpd:C17666,1-Phenylpropyl acetate,C11H14O2,NA,NA,NA,NA,NA
Acetate,cpd:C17688,Aluminum acetoacetate,(C4H5O3)3. Al,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; A ALIMENTARY TRACT AND METABOLISM;  A02 DRUGS FOR ACID RELATED DISORDERS;   A02A ANTACIDS;    A02AB Aluminium compounds;     A02AB05 Aluminium acetoacetate;      C17688  Aluminum acetoacetate,NA,NA
Acetate,cpd:C18243,"2,3,5-Trichloromaleylacetate",C6H3Cl3O5,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments,NA,NA,1.3.1.32;3.1.1.45,R09136 R09137 R09138
Acetate,cpd:C18305,2-Chloro-5-methylmaleylacetate,C7H7ClO5,Toluene degradation;Microbial metabolism in diverse environments,NA,NA,1.3.1.32;3.1.1.45,R09222 R09223
Acetate,cpd:C18306,5-Methylmaleylacetate,C7H8O5,Toluene degradation;Microbial metabolism in diverse environments,NA,NA,1.3.1.32,R09223 R09224
Acetate,cpd:C18310,3-Chloro-2-methylmaleylacetate,C7H7ClO5,Toluene degradation;Microbial metabolism in diverse environments,NA,NA,3.1.1.45,R09220
Acetate,cpd:C18372,Chlorhexidine acetate,C22H30Cl2N10. (C2H4O2)2,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D07669)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AB Antiinfectives and antiseptics for local oral treatment;     A01AB03 Chlorhexidine;      D07669  Chlorhexidine acetate (USP); B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CA Antiinfectives;     B05CA02 Chlorhexidine;      D07669  Chlorhexidine acetate (USP); D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AC Biguanides and amidines;     D08AC02 Chlorhexidine;      D07669  Chlorhexidine acetate (USP);  D09 MEDICATED DRESSINGS;   D09A MEDICATED DRESSINGS;    D09AA Medicated dressings with antiinfectives;     D09AA12 Chlorhexidine;      D07669  Chlorhexidine acetate (USP); R RESPIRATORY SYSTEM;  R02 THROAT PREPARATIONS;   R02A THROAT PREPARATIONS;    R02AA Antiseptics;     R02AA05 Chlorhexidine;      D07669  Chlorhexidine acetate (USP); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01A ANTIINFECTIVES;    S01AX Other antiinfectives;     S01AX09 Chlorhexidine;      D07669  Chlorhexidine acetate (USP);  S02 OTOLOGICALS;   S02A ANTIINFECTIVES;    S02AA Antiinfectives;     S02AA09 Chlorhexidine;      D07669  Chlorhexidine acetate (USP);  S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;   S03A ANTIINFECTIVES;    S03AA Antiinfectives;     S03AA04 Chlorhexidine;      D07669  Chlorhexidine acetate (USP);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  956  Bath and disinfectants preparations;   9562  Disinfectants preparations;    C18372  Chlorhexidine acetate; 99  Agents for not mainly purpose of therapeutic;  992  Amphoteric soap and preparations;   9929  Other agents for disinfections;    C18372  Chlorhexidine acetate,NA,NA
Acetate,cpd:C18374,Clostebol acetate,C21H29ClO3,NA,NA,Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  961  Hormone preparations (except agents for breeding and external use);   9615  Anabolic steroid hormone and preparations;    C18374  Clostebol acetate;Drug groups [BR:br08330(D07732)]; Hormonal agent;  DG01590  Androgen receptor agonist;   DG01605  Anabolic steroid;    DG01632  Clostebol;     D07732  Clostebol acetate,NA,NA
Acetate,cpd:C18375,Osaterone acetate,C22H27ClO5,NA,NA,Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  961  Hormone preparations (except agents for breeding and external use);   9619  Other hormone preparations;    C18375  Osaterone acetate;Target-based classification of drugs [BR:br08310(D11105)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C4 (AR);     D11105  Osaterone acetate (JAN),NA,NA
Acetate,cpd:C18568,Iminoctadine acetate,C18H41N7. (C2H4O2)3,NA,NA,Pesticides [BR:br08007]; Pesticides;  Fungicides;   Aliphatic nitrogen fungicides;    C18568  Iminoctadine acetate,NA,NA
Acetate,cpd:C18588,Sodium fluoroacetate;Sodium monofluoroacetate,C2H2FO2. Na,NA,NA,Pesticides [BR:br08007]; Pesticides;  Rodenticides;   Organofluorine rodenticides;    C18588  Sodium fluoroacetate,NA,NA
Acetate,cpd:C18723,Dodine;Dodecylguanidine acetate,C13H29N3. C2H4O2,NA,NA,Pesticides [BR:br08007]; Pesticides;  Fungicides;   Aliphatic nitrogen fungicides;    C18723  Dodine,NA,NA
Acetate,cpd:C18728,Fentin acetate,C20H18O2Sn,NA,NA,Pesticides [BR:br08007]; Pesticides;  Fungicides;   Organotin fungicides;    C18728  Fentin acetate,NA,NA
Acetate,cpd:C18940,Glyodin;Glyodin acetate,C20H40N2. C2H4O2,NA,NA,NA,NA,NA
Acetate,cpd:C19068,Medinoterb acetate,C13H16N2O6,NA,NA,Pesticides [BR:br08007]; Obsolete pesticides;  Herbicides;   Nitrophenol herbicides;    C19068  Medinoterb acetate,NA,NA
Acetate,cpd:C19119,Dinoseb acetate,C12H14N2O6,NA,NA,Pesticides [BR:br08007]; Obsolete pesticides;  Herbicides;   Nitrophenol herbicides;    C19119  Dinoseb acetate,NA,NA
Acetate,cpd:C19258,Methylazoxymethanol acetate,C4H8N2O3,NA,NA,NA,NA,NA
Acetate,cpd:C19309,Vinyl acetate,C4H6O2,NA,NA,NA,NA,NA
Acetate,cpd:C19546,Vinyl chloride-vinyl acetate copolymer;Pevikon,(C4H6O2)n. (C2H3Cl)n,NA,NA,NA,NA,NA
Acetate,cpd:C19757,(3Z)-Hex-3-en-1-yl acetate;(Z)-3-Hexen-1-ol acetate;cis-3-Hexenyl acetate,C8H14O2,alpha-Linolenic acid metabolism;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C19757  (3Z)-Hex-3-en-1-yl acetate,2.3.1.195,R09631
Acetate,cpd:C19911,Iminodiacetate,C4H7NO4,NA,NA,NA,1.14.14.10,R09798
Acetate,cpd:C19992,"Rhodojaponin I;Grayanotoxane-5,6,10,14,16-pentol, 2,3-epoxy-, 6,14-diacetate, (2beta,3beta,6beta,14R)-",C24H36O8,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010418 Leucothol and grayanotoxane diterpenoids;     C19992  Rhodojaponin I;Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Grayanoids;    C19992  Rhodojaponin I;Natural toxins [BR:br08009]; Phytotoxins;  Terpenoids;   Diterpenoids;    C19992  Rhodojaponin I,NA,NA
Acetate,cpd:C20151,"10beta,14beta-Dihydroxytaxa-4(20),11-dien-5alpha-yl acetate;5alpha-Acetoxy-10beta,14beta-dihydroxytaxadiene",C22H34O4,Diterpenoid biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.14.13.146,R06319 R09867
Acetate,cpd:C20152,"Taxusin;Taxa-4(20),11-diene-5alpha,9alpha,10beta,13alpha-tetrayl tetraacetate",C28H40O8,NA,NA,NA,1.14.14.182;1.14.14.183,R09868 R13019
Acetate,cpd:C20225,Coniferyl acetate,C12H14O4,Phenylpropanoid biosynthesis,NA,NA,1.1.1.318;1.1.1.319;2.3.1.-,R09931 R10248 R10253
Acetate,cpd:C20271,"[(1R)-2,2,3-Trimethyl-5-oxocyclopent-3-enyl]acetate",C10H14O3,"Pinene, camphor and geraniol degradation;Microbial metabolism in diverse environments",NA,NA,6.2.1.38,R10003 R10022 R13091
Acetate,cpd:C20324,"[(1S)-4-Hydroxy-2,2,3-trimethylcyclopent-3-enyl]acetate",C10H16O3,"Pinene, camphor and geraniol degradation",NA,NA,3.7.1.18,R10051
Acetate,cpd:C20465,Coumaryl acetate,C11H12O3,Phenylpropanoid biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.1.1.318;1.1.1.319;2.3.1.-,R10249 R10254 R10289
Acetate,cpd:C20505,Versiconal hemiacetal acetate,C20H16O9,Aflatoxin biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Aflatoxin biosynthesis, malonyl-CoA => aflatoxin B1",NA,1.1.1.353;3.1.1.94,R10399 R10401 R10477
Acetate,cpd:C20506,Versiconol acetate,C20H18O9,Aflatoxin biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.1.1.353;3.1.1.94,R10398 R10399 R10478
Acetate,cpd:C20635,Methyl (indol-3-yl)acetate,C11H11NO2,NA,NA,NA,2.1.1.278,R10452
Acetate,cpd:C21396,Ethylenediaminetriacetic acid;Ethylenediaminetriacetate;ED3A,C8H14N2O6,NA,NA,NA,1.14.14.33,R11454 R11455
Acetate,cpd:C21397,"Ethylenediamine-N,N'-diacetic acid;Ethylenediaminediacetate;EDDA",C6H12N2O4,NA,NA,NA,1.14.14.33,R11455 R11456
Acetate,cpd:C21453,(2-Aminobenzoyl)acetate;2-Aminobenzoylacetate,C9H9NO3,Phenazine biosynthesis;Biosynthesis of secondary metabolites,NA,NA,2.3.1.230;3.1.2.32,R11542 R11589
Acetate,cpd:C21595,Erythromycin 2'-acetate;2'-Acetylerythromycin;2'-O-Acetylerythromycin A,C39H69NO14,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK04 Macrolides and lactone polyketides;   C21595  Erythromycin 2'-acetate;Prodrugs [br08324.html]; C21595,NA,NA
Acetate,cpd:C21619,(2-Hydroxy-1H-indol-3-yl)acetate,C10H9NO3,NA,NA,NA,1.14.13.235,R11730
Acetate,cpd:C22202,"2-Oxoindole-3-acetate;2-Oxoindole-3-acetic acid;2-Indolinone-3-acetate;2-(2-Oxo-1,3-dihydroindol-3-yl)acetate",C10H9NO3,Tryptophan metabolism,NA,NA,1.14.11.-,R12501
Acetate,cpd:C22588,"3,4,5-Trihydroxyphenylacetate;2-(3,4,5-Trihydroxyphenyl)acetic Acid",C8H8O5,NA,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C22588,NA,NA
Acetate,cpd:C22752,Ethylphenidate;Ethyl 2-phenyl-2-(piperidin-2-yl)acetate,C15H21NO2,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22752,NA,NA
Acetate,cpd:C22763,1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine;1-Phenethyl-4-phenyl-4-piperidinol acetate;PEPAP,C21H25NO2,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22763,NA,NA
Acetate,cpd:C22819,Methyl alpha-acetylphenylacetate;MAPA;Methyl 3-oxo-2-phenylbutanoate,C11H12O3,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  C22819,NA,NA
Acetone,cpd:C00111,Glycerone phosphate;Dihydroxyacetone phosphate;3-Hydroxy-2-oxopropyl phosphate,C3H7O6P,Glycolysis / Gluconeogenesis;Pentose and glucuronate interconversions;Fructose and mannose metabolism;Galactose metabolism;Glycerolipid metabolism;Inositol phosphate metabolism;Glycerophospholipid metabolism;Glyoxylate and dicarboxylate metabolism;Propanoate metabolism;Methane metabolism;Carbon fixation in photosynthetic organisms;Nicotinate and nicotinamide metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids,"Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Glycolysis, core module involving three-carbon compounds;Gluconeogenesis, oxaloacetate => fructose-6P;Reductive pentose phosphate cycle (Calvin cycle);Formaldehyde assimilation, xylulose monophosphate pathway;Pentose bisphosphate pathway (nucleoside degradation), archaea, nucleoside/NMP => 3-PGA/glycerone phosphate",NA,1.1.1.8;1.1.1.94;1.1.1.261;1.1.1.408;1.1.1.409;1.1.3.21;1.1.5.3;2.2.1.13;2.3.1.42;2.3.1.245;2.3.1.277;2.5.1.72;2.7.1.29;2.7.1.121;3.1.3.1;3.1.3.2;4.1.1.104;4.1.2.2;4.1.2.13;4.1.2.17;4.1.2.19;4.1.2.29;4.1.2.40;4.1.2.56;4.1.2.57;4.1.2.62;4.1.2.-;4.2.3.3;5.3.1.1,R00842 R00844 R00846 R00848 R00849 R01010 R01011 R01012;R01013 R01014 R01015 R01016 R01068 R01069 R01070 R01785;R01829 R02262 R02263 R02568 R04292 R05378 R05679 R05680;R08650 R08657 R10673 R10760 R11182 R11716 R11717 R11724;R11726 R12289 R12612 R12613 R12668 R12696
Acetone,cpd:C00184,"Glycerone;Dihydroxyacetone;1,3-Dihydroxyacetone;1,3-Dihydroxy-2-propanone;1,3-Dihydroxypropan-2-one",C3H6O3,Glycerolipid metabolism;Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism,"Formaldehyde assimilation, xylulose monophosphate pathway",Compounds with biological roles [BR:br08001]; Carbohydrates;  Monosaccharides;   Ketoses;    C00184  Dihydroxyacetone,1.1.1.6;1.1.1.156;1.1.99.22;2.2.1.3;2.7.1.29;2.7.1.121;3.1.3.1;3.1.3.2,R01010 R01011 R01012 R01034 R01039 R01045 R01440 R06862
Acetone,cpd:C00207,Acetone;Dimethyl ketone;2-Propanone;Propan-2-one,C3H6O,Butanoate metabolism;Metabolic pathways,"Ketone body biosynthesis, acetyl-CoA => acetoacetate/3-hydroxybutyrate/acetone",Lipids [BR:br08002]; FA  Fatty acyls;  FA12 Oxygenated hydrocarbons;   C00207  Propan-2-one;Drug groups [BR:br08330(D02311)]; Metabolizing enzyme substrate;  DG02855  CYP2E1 substrate;   D02311  Acetone;Drug metabolizing enzymes and transporters [br08309.html(D02311)]; Drug metabolizing enzymes;  D02311,1.1.1.80;1.1.1.-;1.14.13.226;1.14.14.141;1.14.14.148;1.14.15.-;2.6.3.1;4.1.1.4;4.1.2.46;4.1.2.47;4.1.99.16;4.2.3.22;6.4.1.6,R01366 R01550 R01553 R03796 R05564 R05568 R05735 R08207;R08543 R09002 R09487 R10703 R10704
Acetone,cpd:C01888,Aminoacetone;1-Amino-2-propanone,C3H7NO,"Glycine, serine and threonine metabolism;Metabolic pathways",NA,NA,1.1.1.75;1.1.1.381;1.4.3.4;1.4.3.21,R02529 R03758 R03759 R10852
Acetone,cpd:C01995,Acetone oxime;Acetoxime,C3H7NO,NA,NA,NA,2.6.3.1,R03796
Acetone,cpd:C02543,Glycerone sulfate;Dihydroxyacetone sulfate,C3H6O6S,NA,NA,NA,NA,NA
Acetone,cpd:C02659,Acetone cyanohydrin;alpha-Hydroxyisobutyronitrile;2-Hydroxy-2-methylpropanenitrile;2-Methyllactonitrile;Acetone cyanhydrin;2-Hydroxyisobutyronitrile,C4H7NO,Cyanoamino acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.14.14.41;2.4.1.63;3.2.1.21;4.1.2.46;4.1.2.47,R01553 R03625 R10038 R10040 R11598 R11642
Acetone,cpd:C03372,Acylglycerone phosphate;Dihydroxyacetone phosphate acyl ester;1-Acyl-glycerone 3-phosphate,C4H6O7PR,Glycerophospholipid metabolism;Ether lipid metabolism;Metabolic pathways,NA,NA,1.1.1.101;2.3.1.42;2.5.1.26,R01013 R02756 R04311
Acetone,cpd:C03505,Hydroxyacetone phosphate;Acetol phosphate,C3H7O5P,NA,NA,NA,1.1.1.7,R04236
Acetone,cpd:C03715,O-Alkylglycerone phosphate;Alkyl-glycerone 3-phosphate;Dihydroxyacetone phosphate alkyl ether,C3H6O6PR,Ether lipid metabolism;Metabolic pathways,NA,NA,1.1.1.101;2.5.1.26;2.7.1.84,R03944 R04311 R04360
Acetone,cpd:C05235,Hydroxyacetone;Acetol;1-Hydroxy-2-propanone;2-Ketopropyl alcohol;Acetone alcohol;Pyruvinalcohol;Pyruvic alcohol;Methylketol,C3H6O2,Propanoate metabolism;Metabolic pathways,NA,NA,1.1.1.6;1.1.1.-;4.1.99.24;4.1.99.25;4.4.1.41,R02528 R10717 R10718 R12150 R12151 R12764
Acetone,cpd:C12088,4-Hydroxycinnamoylmethane;4-Hydroxybenzalacetone;p-Hydroxybenzalacetone;4-(p-Hydroxyphenyl)-3-buten-2-one,C10H10O2,Degradation of flavonoids,NA,NA,2.3.1.212,R10234 R13079
Acetone,cpd:C13297,Geranylgeranylacetone;Teprenone,C23H38O,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01827)]; A ALIMENTARY TRACT AND METABOLISM;  A02 DRUGS FOR ACID RELATED DISORDERS;   A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD);    A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD);     A02BX15 Teprenone;      D01827  Teprenone (JP18/INN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D01827)]; 2  Agents affecting individual organs;  23  Digestive organ agents;   232  Peptic ulcer agents;    2329  Others;     D01827  Teprenone (JP18/INN);Classification of Japanese OTC drugs [BR:br08313(D01827)]; Agents for digestive organs;  11 Stomachics;   D01827  Teprenone (JP18/INN);Risk category of Japanese OTC drugs [BR:br08312(D01827)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Teprenone;    D01827  Teprenone (JP18/INN);Drug groups [BR:br08330(D01827)]; Gastrointestinal agent;  DG01975  Agents for peptic ulcer;   DG02008  Gastric mucosal protectant;    D01827  Teprenone;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01827)]; Chemicals;  D01827  Teprenone;  D01827  Teprenone capsules;Rx-to-OTC switch list in Japan [br08314.html(D01827)]; D01827,NA,NA
Acetone,cpd:C15280,"16alpha,17-Isopropylidenedioxy-6alpha-methylprogesterone;16alpha,17-Dihydroxy-6alpha-methylpregn-4-ene-3,20-dione cyclic acetal with acetone",C25H36O4,NA,NA,NA,NA,NA
Acetone,cpd:C15499,"Pentane-2,4-dione;Acetylacetone;2,4-Dioxopentane",C5H8O2,NA,NA,"Lipids [BR:br08002]; FA  Fatty acyls;  FA12 Oxygenated hydrocarbons;   C15499  Pentane-2,4-dione",1.13.11.50,R07183
Acetone,cpd:C15512,Phenylacetone;1-Phenyl-2-propanone,C9H10O,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  C15512,1.14.13.92,R07201
Acetone,cpd:C17497,Zingerone;Zingiberone;Vanillylacetone;[0]-Paradol,C11H14O3,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1502 Alkyl catechols and derivatives;    C17497  Zingerone;Phytochemical compounds [BR:br08003]; Shikimate / acetate-malonate pathway derived compounds;  Others;   Zingiber derived compounds;    C17497  Zingerone,NA,NA
Acetone,cpd:C19122,Hexachloroacetone,C3Cl6O,NA,NA,Pesticides [BR:br08007]; Obsolete pesticides;  Herbicides;   Others;    C19122  Hexachloroacetone,NA,NA
Butyrate,cpd:C00109,2-Oxobutanoate;2-Ketobutyric acid;2-Oxobutyric acid;2-Oxobutyrate;2-Oxobutanoic acid;alpha-Ketobutyric acid;alpha-Ketobutyrate,C4H6O3,"Glycine, serine and threonine metabolism;Cysteine and methionine metabolism;Valine, leucine and isoleucine biosynthesis;Propanoate metabolism;C5-Branched dibasic acid metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;Isoleucine biosynthesis, pyruvate => 2-oxobutanoate;Isoleucine biosynthesis, threonine => 2-oxobutanoate => isoleucine",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00109  2-Oxobutanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C00109  2-Oxobutanoic acid,1.1.1.27;1.1.1.85;1.2.3.-;1.2.4.4;1.2.7.1;2.2.1.6;2.3.1.54;2.3.3.6;2.5.1.48;2.6.1.42;2.6.1.44;3.5.99.7;3.5.99.10;4.1.1.112;4.3.1.19;4.4.1.1;4.4.1.2;4.4.1.11,R00654 R00993 R00994 R00995 R00996 R00997 R00998 R00999;R01000 R01001 R01199 R01283 R04673 R04770 R04930 R05840;R06987 R08637 R08648 R10991 R10992 R10996 R11098
Butyrate,cpd:C00246,Butanoic acid;Butanoate;Butyrate;Butyric acid,C4H8O2,Butanoate metabolism;Metabolic pathways;Carbohydrate digestion and absorption;Protein digestion and absorption,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C00246  Butyrate; Butanoate; Lipids;  Fatty acids;   Saturated fatty acids;    C00246  Butyric acid (4:0);Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C00246  Butanoic acid;Phytochemical compounds [BR:br08003]; Fatty acids related compounds;  Fatty acids;   Saturated fatty acids;    C00246  Butyric acid,1.3.1.31;2.7.2.7;2.8.3.8;2.8.3.9;3.1.1.51;3.6.1.20;3.7.1.7;6.2.1.2,R01176 R01179 R01365 R01688 R01689 R01690 R03781 R04119
Butyrate,cpd:C00334,4-Aminobutanoate;4-Aminobutanoic acid;4-Aminobutyrate;4-Aminobutyric acid;gamma-Aminobutyric acid;GABA,C4H9NO2,"Alanine, aspartate and glutamate metabolism;Arginine and proline metabolism;beta-Alanine metabolism;Butanoate metabolism;Nicotinate and nicotinamide metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Quorum sensing;cAMP signaling pathway;Neuroactive ligand-receptor interaction;Synaptic vesicle cycle;Retrograde endocannabinoid signaling;GABAergic synapse;Taste transduction;Estrogen signaling pathway;GnRH secretion;Morphine addiction;Nicotine addiction","GABA (gamma-Aminobutyrate) shunt;GABA biosynthesis, eukaryotes, putrescine => GABA;GABA biosynthesis, prokaryotes, putrescine => GABA",Compounds with biological roles [BR:br08001]; Peptides;  Amino acids;   Other amino acids;    C00334  gamma-Aminobutyric acid;  Amines;   Biogenic amines;    C00334  gamma-Aminobutyric acid (GABA); Hormones and transmitters;  Neurotransmitters;   Amino acids;    C00334  GABA;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C00334  4-Aminobutanoic acid;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00058)]; N NERVOUS SYSTEM;  N03 ANTIEPILEPTICS;   N03A ANTIEPILEPTICS;    N03AG Fatty acid derivatives;     N03AG03 Aminobutyric acid;      D00058  gamma-Aminobutyric acid (JAN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00058)]; 2  Agents affecting individual organs;  21  Cardiovascular agents;   219  Miscellaneous;    2190  Miscellaneous;     D00058  gamma-Aminobutyric acid (JAN);Drug groups [BR:br08330(D00058)]; Neuropsychiatric agent;  DG01567  GABA-A receptor agonist;   D00058  gamma-Aminobutyric acid;  DG01565  GABA-B receptor agonist;   D00058  gamma-Aminobutyric acid;  DG03199  Antiepileptic agent;   DG02037  GABA mimetic antiepileptic;    D00058  gamma-Aminobutyric acid;Drug classes [BR:br08332(D00058)]; Neuropsychiatric agent;  DG03199  Antiepileptic agent;   D00058  gamma-Aminobutyric acid;Target-based classification of drugs [BR:br08310(D00058)]; G Protein-coupled receptors;  Metabotropic glutamate receptor family;   GABA (metabotropic);    GABBR;     D00058  gamma-Aminobutyric acid (JAN) &lt;JP&gt;; Ion channels;  Ligand-gated ion channels;   GABA (ionotropic);    GABR;     D00058  gamma-Aminobutyric acid (JAN) &lt;JP&gt;,1.2.1.3;1.2.1.19;1.2.1.-;1.5.3.19;2.1.4.1;2.6.1.19;2.6.1.96;3.4.13.18;3.4.13.20;3.5.1.63;3.5.1.94;3.5.3.7;4.1.1.15;6.3.2.11,R00261 R01648 R01986 R01987 R01989 R01990 R01991 R01992;R02549 R07419 R10102 R10178 R10179
Butyrate,cpd:C01188,3-Hydroxy-2-methylpropanoate;3-Hydroxyisobutyrate;3-Hydroxyisobutyric acid,C4H8O3,NA,NA,NA,1.1.1.31;3.1.2.4,R02047 R03352
Butyrate,cpd:C01205,(R)-3-Amino-2-methylpropanoate;(R)-3-Aminoisobutyrate;D-3-Aminoisobutanoate;(R)-beta-Aminoisobutyrate;(R)-3-Aminoisobutyric acid,C4H9NO2,"Pyrimidine metabolism;Valine, leucine and isoleucine degradation;Metabolic pathways","Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C01205  (R)-3-Aminoisobutyric acid,2.6.1.40;3.5.1.6,R02050 R04666
Butyrate,cpd:C02261,D-2-Aminobutyrate;D-2-Aminobutyric acid;D-2-Aminobutanoic acid;(R)-2-Aminobutanoic acid,C4H9NO2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C02261  (R)-2-Aminobutanoic acid,NA,NA
Butyrate,cpd:C02632,2-Methylpropanoate;2-Methylpropanoic acid;Isobutyric acid;Isobutanoate;Dimethylacetic acid;Isobutyrate,C4H8O2,Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Protein digestion and absorption,"Cumate degradation, p-cumate => 2-oxopent-4-enoate + 2-methylpropanoate",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C02632  2-Methylpropanoate,2.7.2.14;3.7.1.-,R04002 R05364
Butyrate,cpd:C03283,"L-2,4-Diaminobutanoate;alpha,gamma-Diaminobutyrate;L-2,4-Diaminobutyrate",C4H10N2O2,"Glycine, serine and threonine metabolism;Metabolic pathways;Microbial metabolism in diverse environments;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Ectoine biosynthesis, aspartate => ectoine;Ectoine degradation, ectoine => aspartate",NA,2.3.1.178;2.6.1.46;2.6.1.76;3.5.1.125;4.1.1.86,R02293 R06977 R06978 R07650 R09801
Butyrate,cpd:C03284,L-3-Aminoisobutanoate;(S)-3-Aminoisobutyrate;L-3-Aminoisobutyrate;(S)-3-Aminoisobutanoate;(S)-3-Amino-2-methylpropanoate;(S)-beta-Aminoisobutyrate;(S)-3-Aminoisobutyric acid,C4H9NO2,"Valine, leucine and isoleucine degradation;Metabolic pathways",NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C03284  (S)-3-Aminoisobutyric acid,2.6.1.18;2.6.1.22,R04187 R04188
Butyrate,cpd:C03634,"Phorbol 12,13-dibutanoate;Phorbol-12,13-dibutyrate",C28H40O8,NA,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010433 Tigliane and ingenane diterpenoids;     C03634  Phorbol 12,13-dibutanoate",3.1.1.51,R04119
Butyrate,cpd:C05100,3-Ureidoisobutyrate,C5H10N2O3,NA,NA,NA,NA,NA
Butyrate,cpd:C05984,2-Hydroxybutanoic acid;2-Hydroxybutyrate;2-Hydroxybutyric acid;(S)-2-Hydroxybutanoate;(2S)-2-Hydroxybutanoic acid,C4H8O3,Propanoate metabolism,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C05984  2-Hydroxybutanoic acid,1.1.1.27,R01000
Butyrate,cpd:C06001,(S)-3-Hydroxyisobutyrate,C4H8O3,"Valine, leucine and isoleucine degradation;Metabolic pathways",NA,NA,1.1.1.31;3.1.2.4,R05064 R05066
Butyrate,cpd:C06054,2-Oxo-3-hydroxy-4-phosphobutanoate;alpha-Keto-3-hydroxy-4-phosphobutyrate;(3R)-3-Hydroxy-2-oxo-4-phosphonooxybutanoate;(3R)-3-Hydroxy-2-oxo-4-phosphooxybutanoate,C4H7O8P,Vitamin B6 metabolism;Metabolic pathways;Biosynthesis of cofactors,"Pyridoxal-P biosynthesis, erythrose-4P => pyridoxal-P",NA,1.1.1.290;2.6.1.52,R04210 R05085
Butyrate,cpd:C06143,Poly-beta-hydroxybutyrate,(C4H6O2)n,Butanoate metabolism;Metabolic pathways,NA,NA,2.3.1.304;3.1.1.75,R04254 R05118
Butyrate,cpd:C06435,5'-Butyrylphosphoinosine;Inosine 5'-phosphobutyrate,C14H19N4O9P,Purine metabolism,NA,NA,3.6.1.20,R01690
Butyrate,cpd:C06442,"N(gamma)-Acetyldiaminobutyrate;N4-Acetyl-L-2,4-diaminobutyrate;N4-Acetyl-L-2,4-diaminobutanoate;(2S)-4-Acetamido-2-aminobutanoate",C6H12N2O3,"Glycine, serine and threonine metabolism;Metabolic pathways;Microbial metabolism in diverse environments","Ectoine biosynthesis, aspartate => ectoine",NA,2.3.1.178;4.2.1.108,R06978 R06979
Butyrate,cpd:C07335,2-Amino-3-oxo-4-phosphonooxybutyrate;L-2-Amino-3-oxo-4-phosphonooxybutyrate;(2S)-2-Amino-3-oxo-4-phosphonooxybutanoate,C4H8NO7P,Vitamin B6 metabolism;Metabolic pathways;Biosynthesis of cofactors,"Pyridoxal-P biosynthesis, erythrose-4P => pyridoxal-P",NA,1.1.1.262,R05681 R07406
Butyrate,cpd:C08489,"(Z)-3,5-Hexadienyl butyrate",C10H16O2,NA,NA,NA,NA,NA
Butyrate,cpd:C09086,Diterpenoid EF-D;12-Deoxy-phorbol-13-alpha-methylbutyrate-20-acetate,C27H38O7,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010433 Tigliane and ingenane diterpenoids;     C09086  Diterpenoid EF-D;Phytochemical compounds [BR:br08003]; Terpenoids;  Diterpenoids (C20);   Tiglianes;    C09086  Diterpenoid EF-D,NA,NA
Butyrate,cpd:C12045,Ansamitocin P-3;Ansamitosin P-3;Antibiotic C15003P3;C15003P3;Maytansinol isobutyrate;2'-De(acetylmethylamino)-2'-methylmaytansine,C32H43ClN2O9,Biosynthesis of ansamycins;Type I polyketide structures;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PK  Polyketides;  PK05 Ansamycins and related polyketides;   C12045  Ansamitocin P3;Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C12045,2.1.1.-,R09856
Butyrate,cpd:C13358,Hydrocortisone butyrate propionate;Hydrocortisone buteprate;Hydrocortisone probutate,C28H40O7,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C13358  Hydrocortisone butyrate propionate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01886)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC03 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AA Corticosteroids, weak (group I);     D07AA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;    D07AB Corticosteroids, moderately potent (group II);     D07AB11 Hydrocortisone buteprate;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XA Corticosteroids, weak, other combinations;     D07XA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB09 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB03 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D01886)]; Dermatological Agents;  Dermatitis and Pruitus Agents;   Glucocorticoids, Medium Potency;    Hydrocortisone;     D01886  Hydrocortisone probutate (USAN); Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Hydrocortisone;   D01886  Hydrocortisone probutate (USAN);Therapeutic category of drugs in Japan [BR:br08301(D01886)]; 2  Agents affecting individual organs;  26  Epidermides;   264  Analgesics, anti-itchings, astringents, anti-inflammatory agents;    2646  Adrenocorticotropic hormones;     D01886  Hydrocortisone probutate (USAN); Hydrocortisone butyrate propionate (JAN);Drug groups [BR:br08330(D01886)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00012  Hydrocortisone;     D01886  Hydrocortisone probutate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D01886  Hydrocortisone probutate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG00012  Hydrocortisone;    D01886  Hydrocortisone probutate;Drug classes [BR:br08332(D01886)]; Anti-inflammatory;  DG01955  Corticosteroid;   D01886  Hydrocortisone probutate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D01886  Hydrocortisone probutate;Target-based classification of drugs [BR:br08310(D01886)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;Drug metabolizing enzymes and transporters [br08309.html(D01886)]; Drug metabolizing enzymes;  D01886;Topical steroids potency [br08317.html(D01886)]; Classification in Japan;  D01886",NA,NA
Butyrate,cpd:C13870,Tributyrin;Glyceryl tributyrate;Glycerol tributyrate,C15H26O6,NA,NA,Lipids [BR:br08002]; GL  Glycerolipids;  GL03 Triradylglycerols;   GL0301 Triacylglycerols;    C13870  Tributyrin,NA,NA
Butyrate,cpd:C15767,4-(L-gamma-Glutamylamino)butanoate;4-(gamma-L-Glutamylamino)butanoate;gamma-Glutamyl-gamma-aminobutyrate;4-(Glutamylamino)butanoate;gamma-Glutamyl-GABA,C9H16N2O5,Arginine and proline metabolism;Metabolic pathways,"GABA biosynthesis, prokaryotes, putrescine => GABA",NA,1.2.1.99;3.5.1.94,R07417 R07418 R07419
Butyrate,cpd:C15987,4-Methylaminobutyrate;gamma-N-Methylaminobutyrate,C5H11NO2,Nicotinate and nicotinamide metabolism;Metabolic pathways;Microbial metabolism in diverse environments,"Nicotine degradation, pyridine pathway, nicotine => 2,6-dihydroxypyridine/succinate semialdehyde",NA,1.5.3.19;1.5.3.21;3.7.1.19,R07515 R10101 R10102
Butyrate,cpd:C18319,2-Methylbutyrate;2-Methylbutyric acid;2-Methylbutanoic acid,C5H10O2,Protein digestion and absorption,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C18319  2-Methylbutanoic acid,NA,NA
Butyrate,cpd:C19929,"N(alpha)-Acetyl-L-2,4-diaminobutyrate;N-alpha-Acetyl-L-2,4-diaminobutyrate;N2-Acetyl-L-2,4-diaminobutanoate;(2S)-2-Acetamido-4-aminobutanoate",C6H12N2O3,"Glycine, serine and threonine metabolism;Metabolic pathways;Microbial metabolism in diverse environments","Ectoine degradation, ectoine => aspartate",NA,3.5.1.125;3.5.4.44,R09800 R09801
Butyrate,cpd:C20827,3-Hydroxyisovalerate;3-Hydroxy-3-methylbutyrate,C5H10O3,"Valine, leucine and isoleucine degradation;Metabolic pathways",NA,NA,NA,R10759
Butyrate,cpd:C20846,3-Oxo-3-ureidoisobutyrate,C5H8N2O4,Pyrimidine metabolism;Metabolic pathways,NA,NA,3.5.1.95;3.5.2.1,R10777 R10778
Butyrate,cpd:C21015,gamma-L-Glutamyl-L-2-aminobutyrate,C9H16N2O5,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,6.3.2.2;6.3.2.3,R10993 R10994
Butyrate,cpd:C21029,(R)-3-Ureidoisobutyrate;(R)-N-Carbamyl-beta-aminoisobutyrate,C5H10N2O3,Pyrimidine metabolism;Metabolic pathways,"Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate",NA,3.5.1.6;3.5.2.2,R03055 R04666
Butyrate,cpd:C21289,(R)-3-(Indol-3-yl)-2-oxobutyrate;(R)-3-(Indol-3-yl)-2-oxobutanoate;(R)-beta-Methylindolepyruvate,C12H11NO3,NA,NA,NA,1.1.1.397;2.1.1.47,R01972 R11336
Butyrate,cpd:C21297,2-Hydroxy-2-methylpropanoate;2-Hydroxyisobutyrate,C4H8O3,NA,NA,NA,1.2.1.98,R11350
Butyrate,cpd:C21793,4-Phenylbutyrate;4-Phenylbutanoate;4-Phenylbutyric acid,C10H12O2,NA,NA,NA,NA,NA
Formate,cpd:C00058,Formate;Methanoic acid;Formic acid,CH2O2,Phosphonate and phosphinate metabolism;Pyruvate metabolism;Chloroalkane and chloroalkene degradation;Glyoxylate and dicarboxylate metabolism;Methane metabolism;Carbon fixation pathways in prokaryotes;Nitrogen metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism;Degradation of aromatic compounds,Reductive acetyl-CoA pathway (Wood-Ljungdahl pathway),Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C00058  Formate; Methanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C00058  Formic acid,1.1.1.306;1.1.98.6;1.2.1.46;1.2.2.1;1.2.7.12;1.2.98.1;1.8.98.6;1.13.11.41;1.13.11.53;1.13.11.54;1.13.11.72;1.13.11.81;1.13.11.89;1.14.12.11;1.14.13.-;1.14.14.14;1.14.14.154;1.14.15.36;1.14.99.21;1.17.1.9;1.17.1.10;1.17.1.11;1.17.2.3;1.17.5.3;1.17.98.3;1.17.98.4;1.17.98.-;2.3.1.54;2.7.2.6;2.8.3.16;3.1.2.10;3.1.2.12;3.5.1.8;3.5.1.9;3.5.1.10;3.5.1.15;3.5.1.31;3.5.1.49;3.5.1.56;3.5.1.68;3.5.1.88;3.5.1.91;3.5.1.102;3.5.1.106;3.5.1.-;3.5.4.16;3.5.4.25;3.5.4.39;3.5.5.-;3.7.1.9;3.7.1.-;4.1.1.2;4.1.2.36;4.1.2.44;4.1.3.-;4.1.99.5;4.1.99.12;4.1.99.17;4.1.99.23;6.3.1.21;6.3.4.3;6.3.4.17;6.3.4.23,R00134 R00152 R00212 R00424 R00425 R00518 R00519 R00521;R00522 R00524 R00525 R00526 R00527 R00604 R00614 R00653;R00753 R00943 R00944 R00988 R01305 R01959 R02238 R02351;R02509 R02604 R03087 R03146 R03204 R03215 R03472 R03728;R03907 R04268 R04283 R04488 R04911 R05046 R05296 R05635;R05640 R05731 R05865 R06940 R06974 R06975 R06987 R07281;R07290 R07303 R07363 R07364 R07662 R07983 R08060 R08451;R08864 R09094 R09126 R09145 R09152 R09185 R09374 R09481;R09494 R09556 R10301 R10348 R10356 R10376 R10511 R10515;R10797 R11037 R11313 R11592 R11633 R11634 R11635 R11636;R11818 R11919 R11944 R12118 R12121 R12317 R12322 R12323;R12451 R12754
Formate,cpd:C02137,alpha-Oxo-benzeneacetic acid;Benzoylformate;Benzoylformic acid;Phenylglyoxylic acid;Phenylglyoxylate;2-Oxo-2-phenylacetate,C8H6O3,Phenylalanine metabolism;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.1.1.379;1.1.1.-;1.1.99.31;1.2.1.58;3.1.2.25;4.1.1.7,R01764 R02450 R03790 R03792 R03793 R07294 R07664
Formate,cpd:C03590,4-Hydroxyphenylglyoxylate;4-Hydroxybenzoylformate;4-Hydroxyphenylglyoxylic acid;2-(4-Hydroxyphenyl)-2-oxoacetate,C8H6O4,Monobactam biosynthesis;Aminobenzoate degradation;Biosynthesis of vancomycin group antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,NA,NA,1.1.3.46;1.1.99.31;2.6.1.72;2.6.1.103;4.1.1.7,R02672 R04160 R04234 R06626 R06633
Formate,cpd:C05613,Benzylformate,C8H8O2,NA,NA,NA,NA,NA
Formate,cpd:C06456,Phosphonoformate;Foscarmet;Foscarnet,CH3O5P,Phosphonate and phosphinate metabolism;Biosynthesis of secondary metabolites,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; J ANTIINFECTIVES FOR SYSTEMIC USE;  J05 ANTIVIRALS FOR SYSTEMIC USE;   J05A DIRECT ACTING ANTIVIRALS;    J05AD Phosphonic acid derivatives;     J05AD01 Foscarnet;      C06456  Phosphonoformate;Drug groups [BR:br08330]; Antiviral;  DG01937  Anti-cytomegalovirus agent;   DG00651  Foscarnet;    C06456  Phosphonoformate,2.7.7.93,R08866 R08867
Formate,cpd:C12293,Isoamyl formate,C6H12O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C12293  Isoamyl formate,NA,NA
Formate,cpd:C12294,Geranyl formate,C11H18O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C12294  Geranyl formate,NA,NA
Formate,cpd:C12295,Citronellyl formate,C11H20O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010201 Acyclic monoterpenoids;     C12295  Citronellyl formate,NA,NA
Formate,cpd:C14346,"Bisphenol A bis(chloroformate);2,2-Bis[p-(chloroformyloxy)phenyl]propane",C17H14Cl2O4,NA,NA,NA,NA,NA
Formate,cpd:C17945,Phosphonoformyl-CMP;CMP-5'-phosphonoformate,C10H15N3O12P2,Phosphonate and phosphinate metabolism;Biosynthesis of secondary metabolites,NA,NA,2.7.7.93,R08867 R08887
Formate,cpd:C18586,"Calcium formate;Formic acid, calcium salt",(CHO2)2. Ca,NA,NA,Pesticides [BR:br08007]; Pesticides;  Plant growth regulators;   Others;    C18586  Calcium formate,NA,NA
Formate,cpd:C21713,Butyl formate,C5H10O2,NA,NA,NA,1.14.15.23,R11812
Glycolate,cpd:C00160,Glycolate;Glycolic acid;Hydroxyacetic acid,C2H4O3,Chlorocyclohexane and chlorobenzene degradation;Chloroalkane and chloroalkene degradation;Glyoxylate and dicarboxylate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism,Photorespiration,NA,1.1.1.26;1.1.1.29;1.1.1.79;1.1.3.15;1.1.99.14;1.2.1.21;3.1.3.18;3.7.1.28;3.7.1.-;3.8.1.2;3.8.1.3;4.2.99.12,R00465 R00475 R00476 R00717 R01333 R01334 R01335 R01336;R02336 R02857 R05287 R12802
Glycolate,cpd:C00603,(S)-Ureidoglycolate;(-)-Ureidoglycolate,C3H6N2O4,Purine metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.1.1.154;1.1.1.350;3.5.1.116;3.5.3.4;3.5.3.26;4.3.2.3,R00469 R00776 R02422 R02935 R02936 R05554
Glycolate,cpd:C00988,2-Phosphoglycolate;Phosphoglycolic acid,C2H5O6P,Glyoxylate and dicarboxylate metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Carbon metabolism,Photorespiration,NA,3.1.3.18;4.1.1.39,R01334 R03140
Glycolate,cpd:C02086,Thioglycolate;Mercaptoacetic acid;Mercaptoethanoic acid;Thioglycolic acid,C2H4O2S,NA,NA,NA,4.5.1.5,R04003
Glycolate,cpd:C02766,(R)-Ureidoglycolate;(+)-Ureidoglycolate;(+)-Ureidoglycolic acid,C3H6N2O4,NA,NA,NA,NA,NA
Glycolate,cpd:C03173,S-Methylthioglycolate;(Methylsulfanyl)acetic acid;(Methylthio)acetic acid;(Methylsulfanyl)acetate,C3H6O2S,NA,NA,NA,2.1.1.3,R04153
Glycolate,cpd:C03303,[Peptide]-(2S)-2-hydroxyglycine;Peptidylamidoglycolate;Peptidyl(2-hydroxyglycine),C4H7N2O4R(C2H2NOR)n,NA,NA,NA,1.14.17.3;4.3.2.5,R03874 R03912
Glycolate,cpd:C03459,2-Hydroxy-3-oxosuccinate;Oxaloglycolate,C4H4O6,Glyoxylate and dicarboxylate metabolism;Metabolic pathways,NA,NA,1.1.1.92;1.1.1.93,R01749 R01750 R02545 R03128 R06180
Isopropanol,cpd:C01845,Propan-2-ol;2-Propanol;Isopropanol;Isopropyl alcohol,C3H8O,Butanoate metabolism;Metabolic pathways,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00137)]; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AX Other antiseptics and disinfectants;     D08AX05 Isopropanol;      D00137  Isopropyl alcohol (USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00137)]; 2  Agents affecting individual organs;  26  Epidermides;   261  Antimicrobial agents;    2615  Alcohols;     D00137  Isopropyl alcohol (USP); Isopropanol (JP18);Classification of Japanese OTC drugs [BR:br08313(D00137)]; Agents for integumentary system;  54 Disinfectants (incl. special bandages);   D00137  Isopropyl alcohol (USP);Risk category of Japanese OTC drugs [BR:br08312(D00137)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Isopropanol;    D00137  Isopropyl alcohol (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00137)]; Chemicals;  D00137  Isopropanol,1.1.1.80;1.1.1.-;1.14.13.227,R01550 R10702 R10703
Isovalerate,cpd:C00141,3-Methyl-2-oxobutanoic acid;3-Methyl-2-oxobutyric acid;3-Methyl-2-oxobutanoate;2-Oxo-3-methylbutanoate;2-Oxoisovalerate;2-Oxoisopentanoate;alpha-Ketovaline;2-Ketovaline;2-Keto-3-methylbutyric acid;alpha-Ketoisovalerate,C5H8O3,"Valine, leucine and isoleucine degradation;Valine, leucine and isoleucine biosynthesis;Pantothenate and CoA biosynthesis;Lipoic acid metabolism;Glucosinolate biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;Pantothenate biosynthesis, valine/L-aspartate => pantothenate;Leucine biosynthesis, 2-oxoisovalerate => 2-oxoisocaproate;Pantothenate biosynthesis, 2-oxoisovalerate/spermine => pantothenate;Coenzyme A biosynthesis, archaea, 2-oxoisovalerate => 4-phosphopantoate => CoA",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00141  2-Oxoisovalerate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C00141  3-Methyl-2-oxobutanoic acid,1.1.1.84;1.2.1.25;1.2.4.4;1.2.7.7;1.4.1.8;1.4.1.9;1.4.1.23;2.1.2.11;2.3.3.13;2.6.1.6;2.6.1.32;2.6.1.42;2.6.1.66;4.1.2.12;4.2.1.9,R01209 R01210 R01211 R01212 R01213 R01214 R01215 R01216;R01226 R01434 R01701 R02200 R04441 R07160 R07599
Isovalerate,cpd:C04039,"2,3-Dihydroxy-3-methylbutanoate;2,3-Dihydroxy-isovalerate;2,3-Dihydroxy-isovaleric acid",C5H10O4,NA,NA,NA,1.1.1.86;4.2.1.9,R01209 R03051
Isovalerate,cpd:C04181,3-Hydroxy-3-methyl-2-oxobutanoic acid;3-Hydroxy-3-methyl-2-oxobutanoate;2-Oxo-3-hydroxyisovalerate,C5H8O4,"Valine, leucine and isoleucine biosynthesis;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C04181  3-Hydroxy-3-methyl-2-oxobutanoic acid,1.1.1.86;5.4.99.3,R03052 R04440 R05071
Isovalerate,cpd:C04272,"(R)-2,3-Dihydroxy-3-methylbutanoate;(R)-2,3-Dihydroxy-isovalerate;(R)-2,3-Dihydroxy-isovaleric acid;(2R)-2,3-Dihydroxy-3-methylbutanoate;(2R)-2,3-Dihydroxy-3-methylbutanoic acid",C5H10O4,"Valine, leucine and isoleucine biosynthesis;Pantothenate and CoA biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C04272  (2R)-2,3-Dihydroxy-3-methylbutanoic acid",1.1.1.86;1.1.1.382;1.1.1.383;4.2.1.9,R04439 R04440 R04441 R10916
Isovalerate,cpd:C08262,3-Methylbutanoic acid;Isovaleric acid;Isovalerate,C5H10O2,Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of secondary metabolites;Protein digestion and absorption,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C08262  3-Methylbutanoic acid,NA,R08411 R08412
Isovalerate,cpd:C12289,Isoamyl isovalerate,C10H20O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0701 Wax monoesters;    C12289  Isoamyl isovalerate,NA,NA
Isovalerate,cpd:C12290,Ethyl isovalerate,C7H14O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C12290  Ethyl isovalerate,NA,NA
Isovalerate,cpd:C16920,Bornyl isovalerate;Bornyval;Hysterol,C15H26O2,NA,NA,NA,NA,NA
Isovalerate,cpd:C19318,Allyl isovalerate,C8H14O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0701 Wax monoesters;    C19318  Allyl isovalerate,NA,NA
Isovalerate,cpd:C20827,3-Hydroxyisovalerate;3-Hydroxy-3-methylbutyrate,C5H10O3,"Valine, leucine and isoleucine degradation;Metabolic pathways",NA,NA,NA,R10759
Lactate,cpd:C00186,(S)-Lactate;L-Lactate;L-Lactic acid,C3H6O3,Glycolysis / Gluconeogenesis;Fructose and mannose metabolism;Pyruvate metabolism;Propanoate metabolism;Styrene degradation;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;cAMP signaling pathway;HIF-1 signaling pathway;Efferocytosis;Glucagon signaling pathway;Central carbon metabolism in cancer,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Hydroxycarboxylic acids;    C00186  L-Lactate; (S)-2-Hydroxypropanoate,1.1.1.27;1.1.1.436;1.1.2.3;1.1.3.2;1.1.99.7;1.2.1.22;1.13.12.4;2.8.3.1;3.7.1.26;4.1.1.101;4.1.2.36;5.1.2.1,R00196 R00319 R00703 R00753 R01446 R01447 R01449 R01450;R05508 R10691 R11074 R11996 R13050
Lactate,cpd:C00256,(R)-Lactate;D-Lactate;D-Lactic acid;D-2-Hydroxypropanoic acid;D-2-Hydroxypropionic acid,C3H6O3,Pyruvate metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Vancomycin resistance,NA,NA,1.1.1.28;1.1.1.436;1.1.2.4;1.1.2.5;1.1.5.12;1.1.99.6;1.1.99.40;1.2.1.23;3.1.2.6;3.1.6.17;4.2.1.126;4.2.1.130;5.1.2.1;6.1.2.1,R00197 R00198 R00297 R00704 R01448 R01450 R01735 R01736;R08555 R09588 R09796 R11591 R11593 R13049
Lactate,cpd:C00900,2-Acetolactate;2-Hydroxy-2-methyl-3-oxobutanoic acid,C5H8O4,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C00900  2-Hydroxy-2-methyl-3-oxobutanoic acid,1.1.1.86;2.2.1.6;5.4.99.3,R00006 R03050 R03051 R03052
Lactate,cpd:C00994,D-Prephenyllactate,C13H14O8,NA,NA,NA,NA,NA
Lactate,cpd:C01207,"3-(3,4-Dihydroxyphenyl)lactate;3,4-Dihydroxyphenyllactic acid",C9H10O5,NA,NA,NA,NA,NA
Lactate,cpd:C01432,Lactate;Lactic acid;2-Hydroxypropanoic acid;2-Hydroxypropionic acid,C3H6O3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00111)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;   G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;    G01AD Organic acids;     G01AD01 Lactic acid;      D00111  Lactic acid (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00111)]; 7  Agents not mainly for therapeutic purpose;  71  Dispensing medicines;   714  Flavorings, deodorants, coloring agents;    7149  Others;     D00111  Lactic acid (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00111)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Lactic acid;    D00111  Lactic acid (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00111)]; Chemicals;  D00111  Lactic acid",1.1.1.436;3.5.1.124,R11562 R11563 R11564 R11676
Lactate,cpd:C02043,Indolelactate,C11H11NO3,NA,NA,NA,NA,NA
Lactate,cpd:C02914,(S)-2-O-Sulfolactate,C3H6O6S,NA,NA,NA,NA,NA
Lactate,cpd:C03672,3-(4-Hydroxyphenyl)lactate;4-Hydroxyphenyllactate;p-Hydroxyphenyllactate;2-Hydroxy-3-(4-hydroxyphenyl)propanoate,C9H10O4,NA,NA,NA,NA,NA
Lactate,cpd:C03817,(S)-3-(Imidazol-5-yl)lactate,C6H8N2O3,NA,NA,NA,1.1.1.111,R04185 R04186
Lactate,cpd:C03964,(R)-3-(4-Hydroxyphenyl)lactate,C9H10O4,Ubiquinone and other terpenoid-quinone biosynthesis;Tyrosine metabolism;Metabolic pathways;Biosynthesis of secondary metabolites,NA,NA,1.1.1.110;1.1.1.237;2.8.3.17;4.2.1.-,R03337 R03339 R08766 R12492
Lactate,cpd:C04367,"3-(3,5-Diiodo-4-hydroxyphenyl)lactate",C9H8I2O4,NA,NA,NA,1.1.1.96,R03431
Lactate,cpd:C05568,Imidazole lactate;Imidazole lactic acid;2-Hydroxy-3-(1H-imidazol-5-yl)-propanoic acid,C6H8N2O3,Histidine metabolism;Metabolic pathways,NA,NA,NA,R04876
Lactate,cpd:C05607,Phenyllactate;(R)-Phenyllactate;(R)-3-(phenyl)lactate,C9H10O3,"Phenylalanine metabolism;Tropane, piperidine and pyridine alkaloid biosynthesis;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Metabolic pathways;Biosynthesis of secondary metabolites",NA,NA,1.1.1.110;1.1.1.237;2.4.1.-;2.8.3.17,R01370 R01371 R07796 R12916
Lactate,cpd:C05657,6-Hydroxyindolelactate,C11H11NO4,NA,NA,NA,NA,NA
Lactate,cpd:C05823,3-Mercaptolactate;L-3-Mercaptolactate;(R)-3-Mercaptolactate,C3H6O3S,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,1.1.1.27,R03104
Lactate,cpd:C06010,(S)-2-Acetolactate;(S)-2-Hydroxy-2-methyl-3-oxobutanoate;(2S)-2-Hydroxy-2-methyl-3-oxobutanoate;(2S)-2-Hydroxy-2-methyl-3-oxobutanoic acid,C5H8O4,"Valine, leucine and isoleucine biosynthesis;Butanoate metabolism;C5-Branched dibasic acid metabolism;Pantothenate and CoA biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C06010  (2S)-2-Hydroxy-2-methyl-3-oxobutanoic acid,1.1.1.86;1.1.1.382;1.1.1.383;2.2.1.6;4.1.1.5;5.4.99.3,R00226 R02948 R04439 R04672 R05071 R10506 R10916
Lactate,cpd:C11499,(S)-3-Sulfolactate;(2S)-3-Sulfolactate,C3H6O6S,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,1.1.1.310;1.2.1.97,R05693 R05694 R11677 R11678
Lactate,cpd:C11536,(2R)-O-Phospho-3-sulfolactate;(2R)-Phosphosulfolactate,C3H7O9PS,Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,Coenzyme M biosynthesis,NA,3.1.3.71;4.4.1.19,R05789 R07476
Lactate,cpd:C11537,(2R)-3-Sulfolactate;(R)-3-Sulfolactate,C3H6O6S,Cysteine and methionine metabolism;Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,Coenzyme M biosynthesis,NA,1.1.1.37;1.1.1.308;1.1.1.337;1.1.1.338;3.1.3.71;4.4.1.24,R05789 R07136 R07137 R07633 R09545
Lactate,cpd:C12677,Acrinol;Ethacridine lactate,C15H15N3O. C3H6O3,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Inorganic and organic chemicals;   Acrinol hydrate;    C12677  Acrinol;Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  951  Antimicrobials for dermatologic use;   9519  Other antimicrobials for dermatologic use;    C12677  Acrinol;  954  Anti-dermoinfectives;   9549  Other anti-dermoinfectives;    C12677  Acrinol,NA,NA
Lactate,cpd:C16069,3-Sulfolactate,C3H6O6S,NA,NA,NA,NA,R08590
Lactate,cpd:C17205,(R)-2-O-Sulfolactate,C3H6O6S,NA,NA,NA,3.1.6.17,R01448
Lactate,cpd:C17382,Ferrous lactate,C6H10FeO6,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Inorganic and organic chemicals;   Ferrous lactate;    C17382  Ferrous lactate,NA,NA
Lactate,cpd:C17389,Zinc lactate,C6H10O6Zn,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Third-class OTC drugs;  Inorganic and organic chemicals;   Zinc lactate;    C17389  Zinc lactate,NA,NA
Lactate,cpd:C19156,(2S)-2-Phospholactate,C3H7O6P,Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,"F420 biosynthesis, archaea",NA,2.7.7.68,R09397
Lactate,cpd:C19694,D-Alanyl-(R)-lactate;D-Alanyl-D-lactate;(2R)-2-(D-Alanyloxy)propanoic acid;(R)-2-[(R)-2-Aminopropanoyloxy]propanoic acid,C6H11NO4,Vancomycin resistance,NA,NA,6.1.2.1,R09588
Lactate,cpd:C20869,UDPMurNAc(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Lac);UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-lactate;UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-lactate,C40H64N8O27P2,Vancomycin resistance,NA,NA,NA,NA
Lactate,cpd:C20875,Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-lactate;GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Lac)-diphosphoundecaprenol;GlcNAc-(1->4)-MurNAc(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Lac)-diphosphoundecaprenol,C94H155N7O27P2,Vancomycin resistance,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C20875  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-lactate,NA,NA
Lactate,cpd:C20880,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-LL-2,6-diaminopimeloyl-D-alanyl-D-lactate;UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-LL-2,6-diaminopimeloyl-D-alanyl-D-lactate",C41H64N8O29P2,Vancomycin resistance,NA,NA,NA,NA
Lactate,cpd:C20881,"Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-LL-2,6-diaminopimeloyl-D-alanyl-D-Lactate;Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-LL-2,6-diaminopimeloyl-D-alanyl-D-Lactate",C95H155N7O29P2,Vancomycin resistance,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C20881  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-LL-2,6-diaminopimeloyl-D-alanyl-D-Lactate",NA,NA
Lactate,cpd:C20882,"Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-LL-2,6-diaminopimeloyl-(glycyl)-D-alanyl-D-lactate;Und-PP-MurNAc-(GlcNAc)-L-Ala-D-Glu-LL-dap-(Gly)-D-Ala-D-Lac;Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-LL-2,6-diaminopimeloyl-(glycyl)-D-alanyl-D-lactate",C97H158N8O30P2,Vancomycin resistance,NA,"Lipids [BR:br08002]; PR  Prenol lipids;  PR03 Polyprenols;   PR0303 Bactoprenol diphosphates;    C20882  Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-LL-2,6-diaminopimeloyl-(glycyl)-D-alanyl-D-lactate",NA,NA
Lactate,cpd:C22006,(R)-(Indol-3-yl)lactate;(R)-3-(Indol-3-yl)lactate,C11H11NO3,Tryptophan metabolism;Metabolic pathways,NA,NA,1.1.1.110;2.8.3.17,R12256 R12493
Lactate,cpd:C22038,"(R)-3-(3,4-Dihydroxyphenyl)lactate",C9H10O5,Tyrosine metabolism;Metabolic pathways,NA,NA,1.1.1.237;2.3.1.140,R03373 R03374 R08847 R12252
Methanol,cpd:C00132,Methanol;Methyl alcohol;CH3OH,CH4O,Butanoate metabolism;Methane metabolism;Indole alkaloid biosynthesis;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism;Degradation of aromatic compounds,"Methane oxidation, methanotroph, methane => formaldehyde;Methanogenesis, methanol => methane",NA,1.1.1.244;1.1.2.7;1.1.2.10;1.1.3.13;1.1.99.37;1.2.98.1;1.11.1.6;1.11.1.7;1.11.1.21;1.13.11.8;1.13.11.-;1.14.13.25;1.14.14.117;1.14.18.3;2.1.1.90;2.1.1.246;2.3.1.152;2.3.1.232;3.1.1.11;3.1.1.44;3.1.1.59;3.1.1.61;3.1.1.78;3.1.1.82;3.1.1.85;3.1.1.95;3.1.1.97;3.1.1.100;3.1.1.114;3.1.1.122;3.1.1.-;3.1.6.16;3.3.2.14,R00602 R00605 R00608 R00614 R01142 R01143 R01144 R01145;R01146 R02362 R02624 R03551 R04280 R04384 R04409 R04608;R05825 R06250 R06685 R06729 R08149 R08150 R08974 R08975;R09061 R09098 R09273 R09274 R09337 R09518 R09553 R09725;R09846 R10319 R10320 R10545 R10681 R10705 R10983 R11166;R11189 R13238 R13239
Methanol,cpd:C00556,Benzyl alcohol;alpha-Hydroxytoluene;Benzenemethanol;Phenylmethanol;Phenylcarbinol;Hydroxymethylbenzene,C7H8O,Toluene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Toluene degradation, toluene => benzoate","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00077)]; P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS;  P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS;   P03A ECTOPARASITICIDES, INCL. SCABICIDES;    P03AX Other ectoparasiticides, incl. scabicides;     P03AX06 Benzyl alcohol;      D00077  Benzyl alcohol (JP18/NF/INN);Risk category of Japanese OTC drugs [BR:br08312(D00077)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Benzyl alcohol;    D00077  Benzyl alcohol (JP18/NF/INN);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00077)]; Chemicals;  D00077  Benzyl alcohol;New drug approvals in the USA [br08319.html(D00077)]; New molecular entities and new therapeutic biological products;  D00077;New drug approvals in the USA, Europe and Japan [br08328.html(D00077)]; Approval dates by FDA, EMA and PMDA;  D00077",1.1.1.90;1.14.13.-;1.14.15.26;2.3.1.196;2.3.1.224;3.1.1.70;3.5.1.58;3.5.1.64,R01763 R02550 R02551 R02552 R03612 R09528 R10473
Methanol,cpd:C01279,4-Amino-5-hydroxymethyl-2-methylpyrimidine;Toxopyrimidine;4-Amino-2-methyl-5-pyrimidinemethanol;HMP,C6H9N3O,Thiamine metabolism;Metabolic pathways;Biosynthesis of cofactors;ABC transporters,"Thiamine salvage pathway, HMP/HET => TMP",NA,2.7.1.49;3.5.99.2;3.5.99.-,R02133 R03471 R09993
Methanol,cpd:C02390,Methylazoxymethanol;CH3-N(O)=N-CH2OH,C2H6N2O2,NA,NA,NA,2.4.1.171,R03547
Methanol,cpd:C02452,"(-)-Perillyl alcohol;Perillyl alcohol;(S)-Perillyl alcohol;[(4S)-4-(Prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol;p-Mentha-1,8-dien-7-ol;(-)-Perillylalcohol",C10H16O,Monoterpenoid biosynthesis;Limonene degradation;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C02452  Perillyl alcohol;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C02452  Perillyl alcohol,1.1.1.144;1.14.14.52;1.17.99.8,R02470 R03945 R12591
Methanol,cpd:C02909,(2-Naphthyl)methanol;2-Naphthalenemethanol;2-Hydroxymethylnaphthalene,C11H10O,Naphthalene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.1;1.14.12.12;1.14.13.-,R06926 R06927 R06930
Methanol,cpd:C03351,3-Hydroxybenzyl alcohol;3-Hydroxybenzenemethanol,C7H8O2,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.97;1.14.13.-,R04136 R07665
Methanol,cpd:C03947,"Glycerol 1,2-cyclic phosphate;1,3,2-Dioxaphospholane-4-methanol",C3H7O5P,NA,NA,NA,3.1.4.42,R02648
Methanol,cpd:C05562,1H-Imidazole-4-methanol;Imidazole-4-methanol,C4H6N2O,NA,NA,NA,NA,NA
Methanol,cpd:C06317,Vanillyl alcohol;4-Hydroxy-3-methoxy-benzenemethanol;4-Hydroxy-3-methoxybenzyl alcohol;4-Hydroxy-3-methoxybenzenemethanol,C8H10O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.1.3.38,R02877
Methanol,cpd:C07911,"Phenylpropanolamine;(+/-)-Phenylpropanolamine;(R*,S*)-(+/-)-alpha-(1-Aminoethyl)benzenemethanol;(+/-)-Norephedrine",C9H13NO,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08368)]; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01B NASAL DECONGESTANTS FOR SYSTEMIC USE;    R01BA Sympathomimetics;     R01BA01 Phenylpropanolamine;      D08368  Phenylpropanolamine (INN);Drug groups [BR:br08330(D08368)]; Cardiovascular agent;  DG01456  Adrenergic receptor agonist;   DG01041  Phenylpropanolamine;    D08368  Phenylpropanolamine; Metabolizing enzyme inhibitor;  DG01634  CYP1A2 inhibitor;   DG01041  Phenylpropanolamine;    D08368  Phenylpropanolamine;Target-based classification of drugs [BR:br08310(D08368)]; G Protein-coupled receptors;  Rhodopsin family;   Adrenaline;    ADRA1;     D08368  Phenylpropanolamine (INN);    ADRA2;     D08368  Phenylpropanolamine (INN);    ADRB;     D08368  Phenylpropanolamine (INN);Drug metabolizing enzymes and transporters [br08309.html(D08368)]; Drug metabolizing enzymes;  D08368;Narcotics and psychotropics in Japan [br08308.html(D08368)]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  D08368,NA,NA
Methanol,cpd:C08681,"Elatine;Aconitane-4-methanol, 20-ethyl-7,8-(methylenebis(oxy))-, 1,6,14,16-tetramethoxy-2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoate(ester), (1-alpha,6-beta,14-alpha,16-beta)-",C38H50N2O10,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived by amination reactions;   Terpenoid alkaloids;    C08681  Elatine,NA,NA
Methanol,cpd:C10354,2-Hydroxymethylanthraquinone;Anthraquinone-2-methanol,C15H10O3,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1304 Anthracenes and phenanthrenes;    C10354  2-Hydroxymethylanthraquinone;Phytochemical compounds [BR:br08003]; Polyketides;  Anthraquinones;   Anthraquinone type;    C10354  2-Hydroxymethylanthraquinone,NA,NA
Methanol,cpd:C11882,"Abietinol;Abietol;Abieta-7,13-dien-18-ol;((1R,4aR,4bR,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl)methanol",C20H32O,Diterpenoid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0104 C20 isoprenoids (diterpenes);    PR010405 Abietane diterpenoids;     C11882  Abietinol,1.14.14.144;1.14.14.145,R06351 R06354 R10077 R12122
Methanol,cpd:C13638,1-(4'-Hydroxyphenyl)ethanol;4-Hydroxy-alpha-methyl-benzenemethanol;4-(1-Hydroxyethyl)phenol,C8H10O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.1.1.-;1.14.13.-,R06890 R06891
Methanol,cpd:C13785,TRAM-3;(2-Chlorophenyl)diphenylmethanol,C19H15ClO,NA,NA,NA,NA,NA
Methanol,cpd:C14089,1-Hydroxymethylnaphthalene;1-Naphthalenemethanol,C11H10O,Naphthalene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.1;1.14.13.-,R06916 R06917
Methanol,cpd:C14672,p-Chlorobenzhydrol;(4-Chlorophenyl)phenylmethanol,C13H11ClO,NA,NA,NA,NA,NA
Methanol,cpd:C15008,"1,2,3,4,4a,9,10,10a-Octahydro-6-hydroxy-7-isopropyl-1,4a-dimethyl-1-phenanthrenemethanol",C20H30O2,NA,NA,NA,NA,NA
Methanol,cpd:C15161,"2,2-Dimethyl-3-(4-methoxyphenyl)-4-ethyl-7-hydroxy-2H-1-benzopyran-8-methanol diacetate",C25H28O6,NA,NA,NA,NA,NA
Methanol,cpd:C18215,Bis(4-hydroxyphenyl)methanol,C13H12O3,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.1.-.-;1.14.-.-,R09102 R09103
Methanol,cpd:C19258,Methylazoxymethanol acetate,C4H8N2O3,NA,NA,NA,NA,NA
Methanol,cpd:C19561,7-Hydroxymethyl-12-methylbenz[a]anthracene;12-Methylbenz[a]anthracene-7-methanol,C20H16O,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,1.14.14.-;2.8.2.14,R09441 R09444
Methanol,cpd:C19580,alpha-[3-[(Hydroxymethyl)nitrosoamino]propyl]-3-pyridinemethanol,C10H15N3O3,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,1.14.14.1;1.14.14.-,R09425 R09432
Methanol,cpd:C19581,alpha-[3-(Nitrosoamino)propyl]-3-pyridinemethanol,C9H13N3O2,Metabolism of xenobiotics by cytochrome P450;Chemical carcinogenesis - DNA adducts,NA,NA,NA,R09432 R09436
Methanol,cpd:C19800,(3-Phenoxyphenyl)methanol;3-Phenoxybenzenemethanol,C13H12O2,NA,NA,NA,3.1.1.88,R09724
Methanol,cpd:C20441,Furfuryl alcohol;2-Furancarbinol;2-Furanmethanol,C5H6O2,Furfural degradation;Microbial metabolism in diverse environments,NA,NA,1.1.1.-,R10217
Methanol,cpd:C21068,[5-(Aminomethyl)furan-3-yl]methyl phosphate;5-(Aminomethyl)-3-furanmethanol phosphate,C6H10NO5P,Methane metabolism;Metabolic pathways;Biosynthesis of cofactors,Methanofuran biosynthesis,NA,2.6.1.108;2.7.4.31,R11038 R11039
Methanol,cpd:C21069,[5-(Aminomethyl)furan-3-yl]methyl diphosphate;5-(Aminomethyl)-3-furanmethanol diphosphate,C6H11NO8P2,Methane metabolism;Metabolic pathways;Biosynthesis of cofactors,Methanofuran biosynthesis,NA,2.5.1.131;2.7.4.31,R11039 R11040
Methanol,cpd:C21420,"(3,4-Dimethoxyphenyl)methanol;Veratryl alcohol;3,4-Dimethoxybenzyl alcohol",C9H12O3,NA,NA,NA,1.11.1.14,R11502
Methanol,cpd:C21421,"(3,4-Dimethoxyphenyl)methanol radical",C9H11O3,NA,NA,NA,1.11.1.14,R11502
Methanol,cpd:C21568,"4-Hydroxy-2,2'-bipyrrole-5-methanol",C9H10N2O2,Prodigiosin biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Prodigiosin biosynthesis, L-proline => prodigiosin;Undecylprodigiosin biosynthesis, L-proline => undecylprodigiosin",NA,NA,R11667 R11668 R11669
Methanol,cpd:C22012,"[(4S)-4-(5,5-Dimethylcyclohex-1-en-1-yl)-cyclohex-1-en-1-yl]methanol",C15H24O,NA,NA,NA,1.14.14.160,R12227 R12228
Methanol,cpd:C22272,(+)-Perillyl alcohol;(R)-Perillyl alcohol;[(4R)-4-(Prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol,C10H16O,NA,NA,NA,1.17.99.8,R12592
Methanol,cpd:C22778,"11-Hydroxytetrahydrocannabinol;11-Hydroxy-delta9-tetrahydrocannabinol;(6aR,10aR)-6a,7,8,10a-Tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6H-dibenzo[b,d]pyran-9-methanol",C21H30O3,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22778,NA,NA
Phenol,cpd:C00102,"2,6-Dichloroindophenol;2,6-Dichlorophenolindophenol;DCIP",C12H7Cl2NO2,NA,NA,NA,NA,NA
Phenol,cpd:C00146,Phenol;Benzenol;Hydroxybenzene;Phenic acid;Phenylic acid,C6H6O,Tyrosine metabolism;Chlorocyclohexane and chlorobenzene degradation;Benzoate degradation;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Protein digestion and absorption;Chemical carcinogenesis - reactive oxygen species,"Benzene degradation, benzene => catechol","Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00033)]; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05B ANTIVARICOSE THERAPY;    C05BB Sclerosing agents for local injection;     C05BB05 Phenol;      D00033  Phenol (JP18/USP) &lt;JP&gt;; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AE Phenol and derivatives;     D08AE03 Phenol;      D00033  Phenol (JP18/USP) &lt;JP&gt;; N NERVOUS SYSTEM;  N01 ANESTHETICS;   N01B ANESTHETICS, LOCAL;    N01BX Other local anesthetics;     N01BX03 Phenol;      D00033  Phenol (JP18/USP) &lt;JP&gt;; R RESPIRATORY SYSTEM;  R02 THROAT PREPARATIONS;   R02A THROAT PREPARATIONS;    R02AA Antiseptics;     R02AA19 Phenol;      D00033  Phenol (JP18/USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00033)]; 2  Agents affecting individual organs;  25  Urogenital and anal organ agents;   255  Hemorrhoidal preparations;    2559  Others;     D00033  Phenol (JP18/USP); Liquefied phenol (JP18); Phenol for disinfection (JP18);  26  Epidermides;   261  Antimicrobial agents;    2619  Others;     D00033  Phenol (JP18/USP); Liquefied phenol (JP18); Phenol for disinfection (JP18);  27  Dental preparations;   273  Analgesics and sedatives;    2730  Analgesics and sedatives;     D00033  Phenol (JP18/USP); Liquefied phenol (JP18); Phenol for disinfection (JP18); 7  Agents not mainly for therapeutic purpose;  73  Public health agents;   732  Germicides and disinfectants;    7322  Phenols and chlorophenols;     D00033  Phenol (JP18/USP); Liquefied phenol (JP18); Phenol for disinfection (JP18);Classification of Japanese OTC drugs [BR:br08313(D00033)]; Agents for otolaryngologic use;  71 Ear drops;   D00033  Phenol (JP18/USP); Agents for dental and stomatological use;  75 Toothache and pyorrhea remedies;   D00033  Phenol (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00033)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Phenol;    D00033  Phenol (JP18/USP);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  951  Antimicrobials for dermatologic use;   9519  Other antimicrobials for dermatologic use;    C00146  Phenol;Drug groups [BR:br08330(D00033)]; Neuropsychiatric agent;  DG02030  Anesthetics;   DG01675  Local anesthetic;    DG00301  Phenol;     D00033  Phenol;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00033)]; Chemicals;  D00033  Phenol;  D00033  Liquefied phenol;  D00033  Phenol for disinfection",1.14.13.7;1.14.13.244;1.14.14.20;1.14.-.-;2.1.1.25;2.4.2.55;2.7.1.238;3.1.1.2;4.1.1.61;4.1.1.91;4.1.99.2,R00728 R00815 R01238 R01239 R01241 R05625 R07697 R09539;R10042 R10043 R10608 R11653 R12759
Phenol,cpd:C00530,"Hydroquinone;p-Benzenediol;1,4-Benzenediol;1,4-Dihydroxybenzene;Benzene-1,4-diol;Quinol;4-Hydroxyphenol",C6H6O2,Tyrosine metabolism;Chlorocyclohexane and chlorobenzene degradation;Benzoate degradation;Bisphenol degradation;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments;Chemical carcinogenesis - reactive oxygen species,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00073)]; D DERMATOLOGICALS;  D11 OTHER DERMATOLOGICAL PREPARATIONS;   D11A OTHER DERMATOLOGICAL PREPARATIONS;    D11AX Other dermatologicals;     D11AX11 Hydroquinone;      D00073  Hydroquinone (USP);Drug groups [BR:br08330(D00073)]; Cardiovascular agent;  DG01617  Catecholamine synthesis inhibitors;   D00073  Hydroquinone;Target-based classification of drugs [BR:br08310(D00073)]; Enzymes;  Oxidoreductases (EC1);   Other monooxygenases;    TYR;     D00073  Hydroquinone (USP);Dietary phytochemicals [br08012.html]; Other phytochemicals;  C00530,1.6.5.6;1.8.5.7;1.8.5.10;1.13.11.66;1.14.13.64;1.14.13.-;1.14.18.1;2.4.1.218;2.5.1.-;3.1.1.2;3.1.1.-;3.2.1.86;4.1.1.62,R01297 R01299 R02363 R02489 R05133 R05244 R05246 R05267;R05482 R05769 R06851 R06893 R09105 R11659 R13227
Phenol,cpd:C00548,"Phenyl acetate;Acetylphenol;Acetic acid,phenyl ester",C8H8O2,NA,NA,NA,3.1.1.2,R01241
Phenol,cpd:C00590,Coniferyl alcohol;Coniferol;4-(3-Hydroxy-1-propenyl)-2-methoxyphenol;trans-Coniferyl alcohol,C10H12O3,Phenylpropanoid biosynthesis;Biosynthesis of various plant secondary metabolites;Biosynthesis of phenylpropanoids;Metabolic pathways;Biosynthesis of secondary metabolites,"Monolignol biosynthesis, phenylalanine/tyrosine => monolignol;Podophyllotoxin biosynthesis, coniferyl alcohol => podophyllotoxin",Phytochemical compounds [BR:br08003]; Phenylpropanoids;  Monolignols;   Coniferyl alcohol derivatives;    C00590  Coniferyl alcohol;Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C00590,1.1.1.194;1.1.1.195;1.11.1.7;1.11.1.21;1.14.13.-;2.1.1.68;2.3.1.-;2.4.1.111;3.2.1.126,R02593 R02594 R02595 R02596 R06573 R06575 R10253 R12126;R12145
Phenol,cpd:C00850,Aryl sulfate;Phenol sulfate,C6H6O4S,NA,NA,NA,2.8.2.1;2.8.2.22;3.1.6.1,R01242 R01243 R02996
Phenol,cpd:C00854,Cyclohexanol;Hexalin;Hexahydrophenol;Cyclohexan-1-ol,C6H12O,Caprolactam degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.1.1.163;1.1.1.245;1.14.13.-;1.14.15.3,R02229 R06945
Phenol,cpd:C00870,4-Nitrophenol;p-Nitrophenol;PNP;Niphen;4-Hydroxynitrobenzene,C6H5NO3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Inorganic and organic chemicals;   Nitrophenol;    C00870  4-Nitrophenol,1.14.13.29;1.14.13.167;3.1.3.1;3.1.3.2;3.1.3.41;3.1.8.1,R03023 R03024 R05258 R05421 R05548
Phenol,cpd:C01285,"2,6-Dichlorophenol-4-(2,3-dihydro-1,4-naphthoquinone imine);4-(3,5-Dichloro-4-hydroxyphenylimino)tetralin-1-one",C16H11Cl2NO2,NA,NA,NA,NA,NA
Phenol,cpd:C01403,Anisole;Methoxybenzene;Methyl phenyl ether;Phenol methyl ether,C7H8O,NA,NA,NA,2.1.1.25,R01239
Phenol,cpd:C01467,3-Cresol;m-Cresol;3-Hydroxytoluene;3-Methylphenol,C7H8O,Toluene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.13.7;1.14.13.-;4.1.1.52,R03562 R03566 R03567 R07665
Phenol,cpd:C01468,4-Cresol;p-Cresol;4-Hydroxytoluene;4-Methylphenol,C7H8O,Toluene degradation;Nitrotoluene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Protein digestion and absorption,NA,NA,1.14.13.7;1.14.13.236;1.14.13.-;1.17.9.1;4.1.1.83;4.1.99.19,R02675 R03568 R05666 R07312 R07663 R08041 R10246 R12133
Phenol,cpd:C01502,o-Methoxyphenol;Guaiacol;Catechol mono methyl ether;2-Methoxyphenol,C7H8O2,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Therapeutic category of drugs in Japan [BR:br08301(D00117)]; 2  Agents affecting individual organs;  27  Dental preparations;   273  Analgesics and sedatives;    2730  Analgesics and sedatives;     D00117  Guaiacol (JAN);Risk category of Japanese OTC drugs [BR:br08312(D00117)]; Second-class OTC drugs;  Inorganic and organic chemicals;   Guaiacol;    D00117  Guaiacol (JAN),1.11.1.14;1.11.1.16;1.14.14.-;2.1.1.6,R00827 R11501 R11503 R12301
Phenol,cpd:C01542,o-Cresol;2-Hydroxytoluene;o-Methylphenol,C7H8O,Toluene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.13.243,R03560 R03608
Phenol,cpd:C01874,2-Iodophenol,C6H5IO,NA,NA,NA,2.1.1.26,R03746
Phenol,cpd:C01987,2-Aminophenol;2-Hydroxyaniline;2-Aminobenzenol;o-Aminophenol,C6H7NO,Tryptophan metabolism;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.10.3.4;1.13.11.74;4.1.1.-;5.4.4.1,R00074 R02669 R05383 R05405 R08762
Phenol,cpd:C01988,2-Nitrophenol;o-Nitrophenol,C6H5NO3,NA,NA,NA,1.14.13.31,R00828
Phenol,cpd:C02124,4-Chlorophenol;p-Chlorophenol;Parachlorophenol,C6H5ClO,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.11.-;1.14.13.20,R05441 R05493
Phenol,cpd:C02180,Phenylsulfate;Phenol sulfate,C6H6O4S,NA,NA,NA,NA,NA
Phenol,cpd:C02323,Salicyl alcohol;Saligenin;2-Hydroxybenzyl alcohol;2-(Hydroxymethyl)phenol,C7H8O2,NA,NA,NA,2.4.1.172;3.2.1.86,R03558 R05134
Phenol,cpd:C02372,4-Hydroxyaniline;4-Aminophenol;p-Aminophenol;4-Aminobenzenol,C6H7NO,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.4.-.-;1.14.13.27,R02561 R02562 R05482 R05485 R06852
Phenol,cpd:C02453,Phenolic steroid,C18H24O,NA,NA,NA,2.8.2.15,R03946
Phenol,cpd:C02496,"2,4-Dinitrophenol",C6H4N2O5,NA,NA,NA,3.3.2.14,R11189
Phenol,cpd:C02499,2-Hydroxybiphenyl;Orthophenyl phenol;2-Biphenylol;2-Phenylphenol,C12H10O,NA,NA,Pesticides [BR:br08007]; Pesticides;  Others;   Insect repellents;    C02499  2-Hydroxybiphenyl,1.14.13.44;3.13.1.3,R03964 R07311
Phenol,cpd:C02575,Pentachlorophenol;PCP,C6HCl5O,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Chemical carcinogenesis - reactive oxygen species,NA,Endocrine disrupting compounds [BR:br08006]; Pesticides and herbicides;  Others;   C02575  Pentachlorophenol;Pesticides [BR:br08007]; Pesticides;  Insecticides;   Organochlorine insecticides;    C02575  Pentachlorophenol,1.14.13.50,R03982
Phenol,cpd:C02590,Steroid O-sulfate;Phenolic steroid O-sulfate,C18H24O4S,NA,NA,NA,2.8.2.15,R03946
Phenol,cpd:C02625,"2,4-Dichlorophenol",C6H4Cl2O,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,"Endocrine disrupting compounds [BR:br08006]; Pesticides and herbicides;  Others;   C02625  2,4-Dichlorophenol",1.14.11.43;1.14.11.44;1.14.11.-;1.14.13.20,R03997 R05419 R10487 R10542
Phenol,cpd:C02734,Phenolic phosphate;Phenylphosphate;Phenyl phosphate,C6H7O4P,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,2.7.1.238;4.1.1.123,R05603 R05625
Phenol,cpd:C03359,4-Chloro-2-methylphenol,C7H7ClO,NA,NA,NA,1.14.11.43;1.14.11.44,R10527 R10539
Phenol,cpd:C03575,2-Iodophenol methyl ether,C7H7IO,NA,NA,NA,2.1.1.26,R03746
Phenol,cpd:C03822,"2,6-Dichlorophenolindophenol sodium salt;2,6-Dichloroindophenol sodium salt",C12H6Cl2NO2. Na,NA,NA,NA,NA,NA
Phenol,cpd:C04452,4-Nitrophenol-alpha-D-galactopyranoside,C12H15NO8,NA,NA,NA,NA,NA
Phenol,cpd:C05058,m-Aminophenol;3-Aminophenol;3-Hydroxyaniline,C6H7NO,NA,NA,NA,NA,NA
Phenol,cpd:C05627,4-Hydroxystyrene;4-Vinylphenol,C8H8O,Phenylpropanoid biosynthesis;Biosynthesis of secondary metabolites,NA,NA,4.1.1.102,R02952
Phenol,cpd:C05720,"Reduced 2,6-dichlorophenolindophenol;2,6-Dichloro-4-[(4-hydroxyphenyl)amino]-phenol",C12H9Cl2NO2,NA,NA,NA,NA,NA
Phenol,cpd:C05800,2-Hexaprenylphenol,C36H54O,NA,NA,NA,1.14.13.-,R04980
Phenol,cpd:C05801,2-Hexaprenyl-6-hydroxyphenol;3-Hexaprenylcatechol,C36H54O2,NA,NA,NA,1.14.13.-;2.1.1.-,R04980 R04981
Phenol,cpd:C05802,2-Hexaprenyl-6-methoxyphenol,C37H56O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR02 Quinones and hydroquinones;   PR0201 Ubiquinones;    C05802  2-Hexaprenyl-6-methoxyphenol,2.1.1.-,R04981 R06866
Phenol,cpd:C05807,2-Polyprenylphenol;2-(all-trans-Polyprenyl)phenol,C11H14O(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol",Lipids [BR:br08002]; PR  Prenol lipids;  PR00 Other Prenol lipids;   C05807  2-Polyprenylphenol,1.14.13.240;4.1.1.98,R04985 R08768
Phenol,cpd:C05808,5-Hydroxy-2-polyprenylphenol,C11H14O2(C5H8)n,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR00 Other Prenol lipids;   C05808  5-Hydroxy-2-polyprenylphenol,NA,NA
Phenol,cpd:C05810,2-Octaprenylphenol,C46H70O,NA,NA,NA,1.14.13.240;4.1.1.98,R04986 R04987
Phenol,cpd:C05811,2-Octaprenyl-6-hydroxyphenol;3-Octaprenylcatechol,C46H70O2,NA,NA,NA,1.14.13.240;2.1.1.222,R04987 R04988
Phenol,cpd:C05812,2-Octaprenyl-6-methoxyphenol,C47H72O2,NA,NA,NA,2.1.1.222,R04988
Phenol,cpd:C06199,Hordenine;4-[2-(Dimethylamino)ethyl]phenol,C10H15NO,Tyrosine metabolism;Metabolic pathways,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from tyrosine;   Tyramine derivatives;    C06199  Hordenine,2.1.1.-,R03943
Phenol,cpd:C06602,"2,5-Dichlorophenol;2,5-DCP",C6H4Cl2O,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments,NA,NA,NA,R05484
Phenol,cpd:C07096,"2,6-Dichlorophenol",C6H4Cl2O,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,1.14.13.-,R05448
Phenol,cpd:C07098,"2,4,6-Trichlorophenol",C6H3Cl3O,Chlorocyclohexane and chlorobenzene degradation;Microbial metabolism in diverse environments,NA,NA,1.14.14.173;2.1.1.136,R05449 R05754 R13143
Phenol,cpd:C07101,"2,4,5-Trichlorophenol",C6H3Cl3O,Chlorocyclohexane and chlorobenzene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.13.-;1.14.14.-,R05418 R05447
Phenol,cpd:C07523,"Propofol;2,6-Diisopropylphenol",C12H18O,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00549)]; N NERVOUS SYSTEM;  N01 ANESTHETICS;   N01A ANESTHETICS, GENERAL;    N01AX Other general anesthetics;     N01AX10 Propofol;      D00549  Propofol (JAN/USP/INN) &lt;JP/US&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00549)]; 1  Agents affecting nervous system and sensory organs;  11  Agents affecting central nervous system;   111  General anesthetics;    1119  Others;     D00549  Propofol (JAN/USP/INN);Drug groups [BR:br08330(D00549)]; Neuropsychiatric agent;  DG01567  GABA-A receptor agonist;   DG00797  Propofol;    D00549  Propofol;  DG02030  Anesthetics;   DG02027  General anesthetics;    DG00797  Propofol;     D00549  Propofol;Target-based classification of drugs [BR:br08310(D00549)]; Ion channels;  Ligand-gated ion channels;   GABA (ionotropic);    GABR;     D00549  Propofol (JAN/USP/INN) &lt;JP/US&gt;;Prodrugs [br08324.html(D00549)]; D00549;Prodrugs [br08324.html]; C07523",NA,NA
Phenol,cpd:C07908,Mycophenolate mofetil;RS 61443,C23H31NO7,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00752)]; L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L04 IMMUNOSUPPRESSANTS;   L04A IMMUNOSUPPRESSANTS;    L04AA Selective immunosuppressants;     L04AA06 Mycophenolic acid;      D00752  Mycophenolate mofetil (JAN/USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00752)]; Immunological Agents;  Immunosuppressants;   Antimetabolites, Antiproliferative;    Mycophenolic Acid;     D00752  Mycophenolate mofetil (JAN/USP);Therapeutic category of drugs in Japan [BR:br08301(D00752)]; 3  Agents affecting metabolism;  39  Other agents affecting metabolism;   399  Miscellaneous;    3999  Others;     D00752  Mycophenolate mofetil (JAN/USP);Target-based classification of drugs [BR:br08310(D00752)]; Enzymes;  Oxidoreductases (EC1);   Dehydrogenases;    IMPDH;     D00752  Mycophenolate mofetil (JAN/USP) &lt;JP/US&gt;;New drug approvals in Europe [br08329.html(D00752)]; European public assessment reports (EPAR) authorised medicine;  D00752;Pharmacogenomic biomarkers [br08341.html(D00752)]; Polymorphisms and mutations affecting drug response;  D00752;Prodrugs [br08324.html(D00752)]; D00752;Prodrugs [br08324.html]; C07908",NA,NA
Phenol,cpd:C08825,Lophenol;4-Methylcholest-7-en-3-ol;4alpha-Methyl-5alpha-cholest-7-en-3beta-ol,C28H48O,NA,NA,Lipids [BR:br08002]; ST  Sterol lipids;  ST01 Sterols;   ST0101 Cholesterol and derivatives;    C08825  Lophenol;Phytochemical compounds [BR:br08003]; Terpenoids;  Steroids;   Cholestane;    C08825  Lophenol,1.1.1.270,R05691
Phenol,cpd:C09555,"(-)-Laudanidine;(R)-Laudanine;5-[((1R)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-2-methoxyphenol",C20H25NO4,NA,NA,Phytochemical compounds [BR:br08003]; Alkaloids;  Alkaloids derived from tyrosine;   Isoquinoline alkaloids;    C09555  (-)-Laudanidine,2.1.1.291,R10606
Phenol,cpd:C09854,Diosphenol,C10H16O2,NA,NA,Lipids [BR:br08002]; PR  Prenol lipids;  PR01 Isoprenoids;   PR0102 C10 isoprenoids (monoterpenes);    PR010209 Menthane monoterpenoids;     C09854  Diosphenol;Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C09854  Diosphenol,NA,NA
Phenol,cpd:C10247,Batatasin IV;3-[2-(2-Hydroxyphenyl)ethyl]-5-methoxyphenol,C15H16O3,NA,NA,"Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1309 Diphenyl ethers, biphenyls, dibenzyls and stilbenes;    C10247  Batatasin IV;Phytochemical compounds [BR:br08003]; Shikimate / acetate-malonate pathway derived compounds;  Stilbenoids;   Bibenzyls;    C10247  Batatasin IV",NA,NA
Phenol,cpd:C10269,"Lunularin;3,4'-Ethylenebisphenol",C14H14O2,NA,NA,"Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1309 Diphenyl ethers, biphenyls, dibenzyls and stilbenes;    C10269  Lunularin;Phytochemical compounds [BR:br08003]; Shikimate / acetate-malonate pathway derived compounds;  Stilbenoids;   Bibenzyls;    C10269  Lunularin;Dietary phytochemicals [br08012.html]; Other phytochemicals;  C10269",NA,NA
Phenol,cpd:C10469,Isoeugenol;2-Methoxy-4-(prop-1-en-1-yl)phenol,C10H12O2,Phenylpropanoid biosynthesis,NA,NA,1.1.1.319;1.13.11.88;2.1.1.146;2.1.1.279,R07240 R09931 R12302
Phenol,cpd:C10765,"Antiarol;3,4,5-Trimethoxyphenol",C9H12O4,NA,NA,NA,NA,NA
Phenol,cpd:C10785,(15:1)-Cardanol;3-[(Z)-8-Pentadecenyl]phenol,C21H34O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C10785  (15:1)-Cardanol,NA,NA
Phenol,cpd:C10787,"2,6-Dimethoxyphenol;Pyrogallol 1,3-dimethyl ether",C8H10O3,NA,NA,NA,NA,NA
Phenol,cpd:C11206,p-Methylaminophenol sulfate,(C7H9NO)2. H2SO4,NA,NA,NA,NA,NA
Phenol,cpd:C11522,"24-Methylenelophenol;24-Methylidenelophenol;4alpha-Methyl-5alpha-ergosta-7,24-dien-3beta-ol",C29H48O,Steroid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Phytosterol biosynthesis, squalene 2,3-epoxide => campesterol/sitosterol",Lipids [BR:br08002]; ST  Sterol lipids;  ST01 Sterols;   ST0103 Ergosterols and C24-methyl derivatives;    C11522  24-Methylenelophenol,1.14.18.11;2.1.1.143;5.3.3.5,R05776 R07484 R12372 R12378
Phenol,cpd:C11523,"24-Ethylidenelophenol;alpha1-Sitosterol;4-alpha-Methyl-5-alpha-stigmasta-7,Z-24-dien-3-beta-ol;(Z)-24-Ethylidenelophenol",C30H50O,Steroid biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites,"Phytosterol biosynthesis, squalene 2,3-epoxide => campesterol/sitosterol",Lipids [BR:br08002]; ST  Sterol lipids;  ST01 Sterols;   ST0104 Stigmasterols and C24-ethyl derivatives;    C11523  24-Ethylidene lophenol,1.14.18.11;2.1.1.143,R05776 R12379
Phenol,cpd:C11569,"2,2'-(1-Phenyl-1H-1,2,4-triazole-3,5-diyl)bis-phenol",C20H15N3O2,NA,NA,NA,NA,NA
Phenol,cpd:C12251,2-Iodo-6-methoxyphenol,C7H7IO2,NA,NA,NA,NA,NA
Phenol,cpd:C12600,Phenolsulfonphthalein;Phenol red,C19H14O5S,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01200)]; V VARIOUS;  V04 DIAGNOSTIC AGENTS;   V04C OTHER DIAGNOSTIC AGENTS;    V04CH Tests for renal function and ureteral injuries;     V04CH03 Phenolsulfonphthalein;      D01200  Phenolsulfonphthalein (JP18/NF) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D01200)]; 7  Agents not mainly for therapeutic purpose;  72  Intracorporeal diagnostic agents;   722  Various function testing reagents;    7225  Diagnostic reagents for renal function;     D01200  Phenolsulfonphthalein (JP18/NF);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D01200)]; Chemicals;  D01200  Phenolsulfonphthalein;  D01200  Phenolsulfonphthalein injection,NA,NA
Phenol,cpd:C12849,p-Phenolsulfonic acid;p-Hydroxybenzenesulfonic acid;Phenolsulfonic acid;4-Sulfophenol,C6H6O4S,NA,NA,NA,NA,NA
Phenol,cpd:C13620,"Tetrabromobisphenol A;3,3',5,5'-Tetrabromobisphenol A",C15H12Br4O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.97.1.-,R06876
Phenol,cpd:C13621,"Tribromobisphenol A;3,3',5-Tribromobisphenol A",C15H13Br3O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.97.1.-,R06876 R06877
Phenol,cpd:C13622,"Dibromobisphenol A;3,3'-Dibromobisphenol A",C15H14Br2O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.97.1.-,R06877 R06878
Phenol,cpd:C13623,Monobromobisphenol A;3-Monobromobisphenol A,C15H15BrO2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.97.1.-,R06878 R06879
Phenol,cpd:C13624,"Bisphenol A;2,2-Bis(4-Hydroxyphenyl)propane",C15H16O2,Bisphenol degradation;Metabolic pathways;Microbial metabolism in diverse environments;Chemical carcinogenesis - receptor activation,NA,Endocrine disrupting compounds [BR:br08006]; Plasticizers and plastics;  Bisphenols;   C13624  Bisphenol A,1.14.13.-;1.14.-.-;1.97.1.-,R06879 R06880 R06881 R06883 R06884
Phenol,cpd:C13626,5-Hydroxybisphenol A;5-Hydroxybisphenol;BPAcatechol,C15H16O3,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,NA,R06881 R06882
Phenol,cpd:C13628,"4,5-Bisphenol-o-quinone;BPAquinone",C15H14O3,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,NA,R06882
Phenol,cpd:C13637,4-Ethylphenol;p-Ethylphenol,C8H10O,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.14.13.-,R06890
Phenol,cpd:C13638,1-(4'-Hydroxyphenyl)ethanol;4-Hydroxy-alpha-methyl-benzenemethanol;4-(1-Hydroxyethyl)phenol,C8H10O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.1.1.-;1.14.13.-,R06890 R06891
Phenol,cpd:C14130,2-tert-Butylphenol,C10H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14132,4-Octylphenol;4-n-Octylphenol;p-Octylphenol,C14H22O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14132  4-Octylphenol;Endocrine disrupting compounds [BR:br08006]; Plasticizers and plastics;  Alkylphenols;   C14132  4-Octylphenol,NA,NA
Phenol,cpd:C14138,2-sec-Butylphenol;2-(1-Methylpropyl)phenol,C10H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14139,4-sec-Butylphenol;4-(1-Methylpropyl)phenol;1-Hydroxy-4-sec-butylbenzene,C10H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14188,3-tert-Butylphenol,C10H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14200,4-tert-Butylphenol;Butylphen,C10H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14205,"4-tert-Octylphenol;4-t-Octylphenol;4-(1,1,3,3-Tetramethylbutyl)phenol",C14H22O,NA,NA,NA,NA,NA
Phenol,cpd:C14216,"4,4'-Sulfonyldiphenol;Bisphenol S;1,1'-Sulfonylbis(4-hydroxybenzene)",C12H10O4S,NA,NA,NA,NA,NA
Phenol,cpd:C14219,2-Chlorophenol;2-Chloro-1-hydroxybenzene,C6H5ClO,NA,NA,NA,NA,NA
Phenol,cpd:C14223,Phenolphthalin,C20H16O4,NA,NA,NA,NA,NA
Phenol,cpd:C14224,4-Hydroxybiphenyl;4-Phenylphenol,C12H10O,NA,NA,NA,NA,NA
Phenol,cpd:C14225,"Bisphenol B;4,4'-Dihydroxy-2,2-diphenylbutane;2,2-Bis(4-hydroxyphenyl)butane",C16H18O2,NA,NA,NA,NA,NA
Phenol,cpd:C14226,p-tert-Amylphenol;4-t-Amylphenol;4-tert-Pentylphenol,C11H16O,NA,NA,NA,NA,NA
Phenol,cpd:C14234,"Dimethylstilbestrol;(E)-4,4'-(1,2-Dimethyl-1,2-ethenediyl)bisphenol",C16H16O2,NA,NA,NA,NA,NA
Phenol,cpd:C14236,4-Heptyloxyphenol;p-n-Heptyloxyphenol,C13H20O2,NA,NA,NA,NA,NA
Phenol,cpd:C14237,"4-[2,2-Dichloro-1-(4-methoxyphenyl)ethenyl]phenol;Monohydroxymethoxychlor olefin",C15H12Cl2O2,NA,NA,NA,NA,NA
Phenol,cpd:C14238,"1,1-Dichloro-2,2-bis(4-hydroxyphenyl)ethylene;Dihydroxymethoxychlor olefin;4,4'-(Dichloroethenylidene)bis[phenol]",C14H10Cl2O2,NA,NA,NA,NA,NA
Phenol,cpd:C14244,4-(Benzyloxyl)phenol;Monobenzone;4-(Phenylmethoxy)phenol,C13H12O2,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D05072)]; D DERMATOLOGICALS;  D11 OTHER DERMATOLOGICAL PREPARATIONS;   D11A OTHER DERMATOLOGICAL PREPARATIONS;    D11AX Other dermatologicals;     D11AX13 Monobenzone;      D05072  Monobenzone (USP/INN),NA,NA
Phenol,cpd:C14245,4-Dodecylphenol,C18H30O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14245  4-Dodecylphenol,NA,NA
Phenol,cpd:C14258,4-Cumylphenol;p-Cumylphenol;2-Phenyl-2-(4-hydroxyphenyl)propane,C15H16O,NA,NA,NA,NA,NA
Phenol,cpd:C14270,3-Chlorophenol,C6H5ClO,NA,NA,NA,NA,NA
Phenol,cpd:C14276,"4-(3,5-Diphenylcyclohexyl)phenol",C24H24O,NA,NA,NA,NA,NA
Phenol,cpd:C14286,"Phenolphthalein;3,3-Bis(4-hydroxyphenyl)phthalide",C20H14O4,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D05456)]; A ALIMENTARY TRACT AND METABOLISM;  A06 DRUGS FOR CONSTIPATION;   A06A DRUGS FOR CONSTIPATION;    A06AB Contact laxatives;     A06AB04 Phenolphthalein;      D05456  Phenolphthalein (INN);Drug groups [BR:br08330(D05456)]; Gastrointestinal agent;  DG01770  Laxative;   DG00070  Phenolphthalein;    D05456  Phenolphthalein,NA,NA
Phenol,cpd:C14287,"4,4'-Methylenebis(2,6-di-tert-butylphenol)",C29H44O2,NA,NA,NA,NA,NA
Phenol,cpd:C14292,"Dichlorophen;2,2'-Methylenebis(4-chlorophenol)",C13H10Cl2O2,NA,NA,"Pesticides [BR:br08007]; Pesticides;  Fungicides;   Organochlorine fungicides;    C14292  Dichlorophen;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS;  P02 ANTHELMINTICS;   P02D ANTICESTODALS;    P02DX Other anticestodals;     P02DX02 Dichlorophen;      C14292  Dichlorophen;Animal drugs in Japan [BR:br08331]; 97  Agents against pathogenic micro-organisms and parasites (except biological products and disinfectants);  975  Anthelmintics for digestive organs;   9759  Other anthelmintics for digestive organs;    C14292  Dichlorophen",NA,NA
Phenol,cpd:C14294,"Diphenolic acid;4,4-Bis(4-hydroxyphenyl)pentanoic acid",C17H18O4,NA,NA,NA,NA,NA
Phenol,cpd:C14298,"Bis(4-hydroxyphenyl)methane;4,4'-Dihydroxydiphenylmethane;Bisphenol F",C13H12O2,Bisphenol degradation;Microbial metabolism in diverse environments,NA,NA,1.14.-.-,R09102
Phenol,cpd:C14302,"Dinoseb;2,4-Dinitro-6-(1-methylpropyl)phenol",C10H12N2O5,NA,NA,Pesticides [BR:br08007]; Obsolete pesticides;  Herbicides;   Nitrophenol herbicides;    C14302  Dinoseb,NA,NA
Phenol,cpd:C14305,4-Hexyloxyphenol,C12H18O2,NA,NA,NA,NA,NA
Phenol,cpd:C14311,4-Propylphenol,C9H12O,NA,NA,NA,NA,NA
Phenol,cpd:C14331,4-Chloro-m-cresol;4-Chloro-3-methylphenol;Chlorocresol,C7H7ClO,NA,NA,NA,NA,NA
Phenol,cpd:C14339,"3,3'-Dimethylbisphenol A;2,2-Bis(4-hydroxy-3-methylphenyl)propane",C17H20O2,NA,NA,NA,NA,NA
Phenol,cpd:C14340,4-Phenethylphenol;4-(2-Phenylethyl)phenol,C14H14O,NA,NA,NA,NA,NA
Phenol,cpd:C14341,"4,4'-Dihydroxybibenzyl;4,4'-(1,2-Ethanediyl)bisphenol",C14H14O2,NA,NA,"Lipids [BR:br08002]; PK  Polyketides;  PK13 Aromatic polyketides;   PK1309 Diphenyl ethers, biphenyls, dibenzyls and stilbenes;    C14341  4,4'-Dihydroxybibenzyl",NA,NA
Phenol,cpd:C14342,3-Hydroxybiphenyl;3-Phenylphenol,C12H10O,NA,NA,NA,NA,NA
Phenol,cpd:C14345,"Bisphenol A dimethacrylate;2,2-Di(4-methacryloxyphenyl)propane",C23H24O4,NA,NA,NA,NA,NA
Phenol,cpd:C14346,"Bisphenol A bis(chloroformate);2,2-Bis[p-(chloroformyloxy)phenyl]propane",C17H14Cl2O4,NA,NA,NA,NA,NA
Phenol,cpd:C14347,"Bisphenol A bis(2-hydroxyethyl)ether;Bisphenol A ethoxylate;2,2-Bis[4-(2-hydroxyethoxy)phenyl]propane",C19H24O4,NA,NA,NA,NA,NA
Phenol,cpd:C14348,"Bisphenol A diglycidyl ether;2,2-Bis(4-glycidyloxyphenyl)propane",C21H24O4,NA,NA,NA,NA,NA
Phenol,cpd:C14349,"1,1-Bis(4-hydroxyphenyl)ethane;Bisphenol E",C14H14O2,NA,NA,NA,NA,NA
Phenol,cpd:C14350,"2,2-Bis(4-hydroxyphenyl)hexafluoropropane;Bisphenol AF",C15H10F6O2,NA,NA,NA,NA,NA
Phenol,cpd:C14351,4-Butoxyphenol,C10H14O2,NA,NA,NA,NA,NA
Phenol,cpd:C14370,"2-Hydroxy-3,5-dichlorobiphenyl;3,5-Dichloro-2-hydroxybiphenyl;2,4-Dichloro-6-phenylphenol",C12H8Cl2O,NA,NA,NA,NA,NA
Phenol,cpd:C14385,2-Ethylphenol;o-Ethylphenol,C8H10O,NA,NA,NA,NA,NA
Phenol,cpd:C14386,3-Ethylphenol,C8H10O,NA,NA,NA,NA,NA
Phenol,cpd:C14418,3-Nitrophenol;m-Hydroxynitrobenzene,C6H5NO3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.7.1.-,R09288
Phenol,cpd:C14453,4-Bromophenol,C6H5BrO,Metabolism of xenobiotics by cytochrome P450,NA,NA,1.14.14.-,R07073 R07075
Phenol,cpd:C14454,"2,4,6-Tribromophenol",C6H3Br3O,NA,NA,NA,NA,NA
Phenol,cpd:C14462,"3,4-Dichlorophenol",C6H4Cl2O,NA,NA,NA,NA,NA
Phenol,cpd:C14464,4-Butylphenol;4-n-Butylphenol;p-Hydroxybutylbenzene,C10H14O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14464  4-Butylphenol,NA,NA
Phenol,cpd:C14465,4-Hexylphenol;4-n-Hexylphenol,C12H18O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14465  4-Hexylphenol,NA,NA
Phenol,cpd:C14466,4-Pentylphenol;4-n-Pentylphenol;p-Amylphenol,C11H16O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14466  4-Pentylphenol,NA,NA
Phenol,cpd:C14511,"Bisphenol A glycidylmethacrylate;Bis-GMA;2,2-Bis[4-(2-hydroxy-3-methacryloxypropoxy)phenyl]propane;Bisphenol A diglycidyl methacrylate",C29H36O8,NA,NA,NA,NA,NA
Phenol,cpd:C14521,"2,4-Dibromophenol",C6H4Br2O,NA,NA,NA,1.14.19.55,R12013 R12016
Phenol,cpd:C14528,"Tetrachlorobisphenol A;3,3',5,5'-Tetrachlorobisphenol A;Tetrachlorodian;2,2-Bis(4-hydroxy-3,5-dichlorophenyl)propane",C15H12Cl4O2,NA,NA,NA,NA,NA
Phenol,cpd:C14550,4-Nonylphenol;4-n-Nonylphenol;p-Nonylphenol,C15H24O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14550  4-Nonylphenol,NA,NA
Phenol,cpd:C14582,"2,4-Dimethylphenol;2,4-Xylenol;1-Hydroxy-2,4-dimethylbenzene",C8H10O,Toluene degradation;Microbial metabolism in diverse environments,NA,NA,1.17.9.1,R11194
Phenol,cpd:C14602,3-Hydroxyaminophenol;3-Hydroxylaminophenol,C6H7NO2,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,NA,1.7.1.-;5.4.4.3,R06988 R09284 R09288
Phenol,cpd:C14693,"Butylhydroxytoluene;BHT;2,6-Di-t-butyl-4-methylphenol;2,6-Di-tert-butyl-p-cresol;Butylated hydroxytoluene;2,6-Bis(1,1-dimethylethyl)-4-methylphenol",C15H24O,NA,NA,NA,NA,NA
Phenol,cpd:C14697,4-Isopentylphenol;p-Isoamylphenol,C11H16O,NA,NA,NA,NA,NA
Phenol,cpd:C14698,4-Heptylphenol;4-n-Heptylphenol;p-Heptylphenol;p-Hydroxyheptylbenzene,C13H20O,NA,NA,Lipids [BR:br08002]; PK  Polyketides;  PK15 Phenolic lipids;   PK1501 Alkyl phenols and derivatives;    C14698  4-Heptylphenol,NA,NA
Phenol,cpd:C14715,"4-Chloro-3,5-dimethylphenol;Chloroxylenol",C8H9ClO,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D03473)]; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AE Phenol and derivatives;     D08AE05 Chloroxylenol;      D03473  Chloroxylenol (USP/INN);Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  951  Antimicrobials for dermatologic use;   9519  Other antimicrobials for dermatologic use;    C14715  Chloroxylenol;  956  Bath and disinfectants preparations;   9562  Disinfectants preparations;    C14715  Chloroxylenol; 99  Agents for not mainly purpose of therapeutic;  992  Amphoteric soap and preparations;   9925  Cresols and preparations;    C14715  Chloroxylenol,NA,NA
Phenol,cpd:C14719,"Methallenestrilphenol;N-3-(6-Hydroxy-2-naphthyl)-2,2-dimethylpentanoic acid;alpha,alpha-Dimethyl-beta-ethylallenolic acid;beta-Ethyl-6-hydroxy-alpha,alpha-dimethyl-2-naphthalenepropanoic acid",C17H20O3,NA,NA,NA,NA,NA
Phenol,cpd:C14737,"4,3',5'-Trichloro-4'-biphenol;3,4',5-Trichloro-4-biphenylol",C12H7Cl3O,NA,NA,NA,NA,NA
Phenol,cpd:C14741,4-Isopropyl-3-methylphenol;4-Isopropyl-m-cresol;o-Cymen-5y-ol,C10H14O,NA,NA,Classification of Japanese OTC drugs [BR:br08313]; Agents for integumentary system;  54 Disinfectants (incl. special bandages);   C14741  4-Isopropyl-3-methylphenol;  56 Purulent skin remedies;   C14741  4-Isopropyl-3-methylphenol;Animal drugs in Japan [BR:br08331]; 95  Agents for external use;  956  Bath and disinfectants preparations;   9562  Disinfectants preparations;    C14741  4-Isopropyl-3-methylphenol,NA,NA
Phenol,cpd:C14747,"2,2'-Bisphenol F;Bis(2-hydroxyphenyl)methane",C13H12O2,NA,NA,NA,NA,NA
Phenol,cpd:C14841,2-Bromophenol;o-Bromophenol,C6H5BrO,Metabolism of xenobiotics by cytochrome P450,NA,NA,NA,R07074
Phenol,cpd:C14845,"4-Bromophenol-2,3-epoxide",C6H5BrO2,Metabolism of xenobiotics by cytochrome P450,NA,NA,1.14.14.-,R07075 R07076
Phenol,cpd:C14888,"(+)-Methallenestrilphenol;(+)-3-(6-Hydroxy-2-naphthyl)-2,2-dimethylpentanoic acid;(+)-beta-Ethyl-6-hydroxy-alpha,alpha-dimethyl-2-naphthalenepropanoic acid",C17H20O3,NA,NA,NA,NA,NA
Phenol,cpd:C14897,"p-(3,4-Dihydro-6-methoxy-2-naphthyl)phenol",C17H16O2,NA,NA,NA,NA,NA
Phenol,cpd:C14993,Nonylphenol,NA,NA,NA,Endocrine disrupting compounds [BR:br08006]; Plasticizers and plastics;  Alkylphenols;   C14993  Nonylphenol,NA,NA
Phenol,cpd:C15042,4-(2-Pyrazinylethenyl)phenol,C12H10N2O,NA,NA,NA,NA,NA
Phenol,cpd:C15043,2-[2-(4-Pyridinyl)-1-butenyl]phenol,C15H15NO,NA,NA,NA,NA,NA
Phenol,cpd:C15044,"2,3-Dimethoxy-[2-(4-Pyridinyl)-1-butenyl]phenol;4-[1-[(2,3-Dimethoxyphenyl)methylene]propyl]pyridine",C17H19NO2,NA,NA,NA,NA,NA
Phenol,cpd:C15045,4-Chloro-[2-(4-Pyridinyl)-1-butenyl]phenol;4-[1-[(4-Chlorophenyl)methylene]propyl]pyridine,C15H14ClN,NA,NA,NA,NA,NA
Phenol,cpd:C15069,"4,4'-(Butane-1,1-diyl)diphenol;1,1-Bis(4-hydroxyphenyl)butane",C16H18O2,NA,NA,NA,NA,NA
Phenol,cpd:C15082,4-(1-Ethyl-2-phenylbutyl)phenol,C18H22O,NA,NA,NA,NA,NA
Phenol,cpd:C15153,"(-)-Methallenestrilphenol;(-)-3-(6-Hydroxy-2-naphthyl)-2,2-dimethylpentanoic acid;(-)-beta-Ethyl-6-hydroxy-alpha,alpha-dimethyl-2-naphthalenepropanoic acid",C17H20O3,NA,NA,NA,NA,NA
Phenol,cpd:C15168,"4,4'-(2-Ethyl-1-butenylidene)diphenol;1,1-Bis(4-hydroxyphenyl)-2-ethyl-1-butene",C18H20O2,NA,NA,NA,NA,NA
Phenol,cpd:C15193,2-[3-Ethyl-5-(4-methoxyphenyl)-1H-pyrazol-4-yl]phenol,C18H18N2O2,NA,NA,NA,NA,NA
Phenol,cpd:C15206,"3,3-Bis(4-hydroxyphenyl)pentane;4,4'-(1-Ethylpropane-1,1,-diyl)diphenol",C17H20O2,NA,NA,NA,NA,NA
Phenol,cpd:C15208,"Bisphenol A bis(2-hydroxypropyl) ether;Bisphenol A propoxylate;2,2-Bis[4-(2-hydroxy-2-methylethoxy)phenyl]propane",C21H28O4,NA,NA,NA,NA,NA
Phenol,cpd:C15209,Bisphenol A ethoxylate diacrylate,C25H28O6,NA,NA,NA,NA,NA
Phenol,cpd:C15217,4-[1-Ethyl-2-(4-methylphenyl)butyl]phenol;3-(p-Phenyl)-4-(p-tolyl)hexane,C19H24O,NA,NA,NA,NA,NA
Phenol,cpd:C15219,"2,6-Dimethylhexestrol;4-[1-Ethyl-2-(4-hydroxyphenyl)butyl]-3,5-dimethylphenol",C20H26O2,NA,NA,NA,NA,NA
Phenol,cpd:C15220,2-Chloro-4-methylphenol;2-Chloro-p-cresol,C7H7ClO,NA,NA,NA,NA,NA
Phenol,cpd:C15278,"4,4'-(2-Methylpropylidene)bisphenol;4,4'-Isobutylidenediphenol",C16H18O2,NA,NA,NA,NA,NA
Phenol,cpd:C15454,"Hexestrol monomethyl ether;(R*,S*)-4-[1-Ethyl-2-(4-methoxyphenyl)butyl]phenol",C19H24O2,NA,NA,NA,NA,NA
Phenol,cpd:C15463,"(R*,S*)-4-[1-Ethyl-2-(4-fluorophenyl)butyl]phenol",C18H21FO,NA,NA,NA,NA,NA
Phenol,cpd:C15505,"2,3,5,6-Tetrachlorophenol",C6H2Cl4O,NA,NA,NA,1.14.13.50,R07191
Phenol,cpd:C15584,Phenol,C6H6O,NA,NA,NA,2.4.1.35;2.8.2.1;2.8.2.22;3.1.1.2;3.1.6.1;3.1.8.1,R01240 R01242 R01243 R02996 R03979 R07342
Phenol,cpd:C16247,"2,6-Dibromophenol",C6H4Br2O,Fluorobenzoate degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,NA,R07783 R07784
Phenol,cpd:C16414,2-Amino-5-hydroxyl-4-hydroxylamino-6-nitrotoluene;4-Amino-6-hydroxylamino-3-methyl-2-nitrophenol,C7H9N3O4,Nitrotoluene degradation,NA,NA,NA,R08048
Phenol,cpd:C16485,4-Fluorophenol,C6H5FO,NA,NA,NA,NA,NA
Phenol,cpd:C16570,"4-Hydroxy-2,6-dimethylaniline;3,5-Dimethyl-4-aminophenol",C8H11NO,Drug metabolism - cytochrome P450,NA,NA,NA,R08301
Phenol,cpd:C17385,2-Methoxy-5-nitrophenol;5-Nitroguaiacol,C7H7NO4,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Inorganic and organic chemicals;   Mononitroguaiacol;    C17385  5-Nitroguaiacol,NA,NA
Phenol,cpd:C17386,2-Methoxy-4-nitrophenol;4-Nitroguaiacol,C7H7NO4,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Inorganic and organic chemicals;   Mononitroguaiacol;    C17386  4-Nitroguaiacol,NA,NA
Phenol,cpd:C17467,p-Hydroxybenzyl alcohol;4-Hydroxybenzyl alcohol;p-Methylolphenol,C7H8O2,NA,NA,NA,1.17.9.1,R12133 R12134
Phenol,cpd:C17551,"2-Polyprenyl-6-hydroxyphenol;3-Polyprenylcatechol;3-(all-trans-Polyprenyl)benzene-1,2-diol",C11H14O2(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol",NA,1.14.13.240;2.1.1.222,R08768 R08769
Phenol,cpd:C17552,2-Polyprenyl-6-methoxyphenol;2-Methoxy-6-(all-trans-polyprenyl)phenol,C12H16O2(C5H8)n,Ubiquinone and other terpenoid-quinone biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;Biosynthesis of cofactors,"Ubiquinone biosynthesis, prokaryotes, chorismate (+ polyprenyl-PP) => ubiquinol;Ubiquinone biosynthesis, eukaryotes, 4-hydroxybenzoate + polyprenyl-PP => ubiquinol",NA,1.14.13.-;2.1.1.222;4.1.1.-,R08769 R08772 R12658
Phenol,cpd:C17808,Clemaphenol A,C20H22O6,NA,NA,Phytochemical compounds [BR:br08003]; Phenylpropanoids;  Lignans;   Lignans;    C17808  Clemaphenol A,NA,NA
Phenol,cpd:C18393,"Disophenol;2,6-Diiod-4-nitrophenol",C6H3I2NO3,NA,NA,Animal drugs in Japan [BR:br08331]; 97  Agents against pathogenic micro-organisms and parasites (except biological products and disinfectants);  975  Anthelmintics for digestive organs;   9759  Other anthelmintics for digestive organs;    C18393  Disophenol,NA,NA
Phenol,cpd:C18653,"DNOC;4,6-Dinitro-o-cresol;2,4-Dinitro-6-methylphenol",C7H6N2O5,NA,NA,Pesticides [BR:br08007]; Pesticides;  Herbicides;   Nitrophenol herbicides;    C18653  DNOC,NA,NA
Phenol,cpd:C19321,2-Amino-4-nitrophenol,C6H6N2O3,NA,NA,NA,NA,NA
Phenol,cpd:C19322,2-Amino-5-nitrophenol,C6H6N2O3,NA,NA,NA,NA,NA
Phenol,cpd:C19323,4-Amino-2-nitrophenol,C6H6N2O3,NA,NA,NA,NA,NA
Phenol,cpd:C19433,4-Hydroxyazobenzene;4-(Phenylazo)phenol,C12H10N2O,NA,NA,NA,NA,NA
Phenol,cpd:C19944,"3-Hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione;Secophenol",C19H24O3,Steroid degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.14.12,R09819 R09885
Phenol,cpd:C20380,Mycophenolate,C17H20O6,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D05096)]; L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;  L04 IMMUNOSUPPRESSANTS;   L04A IMMUNOSUPPRESSANTS;    L04AA Selective immunosuppressants;     L04AA06 Mycophenolic acid;      D05096  Mycophenolic acid (USAN/INN);Target-based classification of drugs [BR:br08310(D05096)]; Enzymes;  Oxidoreductases (EC1);   Dehydrogenases;    IMPDH;     D05096  Mycophenolic acid (USAN/INN);Pharmacogenomic biomarkers [br08341.html(D05096)]; Polymorphisms and mutations affecting drug response;  D05096;Prodrugs [br08324.html(D05096)]; D05096;Prodrugs [br08324.html]; C20380,3.1.1.93,R10134
Phenol,cpd:C20383,Mycophenolic acid O-acyl-glucuronide,C23H28O12,NA,NA,NA,3.1.1.93,R10134
Phenol,cpd:C20464,Isochavicol;t-Anol;trans-Anol;(E)-4-Propenylphenol;(E)-4-Hydroxypropenylbenzene,C9H10O,Phenylpropanoid biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.1.1.319;2.1.1.279,R10252 R10289
Phenol,cpd:C20588,Tetrabromophenol blue,C19H6Br8O5S,NA,NA,Risk category of Japanese OTC drugs [BR:br08312]; Second-class OTC drugs;  Not used for human;   Vitro diagnostics listed below;    ------  Urine protein kit (OTC);     C20588  Tetrabromophenol blue,NA,NA
Phenol,cpd:C20669,2-Amino-5-chlorophenol,C6H6ClNO,NA,NA,NA,1.13.11.76,R10521
Phenol,cpd:C20712,"(S)-Laudanine;(+)-Laudanidine;5-[((1S)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-2-methoxyphenol",C20H25NO4,NA,NA,NA,2.1.1.291,R10605
Phenol,cpd:C21107,4-(beta-D-Ribofuranosyl)phenol 5'-phosphate,C11H15O8P,Folate biosynthesis,NA,NA,2.4.2.54,R11102
Phenol,cpd:C21890,4-[(E)-2-Isocyanoethenyl]phenol,C9H7NO,NA,NA,NA,1.14.20.10,R12076
Phenol,cpd:C22226,Icosanoyl-[(phenol)carboxyphthiodiolenone synthase],C20H39OSR,NA,NA,NA,NA,NA
Phenol,cpd:C22345,C-Terminal [mycofactocin precursor peptide]-glycyl-L-valyl-4-[2-aminoethenyl]phenol,C15H20N3O3R,NA,NA,NA,1.3.98.7;4.1.99.26,R12724 R12750
Phenol,cpd:C22416,Cremeomycin;6-Carboxy-2-diazonio-3-methoxyphenolate,C8H6N2O4,Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Cremeomycin biosynthesis, aspartate/3,4-AHBA => cremeomycin",Secondary metabolites in pathway maps [br08011.html]; Biosynthetic pathways and modules of secondary metabolites;  C22416,6.7.1.1,R12943
Phenol,cpd:C22751,"Cannabicyclohexanol;2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol",C22H36O2,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22751,NA,NA
Phenylacetate,cpd:C00544,"Homogentisate;Homogentisic acid;2,5-Dihydroxyphenylacetic acid;2,5-Dihydroxyphenylacetate",C8H8O4,Ubiquinone and other terpenoid-quinone biosynthesis;Tyrosine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,"Tyrosine degradation, tyrosine => homogentisate;Tocopherol/tocotorienol biosynthesis, homogentisate + phytyl/geranylgeranyl-PP => tocopherol/tocotorienol;Plastoquinone biosynthesis, homogentisate + solanesyl-PP => plastoquinol",NA,1.13.11.5;1.13.11.27;1.13.12.-;1.14.13.18;1.14.13.63;1.14.13.-;2.5.1.115;2.5.1.116;2.5.1.117;4.1.1.-,R02514 R02515 R02516 R02517 R02518 R02519 R02520 R02521;R05450 R07500 R08782 R10708
Phenylacetate,cpd:C00642,4-Hydroxyphenylacetate;4-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C00642,1.2.1.5;1.2.1.29;1.2.1.39;1.2.1.53;1.2.3.13;1.14.13.18;1.14.14.9;4.1.1.83;6.2.1.-,R00042 R02514 R02516 R02695 R02697 R02698 R02699 R06790;R07312 R13086
Phenylacetate,cpd:C01161,"3,4-Dihydroxyphenylacetate;3,4-Dihydroxyphenylacetic acid;Homoprotocatechuate",C8H8O4,Tyrosine metabolism;Degradation of flavonoids;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Dopaminergic synapse;Cocaine addiction;Amphetamine addiction;Alcoholism,"Homoprotocatechuate degradation, homoprotocatechuate => 2-oxohept-3-enedioate",Dietary phytochemicals [br08012.html]; Flavonoids;  C01161,1.2.1.5;1.2.1.29;1.2.1.39;1.13.11.15;1.14.12.9;1.14.14.9;2.1.1.6,R02698 R03299 R03300 R03302 R03303 R03304 R03306 R13085
Phenylacetate,cpd:C01983,(R)-Mandelate;(R)-2-Hydroxy-2-phenylacetic acid;(R)-2-Hydroxy-2-phenylacetate;(R)-Mandelic acid,C8H8O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CA Antiinfectives;     B05CA06 Mandelic acid;      C01983  (R)-Mandelate; J ANTIINFECTIVES FOR SYSTEMIC USE;  J01 ANTIBACTERIALS FOR SYSTEMIC USE;   J01X OTHER ANTIBACTERIALS;    J01XX Other antibacterials;     J01XX06 Mandelic acid;      C01983  (R)-Mandelate,1.1.1.379;3.5.1.86;5.1.2.2,R03790 R03791 R05783
Phenylacetate,cpd:C01984,(S)-Mandelate;(S)-2-Hydroxy-2-phenylacetic acid;(S)-2-Hydroxy-2-phenylacetate;(S)-Mandelic acid,C8H8O3,Aminobenzoate degradation;Microbial metabolism in diverse environments,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; B BLOOD AND BLOOD FORMING ORGANS;  B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS;   B05C IRRIGATING SOLUTIONS;    B05CA Antiinfectives;     B05CA06 Mandelic acid;      C01984  (S)-Mandelate; J ANTIINFECTIVES FOR SYSTEMIC USE;  J01 ANTIBACTERIALS FOR SYSTEMIC USE;   J01X OTHER ANTIBACTERIALS;    J01XX Other antibacterials;     J01XX06 Mandelic acid;      C01984  (S)-Mandelate,1.1.1.-;1.1.99.31;1.14.16.6;5.1.2.2,R03791 R03792 R03793 R03794 R07664
Phenylacetate,cpd:C02137,alpha-Oxo-benzeneacetic acid;Benzoylformate;Benzoylformic acid;Phenylglyoxylic acid;Phenylglyoxylate;2-Oxo-2-phenylacetate,C8H6O3,Phenylalanine metabolism;Aminobenzoate degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.1.1.379;1.1.1.-;1.1.99.31;1.2.1.58;3.1.2.25;4.1.1.7,R01764 R02450 R03790 R03792 R03793 R07294 R07664
Phenylacetate,cpd:C03076,4-Bromophenylacetate;4-Bromophenylacetic acid,C8H7BrO2,NA,NA,NA,NA,NA
Phenylacetate,cpd:C03077,4-Chlorophenylacetate;4-Chlorophenylacetic acid,C8H7ClO2,Tyrosine metabolism;Dioxin degradation;Microbial metabolism in diverse environments,NA,NA,1.14.12.9;3.5.5.5,R03306 R04140 R05473 R05474
Phenylacetate,cpd:C03768,4-Substituted phenylacetate,C8H7O2R,NA,NA,NA,NA,NA
Phenylacetate,cpd:C05582,Homovanillate;Homovanillic acid;3-Methoxy-4-hydroxyphenylacetate,C9H10O4,Tyrosine metabolism;Metabolic pathways;Dopaminergic synapse,NA,NA,1.2.1.5;2.1.1.6,R03304 R04888 R04889
Phenylacetate,cpd:C05593,3-Hydroxyphenylacetate;3-Hydroxyphenylacetic acid,C8H8O3,Tyrosine metabolism;Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.14.13.63;1.14.14.9,R02515 R02517 R03299 R06791
Phenylacetate,cpd:C05852,2-Hydroxyphenylacetate;2-Hydroxyphenylacetic acid,C8H8O3,Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.13.11.27;1.14.13.-;1.14.14.54,R01372 R05001 R05450 R05487
Phenylacetate,cpd:C06207,"2,6-Dihydroxyphenylacetate",C8H8O4,Phenylalanine metabolism,NA,NA,NA,R05001
Phenylacetate,cpd:C07086,Phenylacetic acid;Benzylformic acid;Phenylacetate;Benzeneacetic acid,C8H8O2,Phenylalanine metabolism;Styrene degradation;Metabolic pathways;Microbial metabolism in diverse environments,"Phenylacetate degradation, phenylaxetate => acetyl-CoA/succinyl-CoA",Prodrugs [br08324.html]; C07086;Narcotics and psychotropics in Japan [br08308.html]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  C07086,1.2.1.5;1.2.1.39;1.14.14.54;3.1.2.-;3.5.1.4;3.5.1.11;3.5.5.1;4.1.1.119;6.2.1.30,R02536 R02537 R02539 R02540 R04103 R05487 R06790 R06791;R07855 R09840 R12504
Phenylacetate,cpd:C22588,"3,4,5-Trihydroxyphenylacetate;2-(3,4,5-Trihydroxyphenyl)acetic Acid",C8H8O5,NA,NA,Dietary phytochemicals [br08012.html]; Flavonoids;  C22588,NA,NA
Phenylacetate,cpd:C22819,Methyl alpha-acetylphenylacetate;MAPA;Methyl 3-oxo-2-phenylbutanoate,C11H12O3,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Stimulants by Control Act Article 2 Appended Table and Cabinet Order;  C22819,NA,NA
Propionate,cpd:C00163,Propanoate;Propionate;Propanoic acid;Propionic acid,C3H6O2,Propanoate metabolism;Ethylbenzene degradation;Nicotinate and nicotinamide metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Carbohydrate digestion and absorption;Protein digestion and absorption,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C00163  Propionate; Propanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C00163  Propanoic acid,1.3.1.125;2.7.2.1;2.7.2.15;2.8.3.1;2.8.3.27;3.7.1.-;4.1.3.32;6.2.1.1;6.2.1.13;6.2.1.17,R00920 R00925 R00928 R01353 R01354 R01355 R01449 R05366;R11773 R13136
Propionate,cpd:C01013,3-Hydroxypropanoate;3-Hydroxypropanoic acid;3-Hydroxypropionate;3-Hydroxypropionic acid;Hydracrylic acid,C3H6O3,Pyrimidine metabolism;beta-Alanine metabolism;Propanoate metabolism;Carbon fixation pathways in prokaryotes;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism,"Malonate semialdehyde pathway, propanoyl-CoA => acetyl-CoA;Hydroxypropionate-hydroxybutylate cycle;3-Hydroxypropionate bi-cycle;Pyrimidine degradation, uracil => 3-hydroxypropanoate",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Hydroxycarboxylic acids;    C01013  3-Hydroxypropanoate,1.1.1.59;1.1.1.298;1.1.1.-;3.1.2.4;6.2.1.36;6.2.1.-,R01608 R03157 R03158 R09286 R09289
Propionate,cpd:C01198,3-(2-Hydroxyphenyl)propanoate;2-Hydroxyphenylpropanoate;3-(2-Hydroxyphenyl)propionic acid;Melilotate;3-(2-Hydroxyphenyl)propionate,C9H10O3,Phenylalanine metabolism;Polycyclic aromatic hydrocarbon degradation;Biosynthesis of various plant secondary metabolites;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,1.3.1.11;1.14.13.4;3.1.1.35,R03369 R03692 R03709 R04899 R05537
Propionate,cpd:C02642,3-Ureidopropionate;3-Ureidopropanoate;beta-Ureidopropionic acid;N-Carbamoyl-beta-alanine,C4H8N2O3,Pyrimidine metabolism;beta-Alanine metabolism;Pantothenate and CoA biosynthesis;Metabolic pathways,"Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate",NA,3.5.1.6;3.5.2.2,R00905 R02269
Propionate,cpd:C03401,"L-2,3-Diaminopropanoate;L-2,3-Diaminopropionate;L-2,3-Diaminopropionic acid;L-2,3-Diaminopropanoic acid;3-Amino-L-alanine;(S)-2,3-Diaminopropanoate;(2S)-2,3-Diaminopropanoic acid",C3H8N2O2,Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites,"Staphyloferrin B biosynthesis, L-serine => staphyloferrin B;Dapdiamides biosynthesis, L-2,3-diaminopropanoate => dapdiamide A/B/C","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0110 Amino fatty acids;    C03401  (2S)-2,3-Diaminopropanoic acid",1.5.1.51;2.3.1.58;6.3.2.46;6.3.2.54;6.3.2.55,R04211 R10940 R11655 R12308 R12311
Propionate,cpd:C04067,"Diethyl 2-methyl-3-oxosuccinate;Diethyl oxalpropionate;Butanedioic acid, 2-methyl-3-oxo-, 1,4-diethyl ester",C9H14O5,NA,NA,NA,1.1.1.229,R04387
Propionate,cpd:C05565,Hydantoin-5-propionate;Hydantoin-propionate,C6H8N2O4,Histidine metabolism,NA,NA,1.14.13.-;1.17.3.2,R00069 R04875
Propionate,cpd:C06389,2-Arylpropionate,C3H5O2R,NA,NA,NA,4.1.1.76,R05173
Propionate,cpd:C06393,"2,3-Diaminopropanoate;2,3-Diaminopropionate;2,3-Diaminopropionic acid;2,3-Diaminopropanoic acid",C3H8N2O2,NA,NA,NA,4.3.1.15,R00195
Propionate,cpd:C07114,3-Oxo-3-phenylpropanoate;Benzoylacetate;3-Oxo-3-phenylpropionate;3-Oxo-3-phenylpropionic acid,C9H8O3,Ethylbenzene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,6.2.1.-;6.4.1.8,R05452 R05453
Propionate,cpd:C07813,Beclomethasone dipropionate;Beclometasone dipropionate,C28H37ClO7,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00689)]; A ALIMENTARY TRACT AND METABOLISM;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA07 Beclometasone;      D00689  Beclomethasone dipropionate (USP) &lt;JP/US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AC Corticosteroids, potent (group III);     D07AC15 Beclometasone;      D00689  Beclomethasone dipropionate (USP) &lt;JP/US&gt;; R RESPIRATORY SYSTEM;  R01 NASAL PREPARATIONS;   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;    R01AD Corticosteroids;     R01AD01 Beclometasone;      D00689  Beclomethasone dipropionate (USP) &lt;JP/US&gt;;  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;   R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;    R03BA Glucocorticoids;     R03BA01 Beclometasone;      D00689  Beclomethasone dipropionate (USP) &lt;JP/US&gt;;USP drug classification [BR:br08302(D00689)]; Respiratory Tract/Pulmonary Agents;  Anti-inflammatories, Inhaled Corticosteroids;   Beclomethasone;    D00689  Beclomethasone dipropionate (USP);Therapeutic category of drugs in Japan [BR:br08301(D00689)]; 1  Agents affecting nervous system and sensory organs;  13  Agents affecting sensory organs;   132  Otic and nasal agents;    1329  Others;     D00689  Beclomethasone dipropionate (USP); Beclometasone dipropionate (JP18); 2  Agents affecting individual organs;  22  Respiratory organ agents;   229  Miscellaneous;    2290  Miscellaneous;     D00689  Beclomethasone dipropionate (USP); Beclometasone dipropionate (JP18);  24  Hormones;   245  Adrenal hormone preparations;    2459  Others;     D00689  Beclomethasone dipropionate (USP); Beclometasone dipropionate (JP18);Classification of Japanese OTC drugs [BR:br08313(D00689)]; Agents for otolaryngologic use;  70 Nasal sprays for inflammation;   D00689  Beclomethasone dipropionate (USP);Risk category of Japanese OTC drugs [BR:br08312(D00689)]; Designated second-class OTC drugs;  Inorganic and organic chemicals;   Beclometasone dipropionate;    D00689  Beclomethasone dipropionate (USP); Second-class OTC drugs;  Inorganic and organic chemicals;   Beclometasone dipropionate;    D00689  Beclomethasone dipropionate (USP);Drug groups [BR:br08330(D00689)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00097  Beclometasone;     D00689  Beclomethasone dipropionate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    D00689  Beclomethasone dipropionate;Drug classes [BR:br08332(D00689)]; Anti-inflammatory;  DG01955  Corticosteroid;   D00689  Beclomethasone dipropionate;Target-based classification of drugs [BR:br08310(D00689)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D00689  Beclomethasone dipropionate (USP) &lt;JP/US&gt;;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00689)]; Chemicals;  D00689  Beclometasone dipropionate;Drug metabolizing enzymes and transporters [br08309.html(D00689)]; Drug metabolizing enzymes;  D00689;Rx-to-OTC switch list in Japan [br08314.html(D00689)]; D00689",NA,NA
Propionate,cpd:C08155,Nandrolone phenpropionate;Nandrolone phenylpropionate,C27H34O3,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00956)]; A ALIMENTARY TRACT AND METABOLISM;  A14 ANABOLIC AGENTS FOR SYSTEMIC USE;   A14A ANABOLIC STEROIDS;    A14AB Estren derivatives;     A14AB01 Nandrolone;      D00956  Nandrolone phenpropionate (USP); S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01X OTHER OPHTHALMOLOGICALS;    S01XA Other ophthalmologicals;     S01XA11 Nandrolone;      D00956  Nandrolone phenpropionate (USP);Drug groups [BR:br08330(D00956)]; Hormonal agent;  DG01590  Androgen receptor agonist;   DG01605  Anabolic steroid;    DG00142  Nandrolone;     D00956  Nandrolone phenpropionate;Target-based classification of drugs [BR:br08310(D00956)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C4 (AR);     D00956  Nandrolone phenpropionate (USP),NA,NA
Propionate,cpd:C08158,Testosterone propionate,C22H32O3,NA,NA,Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0202 C19 steroids (androgens) and derivatives;    C08158  Testosterone propionate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00959)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03B ANDROGENS;    G03BA 3-oxoandrosten (4) derivatives;     G03BA03 Testosterone;      D00959  Testosterone propionate (JP18/USP);Risk category of Japanese OTC drugs [BR:br08312(D00959)]; First-class OTC drugs;  Inorganic and organic chemicals;   Testosterone propionate;    D00959  Testosterone propionate (JP18/USP);Drug groups [BR:br08330(D00959)]; Hormonal agent;  DG01590  Androgen receptor agonist;   DG00460  Testosterone;    D00959  Testosterone propionate;  DG02006  Testosterone;   DG00460  Testosterone;    D00959  Testosterone propionate;Target-based classification of drugs [BR:br08310(D00959)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C4 (AR);     D00959  Testosterone propionate (JP18/USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00959)]; Chemicals;  D00959  Testosterone propionate;  D00959  Testosterone propionate injection,NA,NA
Propionate,cpd:C08276,3-(Methylthio)propanoate;3-(Methylthio)propionic acid;3-Methylthiopropionate;3-(Methylsulfanyl)propanoate;3-Methylthiopropanoic acid,C4H8O2S,Cysteine and methionine metabolism;Sulfur metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0113 Thia fatty acids;    C08276  3-Methylthiopropanoic acid,1.13.11.53;2.1.1.269;6.2.1.44,R07363 R10333 R10820
Propionate,cpd:C12306,Allyl cyclohexylpropionate;2-Propenyl 3-cyclohexylpropanoate,C12H20O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0701 Wax monoesters;    C12306  Allyl cyclohexylpropionate,NA,NA
Propionate,cpd:C13077,Estradiol dipropionate,C24H32O4,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0201 C18 steroids (estrogens) and derivatives;    C13077  Estradiol dipropionate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01617)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03C ESTROGENS;    G03CA Natural and semisynthetic estrogens, plain;     G03CA03 Estradiol;      D01617  Estradiol dipropionate (JAN);Drug groups [BR:br08330(D01617)]; Hormonal agent;  DG01986  Estrogen;   DG00462  Estradiol;    D01617  Estradiol dipropionate;  DG01584  Estrogen receptor agonist;   DG00462  Estradiol;    D01617  Estradiol dipropionate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00462  Estradiol;     D01617  Estradiol dipropionate;Target-based classification of drugs [BR:br08310(D01617)]; Nuclear receptors;  Estrogen like receptors;   Estrogen receptor;    NR3A (ESR);     D01617  Estradiol dipropionate (JAN);Drug metabolizing enzymes and transporters [br08309.html(D01617)]; Drug metabolizing enzymes;  D01617",NA,NA
Propionate,cpd:C13358,Hydrocortisone butyrate propionate;Hydrocortisone buteprate;Hydrocortisone probutate,C28H40O7,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0203 C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives;    C13358  Hydrocortisone butyrate propionate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01886)]; A ALIMENTARY TRACT AND METABOLISM;  A01 STOMATOLOGICAL PREPARATIONS;   A01A STOMATOLOGICAL PREPARATIONS;    A01AC Corticosteroids for local oral treatment;     A01AC03 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;  A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;   A07E INTESTINAL ANTIINFLAMMATORY AGENTS;    A07EA Corticosteroids acting locally;     A07EA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; C CARDIOVASCULAR SYSTEM;  C05 VASOPROTECTIVES;   C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;    C05AA Corticosteroids;     C05AA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; D DERMATOLOGICALS;  D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;   D07A CORTICOSTEROIDS, PLAIN;    D07AA Corticosteroids, weak (group I);     D07AA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;    D07AB Corticosteroids, moderately potent (group II);     D07AB11 Hydrocortisone buteprate;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;   D07X CORTICOSTEROIDS, OTHER COMBINATIONS;    D07XA Corticosteroids, weak, other combinations;     D07XA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;  H02 CORTICOSTEROIDS FOR SYSTEMIC USE;   H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;    H02AB Glucocorticoids;     H02AB09 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01B ANTIINFLAMMATORY AGENTS;    S01BA Corticosteroids, plain;     S01BA02 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;   S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;    S01CB Corticosteroids/antiinfectives/mydriatics in combination;     S01CB03 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;  S02 OTOLOGICALS;   S02B CORTICOSTEROIDS;    S02BA Corticosteroids;     S02BA01 Hydrocortisone;      D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D01886)]; Dermatological Agents;  Dermatitis and Pruitus Agents;   Glucocorticoids, Medium Potency;    Hydrocortisone;     D01886  Hydrocortisone probutate (USAN); Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal);  Hydrocortisone;   D01886  Hydrocortisone probutate (USAN);Therapeutic category of drugs in Japan [BR:br08301(D01886)]; 2  Agents affecting individual organs;  26  Epidermides;   264  Analgesics, anti-itchings, astringents, anti-inflammatory agents;    2646  Adrenocorticotropic hormones;     D01886  Hydrocortisone probutate (USAN); Hydrocortisone butyrate propionate (JAN);Drug groups [BR:br08330(D01886)]; Anti-inflammatory;  DG01955  Corticosteroid;   DG02068  Glucocorticoid;    DG00012  Hydrocortisone;     D01886  Hydrocortisone probutate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D01886  Hydrocortisone probutate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG00012  Hydrocortisone;    D01886  Hydrocortisone probutate;Drug classes [BR:br08332(D01886)]; Anti-inflammatory;  DG01955  Corticosteroid;   D01886  Hydrocortisone probutate; Dermatological agent;  DG03243  Atopic dermatitis agent;   D01886  Hydrocortisone probutate;Target-based classification of drugs [BR:br08310(D01886)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C1 (GR);     D01886  Hydrocortisone probutate (USAN) &lt;JP/US&gt;;Drug metabolizing enzymes and transporters [br08309.html(D01886)]; Drug metabolizing enzymes;  D01886;Topical steroids potency [br08317.html(D01886)]; Classification in Japan;  D01886",NA,NA
Propionate,cpd:C14603,17beta-Hydroxyestr-4-en-3-one cyclopentanepropionate;19-Nortestosterone cyclopentylpropionate,C26H38O3,NA,NA,NA,NA,NA
Propionate,cpd:C14624,"Androstane-3,17-diol dipropionate;5alpha-Androstane-3alpha,17beta-diol dipropionate",C25H40O4,NA,NA,NA,NA,NA
Propionate,cpd:C14634,Methandriol dipropionate,C26H40O4,NA,NA,Drug groups [BR:br08330(D08197)]; Hormonal agent;  DG01590  Androgen receptor agonist;   DG01605  Anabolic steroid;    DG01276  Methandriol;     D08197  Methandriol dipropionate;Target-based classification of drugs [BR:br08310(D08197)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C4 (AR);     D08197  Methandriol dipropionate,NA,NA
Propionate,cpd:C14640,Estradiol 17beta-cyclopentylpropionate;Estradiol cypionate,C26H36O3,NA,NA,"Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D04063)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03C ESTROGENS;    G03CA Natural and semisynthetic estrogens, plain;     G03CA03 Estradiol;      D04063  Estradiol cypionate (USP) &lt;US&gt;;USP drug classification [BR:br08302(D04063)]; Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers);  Estrogens;   Estradiol;    D04063  Estradiol cypionate (USP);Drug groups [BR:br08330(D04063)]; Hormonal agent;  DG01986  Estrogen;   DG00462  Estradiol;    D04063  Estradiol cypionate;  DG01584  Estrogen receptor agonist;   DG00462  Estradiol;    D04063  Estradiol cypionate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00462  Estradiol;     D04063  Estradiol cypionate;Drug classes [BR:br08332(D04063)]; Endocrine and hormonal agent;  DG01986  Estrogen;   D04063  Estradiol cypionate;  DG01584  Estrogen receptor agonist;   D04063  Estradiol cypionate;Target-based classification of drugs [BR:br08310(D04063)]; Nuclear receptors;  Estrogen like receptors;   Estrogen receptor;    NR3A (ESR);     D04063  Estradiol cypionate (USP) &lt;US&gt;;Drug metabolizing enzymes and transporters [br08309.html(D04063)]; Drug metabolizing enzymes;  D04063",NA,NA
Propionate,cpd:C14645,"Estradiol-17-phenylpropionate;Estra-1,3,5(10)-triene-3,17beta-diol 17-benzenepropionate",C27H32O3,NA,NA,NA,NA,NA
Propionate,cpd:C14667,Testosterone phenylpropionate;17beta-Hydroxyandrost-4-en-3-one 3-phenylpropionate,C28H36O3,NA,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D08574)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03B ANDROGENS;    G03BA 3-oxoandrosten (4) derivatives;     G03BA03 Testosterone;      D08574  Testosterone phenylpropionate;Drug groups [BR:br08330(D08574)]; Hormonal agent;  DG01590  Androgen receptor agonist;   DG00460  Testosterone;    D08574  Testosterone phenylpropionate;  DG02006  Testosterone;   DG00460  Testosterone;    D08574  Testosterone phenylpropionate;Target-based classification of drugs [BR:br08310(D08574)]; Nuclear receptors;  Estrogen like receptors;   3-Ketosteroid receptor;    NR3C4 (AR);     D08574  Testosterone phenylpropionate,NA,NA
Propionate,cpd:C14973,17beta-Hydroxy-7alpha-mercaptoandrost-4-en-3-one 7-propionate;S-(17beta-Hydroxy-3-oxoandrost-4-en-7alpha-yl)propanethioate,C22H32O3S,NA,NA,NA,NA,NA
Propionate,cpd:C15009,"17beta-Hydroxyandrost-4-ene-3,11-dione propionate",C22H30O4,NA,NA,NA,NA,NA
Propionate,cpd:C15088,4-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;4-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C15112,"4,4-Difluoro-17beta-hydroxyandrost-5-en-3-one propionate",C22H30F2O3,NA,NA,NA,NA,NA
Propionate,cpd:C15180,17beta-Hydroxy-4-mercaptoandrost-4-en-3-one 4-acetate 17-propionate,C24H34O4S,NA,NA,NA,NA,NA
Propionate,cpd:C15253,16beta-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;16beta-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C15266,17abeta-Hydroxy-D-homoandrost-4-en-3-one propionate;D-Homotestosterone propionate,C23H34O3,NA,NA,NA,NA,NA
Propionate,cpd:C15273,17beta-Hydroxy-5alpha-androst-1-en-3-one propionate,C22H32O3,NA,NA,NA,NA,NA
Propionate,cpd:C15289,"16alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate",C25H36O5,NA,NA,NA,NA,NA
Propionate,cpd:C15290,"2alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate;2alpha-Hydroxytestosterone dipropionate",C25H36O5,NA,NA,NA,NA,NA
Propionate,cpd:C15314,"11beta,17beta-Dihydroxyandrost-4-en-3-one 17-propionate;11beta-Hydroxytestosterone 17-propionate",C22H32O4,NA,NA,NA,NA,NA
Propionate,cpd:C15321,6alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;6alpha-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C15331,"17beta-Hydroxy-6beta-methyl-5alpha-androstan-3-one propionate;4,5alpha-Dihydro-6beta-methyltestosterone propionate",C23H36O3,NA,NA,NA,NA,NA
Propionate,cpd:C15350,"Estra-1,3,5(10)-triene-3,16alpha-diol dipropionate",C24H32O4,NA,NA,NA,NA,NA
Propionate,cpd:C15359,6-(Dibromomethylene)-17beta-hydroxy-androst-4-en-3-one propionate,C23H30Br2O3,NA,NA,NA,NA,NA
Propionate,cpd:C15373,5alpha-Androstan-17beta-ol propionate,C22H36O2,NA,NA,NA,NA,NA
Propionate,cpd:C15374,17beta-Hydroxy-7alpha-methylandrost-4-en-3-one propionate;7alpha-Methyltestosterone propionate,C23H34O3,NA,NA,NA,NA,NA
Propionate,cpd:C15408,2alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;2alpha-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C15409,17beta-Hydroxy-A-norandrost-3(5)-en-2-one propionate,C21H30O3,NA,NA,NA,NA,NA
Propionate,cpd:C15446,6beta-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;6beta-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C15447,16alpha-Fluoro-17beta-hydroxyandrost-4-en-3-one propionate;16alpha-Fluorotestosterone propionate,C22H31FO3,NA,NA,NA,NA,NA
Propionate,cpd:C18379,Calcium propionate,C6H10CaO4,NA,NA,Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  963  Mineral and preparations;   9631  Calcium compounds and preparations (except calcium iodid and calcium bromide);    C18379  Calcium propionate;  969  Other agents affecting metabolism;   9696  Organic acid and preparations;    C18379  Calcium propionate,NA,NA
Propionate,cpd:C18384,Magnesium dipropionate,C6H10MgO4,NA,NA,Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  969  Other agents affecting metabolism;   9696  Organic acid and preparations;    C18384  Magnesium dipropionate,NA,NA
Propionate,cpd:C18830,Ethyl 3-(N-butylacetamido)propionate;Ethyl butylacetylaminopropionate,C11H21NO3,NA,NA,Pesticides [BR:br08007]; Pesticides;  Others;   Insect repellents;    C18830  Ethyl 3-(N-butylacetamido)propionate,NA,NA
Propionate,cpd:C20967,"N(beta)-Epoxysuccinamoyl-DAP;N(beta)-Epoxysuccinamoyl-diaminopropionate;3-({[(2R,3R)-3-Carbamoyloxiran-2-yl]carbonyl}amino)-L-alanine",C7H11N3O5,NA,NA,NA,6.3.2.47,R10941
Propionate,cpd:C22312,3-Sulfanylpropanoate;3-Mercaptopropionate;3-Mercaptopropanoic acid,C3H6O2S,NA,NA,NA,1.13.11.91,R12662
Propionate,cpd:C22797,Desmethylprodine;MPPP;1-Methyl-4-phenyl-4-piperidinol propionate,C15H21NO2,NA,NA,Narcotics and psychotropics in Japan [br08308.html]; Narcotics by Cabinet Order Article 1 (157 substances);  C22797,NA,NA
Propyl alcohol,cpd:C01845,Propan-2-ol;2-Propanol;Isopropanol;Isopropyl alcohol,C3H8O,Butanoate metabolism;Metabolic pathways,NA,Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00137)]; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AX Other antiseptics and disinfectants;     D08AX05 Isopropanol;      D00137  Isopropyl alcohol (USP) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00137)]; 2  Agents affecting individual organs;  26  Epidermides;   261  Antimicrobial agents;    2615  Alcohols;     D00137  Isopropyl alcohol (USP); Isopropanol (JP18);Classification of Japanese OTC drugs [BR:br08313(D00137)]; Agents for integumentary system;  54 Disinfectants (incl. special bandages);   D00137  Isopropyl alcohol (USP);Risk category of Japanese OTC drugs [BR:br08312(D00137)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Isopropanol;    D00137  Isopropyl alcohol (USP);Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00137)]; Chemicals;  D00137  Isopropanol,1.1.1.80;1.1.1.-;1.14.13.227,R01550 R10702 R10703
Propyl alcohol,cpd:C05235,Hydroxyacetone;Acetol;1-Hydroxy-2-propanone;2-Ketopropyl alcohol;Acetone alcohol;Pyruvinalcohol;Pyruvic alcohol;Methylketol,C3H6O2,Propanoate metabolism;Metabolic pathways,NA,NA,1.1.1.6;1.1.1.-;4.1.99.24;4.1.99.25;4.4.1.41,R02528 R10717 R10718 R12150 R12151 R12764
Propyl alcohol,cpd:C05944,"Pantothenol;(R)-2,4-Dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide;Dexpanthenol;2,4-Dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide;(+)-Panthenol;Bepanthen;Bepanthene;Bepantol;D-(+)-2,4-Dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutyramide;Cozyme;D(+)-Panthenol;D(+)-Pantothenyl alcohol;D-P-A Injection;D-Panthenol;d-Pantothenol;d-Pantothenyl alcohol;Ilopan;Motilyn;Panadon;Panthenol;Panthoderm;Pantol;Pantothenyl alcohol;N-Pantoyl-propanolamine;Provitamin B;Synapan;Thenalton;Zentinic",C9H19NO4,Pantothenate and CoA biosynthesis,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA08 Fatty amides;   FA0802 N-acyl amines;    C05944  Pantothenol;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D00193)]; A ALIMENTARY TRACT AND METABOLISM;  A11 VITAMINS;   A11H OTHER PLAIN VITAMIN PREPARATIONS;    A11HA Other plain vitamin preparations;     A11HA30 Dexpanthenol;      D00193  Dexpanthenol (USP/INN) &lt;JP&gt;; D DERMATOLOGICALS;  D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS;   D03A CICATRIZANTS;    D03AX Other cicatrizants;     D03AX03 Dexpanthenol;      D00193  Dexpanthenol (USP/INN) &lt;JP&gt;; S SENSORY ORGANS;  S01 OPHTHALMOLOGICALS;   S01X OTHER OPHTHALMOLOGICALS;    S01XA Other ophthalmologicals;     S01XA12 Dexpanthenol;      D00193  Dexpanthenol (USP/INN) &lt;JP&gt;;Therapeutic category of drugs in Japan [BR:br08301(D00193)]; 3  Agents affecting metabolism;  31  Vitamins;   313  Vitamin B preparations;    3133  Pantothenic acids;     D00193  Dexpanthenol (USP/INN); Panthenol (JAN);Classification of Japanese OTC drugs [BR:br08313(D00193)]; Agents for ophthalmologic use;  62 General eye drops;   D00193  Dexpanthenol (USP/INN); Agents for dental and stomatological use;  74 Stomatitis remedies;   D00193  Dexpanthenol (USP/INN);Risk category of Japanese OTC drugs [BR:br08312(D00193)]; Third-class OTC drugs;  Inorganic and organic chemicals;   Panthenol;    D00193  Dexpanthenol (USP/INN);Target-based classification of drugs [BR:br08310(D00193)]; G Protein-coupled receptors;  Rhodopsin family;   Acetylcholine (muscarinic);    CHRM3;     D00193  Dexpanthenol (USP/INN) &lt;JP&gt;,NA,R03927
Propyl alcohol,cpd:C05979,Propane-1-ol;Propanol;1-Propanol;Propan-1-ol;Propyl alcohol;1-Hydroxypropane;Ethylcarbinol;n-Propanol;n-Propyl alcohol;Optal;Osmosol extra;UN 1274,C3H8O,Propanoate metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA05 Fatty alcohols;   C05979  1-Propanol;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]; D DERMATOLOGICALS;  D08 ANTISEPTICS AND DISINFECTANTS;   D08A ANTISEPTICS AND DISINFECTANTS;    D08AX Other antiseptics and disinfectants;     D08AX03 Propanol;      C05979  Propane-1-ol,1.1.1.202;2.3.1.152,R02377 R05061
Propyl alcohol,cpd:C06576,p-Cumic alcohol;4-Isopropylbenzyl alcohol,C10H14O,Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Cymene degradation, p-cymene => p-cumate",Phytochemical compounds [BR:br08003]; Terpenoids;  Monoterpenoids (C10);   Cyclic monoterpenes;    C06576  p-Cumic alcohol,1.14.15.25,R05232 R05266
Propylene glycol,cpd:C00583,"Propane-1,2-diol;1,2-Propanediol;Propylene glycol",C3H8O2,Propanoate metabolism;Metabolic pathways,NA,Therapeutic category of drugs in Japan [BR:br08301(D00078)]; 7  Agents not mainly for therapeutic purpose;  71  Dispensing medicines;   713  Solvents;    7139  Others;     D00078  Propylene glycol (JP18/USP);Animal drugs in Japan [BR:br08331]; 96  Agents affecting metabolism;  964  Saccharide preparations and blood substitutes;   9646  Propylene glycol and preparations;    C00583  Propylene glycol;Drugs listed in the Japanese Pharmacopoeia [BR:br08311(D00078)]; Chemicals;  D00078  Propylene glycol,1.1.1.6;1.1.1.21;1.1.1.55;1.1.1.77;4.2.1.28,R02257 R02259 R02376 R02577 R10717
Propylene glycol,cpd:C02912,"(R)-Propane-1,2-diol;(R)-1,2-Propanediol;(R)-Propylene glycol",C3H8O2,NA,NA,NA,1.1.1.77,R03080
Propylene glycol,cpd:C02917,"(S)-Propane-1,2-diol;(S)-1,2-Propanediol;(S)-Propylene glycol",C3H8O2,NA,NA,NA,1.1.1.77,R02258
Propylene glycol,cpd:C19356,"1-tert-Butoxy-2-propanol;1-(1,1-Dimethylethoxy)-2-propanol;Propylene glycol mono-t-buthyl ether",C7H16O2,NA,NA,NA,NA,NA
Pyruvate,cpd:C00022,Pyruvate;Pyruvic acid;2-Oxopropanoate;2-Oxopropanoic acid;Pyroracemic acid,C3H4O3,"Glycolysis / Gluconeogenesis;Citrate cycle (TCA cycle);Pentose phosphate pathway;Pentose and glucuronate interconversions;Ascorbate and aldarate metabolism;Alanine, aspartate and glutamate metabolism;Glycine, serine and threonine metabolism;Monobactam biosynthesis;Cysteine and methionine metabolism;Valine, leucine and isoleucine biosynthesis;Arginine and proline metabolism;Tyrosine metabolism;Phenylalanine metabolism;Benzoate degradation;Taurine and hypotaurine metabolism;Phosphonate and phosphinate metabolism;D-Amino acid metabolism;Pyruvate metabolism;Dioxin degradation;Xylene degradation;Glyoxylate and dicarboxylate metabolism;Butanoate metabolism;C5-Branched dibasic acid metabolism;Methane metabolism;Carbon fixation in photosynthetic organisms;Carbon fixation pathways in prokaryotes;Thiamine metabolism;Nicotinate and nicotinamide metabolism;Pantothenate and CoA biosynthesis;Lipoic acid metabolism;Terpenoid backbone biosynthesis;Biosynthesis of various other secondary metabolites;Biosynthesis of various antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid;Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of alkaloids derived from terpenoid and polyketide;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;2-Oxocarboxylic acid metabolism;Degradation of aromatic compounds;Biosynthesis of amino acids;Biosynthesis of cofactors;Vancomycin resistance;Phosphotransferase system (PTS);HIF-1 signaling pathway;AMPK signaling pathway;Insulin secretion;Glucagon signaling pathway;Type II diabetes mellitus;Insulin resistance;Central carbon metabolism in cancer;Diabetic cardiomyopathy","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Glycolysis, core module involving three-carbon compounds;Entner-Doudoroff pathway, glucose-6P => glyceraldehyde-3P + pyruvate;Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;D-Glucuronate degradation, D-glucuronate => pyruvate + D-glyceraldehyde 3P;C5 isoprenoid biosynthesis, non-mevalonate pathway;CAM (Crassulacean acid metabolism), light;C4-dicarboxylic acid cycle, NAD - malic enzyme type;C4-dicarboxylic acid cycle, NADP - malic enzyme type;Reductive citrate cycle (Arnon-Buchanan cycle);Pyruvate oxidation, pyruvate => acetyl-CoA;Semi-phosphorylative Entner-Doudoroff pathway, gluconate => glycerate-3P;Non-phosphorylative Entner-Doudoroff pathway, gluconate/galactonate => glycerate;Dicarboxylate-hydroxybutyrate cycle;3-Hydroxypropionate bi-cycle;Isoleucine biosynthesis, pyruvate => 2-oxobutanoate;Catechol meta-cleavage, catechol => acetyl-CoA / 4-methylcatechol => propanoyl-CoA;Incomplete reductive citrate cycle, acetyl-CoA => oxoglutarate;D-Galacturonate degradation (bacteria), D-galacturonate => pyruvate + D-glyceraldehyde 3P;Semi-phosphorylative Entner-Doudoroff pathway, gluconate/galactonate => glycerate-3P;Betaine degradation, bacteria, betaine => pyruvate",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00022  Pyruvate; 2-Oxopropanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C00022  2-Oxopropanoic acid,1.1.1.27;1.1.1.28;1.1.1.38;1.1.1.39;1.1.1.40;1.1.1.83;1.1.1.436;1.1.2.3;1.1.2.4;1.1.2.5;1.1.3.2;1.1.5.12;1.1.99.6;1.1.99.7;1.1.99.40;1.2.1.22;1.2.1.23;1.2.1.49;1.2.1.51;1.2.1.104;1.2.3.3;1.2.3.6;1.2.3.15;1.2.4.1;1.2.5.1;1.2.7.1;1.2.7.11;1.2.7.-;1.4.1.1;1.4.1.17;1.4.3.3;1.4.3.19;1.5.1.11;1.5.1.16;1.5.1.17;1.5.1.22;1.5.1.23;1.5.1.24;1.5.1.26;1.5.1.28;1.5.1.52;1.14.11.43;1.14.11.44;2.1.3.1;2.2.1.6;2.2.1.7;2.2.1.12;2.3.1.54;2.3.3.21;2.6.1.2;2.6.1.12;2.6.1.15;2.6.1.18;2.6.1.21;2.6.1.30;2.6.1.37;2.6.1.40;2.6.1.41;2.6.1.43;2.6.1.44;2.6.1.46;2.6.1.47;2.6.1.51;2.6.1.56;2.6.1.58;2.6.1.66;2.6.1.71;2.6.1.77;2.6.1.84;2.6.1.96;2.6.1.99;2.6.1.108;2.6.1.113;2.6.1.115;2.6.1.119;2.6.3.1;2.7.1.40;2.7.1.121;2.7.3.9;2.7.9.1;2.7.9.2;2.8.1.2;3.1.3.60;3.3.2.1;3.3.2.13;3.3.2.15;3.5.99.10;3.7.1.5;3.7.1.6;3.7.1.20;3.7.1.23;3.7.1.26;3.7.1.-;3.11.1.3;4.1.1.1;4.1.1.64;4.1.1.78;4.1.1.112;4.1.1.-;4.1.2.14;4.1.2.18;4.1.2.20;4.1.2.21;4.1.2.23;4.1.2.28;4.1.2.34;4.1.2.45;4.1.2.51;4.1.2.52;4.1.2.53;4.1.2.54;4.1.2.55;4.1.2.58;4.1.2.64;4.1.2.-;4.1.3.3;4.1.3.16;4.1.3.17;4.1.3.22;4.1.3.25;4.1.3.27;4.1.3.30;4.1.3.32;4.1.3.38;4.1.3.39;4.1.3.40;4.1.3.42;4.1.3.43;4.1.3.44;4.1.3.45;4.1.3.46;4.1.99.1;4.1.99.2;4.2.1.-;4.2.99.20;4.2.99.21;4.3.1.10;4.3.1.13;4.3.1.15;4.3.1.17;4.3.1.18;4.3.1.19;4.3.3.7;4.3.3.8;4.4.1.1;4.4.1.13;4.4.1.15;4.4.1.24;4.4.1.25;4.4.1.28;4.4.1.35;4.4.1.36;4.4.1.-;4.5.1.2;6.4.1.1;7.2.4.2,R00006 R00008 R00014 R00195 R00196 R00197 R00198 R00199;R00200 R00203 R00205 R00206 R00207 R00208 R00209 R00210;R00211 R00212 R00213 R00214 R00215 R00216 R00217 R00218;R00219 R00220 R00221 R00223 R00224 R00226 R00237 R00258;R00297 R00324 R00325 R00344 R00350 R00353 R00368 R00369;R00396 R00398 R00400 R00409 R00430 R00452 R00453 R00470;R00471 R00532 R00543 R00562 R00572 R00576 R00585 R00659;R00666 R00673 R00692 R00703 R00704 R00724 R00728 R00750;R00782 R00906 R00907 R00930 R00985 R00986 R01012 R01031;R01032 R01064 R01085 R01138 R01147 R01148 R01196 R01215;R01261 R01286 R01302 R01335 R01344 R01355 R01447 R01576;R01584 R01645 R01647 R01683 R01699 R01712 R01782 R01784;R01811 R01858 R01874 R02050 R02261 R02271 R02293 R02320;R02408 R02628 R02721 R02754 R02953 R02970 R03001 R03037;R03050 R03081 R03105 R03145 R03277 R03465 R03502 R03528;R03732 R03796 R03854 R04152 R04187 R04350 R04672 R04861;R04941 R05136 R05298 R05538 R05544 R05553 R05605 R05636;R05648 R05652 R05861 R06602 R06603 R06913 R06923 R06934;R07399 R07633 R07634 R07685 R07692 R07713 R08166 R08170;R08197 R08200 R08253 R08570 R08648 R08654 R08660 R08667;R08686 R08698 R08714 R09048 R09088 R09238 R09254 R09366;R10147 R10178 R10180 R10283 R10487 R10527 R10539 R10542;R10550 R10552 R10583 R10597 R10616 R10674 R10691 R10866;R10992 R11023 R11038 R11099 R11141 R11213 R11257 R11352;R11463 R11591 R11593 R11676 R11864 R11996 R12188 R12212;R12237 R12343 R12622 R12689 R12707 R12768 R13049 R13050;R13181 R13209
Pyruvate,cpd:C00074,Phosphoenolpyruvate;Phosphoenolpyruvic acid;PEP,C3H5O6P,"Glycolysis / Gluconeogenesis;Citrate cycle (TCA cycle);Phenylalanine, tyrosine and tryptophan biosynthesis;Phosphonate and phosphinate metabolism;Pyruvate metabolism;Methane metabolism;Carbon fixation in photosynthetic organisms;Carbon fixation pathways in prokaryotes;Biosynthesis of various alkaloids;Biosynthesis of various antibiotics;Biosynthesis of various plant secondary metabolites;Biosynthesis of plant secondary metabolites;Biosynthesis of phenylpropanoids;Biosynthesis of terpenoids and steroids;Biosynthesis of alkaloids derived from shikimate pathway;Biosynthesis of plant hormones;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors;Phosphotransferase system (PTS);Glucagon signaling pathway;Proximal tubule bicarbonate reclamation;Central carbon metabolism in cancer","Glycolysis (Embden-Meyerhof pathway), glucose => pyruvate;Glycolysis, core module involving three-carbon compounds;Gluconeogenesis, oxaloacetate => fructose-6P;Shikimate pathway, phosphoenolpyruvate + erythrose-4P => chorismate;CAM (Crassulacean acid metabolism), dark;CAM (Crassulacean acid metabolism), light;C4-dicarboxylic acid cycle, phosphoenolpyruvate carboxykinase type;C4-dicarboxylic acid cycle, NAD - malic enzyme type;C4-dicarboxylic acid cycle, NADP - malic enzyme type;Reductive citrate cycle (Arnon-Buchanan cycle);Formaldehyde assimilation, serine pathway;Coenzyme M biosynthesis;Dicarboxylate-hydroxybutyrate cycle;Fosfomycin biosynthesis, phosphoenolpyruvate => fosfomycin",NA,2.5.1.7;2.5.1.19;2.5.1.54;2.5.1.55;2.5.1.56;2.5.1.57;2.5.1.95;2.5.1.97;2.5.1.101;2.5.1.132;2.5.1.-;2.7.1.40;2.7.1.121;2.7.3.9;2.7.7.105;2.7.9.1;2.7.9.2;3.1.3.60;4.1.1.31;4.1.1.32;4.1.1.38;4.1.1.49;4.2.1.11;4.4.1.19;5.4.2.9,R00199 R00200 R00206 R00208 R00341 R00345 R00346 R00430;R00431 R00572 R00658 R00659 R00660 R00661 R00724 R00726;R01012 R01138 R01804 R01826 R01858 R02320 R02628 R02769;R03254 R03460 R04435 R06591 R07476 R09760 R09841 R10304;R11439 R12565 R12567 R12646
Pyruvate,cpd:C00166,Phenylpyruvate;Phenylpyruvic acid;alpha-Ketohydrocinnamic acid;keto-Phenylpyruvate;3-Phenyl-2-oxopropanoate;2-Oxo-3-phenylpropanoate,C9H8O3,"Phenylalanine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;D-Amino acid metabolism;Tropane, piperidine and pyridine alkaloid biosynthesis;Biosynthesis of plant secondary metabolites;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Phenylalanine biosynthesis, chorismate => phenylpyruvate => phenylalanine",NA,1.1.1.110;1.1.1.237;1.4.1.20;1.4.3.2;1.4.5.1;1.13.11.27;2.1.1.281;2.3.3.-;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.21;2.6.1.28;2.6.1.57;2.6.1.58;2.6.1.64;2.6.1.70;2.6.1.-;4.1.1.43;4.1.1.-;4.2.1.51;4.2.1.91;5.3.2.1,R00688 R00689 R00692 R00694 R00695 R01370 R01371 R01372;R01373 R01374 R01375 R01376 R01377 R01378 R01582 R10431;R10499 R10500 R11068
Pyruvate,cpd:C00168,Hydroxypyruvate;Hydroxypyruvic acid;3-Hydroxypyruvate;3-Hydroxypyruvic acid,C3H4O4,"Glycine, serine and threonine metabolism;Glyoxylate and dicarboxylate metabolism;Methane metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism","Formaldehyde assimilation, serine pathway;Photorespiration",NA,1.1.1.26;1.1.1.29;1.1.1.79;1.1.1.81;1.4.1.7;2.6.1.45;2.6.1.51;4.1.1.40;5.3.1.22,R00581 R00585 R00588 R01388 R01390 R01392 R01393 R01394
Pyruvate,cpd:C00331,Indolepyruvate;Indolepyruvic acid;(Indol-3-yl)pyruvate;Indole-3-pyruvate;3-(Indol-3-yl)pyruvate,C11H9NO3,Tryptophan metabolism;Metabolic pathways,NA,NA,1.1.1.110;1.2.7.8;1.4.1.19;1.4.3.2;1.14.13.168;2.1.1.47;2.6.1.27;2.6.1.28;2.6.1.99;2.6.1.-;4.1.1.43;4.1.1.74,R00675 R00676 R00677 R00684 R01376 R01972 R01973 R01974;R07161 R10180 R10181 R12055 R12256
Pyruvate,cpd:C00957,Mercaptopyruvate;2-Oxo-3-sulfanylpropanoate;3-Mercaptopyruvic acid;3-Mercaptopyruvate,C3H4O3S,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,1.1.1.27;2.6.1.1;2.6.1.3;2.8.1.2,R00895 R00896 R03104 R03105 R12689
Pyruvate,cpd:C01179,3-(4-Hydroxyphenyl)pyruvate;4-Hydroxyphenylpyruvate;p-Hydroxyphenylpyruvic acid,C9H8O4,"Ubiquinone and other terpenoid-quinone biosynthesis;Monobactam biosynthesis;Tyrosine metabolism;Phenylalanine, tyrosine and tryptophan biosynthesis;Novobiocin biosynthesis;Isoquinoline alkaloid biosynthesis;Biosynthesis of various antibiotics;Biosynthesis of vancomycin group antibiotics;Biosynthesis of plant secondary metabolites;Biosynthesis of alkaloids derived from shikimate pathway;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors","Tyrosine biosynthesis, chorismate => HPP => tyrosine;Tyrosine degradation, tyrosine => homogentisate",NA,1.1.1.110;1.1.1.237;1.2.3.13;1.3.1.12;1.3.1.13;1.4.1.20;1.4.3.2;1.13.11.27;1.13.11.46;2.5.1.111;2.6.1.1;2.6.1.5;2.6.1.9;2.6.1.57;2.6.1.58;2.6.1.103;4.1.1.80;5.3.2.1,R00042 R00729 R00734 R01728 R01730 R02521 R03337 R03339;R03341 R03342 R05778 R06626 R06632 R06757 R09254 R09830
Pyruvate,cpd:C01244,"3,5-Diiodo-4-hydroxyphenylpyruvate;3-(3,5-Diiodo-4-hydroxyphenyl)pyruvate",C9H6I2O4,NA,NA,NA,1.1.1.96;2.6.1.24,R03207 R03431
Pyruvate,cpd:C01256,[Pyruvate dehydrogenase (acetyl-transferring)],C4H6N2O3R2,NA,NA,NA,2.7.11.2;3.1.3.43,R03449 R03450
Pyruvate,cpd:C01275,(3E)-4-(2-Carboxyphenyl)-2-oxobut-3-enoate;trans-2'-Carboxybenzalpyruvate,C11H8O5,NA,NA,NA,1.13.11.38;4.1.2.34,R03465 R03466
Pyruvate,cpd:C01293,[Pyruvate dehydrogenase (acetyl-transferring)] phosphate,C4H7N2O6PR2,NA,NA,NA,2.7.11.2;3.1.3.43,R03449 R03450
Pyruvate,cpd:C02119,3-Acylpyruvate,C4H3O4R,NA,NA,NA,3.7.1.5,R00543
Pyruvate,cpd:C02132,"Acetylpyruvate;Acetylpyruvic acid;2,4-Dioxopentanoate",C5H6O4,NA,NA,NA,3.7.1.6,R00324
Pyruvate,cpd:C02150,Formylpyruvate,C4H4O4,NA,NA,NA,NA,NA
Pyruvate,cpd:C02167,"Maleylpyruvate;Maleylpyruvic acid;3-Maleylpyruvate;(2Z)-4,6-Dioxohept-2-enedioic acid",C7H6O6,Tyrosine metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,"Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0117 Dicarboxylic acids;    C02167  (2Z)-4,6-Dioxohept-2-enedioic acid",1.13.11.4;3.1.1.91;3.7.1.23;5.2.1.2;5.2.1.4,R02656 R03868 R10135 R11257
Pyruvate,cpd:C02193,Pyruvate oxime,C3H5NO3,NA,NA,NA,2.6.3.1,R03796
Pyruvate,cpd:C02514,3-Fumarylpyruvate,C7H6O6,Tyrosine metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,3.7.1.5;3.7.1.20;5.2.1.2;5.2.1.4,R01085 R03868
Pyruvate,cpd:C02601,[Pyruvate kinase],C4H6N2O3R2,NA,NA,NA,3.1.3.49,R03993
Pyruvate,cpd:C02763,2-Hydroxy-3-phenylpropenoate;enol-Phenylpyruvate;enol-Phenylpyruvic acid;enol-alpha-Ketohydrocinnamic acid,C9H8O3,Phenylalanine metabolism;Metabolic pathways,NA,NA,5.3.2.1,R01378
Pyruvate,cpd:C02798,3-Phosphonopyruvate,C3H5O6P,Phosphonate and phosphinate metabolism;Biosynthesis of various antibiotics;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments,"Fosfomycin biosynthesis, phosphoenolpyruvate => fosfomycin",NA,2.3.3.19;2.6.1.-;3.11.1.3;4.1.1.82;5.4.2.9,R00661 R04051 R04053 R08200 R11708
Pyruvate,cpd:C03232,3-Phosphonooxypyruvate;3-Phosphonooxypyruvic acid;3-Phosphohydroxypyruvate;3-Phosphohydroxypyruvic acid;3-Phosphooxypyruvate,C3H5O7P,"Glycine, serine and threonine metabolism;Cysteine and methionine metabolism;Methane metabolism;Metabolic pathways;Biosynthesis of secondary metabolites;Microbial metabolism in diverse environments;Carbon metabolism;Biosynthesis of amino acids","Serine biosynthesis, glycerate-3P => serine",NA,1.1.1.95;2.6.1.52,R01513 R04173
Pyruvate,cpd:C03277,Imidazol-5-yl-pyruvate;3-(Imidazol-5-yl)pyruvate;Imidazole pyruvate;Imidazole pyruvic acid,C6H6N2O3,Histidine metabolism;Metabolic pathways,NA,NA,1.1.1.111;2.6.1.38,R01161 R04185 R04186 R04874 R04876
Pyruvate,cpd:C03808,[Pyruvate kinase] phosphate,C4H7N2O6PR2,NA,NA,NA,3.1.3.49,R03993
Pyruvate,cpd:C03832,"3,5,3'-Triiodothyropyruvate;3-[4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-2-oxopropanoate",C15H9I3O5,NA,NA,NA,2.6.1.26,R03952
Pyruvate,cpd:C03987,3-Iodo-4-hydroxyphenylpyruvate,C9H7IO4,NA,NA,NA,NA,NA
Pyruvate,cpd:C04045,"3-(3,4-Dihydroxyphenyl)pyruvate;3,4-Dihydroxyphenylpyruvate",C9H8O5,Tyrosine metabolism;Metabolic pathways,NA,NA,1.1.1.237;1.13.12.15;2.6.1.49,R02077 R03373 R08920 R12252
Pyruvate,cpd:C04264,3-[(4-Bromophenyl)sulfanyl]-2-oxopropanoate;S-(4-Bromophenyl)-mercaptopyruvate,C9H7BrO3S,NA,NA,NA,2.6.1.75,R04338
Pyruvate,cpd:C04285,"3,5-Dibromo-4-hydroxyphenylpyruvate",C9H6Br2O4,NA,NA,NA,NA,NA
Pyruvate,cpd:C04286,"3,5-Dinitro-4-hydroxyphenylpyruvate",C9H6N2O8,NA,NA,NA,NA,NA
Pyruvate,cpd:C04323,"3,5-Dichloro-4-hydroxyphenylpyruvate",C9H6Cl2O4,NA,NA,NA,NA,NA
Pyruvate,cpd:C04631,UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine;UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine;UDP-N-acetylglucosamine-3-O-pyruvateether;UDP-N-acetylglucosamine enolpyruvate;UDP-N-acetyl-3-O-(1-carboxyvinyl)-alpha-D-glucosamine,C20H29N3O19P2,Amino sugar and nucleotide sugar metabolism;Peptidoglycan biosynthesis;Metabolic pathways;Biosynthesis of nucleotide sugars,NA,NA,1.3.1.98;2.5.1.7,R00660 R03191 R03192
Pyruvate,cpd:C04682,[Methylmalonyl-CoA:pyruvate carboxytransferase];Holo-[methylmalonyl-CoA:pyruvate carboxytransferase];Biotin-[methylmalonyl-CoA:pyruvate carboxytransferase];Holo-[methylmalonyl-CoA-carboxyltransferase];Biotin-[methylmalonyl-CoA-carboxyltransferase],C17H27N5O4SR2,NA,NA,NA,6.3.4.9,R04563
Pyruvate,cpd:C04736,Apo-[methylmalonyl-CoA:pyruvate carboxytransferase];Apo-[methylmalonyl-CoA-carboxyltransferase],C7H13N3O2R2,NA,NA,NA,6.3.4.9,R04563
Pyruvate,cpd:C05350,2-Hydroxy-3-(4-hydroxyphenyl)propenoate;4-Hydroxy-enol-phenylpyruvate,C9H8O4,Tyrosine metabolism;Metabolic pathways,NA,NA,5.3.2.1,R03342
Pyruvate,cpd:C05527,3-Sulfinylpyruvate;3-Sulfinopyruvate,C3H4O5S,Cysteine and methionine metabolism;Metabolic pathways,NA,NA,1.4.1.-;2.6.1.1,R02618 R02619 R04861
Pyruvate,cpd:C05528,3-Sulfopyruvate;3-Sulfopyruvic acid,C3H4O6S,Cysteine and methionine metabolism;Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Biosynthesis of cofactors,Coenzyme M biosynthesis,NA,1.1.1.37;1.1.1.310;1.1.1.337;1.1.1.338;2.6.1.1;4.1.1.79,R02433 R05693 R05694 R05774 R07136 R07137 R08590
Pyruvate,cpd:C05644,3-Methylindolepyruvate,C12H11NO3,Tryptophan metabolism;Metabolic pathways,NA,NA,2.1.1.47,R01973
Pyruvate,cpd:C05646,5-Hydroxyindolepyruvate,C11H9NO4,Tryptophan metabolism;Metabolic pathways,NA,NA,2.6.1.27,R02700
Pyruvate,cpd:C06033,Parapyruvate;4-Hydroxy-4-methyl-2-oxoglutarate,C6H8O6,Benzoate degradation;C5-Branched dibasic acid metabolism;Metabolic pathways;Microbial metabolism in diverse environments,NA,NA,4.1.3.17;4.2.1.-,R00008 R03995 R05077 R05078
Pyruvate,cpd:C06203,trans-o-Hydroxybenzylidenepyruvate;(3E)-4-(2-Hydroxyphenyl)-2-oxobut-3-enoate,C10H8O4,Naphthalene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Naphthalene degradation, naphthalene => salicylate",NA,4.1.2.45;5.99.1.4,R05136 R05137
Pyruvate,cpd:C06367,1-Carboxyvinyl carboxyphosphonate;Carboxyphosphonoenolpyruvate,C4H5O7P,Phosphonate and phosphinate metabolism;Biosynthesis of secondary metabolites,NA,NA,2.7.8.23,R05165 R08868 R08887
Pyruvate,cpd:C06368,3-(Hydrohydroxyphosphoryl)pyruvate;(Hydroxyphosphinyl)pyruvate;3-Phosphinopyruvate,C3H5O5P,Phosphonate and phosphinate metabolism;Biosynthesis of secondary metabolites,NA,NA,2.3.3.18;2.7.8.23,R05165 R08869 R08870
Pyruvate,cpd:C12456,3-Dimethylallyl-4-hydroxyphenylpyruvate;3-(4-Hydroxy-3-prenylphenyl)pyruvate;3-[4-Hydroxy-3-(2-methylprop-1-en-1-yl)phenyl]-2-oxopropanoate,C14H16O4,Novobiocin biosynthesis;Biosynthesis of secondary metabolites,NA,NA,1.13.11.83;2.5.1.111,R06757 R06758 R06762
Pyruvate,cpd:C14086,2-Hydroxy-3-methylbenzalpyruvate,C11H10O4,Naphthalene degradation;Microbial metabolism in diverse environments;Degradation of aromatic compounds,NA,NA,4.2.1.-;5.3.99.-,R06912 R06913
Pyruvate,cpd:C14095,2-Hydroxy-3-carboxybenzalpyruvate;3-(3-Carboxy-3-oxo-1-propenyl)-2-hydroxy-benzoic acid,C11H8O6,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,4.2.1.-;5.3.99.-,R06922 R06923
Pyruvate,cpd:C14107,2-Hydroxy-4-hydroxymethylbenzalpyruvate,C11H10O5,Naphthalene degradation;Microbial metabolism in diverse environments,NA,NA,4.2.1.-;5.3.99.-,R06933 R06934
Pyruvate,cpd:C16149,(3Z)-4-(2-Carboxyphenyl)-2-oxobut-3-enoate;cis-2'-Carboxybenzalpyruvate,C11H8O5,Polycyclic aromatic hydrocarbon degradation;Microbial metabolism in diverse environments,NA,NA,1.13.11.38;4.1.2.34,R07657 R07713
Pyruvate,cpd:C16624,Isoniazid pyruvate,C9H9N3O3,Drug metabolism - other enzymes,NA,NA,NA,R08253
Pyruvate,cpd:C17946,Carboxyphosphonopyruvate,C4H5O7P,NA,NA,NA,2.7.8.23,R08868 R08869
Pyruvate,cpd:C18904,Methylselenopyruvate;beta-Methylselenopyruvate,C4H6O3Se,Selenocompound metabolism,NA,NA,2.6.1.-,R09373
Pyruvate,cpd:C20646,(3S)-2-Oxo-3-phenylbutanoate;(3S)-beta-Methylphenylpyruvate,C10H10O3,NA,NA,NA,2.1.1.281;2.6.1.57;2.6.1.107,R10431 R10845
Pyruvate,cpd:C21272,3-(4-Aminophenyl)pyruvate;p-Aminophenylpyruvic acid;p-Aminophenylpyruvate,C9H9NO3,NA,NA,NA,1.3.1.121,R12523
Pyruvate,cpd:C21289,(R)-3-(Indol-3-yl)-2-oxobutyrate;(R)-3-(Indol-3-yl)-2-oxobutanoate;(R)-beta-Methylindolepyruvate,C12H11NO3,NA,NA,NA,1.1.1.397;2.1.1.47,R01972 R11336
Trimethylamine,cpd:C00565,"Trimethylamine;(CH3)3N;N,N-Dimethylmethanamine",C3H9N,Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Carbon metabolism,"Methanogenesis, methylamine/dimethylamine/trimethylamine => methane",NA,1.5.8.2;1.7.2.3;1.14.13.148;1.14.13.239;1.21.4.4;2.1.1.247;2.1.1.250;2.1.1.252;4.3.99.4,R02511 R02560 R04877 R05623 R07228 R09124 R10016 R10017;R10285 R11875 R11911
Trimethylamine,cpd:C01104,Trimethylamine N-oxide;(CH3)3NO,C3H9NO,Methane metabolism;Metabolic pathways;Microbial metabolism in diverse environments;Two-component system,NA,NA,1.7.2.3;1.14.13.148;4.1.2.32,R02512 R02560 R05623
Valerate,cpd:C00141,3-Methyl-2-oxobutanoic acid;3-Methyl-2-oxobutyric acid;3-Methyl-2-oxobutanoate;2-Oxo-3-methylbutanoate;2-Oxoisovalerate;2-Oxoisopentanoate;alpha-Ketovaline;2-Ketovaline;2-Keto-3-methylbutyric acid;alpha-Ketoisovalerate,C5H8O3,"Valine, leucine and isoleucine degradation;Valine, leucine and isoleucine biosynthesis;Pantothenate and CoA biosynthesis;Lipoic acid metabolism;Glucosinolate biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids;Biosynthesis of cofactors","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;Pantothenate biosynthesis, valine/L-aspartate => pantothenate;Leucine biosynthesis, 2-oxoisovalerate => 2-oxoisocaproate;Pantothenate biosynthesis, 2-oxoisovalerate/spermine => pantothenate;Coenzyme A biosynthesis, archaea, 2-oxoisovalerate => 4-phosphopantoate => CoA",Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C00141  2-Oxoisovalerate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C00141  3-Methyl-2-oxobutanoic acid,1.1.1.84;1.2.1.25;1.2.4.4;1.2.7.7;1.4.1.8;1.4.1.9;1.4.1.23;2.1.2.11;2.3.3.13;2.6.1.6;2.6.1.32;2.6.1.42;2.6.1.66;4.1.2.12;4.2.1.9,R01209 R01210 R01211 R01212 R01213 R01214 R01215 R01216;R01226 R01434 R01701 R02200 R04441 R07160 R07599
Valerate,cpd:C00803,Pentanoate;Valerate;Pentanoic acid;Valeric acid;Valerianic acid;n-Pentanoate;n-Valeric acid,C5H10O2,NA,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   Monocarboxylic acids;    C00803  Valerate; Pentanoate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0101 Straight chain fatty acids;    C00803  Pentanoic acid,3.5.1.50,R02938
Valerate,cpd:C01110,5-Amino-2-oxopentanoic acid;5-Amino-2-oxopentanoate;2-Oxo-5-amino-pentanoate;2-Oxo-5-aminopentanoate;alpha-Keto-delta-aminopentanoate;2-Oxo-5-aminovalerate,C5H9NO3,Arginine and proline metabolism;D-Amino acid metabolism;Metabolic pathways,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C01110  5-Amino-2-oxopentanoic acid,1.4.3.3;2.6.1.21,R02457 R02459 R03249 R03250
Valerate,cpd:C03465,3-Methyl-2-oxopentanoate;2-Oxo-3-methylvalerate,C6H10O3,NA,NA,NA,NA,NA
Valerate,cpd:C03589,4-Hydroxy-2-oxopentanoate;4-Hydroxy-2-oxovalerate,C5H8O4,Phenylalanine metabolism;Benzoate degradation;Dioxin degradation;Xylene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds,"Trans-cinnamate degradation, trans-cinnamate => acetyl-CoA;Catechol meta-cleavage, catechol => acetyl-CoA / 4-methylcatechol => propanoyl-CoA",NA,4.1.1.-;4.1.3.39;4.2.1.80,R00750 R02601 R04223
Valerate,cpd:C04039,"2,3-Dihydroxy-3-methylbutanoate;2,3-Dihydroxy-isovalerate;2,3-Dihydroxy-isovaleric acid",C5H10O4,NA,NA,NA,1.1.1.86;4.2.1.9,R01209 R03051
Valerate,cpd:C04104,"2,3-Dihydroxy-3-methylpentanoate;2,3-Dihydroxy-3-methylvalerate",C6H12O4,NA,NA,NA,NA,NA
Valerate,cpd:C04181,3-Hydroxy-3-methyl-2-oxobutanoic acid;3-Hydroxy-3-methyl-2-oxobutanoate;2-Oxo-3-hydroxyisovalerate,C5H8O4,"Valine, leucine and isoleucine biosynthesis;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine",Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C04181  3-Hydroxy-3-methyl-2-oxobutanoic acid,1.1.1.86;5.4.99.3,R03052 R04440 R05071
Valerate,cpd:C04272,"(R)-2,3-Dihydroxy-3-methylbutanoate;(R)-2,3-Dihydroxy-isovalerate;(R)-2,3-Dihydroxy-isovaleric acid;(2R)-2,3-Dihydroxy-3-methylbutanoate;(2R)-2,3-Dihydroxy-3-methylbutanoic acid",C5H10O4,"Valine, leucine and isoleucine biosynthesis;Pantothenate and CoA biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C04272  (2R)-2,3-Dihydroxy-3-methylbutanoic acid",1.1.1.86;1.1.1.382;1.1.1.383;4.2.1.9,R04439 R04440 R04441 R10916
Valerate,cpd:C05941,2-Oxo-4-hydroxy-5-aminovalerate,C5H9NO4,D-Amino acid metabolism,NA,NA,NA,R04446 R09253
Valerate,cpd:C06007,"(R)-2,3-Dihydroxy-3-methylpentanoate;(R)-2,3-Dihydroxy-3-methylvalerate;(2R,3R)-2,3-Dihydroxy-3-methylpentanoate;(2R,3R)-2,3-Dihydroxy-3-methylpentanoic acid",C6H12O4,"Valine, leucine and isoleucine biosynthesis;Metabolic pathways;Biosynthesis of secondary metabolites;2-Oxocarboxylic acid metabolism;Biosynthesis of amino acids","Valine/isoleucine biosynthesis, pyruvate => valine / 2-oxobutanoate => isoleucine;Isoleucine biosynthesis, threonine => 2-oxobutanoate => isoleucine","Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0105 Hydroxy fatty acids;    C06007  (2R,3R)-2,3-Dihydroxy-3-methylpentanoic acid",1.1.1.86;4.2.1.9,R05068 R05070
Valerate,cpd:C06255,2-Oxopentanoic acid;2-Oxovalerate;2-Oxopentanoate;alpha-Ketovaleric acid,C5H8O3,NA,NA,Compounds with biological roles [BR:br08001]; Organic acids;  Carboxylic acids;   2-Oxocarboxylic acids;    C06255  2-Oxovalerate;Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0106 Oxo fatty acids;    C06255  2-Oxopentanoic acid,4.1.3.-,R05063
Valerate,cpd:C08262,3-Methylbutanoic acid;Isovaleric acid;Isovalerate,C5H10O2,Biosynthesis of alkaloids derived from histidine and purine;Biosynthesis of secondary metabolites;Protein digestion and absorption,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA01 Fatty Acids and Conjugates;   FA0102 Branched fatty acids;    C08262  3-Methylbutanoic acid,NA,R08411 R08412
Valerate,cpd:C10988,Fenvalerate;Pydrin,C25H22ClNO3,NA,NA,Endocrine disrupting compounds [BR:br08006]; Pesticides and herbicides;  Pyrethroid pesticides;   C10988  Fenvalerate;Pesticides [BR:br08007]; Pesticides;  Insecticides;   Pyrethroid insecticides;    C10988  Fenvalerate,NA,NA
Valerate,cpd:C12289,Isoamyl isovalerate,C10H20O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0701 Wax monoesters;    C12289  Isoamyl isovalerate,NA,NA
Valerate,cpd:C12290,Ethyl isovalerate,C7H14O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0710 Short fatty esters;    C12290  Ethyl isovalerate,NA,NA
Valerate,cpd:C12859,Estradiol valerate,C23H32O3,NA,NA,"Lipids [BR:br08002]; ST  Sterol lipids;  ST02 Steroids;   ST0201 C18 steroids (estrogens) and derivatives;    C12859  Estradiol valerate;Anatomical Therapeutic Chemical (ATC) classification [BR:br08303(D01413)]; G GENITO URINARY SYSTEM AND SEX HORMONES;  G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;   G03C ESTROGENS;    G03CA Natural and semisynthetic estrogens, plain;     G03CA03 Estradiol;      D01413  Estradiol valerate (JAN/USP/INN) &lt;JP/US&gt;;USP drug classification [BR:br08302(D01413)]; Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers);  Estrogens;   Estradiol;    D01413  Estradiol valerate (JAN/USP/INN);Therapeutic category of drugs in Japan [BR:br08301(D01413)]; 2  Agents affecting individual organs;  24  Hormones;   247  Estrogen and progesterone preparations;    2473  Estradiols;     D01413  Estradiol valerate (JAN/USP/INN);Drug groups [BR:br08330(D01413)]; Hormonal agent;  DG01986  Estrogen;   DG00462  Estradiol;    D01413  Estradiol valerate;  DG01584  Estrogen receptor agonist;   DG00462  Estradiol;    D01413  Estradiol valerate; Metabolizing enzyme substrate;  DG01633  CYP3A/CYP3A4 substrate;   DG02913  CYP3A4 substrate;    DG00462  Estradiol;     D01413  Estradiol valerate;Drug classes [BR:br08332(D01413)]; Endocrine and hormonal agent;  DG01986  Estrogen;   D01413  Estradiol valerate;  DG01584  Estrogen receptor agonist;   D01413  Estradiol valerate;Target-based classification of drugs [BR:br08310(D01413)]; Nuclear receptors;  Estrogen like receptors;   Estrogen receptor;    NR3A (ESR);     D01413  Estradiol valerate (JAN/USP/INN) &lt;JP/US&gt;;Drug metabolizing enzymes and transporters [br08309.html(D01413)]; Drug metabolizing enzymes;  D01413",NA,NA
Valerate,cpd:C14663,Testosterone isocaproate;17beta-Hydroxyandrost-4-ene-3-one 4-methylvalerate,C25H38O3,NA,NA,NA,NA,NA
Valerate,cpd:C16920,Bornyl isovalerate;Bornyval;Hysterol,C15H26O2,NA,NA,NA,NA,NA
Valerate,cpd:C18147,Esfenvalerate,C25H22ClNO3,NA,NA,Endocrine disrupting compounds [BR:br08006]; Pesticides and herbicides;  Pyrethroid pesticides;   C18147  Esfenvalerate;Pesticides [BR:br08007]; Pesticides;  Insecticides;   Pyrethroid insecticides;    C18147  Esfenvalerate,NA,NA
Valerate,cpd:C19318,Allyl isovalerate,C8H14O2,NA,NA,Lipids [BR:br08002]; FA  Fatty acyls;  FA07 Fatty esters;   FA0701 Wax monoesters;    C19318  Allyl isovalerate,NA,NA
Valerate,cpd:C20827,3-Hydroxyisovalerate;3-Hydroxy-3-methylbutyrate,C5H10O3,"Valine, leucine and isoleucine degradation;Metabolic pathways",NA,NA,NA,R10759
p-Cresol,cpd:C01468,4-Cresol;p-Cresol;4-Hydroxytoluene;4-Methylphenol,C7H8O,Toluene degradation;Nitrotoluene degradation;Metabolic pathways;Microbial metabolism in diverse environments;Degradation of aromatic compounds;Protein digestion and absorption,NA,NA,1.14.13.7;1.14.13.236;1.14.13.-;1.17.9.1;4.1.1.83;4.1.99.19,R02675 R03568 R05666 R07312 R07663 R08041 R10246 R12133
p-Cresol,cpd:C14693,"Butylhydroxytoluene;BHT;2,6-Di-t-butyl-4-methylphenol;2,6-Di-tert-butyl-p-cresol;Butylated hydroxytoluene;2,6-Bis(1,1-dimethylethyl)-4-methylphenol",C15H24O,NA,NA,NA,NA,NA
p-Cresol,cpd:C15220,2-Chloro-4-methylphenol;2-Chloro-p-cresol,C7H7ClO,NA,NA,NA,NA,NA
DSS-d6,NA,NA,NA,NA,NA,NA,NA,NA
Valproate,NA,NA,NA,NA,NA,NA,NA,NA
